Within-person variation in coronary risk factors: implications for the aetiology and prevention of coronary heart disease. by Emberson, J.R.
W ITHIN-PERSON VARIATION IN 
CORONARY RISK FACTORS: IMPLICATIONS 
FOR THE AETIOLOGY AND PREVENTION  
OF CORONARY HEART DISEASE
THESIS
presented for the degree of D O CTO R OF PHILOSOPHY 
in the Faculty of Medicine 
(Field of Study -  Epidemiology).
by Jonathan  R Emberson
D epartm ent of Prim ary Care and Population Sciences, 
Royal Free and University College Medical School, 
University of London
A ugust 2004
UMI Number: U591705
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a complete manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
Dissertation Publishing
UMI U591705
Published by ProQuest LLC 2013. Copyright in the Dissertation held by the Author.
Microform Edition © ProQuest LLC.
All rights reserved. This work is protected against 
unauthorized copying under Title 17, United States Code.
ProQuest LLC 
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106-1346
A b stra c t
Epidemiological studies clearly demonstrate the importance of numerous risk factors for 
coronary heart disease (CHD), including blood lipids, blood pressure, cigarette smoking 
and physical inactivity. These factors are widely believed to account for only around 50% 
of CHD cases. However, “within-person” variation in coronary risk factors can affect the 
size and even direction of estimated aetiological relationships, and though these effects 
have been explored for the univariate relations of blood pressure and blood cholesterol, 
much uncertainty remains. In this thesis, data from the British Regional Heart Study, 
a prospective study of cardiovascular disease in middle-aged British men, is used to in­
vestigate the extent and effects of “within-person variation” in a range of coronary risk 
factors. The effects on estimated relations with CHD are examined and the combined 
importance of the major risk factors to CHD risk assessed. The potential effectiveness 
of different CHD prevention strategies, and the size and cause of social inequalities in 
CHD are also estimated. The findings reveal a high degree of within -person variation in 
both established and novel coronary risk factors. Taking within-person variation into ac­
count, CHD risk-relations for blood lipids, blood pressure, cigarette smoking and physical 
inactivity increase in magnitude; though the estimated protective effect from moderate 
alcohol intake is reduced. After correction for within-person variation, blood cholesterol, 
blood pressure and cigarette smoking together account for at least 75 -80% of CHD cases 
in British men. Moderate population-wide improvements in these risk factors could there­
fore greatly reduce population levels of CHD, while “high- risk” strategies, unless applied 
to a large proportion of the population, are likely to have only a limited effect. Narrow­
ing social inequalities in CHD would also have a comparatively modest effect on CHD 
compared with population-wide control of the key causal coronary risk factors.
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C hapter 1
Introduction
1.1 Sum m ary
Despite impressive falls over the latter half of the 20th century, coronary heart disease 
(CHD) remains the single most common cause of death in the United Kingdom and is an 
increasingly important problem worldwide. Over the last 50 years, epidemiological stud­
ies have clearly demonstrated the importance of numerous risk factors for CHD, such as 
adverse blood lipids, high blood pressure, and “lifestyle characteristics” such as cigarette 
smoking and physical inactivity. Many other “novel” risk factors have also subsequently 
been implicated as potentially important. However, the contributions of these established 
and novel risk factors to CHD risk are not completely understood. In particular, it is 
unclear what contribution the established major coronary risk factors make to individual 
variation in CHD risk. The effects that “within-person variation” in coronary risk factors 
have on estimated disease relationships (often resulting in underestimation of true rela­
tionships) has added to this uncertainty, and though these issues have been explored for 
the most established risk factors such as blood pressure and blood cholesterol, they have 
usually only been considered in a univariate setting. In this thesis, data from the British 
Regional Heart Study (BRHS), a prospective study of cardiovascular disease established in 
1978-80 and comprising 7,735 middle-aged British men followed for cardiovascular mor­
bidity and all-cause mortality for over 20 years, are used to investigate the extent and 
effects of within-person variation in a range of known coronary risk factors. In particular, 
the effect that within-person variation has on: (1) estimated relationships with CHD; (2) 
the combined importance of the three strongest risk factors to population levels of CHD;
22
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(3) the potential effectiveness of different CHD prevention strategies; and (4) the true 
size and explanation of social inequalities in CHD, are examined. Particular strengths of 
the BRHS that axe important for addressing these research hypotheses are the socially 
and geographically representative nature of the study population, the non-interventional 
nature of the study, the high rates of follow-up, and, crucially, the availability of repeated 
measurements of both physical and biochemical risk factors and lifestyle characteristics at 
various points throughout the study period.
1.2 Background
1.2 .1  T h e  coron ary  heart d isea se  ep id em ic
Diseases of the heart and circulatory system, and in particular those diseases falling under 
the definition of coronary heart disease (CHD), are by far the most common cause of 
death in Western societies and are an increasingly important cause of death worldwide.1;2 
In 2001, coronary (ischaemic) heart disease accounted for an estimated 13% of all deaths 
worldwide (representing approximately 3.8 million men and 3.4 million women), around 
the same number as all cancers combined, nearly twice the number of deaths due to 
respiratory infections and nearly three times the number of HIV/AIDS deaths.1 In the 
United Kingdom, coronary heart disease accounts for around one half of all circulatory 
deaths (three fifths in men) and is the cause of death for about one in four men and one in 
six women; over a third of these occur in individuals under 75 years of age.3 However, at 
the beginning of the 20th century, CHD was only the fourth most common cause of death 
in the United Kingdom behind pneumonia, tuberculosis and diarrhoeal disease. By 1910, 
it had already reached first place with substantial increases in the proportion of deaths 
attributable to CHD being observed throughout the first half of the 20th century (see 
Figure 1.1). W ith the exception of a drop in CHD mortality during the 1940’s (thought 
to be caused by the effects of rationing during the Second World War), CHD continued 
to increase in the UK throughout the 20th century until the 1970’s, when the epidemic 
reached its peak. The last 30 years have seen a substantial fall in the incidence of CHD 
in the United Kingdom, however rates in the UK have not fallen as dramatically as those 
in other countries (see Figure 1.2). In addition, the absolute number of people who die 
from CHD in the UK (and many other Western societies) has changed very little despite
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these falls in incidence. Furthermore, the number of chronically ill CHD patients may even 
be increasing in these countries as the population ages and survival improves.4’5 For this 
reason, the overall burden of CHD, and other vascular diseases, in developed countries is 
unlikely to decrease in the coming years, and may even increase.6
In developing countries, in particular India and those in South East Asia, a new epi­
demic of CHD has been emerging,7-9 and while the relative contribution of CHD to all 
mortality in these countries is currently lower than that for developed countries, the total 
CHD mortality from these countries contributes a substantially greater share to the global 
burden of CHD than that from developed countries (because of the much larger popula­
tions in these countries). In 1998, for instance, it was estimated that over 85% of the global 
burden of cardiovascular disease (predominantly CHD) was from low and middle-income 
countries.7 Furthermore, the number of deaths from CHD in these countries is predicted 
to increase substantially in the coming decades, both with decreasing risks of death from 
other causes (particularly infections /  nutritional disorders) and increasing levels of ad­
verse CHD risk factors. In fact, by 2020, it is estimated that the number of deaths from 
CHD in developing countries will be over twice that observed in 1990 (compared with 
roughly a 40% expected increase in developed countries).7
1.2 .2  P a th o p h y sio lo g y
Coronary heart disease covers a range of clinical syndromes that include chronic conditions 
such as angina pectoris, and acute events such as myocardial infarction, myocardial insuf­
ficiency, and sudden death, but regardless of the clinical manifestations of CHD, the com­
mon underlying pathology is atherosclerosis of the coronary arteries resulting in ischaemia 
of the myocardium.10 Arteries are made up of an inner lining called the endothelium 
(an elastic membrane that allows the artery to expand and contract), a layer of smooth 
muscle, and a layer of connective tissue. Atherosclerosis is a disease of the endothelium 
in which the arterial channel (lumen) is narrowed by the formation of raised patches of 
atheromous plaque that develop in the endothelium. These plaques (also known as lesions 
or atheroma) are built up over a period of time and consist of a mixture of low-density 
lipoproteins, fibrous tissue, decaying muscle cells, blood platelets, calcium and cholesterol 
that axe deposited in the walls of coronary arteries. As plaques grow in size, the inner 
layer of the artery wall thickens, the artery narrows and the amount of blood that can
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flow through the artery is reduced. This reduces the amount of oxygen reaching the heart 
causing myocardial ischaemia and can often lead to symptoms such as exertional chest 
pain (angina pectoris). However, the real danger of plaque lies in their tendency to fissure 
(rupture) and ulcerate.11 When this happens the lipid content of the plaque mixes freely 
with the blood, resulting in the formation of a thrombus (blood clot), which may occlude 
the artery, leading to an acute “major” coronary event (myocardial infarction or sudden 
death). Even if such an occlusion does not occur however, fissure healing may result in a 
larger plaque and a progression of arterial obstruction. A variety of factors accelerate the 
development of coronary atherosclerosis, including increased blood cholesterol, increased 
blood pressure, cigarette smoking and diabetes12 (see chapter 2).
1.2 .3  C lin ica l m an ifesta tio n s o f  C H D
Coronary heart disease may present as an acute or severe event (including myocardial in­
farction and sudden death originating from the myocardium); as a chronic event (angina); 
or as a range of other conditions including, for example, heart failure and atrial fibrillar- 
tion. For acute and chronic myocardial ischaemia, the first symptom is usually chest pain, 
though the disease may be well advanced by the time these symptoms are manifest. In 
fact, symptomatic CHD is usually thought of as the end-process of a disease pre-dated 
by long-standing sub-clinical atherosclerosis.13;14 As previously described, a myocardial 
infarction occurs when the blood supply to the heart is blocked by a blood clot in one of 
the coronary arteries, leading to damage or death (infarction) of the affected tissues. This 
will usually result in severe chest pain behind the sternum (breast bone), often radiating 
towards the left arm, and can quickly result in death depending on the severity of the 
episode and the speed with which treatment is received. Angina (shortened from “angina 
pectoris” from the Latin for “tight chest”) is also caused by a restriction, or slowing down, 
of the blood flow to the heart, usually due to the obstruction of a coronary artery by 
atheroma. The symptoms of angina are similar to those of a myocardial infarction (such 
as a constricting feeling in the centre of the chest), and are caused when the narrowed 
artery fails to supply enough blood to the heart, usually when demand is increased, such 
as during periods of exertion. The pain from angina usually recedes within a few minutes 
of ceasing exertion.
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1.3 E pidem iological stud ies and C H D
1.3.1 R isk  factors (and  causal factors)
A risk factor for coronary heart disease may be defined as any characteristic found in 
healthy individuals that is related to the subsequent development of CHD. In general 
terms, risk factors may be grouped into one of the following categories:
1. Factors that are causally related to disease risk through known biological pathways, 
either by directly causing a change in the risk of disease (such as the influence of 
cigarette smoking on lung cancer risk), or else leading to a change in disease risk 
because of their effects on other risk factors (for instance, the influence of body mass 
index on disease risk may be partially attributable to its effects on blood pressure). 
Removing or reducing exposure to causally related risk factors should lead to a 
subsequent reduction in disease risk, though the extent of “reversibility” will usually 
depend on the duration of exposure to the risk factor;
2. Factors that act as “surrogate markers” for one or more other influences that cause 
disease, but do not themselves cause disease (for instance, income may be found to 
be related to the risk of a particular disease occurring, not because it causes disease, 
but because it is related to other factors that do, such as diet, social factors and 
the propensity to smoke cigarettes). When the relationship between these factors 
and disease can be accounted for by its relationships with these other “confounding” 
factors, we say that the risk factor is not “independently” related to disease risk.
The key feature that distinguishes type 1 from type 2 above is that in the latter case, the 
likelihood of disease may not necessarily be reversed by altering exposure to the risk factor 
(indeed the risk factor may not even be reversible, e.g. gender). Assessing the extent to 
which a relationship between a risk factor for CHD is causal and the extent to which it may 
be due to “confounding” by other factors has long been one of the aims of the observational 
epidemiological study. Observational epidemiological studies provide the key source of 
information for estimating the magnitude of risk-relationships, as they allow assessment 
of differences in disease risk corresponding to long-term differences in risk factor exposure 
(whereas trials, for instance, may not identify true risk associations because of, for instance, 
problems with compliance and incomplete reversibility). However, it is usually only by
C H APTER1. INTRODUCTION 27
combining evidence from pathological studies, observational epidemiological studies and 
randomised controlled trials (to assess the extent that risk can be reduced through removal 
of the risk factor), that a risk factor’s “causality” may truly be established beyond doubt.
1 .3 .2  R isk  a sso c ia tio n s and  “w ith in -p e r so n  varia tion ”
One of the primary objectives of the observational study is to examine how exposure to 
one or more characteristics (risk factors) influences the risk of developing disease. In the 
prospective cohort study this may be done by studying individuals over a long period of 
time and relating their personal characteristics prospectively to the occurrence of partic­
ular disease “events” . A variety of statistical measures are then available with which one 
may quantify the nature and strength of these relationships (for example, the relative risk; 
see chapter 3). The magnitude of these estimates, as well as the precision with which they 
can be estimated, greatly influences the relative importance that is likely to be given to 
control of the risk factor in the population and may also influence whether other, perhaps 
as yet unknown, risk factors are thought to play a critical role.
In order to estimate these associations, prospective epidemiological studies have his­
torically used single “baseline” assessments of risk factor exposure and related these to 
subsequent disease events. However, for single continuous risk factors that display linear 
“dose-response” relationships with disease risk, it is now well recognised that the use of 
baseline measures in analyses tends to result in underestimation of their importance.15-18 
This is because differences in risk factor levels observed among a group of individuals at 
a “baseline” examination tend to be larger than the true underlying differences that exist 
among the individuals over a period of time (because of “within-person variation” : mea­
surement errors; short term deviations from average levels; and risk factor changes over 
time). Consequently any observed differences in disease risk that are displayed by baseline 
levels of the risk factor are likely to underestimate the true differences in risk correspond­
ing to that range of exposure levels. This becomes particularly important when the risk 
factor is causally related to the risk of disease because it affects the relative weight that 
is applied to controlling the risk factor in the population. The tendency to underestimate 
associations between risk factors and disease when basing analyses on single risk factor 
measurements has become known as “regression dilution bias” ,17’19’20 however the wider 
implications of “within-person variation” in risk factors are not limited only to continuous
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risk exposures. Risk factors that are categorical in their nature (such as cigarette smok­
ing) are also subject to measurement errors and changes over time, and only by assessing 
and accounting for these effects can their true importance in an epidemiological study 
be evaluated. However, with the exception of studies of the effects of misclassification 
in dichotomous factors on risk associations,21-24 relatively few studies have been able to 
examine these influences. A further complication arises when analyses are adjusted for 
more than one risk factor subject to within-person variation. Under such conditions, the 
practice of applying univariate correction methods may not be appropriate, as the extent 
and direction of any bias depends on the correlation structure between the variables and 
their individual relationships with the disease.25-27 These issues give rise to the following 
important questions:
(Ql) W hat is the extent of within-person variation in continuous and 
categorical risk factors for coronary heart disease?
(Q2) W hat effect does this variation have on estimated relationships 
with coronary heart disease risk?
1.4 S tudying  th e  effects o f  w ith in -p erson  variation
1.4.1 Im pact on  u n d erstan d in g  th e  cau ses o f  C H D
Epidemiological studies have overwhelmingly demonstrated the importance of environ­
mental and behavioural conditions in the development of atherosclerosis and CHD, and in 
particular the role of three risk factors: serum total cholesterol, blood pressure and ciga­
rette smoking.28’29 The contribution of these, and other, established risk factors to CHD 
risk has been debated however, with many authors claiming tha t only approximately half 
of CHD cases may be “explained” by adverse levels of these factors.30-40 Numerous novel 
risk factors have been proposed as potentially important contributors to CHD risk, with 
varying degrees of evidence to support them (see Chapter 2). However the effect that 
within-person variation in the established risk factors has on their estimated contribu­
tion to overall CHD risk has not been adequately assessed. Though several studies have
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suggested that the true contribution of the established risk factors to CHD risk may be 
somewhat greater than one half,41-47 these have not taken within-person variation into 
account. There is therefore a need to address the following issue:
(Q3) How does within-person variation in the established coronary risk 
factors affect our understanding of the relative contribution of dif­
ferent causes of CHD?
1.4 .2  Im p act on  C H D  prim ary p reven tion  stra teg ies
Two approaches to the primary prevention of CHD axe widely recognized - the “high- 
risk” and the “population” approaches.48 Historically, high-risk approaches focussed on 
the control of individual risk factors for CHD, including cigarette smoking, high blood pres­
sure and high blood cholesterol level.48’49 However, the potential effectiveness of high-risk 
strategies has increased markedly during the past two decades, both with the availability of 
scoring systems to detect absolute CHD risk,50 and with the advent of several treatments 
which produce marked reductions in CHD risk in high risk subjects.51 In contrast, popu­
lation strategies to prevention focus on tackling the determinants of disease by seeking to 
cause a downwards shift in the population distributions of the strongest risk factors. The 
great strength of the population strategy lies in the observation that (in Western coun­
tries) most CHD cases occur not amongst the small number of individuals at greatest risk, 
but amongst the much larger numbers of individuals who axe at modexate (average) levels 
of absolute risk.52 However, whilst it has been demonstrated that the effectiveness of the 
population strategy has probably been underestimated by the failure to take account of 
within-person variation,49 little attempt has so fax been made to examine the potential 
impact of current high-risk strategies and to compare these with the potential impact of 
population strategies. This leads to the question:
(Q4) How does within-person variation in risk factors affect our under­
standing of the potential impact of different strategies for CHD 
prevention?
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1 .4 .3  Im pact on  th e  u n derstan d in g  o f  soc ia l in eq u a lities  in C H D
Social inequalities in the incidence of CHD in the UK, with higher rates amongst lower 
social class groups, are well documented,53’54 but while absolute CHD rates have fallen 
during the last 20 years, the fall has been concentrated among the highest social class 
groups so that the relative differences between those at the top and those at the bottom 
of the social scale have widened.54 Consequently, recent CHD prevention policies in the 
United Kingdom have placed considerable emphasis on reducing these inequalities.54’55 
However, several important issues remain unresolved. First, little attention has been 
given to the observation that (like causally related risk factors), markers of socio-economic 
status are not always precisely estimated and may change over time. The effect of this on 
the size of estimated social inequalities has not been assessed. Furthermore, the relative 
contribution of adult and early life factors to social inequalities in coronary heart disease, 
as well as the likely value of identifying further factors influencing social inequalities, 
remains uncertain. Therefore:
(Q5) How does within-person variation in risk factors affect our under­
standing of social variations in CHD?
(Q6) How does this affect the estimated effectiveness of strategies aimed 
at reducing social inequalities in CHD?
1.5 T he B ritish  R egional H eart Study: an op portu n ity  to  
stu d y  th e  effects o f w ith in -p erson  variation
The British Regional Heart Study (BRHS) is a prospective study of cardiovascular disease 
in 7,735 middle-aged men from 24 socially and geographically representative British towns. 
Study participants have had a wide range of risk exposures measured, and have been 
followed for fatal and non-fatal cardiovascular events since their enrollment into the study 
between 1978 and 1980, with very few losses to follow-up. The major aims of the BRHS 
are: (i) to determine the reasons for the geographic variation in cardiovascular disease in 
Britain; (ii) to investigate the individual determinants of cardiovascular disease; and (iii) to
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study the occurrence, natural history and management of cardiovascular disease in Britain. 
This thesis aims to make a contribution to these aims by: (1) estimating the extent and 
effects of within-person variation in coronary risk factors on the estimated importance of 
the “established” coronary risk factors; (2) estimating the potential combined contribution 
of the strongest risk factors to population levels of CHD; (3) estimating the potential 
effectiveness of different strategies for the primary prevention of CHD; and (4) estimating 
the size of social class differences in CHD, the extent to which they may be explained by 
established CHD factors, and the implications this has for strategies aimed at reducing 
social inequalities in CHD.
Complete details of the BRHS methodology are presented in chapter 4. The baseline 
examination in 1978-80 consisted of a physical examination, an administered questionnaire 
(ascertaining social and lifestyle characteristics, history of previous disease, current CHD 
symptoms, and medication use), a non-fasting blood sample, and a resting electrocardio­
gram (ECG). Since the baseline examination, the men have been followed up for both fatal 
and non-fatal CHD events through National Health Service (NHS) central registers and 
biennial reviews of patients’ General Practice medical records. A re-screening of surviving 
study participants after 20 years of follow-up (at which physical and biochemical measures 
were taken), together with similar examinations for men from two towns in 1996, as well 
as for an age-matched group of men over a one-week period in 2000, provides the neces­
sary information on the effects of within-person variability in physical and biochemical 
risk factors. Furthermore, changes in lifestyle characteristics have been ascertained from 
postal questionnaires sent to surviving study participants after approximately 5, 13, 17 
and 20 years of follow-up.
Two key features of the design of the BRHS axe particular strengths with regard to 
addressing the objectives in this thesis. First, the BRHS is a representative population- 
based study and has accurate information on both fatal and non-fatal coronary heart 
disease events. Deaths from coronary heart disease were defined as all deaths with an 
International Classification of Diseases (ICD) code (9th revision) of 410-414 (including 
sudden death of presumed cardiac origin), while non-fatal myocardial infarction was de­
fined according to established World Health Organisation (WHO) criteria. The primary 
outcome considered in this thesis is “major CHD” , defined as coronary death or non-fatal 
myocardial infarction. A second advantage of the BRHS is that the study is purely obser­
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vational - no attem pt was made to influence clinical practice in the participating general 
practices.
1.6 O bjectives and structure o f th e  thesis
This thesis presents an epidemiological study of risk factors for coronary heart disease in 
British men, with an emphasis on the role that within-person variation in risk exposures 
has on disease relationships and prevention strategies. The aims of this thesis are listed 
below:
1. To estimate the extent of regression dilution bias in established and novel coronary 
risk factors over the 20-year study period, to assess whether the size of this bias 
varies with age, history of previous CHD, area of residence or social class, and to 
estimate the extent of within-person variation in “lifestyle” risk factors for CHD 
over the 20-year study period.
2. To examine the influence of regression dilution bias in continuous risk factors and 
within-person variation in lifestyle risk factors on the estimated age-adjusted (uni­
variate) relationships between usual or average levels of these characteristics and 
major CHD risk over the 20-year study period.
3. To examine the potential combined contribution of the three strongest risk factors 
to major CHD risk (blood cholesterol, blood pressure and cigarette smoking) in 
individuals initially free from CHD, after correction for regression dilution bias.
4. To compare the potential effectiveness of high-risk and population approaches to 
the primary prevention of major CHD, after correction for regression dilution bias.
5. To estimate the size of social inequalities in CHD after adjustment for imprecision 
in the ascertainment of socio-economic status, to estimate the extent to which these 
differences may be attributed to differences in the established coronary risk fac­
tors, and to assess the potential effectiveness of strategies aimed at reducing social 
inequalities in CHD.
The content of each chapter is outlined below:
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•  Chapter 1 gives a general introduction to coronary heart disease in the United 
Kingdom, outlines some of the difficulties of estimating risk relationships with CHD, 
and presents the thesis objectives.
• Chapter 2 provides the epidemiological background to the research presented in 
this thesis, including a review of the evidence surrounding both the established as 
well as the new risk factors for CHD, a review of social and geographic inequalities 
in CHD in the United Kingdom, and a review of the different approaches to the 
primary prevention of CHD.
• Chapter 3 provides the statistical background to the research presented in this 
thesis, including a review of the effects of within-person variation in risk factors on 
estimated disease relationships, and a summary of the particular statistical tech­
niques and regression based approaches that are used in the thesis.
• Chapter 4 describes the methods of the British Regional Heart Study, with partic­
ular attention given to the methods and definitions relevant to this thesis.
• Chapter 5 is the first of five results chapters. The effects of regression dilution 
bias in established and novel coronary risk factors over a 20-year period are esti­
mated, the extent to which they differ depending on previous CHD and social and 
geographic factors is assessed, and the consistency of the results with those of other 
similar studies is discussed. Furthermore, the extent of “within-person variation” in 
“lifestyle” characteristics over the 20-year follow-up period is assessed.
• Chapter 6 uses these estimates of within-person variation to examine the effects 
that they have on univariate relationships with 20-year major CHD risk. The consis­
tency of effects over the 20-year period is explored, and the combined (multivariate) 
effects of regression dilution in two factors measured with error and subject to vari­
ation over time are examined.
• Chapter 7 examines the combined contribution of blood lipids, blood pressure and 
cigarette smoking to population levels of CHD among men initially free from CHD 
followed over the first ten years of the study (1978/80 - 1988/90).
• Chapter 8 estimates the potential effectiveness of high-risk strategies to the pri­
mary prevention of major CHD compared with population strategies of prevention,
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and is again based on men initially free from CHD followed over the first ten years.
• C h a p te r  9 estimates the size of social inequalities in major CHD in men initially 
free from CHD followed over the first 20 years, and estimates the extent to which 
these differences are explained by established adult and early life factors.
• C h ap te r  10 draws together the findings from this thesis and considers the implica­
tions for future epidemiological studies, future CHD research, and public health.
1.6.1 C hoice  o f  prim ary en d p oin t
The primary endpoint used in this thesis is the development of major CHD within 20 
years (defined as non-fatal myocardial infarction or death from coronary heart disease; 
see Chapter 4 for details of case ascertainment). This endpoint for chosen in preference 
to a stricter definition of CHD (coronary death only) or an expanded endpoint (including 
a diagnosis of angina) in order to strike a balance between obtaining a hard (accurately 
defined) clinical endpoint on the one hand, while allowing for as many clinical events 
to be included in analyses as possible (for the sake of statistical power) on the other. 
In the results chapters of this thesis, the risk of major CHD over 20 years is primarily 
examined only in men initially free from symptoms or a diagnosis or CHD, in order to 
reduce the potential role that reverse causality bias may play. However, in chapter 6, 
analyses are based on all study participants (including those with pre-existing disease), in 
order to present a representative picture of the age-adjusted associations in the population 
of middle-aged British men between 1978/80 and 1998/2000. Furthermore, in chapters 7 
and 8, 10-year follow-up data is used in analyses in preference to 20-year follow-up data. 
This was for a number of reasons: (1) the specific interest in considering preventable (i.e. 
early) major CHD in these chapters; (2) the desire to exclude the potential influence of the 
increased use of risk reducing drugs taken during the 1990’s from results; (3) the ability to 
compare findings with current national primary prevention guidelines (which are based on 
10-year CHD risk); and (4) the desire to adjust for regression dilution bias using real data 
observed over a four-year period, rather than estimating the “likely” effects of regression 
dilution bias at ten years (see chapter 5).
Each of the results in chapters 5 to 9 follow the same format: a summary of findings; 
a brief description of the background to the specific objectives in that chapter; the ob­
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jectives and content of the chapter; a section detailing the methodology specific to that 
chapter; results; and discussion in which the validity and interpretation of the findings 
are considered in the context of the existing literature. Implications of the findings are 
not discussed in each individual chapter but are considered together in chapter 10. The 
thesis appendices include copies of the publications (to date) arising from this research 
(Appendix A), and the baseline questionnaire of the BRHS (Appendix B).
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Figure 1.1: Age standardised CHD mortality rates in the United Kingdom between 1920 
and 2000
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Figure 1.2: Age standardised CHD mortality rates in the UK, the USA and Australia 
between 1968 and 1998 in men aged 35-74 years (Source: World Health Organization 
statistics, 2001)
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Chapter 2
R eview  of the epidem iology of 
CHD
2.1 Sum m ary
Over the last fifty years, epidemiological studies have consistently demonstrated the im­
portance of several risk factors for coronary heart disease, including adverse blood lipids, 
high blood pressure, cigarette smoking, physical inactivity, diabetes, and obesity. A com­
bination of both observational and experimental evidence suggests that several of these 
are causal; randomised controlled trials clearly demonstrate the benefits on CHD risk of 
reducing blood cholesterol and blood pressure, while epidemiological studies show that 
smoking cessation, weight reduction and increased physical activity all reduce the sub­
sequent risk of CHD. More recently however (as the processes underlying atherosclerosis 
have become better understood), there has been considerable interest in the potential role 
of new risk factors for CHD, including infections, and nutritional, inflammatory, haemo­
static and genetic factors, as well as the possibility that CHD may be determined by “early 
life” factors. Interest in these new mechanisms has been fuelled by the widely held opinion 
that the “established” risk factors only explain about 50% of all CHD events that occur. 
Furthermore, geographic and social inequalities in CHD disease have been found to be only 
partially attributable to the established risk factors, further motivating the study of new 
disease mechanisms. The extent to which an individual’s risk of CHD is determined by 
already known risk factors, and the overall importance of these factors to population levels 
of CHD, has important implications for the potential effectiveness of primary prevention
38
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policies aimed at reducing CHD incidence in the United Kingdom.
2.2 In troduction
This chapter provides the epidemiological background to the major areas of study in this 
thesis. Section 2.3 introduces the various types of study that have helped determine the 
causes of CHD, in particular the prospective cohort study, and gives brief descriptions of 
the design and main findings of three of the earliest and most influential studies of coronary 
heart disease. In sections 2.4 and 2.5, the epidemiological and trial evidence for the role 
of the established and new coronary risk factors is presented, with emphasis given to the 
description of the mechanisms of action involved. The potential combined contribution of 
these factors to overall CHD risk is presented in section 2.6 and, in particular, a review 
of the claim that “only half of CHD risk may be attributed to the established risk factors” 
is provided. Section 2.7 reviews the different approaches to the prevention of CHD, both 
in individuals with and individuals without a history of diagnosed CHD, and describes 
the relative merits of these approaches. Section 2.8 describes the geographic and social 
inequalities in CHD risk that have been observed in many countries including the United 
Kingdom for many years, and the extent to which they are determined by known differences 
in the levels of the established risk factors.
2.3 Early E pidem iological S tudies
As death rates from coronary heart disease in Western countries began to increase during 
the 20th century, it became clear that there were substantial variations in CHD mortality 
between different countries. This raised the possibility that coronary heart disease was a 
preventable disease, and not an inevitable consequence of ageing. Following the Second 
World War, several observational studies were initiated to investigate the possible reasons 
for these differences in CHD mortality between different countries. These tended to be 
either pathological studies (that investigated the determinants of pathologically defined 
coronary heart disease), or epidemiological (cohort) studies (that aimed to identify risk 
factors for the development of CHD in individuals). One of the earliest and most influen­
tial pathological studies was the International Atherosclerosis Project56 which aimed to 
quantify the role of atherosclerosis in the development of coronary heart disease in differ­
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ent populations. At about the same time, observational cohort studies were initiated to 
identify risk factors for CHD within a particular population. Part of the reason for this 
was because there was growing interest in the possibility of being able to identify individ­
uals without symptomatic CHD but at high-risk of developing it. These cohort studies 
tended to be either cross-sectional studies (comparing risk factors with the prevalence of 
CHD at a single point in time) or prospective studies (comparing risk factors in individ­
uals with the subsequent incidence of disease). In addition, some retrospective studies 
(looking at historical data) were also initiated. Of these types of study, the prospective 
cohort study has become the established design for identifying risk factors for CHD be­
cause, crucially, assessments of individuals are made before the CHD event occurs. Two of 
the earliest prospective cohort studies (the Seven Countries Study29 and the Framingham 
Heart Study28) were particularly instrumental in identifying some of the causes of CHD, 
as well as helping to explain why CHD was common in some countries, but much less so in 
others. In particular, by collecting prospective data on individuals from several different 
countries, the design of the Seven Countries Study allowed the study of both the reasons 
for differences in CHD mortality between different populations as well as the study of 
the reasons for differences in CHD within particular populations (i.e. the causes of CHD 
at both the population and the individual level could be examined). In contrast, the 
Framingham Heart Study included participants from a single population, concentrating 
on assessing the determinants of CHD at the individual level, and in particular to de­
velop methods for identifying individuals at greatest risk of developing CHD. The primary 
aims and findings from these studies, as well as those of the International Atherosclerosis 
Project, are now briefly described.
2.3 .1  T h e  In tern ation a l A th erosclerosis  P ro je c t
The International Atherosclerosis Project56 (carried out between 1960 and 1965) assessed 
atherosclerotic lesions and stenosis from 22,509 men and women who died aged 10-69 years 
from 14 countries in North, South and Central America, the Philippines, Jamaica, South 
Africa and Norway. The primary aims of the study were:
1. To assess the degree of atherosclerosis amongst individuals who died of causes unre­
lated to atherosclerosis.
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2. To compare the level of atherosclerosis amongst communities with high coronary 
heart disease rates with those of communities with lower rates, and
3. To assess other circumstances (risk factors) that may aggravate the degree of atheroscle­
rosis observed in individuals.
The study found that some degree of atherosclerosis is seen in all humans, but higher 
levels are consistently observed in communities where coronary heart disease rates are 
highest. At the population level, environmental conditions were found to be more im­
portant determinants of severe atherosclerosis than race or sex. In particular, the degree 
of atherosclerosis in a population was closely associated with both the proportion of to­
tal calories derived from fat and the average serum total cholesterol concentration in the 
population. Race did not appear to affect the level of atherosclerosis and substantial sex 
differences were only apparent in populations of high average atherosclerosis. The sever­
ity of atherosclerosis in a population was strongly related to the rates of clinical disease 
within that population, though other aggravating factors such as diabetes and hyperten­
sion further increased the likelihood of disease, particularly in populations with high levels 
of atherosclerosis. Within a population, individual levels of atherosclerosis varied consid­
erably, suggesting that genetic factors influencing susceptibility to atherosclerosis at the 
tissue level (arteries) and the systemic level (lipid metabolism) may also be playing an 
important role.
The findings of the International Atherosclerosis Project have since been substanti­
ated and extended in other pathological studies. In the Pathobiological Determinants of 
Atherosclerosis in Youth (PDAY) study, for instance, the percentage of intimal surface 
involved in atherosclerotic lesions in both the aorta and the right coronary artery was 
found to be positively associated with serum LDL and vLDL cholesterol, and negatively 
associated with serum HDL cholesterol, while serum thiocyanate (a marker for cigarette 
smoking) was strongly and independently associated with the prevalence of raised le­
sions.57
2 .3 .2  T he Seven  C oun tries S tu d y
The Seven Countries Study29 was the first study of its kind to examine the prospective 
relationships between lifestyle, diet, and the rates of cardiovascular disease in populations
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with contrasting patterns of heart disease. The study (established by Ancel Keys in the 
early 1950’s) consisted of 16 cohorts of men (initially aged 40-59) drawn from seven coun­
tries (the United States, Japan, Yugoslavia, Finland, Italy, the Netherlands and Greece) 
which were known to have widely differing levels of CHD mortality and which were sus­
pected to have different dietary habits. Baseline data on more than 12,000 men were 
collected between 1957 and 1962, and individuals have been followed-up for cardiovascu­
lar events until the present day. Though the Seven Countries Study contains information 
on the relationship between specific risk factors and CHD in individuals (within each 
population), the primary focus of the study was to examine the reasons for international 
differences. In reports published after 5 and 10 years of follow-up, the study established 
that the key determinant of a population’s risk of CHD was the mean serum total choles­
terol concentration in the population, which was determined to a large degree by the 
percentage of total calories derived from saturated fats.29 The low CHD rates observed in 
the Mediterranean countries of the Seven Countries Study gave rise to the suggestion that 
these countries were being “protected” from CHD by the composition of their national 
diets. Indeed, the Seven Countries Study is credited with discovering the “Mediterranean 
diet” , as well as introducing the idea of mass causes and preventability of coronary heart 
disease.
2 .3 .3  T h e  F ram ingham  H eart S tu d y
The Framingham Heart Study28 was established in 1948 in Framingham, Massachusetts. 
The study was set up as a prospective observational study of approximately 5,000 men and 
women aged 30-59, and was initiated to investigate the strength of associations between 
lifestyle factors and physical and biological measurements with the risks of subsequent 
cardiovascular disease, in order to quantify the probability that any given member of a 
group of individuals at increased risk of CHD would suffer an episode of CHD within a 
certain time period. Physical and biochemical measurements were examined at a baseline 
assessment and re-examined every two years, with follow-up for cardiovascular mortality 
and morbidity continuing until the present day. Between 1968 and 1975, a second study 
comprising the offspring from the original Framingham study participants was established. 
These two Framingham studies (the Framingham Heart Study and the Framingham Off­
spring Study) have since become synonymous with the concept of “risk-scoring” through­
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out the world.
Since the Framingham Heart Study was initiated, its design has been replicated in a 
vast number of subsequent prospective cohort studies, including further studies of Amer­
ican populations (e.g. the US Health Professionals study,58 the Nurses’ Health Study59 
and the Multiple Risk Factor Intervention Trial60), British populations (e.g. the British 
Regional Heart Study,61 the Whitehall study,62 the Renfrew/Paisley study63 and the Scot­
tish Heart and Health Study64), other European populations (e.g. the Paris65 and Oslo66 
studies) and other non-European populations (e.g. the Shanghai study67 and the Puerto 
Rico Heart Health Program68). Together, these studies have identified a vast number of 
risk factors associated with increased risk of CHD, as now described.
2.4 T he estab lished  coronary risk factors
The early observational studies identified large differences in the risk of CHD between 
individuals, and the role of three important modifiable risk factors for CHD were quickly 
established: high blood total cholesterol, high blood pressure and cigarette smoking. These 
three risk factors were particularly relevant to the CHD epidemics developing in Western 
countries, not only because the relative risks associated with them were high, but because, 
crucially, they were widely distributed in these populations. Numerous subsequent studies 
have supported these early findings, and have also helped to establish other risk factors 
including physical inactivity, obesity, and diabetes, as important contributors to CHD 
risk. Together, these observational studies have contributed towards the wealth of evi­
dence that now exists indicating that, at the population level, it is the lifestyle associated 
with “Western” cultures -  a diet rich in saturated fats and calories, tobacco smoking and 
physical inactivity -  that have important roles as causes of the mass occurrence of CHD in 
populations and as contributing factors to the risk of CHD in individuals within popula­
tions.69 In the sections that follow, a description of each of these established risk factors is 
provided, with particular emphasis on the strength and consistency of the epidemiological 
evidence, the consistency between the epidemiological evidence and the evidence from ex­
perimental studies (trials), the mechanisms through which they influence CHD risk, and 
the factors that determine their levels.
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2.4 .1  B lo o d  to ta l ch o lestero l 
Epidem iological and trial evidence
Cross-sectional studies, prospective cohort studies and clinical trials have all emphati­
cally demonstrated that the risk of CHD increases with increasing levels of blood total 
cholesterol. This relationship has been shown to hold across populations at different CHD 
risks and populations with different average cholesterol levels, and has been shown to 
exist for both men and women, in individuals with or without pre-existing disease, and 
in individuals of all races. Furthermore, evidence from multiple prospective studies has 
demonstrated that the relationship is continuous with no “threshold” level below which a 
lower blood total cholesterol level does not confer a lower CHD risk70-73 (see Figure 2.1). 
By pooling the findings from several prospective cohort studies, it has been estimated 
that, irrespective of initial cholesterol level, a 0.6 mmol/1 lower serum cholesterol level is 
associated with a 54% lower risk of CHD at age 40 years, a 39% lower risk a t age 50 and 
a 27% lower risk at age 60.70
Can the risk associated with a high blood cholesterol level be reversed? Early clinical 
trials of cholesterol reduction led to mixed results; randomised trials of the use of fibrates to 
lower cholesterol suggested that, despite reductions in CHD mortality, these drugs may in­
crease the risk of total mortality.74-76 In the World Health Organization trial of clofibrate, 
for instance, total mortality increased by 47% in the clofibrate group during treatm ent,74 
with the increase in mortality only levelling off a few years after clofibrate use was stopped. 
However, a parallel increase in non-cardiovascular deaths was not observed in dietary trials 
of cholesterol reduction (despite these trials showing similar reductions in CHD mortal­
ity77), suggesting that the observed increase in mortality from non-cardiovascular causes 
following treatment with fibrates may have been due to specific effects of the drug rather 
than to adverse effects following cholesterol reduction per se. The debate over whether 
cholesterol reduction increased the risk of death from non-cardiovascular causes was not 
definitively resolved, however, until the advent of a new class of lipid lowering drugs, 3- 
hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, or statins. Six 
large randomised placebo-controlled trials of these drugs (published between 1994 and 
2002; see table 2.1) emphatically demonstrated that treatment with statins substantially 
reduced the subsequent risk of CHD and total mortality in both populations with78-81
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and populations without82’83 previous CHD. Furthermore, the largest of these studies 
(the Heart Protection Study)78 further demonstrated these benefits to be similar in indi­
viduals without diagnosed coronary disease as in those who had cerebrovascular disease, 
peripheral artery disease, or diabetes, to be similar in men and women, in those aged under 
70 years and those aged 70 or over, and, most notably, in those who presented with rela­
tively low blood cholesterol levels (LDL cholesterol below 3.0 mmol/L or total cholesterol 
below 5.0 mmol/L) compared with those with higher levels. In a meta-analysis of the five 
trials that had been reported by 1999 (4S,80 WOSCOPS,82 CARE,79 LIPID81 and AF- 
CAPS/TexCAPS83), it was concluded that statin drug treatment reduced major coronary 
event risk by 31% and all-cause mortality risk by 21%.84 However, since the degree of risk 
reduction in these trials was predominantly determined by the level of cholesterol reduc­
tion achieved, greater reductions in risk are likely to be possible from statin doses that 
produce larger reductions in cholesterol.73 This is supported by data from the first five 
statin trials (shown in Figure 2.2; reproduced from Ballantyne85), where the CHD event 
rates in the placebo and treatment arms of these studies have been plotted against the 
blood cholesterol levels achieved. In both primary- and secondary-prevention patients, it 
can be seen that the CHD event rate decreased with successively lower concentrations of 
low-density lipoprotein cholesterol achieved with either statin therapy or placebo (consis­
tent with the observational relationship). This suggests that further reversal of CHD risk 
would have been possible had greater reductions in cholesterol been achieved.
How does blood cholesterol influence CHD risk?
The causal mechanism behind blood total cholesterol and CHD risk is complex, and only 
a brief review is provided here. Serum total cholesterol is made of various different com­
ponents including low-density lipoprotein (LDL) cholesterol and high-density lipoprotein 
(HDL) cholesterol. The LDL component is the major atherogenic influence; increased 
LDL cholesterol can lead to the formation of lipid-rich plaques on the walls of the ar­
teries increasing the risk of thrombosis, usually through plaque rupture or fissure (see 
section 1.2.2). In contrast, HDL cholesterol carries the LDL away from the arteries back 
to the liver, where it is excreted from the body. It is also thought that HDL removes 
excess cholesterol from plaques and hence slows their growth. HDL cholesterol is there­
fore often referred to as the “good” cholesterol, as high HDL reduces the risk of CHD. In
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addition, the protein constituents of LDL and HDL cholesterol (known as the apolipopro- 
teins) are increasingly becoming recognised as important markers of lipid metabolism and 
transportation, though these axe not described further here.
Statins work primarily by targeting LDL cholesterol -  they inhibit the HMG-CoA 
reductase enzyme in the liver (which controls the rate of cholesterol production in the 
body) slowing down the production of cholesterol and increasing the liver’s ability to 
remove the LDL cholesterol component already in the blood. Though the extent to which 
the benefits of statins are due entirely to reductions in LDL cholesterol has been debated 
(it has been claimed that statins may have other beneficial “non-lipid” effects),86’87 recent 
evidence from two of the statin trials indicated that virtually all of the treatment effects 
could be explained by the “on-study” lipid changes.88’89
Low blood cholesterol and all-cause m ortality
In contrast to the continuous positive relationship between total cholesterol and the risk 
of CHD, the extent to which a lower serum total cholesterol level may lower the risk of 
all-cause mortality was (until the publication of the statin trials) hotly debated. Low 
blood cholesterol has been found to be associated with an increased risk of mortality 
from non-cardiovascular causes, particularly cancer, in numerous studies.90-101 Most,90-97 
though not all,98-101 have found this relationship to be explained, at least partially, by the 
preclinical effects of cancer on blood cholesterol levels. This is reflected by the observation 
that the cancer-cholesterol relationship tends to be markedly attenuated when events in 
the first few years of follow-up are excluded. In a systematic review carried out in 1994 of 
10 large prospective studies, 2 international studies and 28 randomised trials, the authors 
concluded that there was:
“...no evidence that low or reduced serum total cholesterol increased mortality 
from any cause other than haemorrhagic stroke”
but even then that:
“...the risks would be outweighed by the decreased risks from CHD.”102
These views have since been supported by the randomised controlled trials of statins; 
even in individuals with initially “average” cholesterol levels, statins significantly reduce 
all-cause mortality and have no adverse effects on cancer incidence.78’103
CHAPTER 2. R E VIEW  OF THE EPIDEMIOLOGY OF CHD 47
D eterm inants o f blood cholesterol
The main determinants of serum total cholesterol concentrations in populations are dietary 
intake levels of saturated fat, polyunsaturated fat, and cholesterol.104-107 Of these, satu­
rated fatty acids axe the most important; a diet high in saturated fats leads to increased 
serum total cholesterol. In contrast, polyunsaturated fatty acids lower serum cholesterol 
(monounsaturated fatty acids have no independent additional effects). Dietary cholesterol 
(which is found only in animal products) also increases levels of serum total cholesterol, 
though its effects are lower than those of the saturated fats. Cholesterol concentrations 
are also affected by reduced energy intakes resulting in weight loss108 and possibly also 
by specific dietary supplements such as fibre,109 garlic,110 and fish oils.111 Though diet is 
the most important contributing factor to average blood cholesterol levels in a population, 
it directly contributes only approximately 20% of the cholesterol present in the human 
body, the remaining 80% being produced by the liver. However, diets rich in saturated 
fats can lead to the liver increasing cholesterol production, and so the overall importance 
of diet on blood cholesterol is greater than these figures first suggest. In addition to 
diet, genetic factors are also likely to play a role in determining the variation in blood 
cholesterol levels observed between individuals.112 A clear example of this is provided by 
familial hypercholesterolaemia, a condition affecting approximately 1 in 500 individuals 
(in Western countries), caused by a mutation in the LDL receptor gene and characterised 
by vastly increased cholesterol levels in the blood (see section 2.5.7).
2 .4 .2  B lo o d  pressure  
Epidem iological and trial evidence
As with blood total cholesterol, analysis of multiple prospective studies has emphatically 
demonstrated that the relationship between blood pressure and CHD (and stroke) is con­
tinuous with no thresholds below which risk does not continue to decrease (as least down 
to 75 mmHg for diastolic pressure and 115 mmHg for systolic pressure). In the Prospective 
Studies Collaboration, data on approximately one million individuals from 61 prospective 
studies revealed that a difference of approximately 20 mmHg in systolic pressure or 10 
mmHg in diastolic pressure corresponds to a more than two-fold difference in the risk of 
fatal CHD during middle-age113 (see Figure 2.3), with this relative risk difference atten­
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uating with increasing age. Furthermore, analysis of approximately 60,000 non-vascular 
deaths from the same study has shown that there are no appreciable risks associated with 
low blood pressure.113
Lowering blood pressure reduces CHD risk, irrespective of how this is achieved.114-120 
This can be seen in Figure 2.4, for example, where the effects of different blood pressure 
lowering drugs on cardiovascular mortality risk from 27 randomised controlled trials are 
shown.120 The most common classes of blood pressure lowering drugs are diuretics, /3- 
blockers, calcium channel blockers and angiotensin converting enzyme (ACE) inhibitors. 
Interestingly, these drugs lower blood pressure in different ways: diuretics assist the kid­
ney to excrete fluids and salt and can also help to widen blood vessels, /3-blockers block 
adrenaline thus slowing the heartbeat, calcium channel blockers block the calcium needed 
for muscle contraction and hence reduce arterial or heart muscle tension, while ACE in­
hibitors interrupt the formation of angiotensin II which makes blood vessels contract. To 
assess the relative effectiveness of different blood pressure lowering drugs, the Antihy­
pertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) was 
initiated. This trial included over 33,000 high risk hypertensive men and women aged 
55 or over who were randomised to receive either chlorthalidone (a diuretic), amlodipine 
(a calcium channel blocker) or lisinopril (an ACE inhibitor). The primary results of the 
ALLHAT study (reported in 2002) showed that over 5 years of follow-up, there were no 
differences in CHD or all-cause mortality risk between the amlodipine and chlorthalidone 
treatment groups or between the lisinopril and chlorthalidone groups.121 These findings 
were subsequently confirmed in an overview of 29 randomised controlled trials (including 
ALLHAT) published in 2003.116 The authors from the Blood Pressure Lowering Trial- 
ists’ Collaboration reported no significant differences in total major cardiovascular events 
between treatment regimes based on ACE inhibitors, calcium channel blockers, diuretics 
or /3-blockers, and found that for every outcome other than heart failure, the difference 
between randomised groups in achieved blood pressure reduction was directly related to 
the observed difference in disease risk. By combining several blood pressure lowering drugs 
together, greater reductions in blood pressure (and hence greater reductions in CHD risk) 
are likely to be achievable than with any single drug in isolation.115’122 A recent analysis 
of 354 randomised trials of blood pressure lowering agents examined this hypothesis and 
found that the blood pressure lowering effects of different categories of drugs were addi­
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tive. The authors estimated that a combination of three drugs at half standard dose (for 
example, a diuretic, a beta blocker and an ACE inhibitor) would lower blood pressure by 
20 mmHg systolic and 11mm Hg diastolic, approximately three times that of any single 
drug at half dose, or twice that of any single drug at standard dose, and would also result 
in fewer side effects.122
How does blood pressure influence CHD risk?
Given the vast amount of evidence relating blood pressure to CHD risk, as well as the 
number of clinical trials that have demonstrated CHD risk to be reversible through blood 
pressure lowering drugs, relatively little is actually known about the mechanism through 
which blood pressure influences CHD risk. However, it is thought that the effects may, at 
least partially, be mediated through inflammatory processes (see section 2.5.3), possibly 
through the formation of free radicals, as well as through haemodynamic effects.
D eterm inants o f blood pressure
One of the most important determinants of the average blood pressure level within a soci­
ety, as well as differences in blood pressure between societies, is dietary salt intake.123-126 
At age 60-69, it has been estimated that a difference in sodium intake of 100 mmol per day 
(approximately 6 grams of salt a day) is associated with an average difference in systolic 
blood pressure of around 10 mmHg,126 and an average diastolic blood pressure difference 
of around 5 mmHg. These associations are similar in countries with high average blood 
pressure (usually developed countries) and countries with low average blood pressure, and 
are consistent with the observed effects on blood pressure reported in salt reduction tri­
als.127 However, dietary salt is by no means the sole determinant of an individual’s blood 
pressure level. Factors such as physical inactivity, increased body mass index,128 a diet 
low in fruit and vegetables and high in saturated fa t,129 low potassium intake130 and high 
alcohol intake131 are all associated with increased blood pressure independently of dietary 
salt intake. Low birth weight has also been found to be associated with increased adult 
blood pressure levels,132-135 though the strength of this relationship is more controver­
sial.136 Furthermore, it is possible that since black individuals and those with a family 
history of high blood pressure are more likely to have high blood pressure,137 genetic 
factors may play some role in determining blood pressure levels.
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2 .4 .3  C ig a rette  sm oking
Once the link between cigarette smoking and lung cancer was established in 1950138;139 
(a finding later confirmed by both the Seven Countries Study and the Framingham Heart 
Study), observational cohort studies in Britain and the USA were initiated to explore the 
prospective relationships not only with lung cancer, but also with deaths from other causes, 
including CHD.140’141 The British study consisted of 40,000 doctors (the British Doctors 
Study) and initial results published in 1954 demonstrated for the first time that cigarette 
smokers were at a substantially greater risk of dying from CHD than non-smokers.142 
Subsequent reports after ten ,143 twenty,144 forty145 and now fifty146 years have reiterated 
these findings and have shown that though the relative risk of fatal CHD for smokers 
relative to non-smokers is smaller than that observed for the various forms of cancer more 
closely related to smoking (e.g. lung cancer), the greater number of deaths attributable to 
vascular causes meant that the absolute excess mortality from vascular diseases in cigarette 
smokers was more than double that attributed to cancers. Indeed, cigarette smoking is 
currently estimated to kill over two million people a year in developed countries (half 
during middle age), which accounts for approximately one sixth of the adult deaths each 
year in these populations.147;148 Of these, over half are due to cardiovascular disease. More 
recent studies have further established that this adverse effect of smoking is related both 
to the amount of tobacco smoked and the duration of smoking.149’150 A study of 14,000 
survivors of myocardial infarction (cases) and 32,000 of their relatives (controls) carried 
out in 1995 further identified the importance of tar yields in the development of non- 
fatal myocardial infarction.151 In addition, passive smoking has now also been shown to 
increase the risk of CHD and other smoking related diseases.152-154 Non-smokers who live 
with smokers may have up to a 30% increased risk of CHD over non-smokers who are not 
exposed to environmental tobacco smoke,153’154 though the true risks associated with all 
passive smoking (not just smoking in the home) may be even greater.155’156
M echanisms and effects o f smoking cessation
The exact mechanisms through which tobacco smoking increases the risk of atherosclerotic 
disease are not yet fully understood, though it is thought that they are multiple. In 
particular, cigarette smoking is thought to affect both atherosclerotic and thrombotic 
(clotting) processes, is thought to damage the endothelium through free radical formation,
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to affect platelet formation and aggregation, and even to have adverse effects on blood 
lipids.157-162 However, regardless of the true nature of the mechanism, it is well established 
that stopping smoking, even during middle age, substantially reverses the risks of CHD 
and death .144’145’163-167 Data published in 1992 from the British Regional Heart Study, 
for instance, indicated that middle-aged men who had quit smoking for more than five 
years did not differ appreciably in their risk of CHD over the following 10 years from men 
who had never smoked cigarettes.168
2 .4 .4  P h y sica l in a c tiv ity
Physical inactivity was first regarded as a potential contributing factor to CHD in the early 
years following the Second World War when Professor Jeremy Morris and his colleagues 
observed that bus conductors (whose jobs required them to be physically active) had ap­
proximately half the CHD risk of that of bus drivers (whose jobs were more sedentary).169 
However, at the time, there was much scepticism about the role of physical activity in 
CHD risk, the conventional thinking was that CHD resulted from hypertension, hyperc- 
holesterolaemia and obesity. Indeed it was not really until the publication of results from 
two large studies of middle-aged British civil servants (initiated in 1968 and 1976),170;171 
as well as a study of approximately 17,000 Harvard alumni (followed between 1962 and 
1978),172 that physical inactivity became widely established as an independent risk factor 
for CHD.
Since these early studies, numerous subsequent studies have demonstrated the pro­
tective effects of physical activity on the risk of CHD173-177 leading to it becoming uni­
versally recognised as a protective factor for CHD. Though many of these studies were 
based on middle-aged men, the benefits of physical activity on the risk of CHD have 
also been substantially demonstrated for women.178-182 Furthermore, physical activity 
has been shown to reduce CHD risk in specific groups of high-risk individuals, including 
the elderly,179’183-186 men with established CHD187-189 and individuals with diabetes.190 
However, despite this wealth of evidence, there have been conflicting findings regarding 
the type, frequency and intensity of physical activity that is needed to achieve benefit. 
The influential study of middle-aged British office workers by Morris and colleagues found 
that in order to achieve reductions in CHD risk, leisure time physical activity needed to 
consist of vigorous aerobic activity at least twice a week, and that recreational work such
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as walking, gardening and “Do-It-Yourself” (DIY) did not provide protection.171 These 
findings were later supported by studies of Finnish191 and German192 men, which helped 
develop the view that in order to be beneficial, leisure time physical activity needed to 
be frequent and vigorous in nature. This viewpoint has been questioned in recent times, 
with many studies demonstrating that even light to moderate levels of physical activity 
significantly reduced the risks of developing CHD.176;186;193-195 In addition, the uptake of 
physical activity among sedentary individuals, even in later fife, has been shown to confer 
significantly lower risks of CHD and all cause mortality.196
M echanisms
The strength and consistency of the relationship between physical activity and CHD 
strongly suggests a causal relationship, though mechanisms are still unclear. Physical 
activity is associated with several other coronary risk factors, including blood pressure197 
and blood lipids.198’199 Therefore the relationship between physical activity and CHD 
could be mediated at least partially through these risk factors. However, most studies 
have found associations between physical activity and CHD to be independent of these 
risk factors. Alternatively, since physical activity reduces insulin resistance (see section 
2.4.6),200;201 insulin and other components of the “insulin resistance syndrome” may be 
influencing the physical activity-CHD relationship. However, to date, few prospective 
studies have examined this possibility, and one that has found no evidence in favour 
of this hypothesis.202 A further suggestion is that physical activity may reduce CHD risk 
through its effects in the acute phase of CHD, possibly through clotting processes, platelet 
aggregation or increased fibrinolytic activity (see section 2.5),203-205 though this has not 
yet been conclusively established.
2 .4 .5  D ia b e te s
Insulin (a hormone released by the pancreas in response to increased levels of sugar in the 
blood) is important in order for glucose (blood sugar) to be absorbed into the body’s cells. 
Diabetes mellitus is a disease defined by increased levels of glucose in the blood caused by a 
relative or absolute deficiency of insulin. There are two forms of diabetes: type I, or insulin 
dependent diabetes, and type II, or non-insulin dependent diabetes. Type I diabetes is a 
disease of the pancreas gland whereby the body is deficient in insulin, leading to increased
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glucose levels in the bloodstream. Affected individuals need insulin injections in order to 
keep blood glucose levels as close to normal as possible. Type II diabetes generally occurs 
because of a metabobc failure at the cellular level -  cells become “resistant” to the effects 
of insulin, and the concentration of glucose in the blood, unable to enter the cell, begins 
to rise. The body’s natural response to insulin resistance is to secrete more insulin from 
the pancreas until the glucose is taken up by the cells. However, if the pancreas cannot 
sustain this state of hyperinsulinaemia (high insulin levels in the blood), blood glucose 
levels will increase leading to type II diabetes. Typically, individuals with type II diabetes 
do not require insulin injections as the diabetes can usually be controlled through dietary 
or pharmacological means.
Both type I and type II diabetes are associated with a markedly increased risk of CHD 
and other vascular diseases.206’207 Prospective epidemiological studies on large cohorts of 
diabetic patients have shown that the degree of hyperglycaemia (high blood glucose) is 
positively associated with the subsequent risk of CHD.208-210 However, in a large multicen­
tre trial of Type II diabetics (the United Kingdom Prospective Diabetes Study211), there 
were no apparent effects of glucose control on the risk of coronary or all-cause mortality 
over ten years of follow-up.212 Conventional coronary risk factors (e.g. high cholesterol, 
high blood pressure, cigarette smoking) appear to have the same relative impact in dia­
betics as non-diabetics, and so the absolute CHD risks of diabetics are (at any given risk 
factor levels) considerably greater than those for non-diabetics.213’214 Several randomised 
controlled trials and meta-analyses have confirmed that the benefits of reducing blood 
cholesterol215-217 and blood pressure218-220 extend to patients with diabetes. Therefore, 
the absolute benefits from risk factor modification, including smoking cessation, in diabetic 
patients are particularly great. Given the increased CHD risks experienced by diabetic 
patients, it is natural to wonder whether lesser degrees of disturbance to the glucose and 
insulin metabolism also lead to increased CHD risks. These questions are now considered 
further.
2 .4 .6  O besity, in su lin  resistan ce  and  th e  m eta b o lic  syn drom e  
Obesity and CHD
In the United States (and, increasingly, in the United Kingdom) obesity is becoming a 
national epidemic.221 Although it is well established that obesity is an important determi­
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nant of raised blood pressure222 and type II diabetes,223 the evidence for obesity as a risk 
factor for CHD, once blood pressure and blood lipids are taken into account, has been less 
well established. However, results from large prospective studies in both men and women 
have demonstrated that the risk of CHD does increase progressively as body mass index 
increases, that this increase is independent of blood pressure and blood cholesterol and 
that it begins a t even moderate levels of weight gain and overweight.224-230 In middle- 
aged American men and women, CHD risk has been shown to be as much as three to four 
times higher in those who are obese (a BMI of at least 30 kg/m2) compared with those 
who are lean (a BMI of <23kg/m2).224’228 A recent meta-analysis of the effects of body 
mass index on CHD risk in Chinese adults estimated a 7% increase in risk per 1 kg/m2 
increase in BMI, indicating a slightly lower (twofold) difference in CHD risk between those 
with a BMI of 20 and those with a BMI of 30.229 Though most attention has been based 
on the role of general adiposity (as measured by body mass index), numerous studies have 
now indicated that central adiposity (defined as an increased intra-abdominal fat mass 
and measured by the “waist-hip” ratio) may be more strongly related to the risk of CHD 
than BMI, particularly in women.228:231-233 In a study of approximately 33,000 women 
aged 55 to 69, nearly a threefold gradient in CHD mortality was observed between those 
in the lowest and highest tertiles of waist-hip ratio, and this was independent of other risk 
markers including body mass index.233 In contrast BMI, showed no independent relation 
to CHD mortality in this population.
Insulin resistance, the m etabolic syndrom e and CHD
As well as increasing CHD risk, obesity, and in particular central obesity, is an important 
factor in the development of “insulin resistance” (the slow uptake of glucose into the tis­
sues; see section 2.4.5). Although it is difficult to differentiate the relative effects of insulin 
resistance and hyperinsulinaemia as distinct entities, it is clear from a large body of basic, 
animal and human studies that insulin resistance is associated with significantly increased 
CHD risk, due in part to its associations with high blood pressure, high triglycerides and 
low HDL cholesterol.234-238 In fact, the close nature of the inter-relationships between 
central obesity, insulin resistance, high blood pressure and adverse blood lipids has led to 
the four conditions becoming known as a  syndrome referred to as the metabolic syndrome, 
syndrome X or the insulin resistance syndrome.239 The interest in the metabolic syndrome
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lies not just in the observation that individuals with the syndrome are at higher risk of 
diabetes240 and CHD241 than individuals without the syndrome (as would be expected be­
cause, with the possible exception of insulin resistance, the traits of the syndrome are well 
established risk factors for these diseases), but also in the hypothesis that the metabolic 
syndrome may increase risk for adverse outcomes to a greater degree than predicted by the 
individual components. This hypothesis is supported by a recent analysis that indicated 
that the syndrome traits interact to increase atherosclerosis of the carotid artery by a 
greater degree than would be expected solely from their additive effects.242 Furthermore, 
secondary analyses of two cholesterol lowering trials found that among patients allocated 
to the placebo arm, the excess risks of major coronary events experienced by those with the 
metabolic syndrome were over and above that which could be explained by the traditional 
risk factors.243
2 .4 .7  G ender and  horm one rep lacem ent th erap y
In addition to being the single most common cause of death in men, coronary heart dis­
ease is also the most common cause of death in women, accounting for 13% of all female 
deaths (approximately seven times the number that are caused by breast cancer).1 How­
ever, at any given age, women have a substantially lower risk of CHD compared with 
men.244’245 For years, it was thought that the excess risk experienced by men was ex­
plained by unhealthy behaviours that were more socially acceptable for men than women 
(such as cigarette smoking, heavy alcohol use, and a poorer diet) rather than being caused 
by inherent sex differences in physiology.246 However, studies adjusting for such behaviours 
generally found that while these factors contributed to the observed difference in CHD risk 
by gender, they did not fully explain the increased risk of CHD in men.247 Subsequently, 
considerable attention was drawn to the potential role of oestrogen as a protective factor 
in premenopausal women, a hypothesis prompted in part by the observation that the rel­
ative differences in CHD incidence and mortality between men and women decreases with 
increasing age. This, in turn, led to the suggestion tha t hormone (oestrogen) replacement 
therapy (HRT) after the menopause could have a potential cardioprotective role. Ob­
servational studies appeared at first to support this view; in a review of epidemiological 
studies of the effect of postmenopausal oestrogen on coronary heart disease risk in 1991, 
Stampfer and Colditz248 estimated that the relative reduction in CHD risk associated
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with ever taking HRT compared with never taking HRT was 50% (95% Cl 44% to 57%), 
concluding that, “...the bulk of evidence strongly supports a protective effect of oestro- 
gens that is unlikely to be explained by confounding factors...”. In 1998 however, the first 
large, randomised, placebo-controlled trial of the effect of combined oestrogen/progestin 
hormone replacement therapy on coronary events -  the Heart Progestin/Estrogen Replace­
ment Study (HERS) -  reported no beneficial effect of combined therapy on CHD events 
in women with established coronary disease.249 In 2002, the Women’s Health Initiative 
(WHI) trial of oestrogen plus progestin in 16,608 healthy postmenopausal women found 
that the relative risk of CHD was actually 29% higher (95% Cl 2% to 63%) among those 
on active therapy compared with those on placebo (the combined therapy arm was actu­
ally stopped early by the data and safety monitoring board because of an increased risk of 
breast cancer).250 In 2004, the oestrogen only arm of the WHI trial was also terminated 
early after showing that oestrogen alone increased the risk of stroke and had no effect on 
the risk of CHD.251
Why therefore, is there such a discrepancy between the findings from the randomised 
controlled trials and the observational studies? In contrast to the 1991 claim of Stampfer 
and Colditz,248 it appears that residual confounding may provide the answer after all. 
In particular, HRT use is strongly related to socio-economic status throughout the life 
course,252 which in turn is strongly related to CHD risk (see section 2.8.1). Regardless 
of the full reasons behind these differences however, the HRT-CHD relationship provides 
a valuable reminder as to why evidence from observational studies (even very good ones) 
should, wherever possible, always be interpreted in the context of supporting evidence 
from randomised controlled trials, and should not necessarily be accepted as fact.253’254
2 .4 .8  A lcoh o l
The relationship between alcohol and CHD risk (and total mortality) has consistently been 
shown to be U- (or J-) shaped, with individuals who drink light to moderate amounts of 
alcohol generally being around 25-30% less likely to experience CHD than individuals 
who do not drink, and individuals who drink excessively to be at increased risk of CHD 
(as well as other diseases).255-257 This relationship has been consistently demonstrated 
for both men and women in a large number of prospective studies across many different 
populations.258-264 But the issue of whether alcohol is causally protective at low doses has
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been difficult to establish from prospective studies alone, due in part to  the difficulties 
of comparing non-drinkers (a group consisting of a mixture of ex-drinkers and lifelong 
teetotallers) with regular occasional or light drinkers. Previously, it has been suggested 
that the protective effects of alcohol were due to a combination of adverse social and 
lifestyle characteristics among non-drinkers with particularly favourable characteristics of 
regular light/ moderate drinkers and not due to alcohol itself.265 However, in recent times, 
many studies have shown the benefits of alcohol to be independent of pre-existing disease, 
other coronary risk factors, and to be present even after exclusion of events early on in 
the follow-up period.266’267 It is therefore now widely accepted that a moderate level of 
alcohol intake does protect against CHD risk. Several questions remain however.
1. How does alcohol influence C H D  risk?
Current opinion on this matter suggests the effects are mediated primarily through 
effects on lipids and fibrinolytic activity.268 In particular, it has been estimated that 
between 40 and 60% of the protective effect of alcohol may be attributed to increases 
in HDL cholesterol269-272 (though the true figure may be somewhat larger due to 
measurement errors in recording alcohol consumption and biological variability in 
HDL cholesterol). In addition, alcohol appears to improve fibrinolytic activity (see 
section 2.5.4) by reducing platelet aggregability273’274 and reducing fibrinogen and 
factor VII levels.275;276
2. D oes th e  ty p e  o f alcohol m a tte r?
Whether or not different risks and benefits are associated with different types of 
alcoholic beverages is an important issue. Of particular interest is the possibility 
that substances in wine may have beneficial effects in addition to those of ethanol. 
Indeed, it has often been suggested that despite high smoking rates and high fat 
diets, the French experience low rates of cardiovascular disease because of their 
high levels of wine intake.274 Numerous studies have therefore aimed to assess the 
specific effects of wine, beer and spirits on CHD risk. In populations where all three 
types of drink are commonly consumed, these studies have indeed often found wine 
drinkers to be at lower risk of CHD than beer or spirit drinkers.277-279 A recent 
meta-analysis of 26 such studies estimated that wine reduced the risk of CHD by 
32% whereas beer reduced this risk by 22%.280 However, as yet, it remains unclear
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as to which substances in wine may be having effects in addition to those of ethanol, 
though many have been suggested.281-283
3. D oes the pattern o f drinking matter?
Drinking pattern has been shown to be predictive of CHD risk independently of 
average volume intake;266’284 several studies have found that episodic consumption 
of large amounts of alcohol (binge drinking), rather than reducing CHD risk, leads 
to increased risks of CHD and all-cause mortality.285-288 Whether or not this is due 
to differential effects on HDL cholesterol is unclear,285’289 though it may be due, in 
part at least, to the different effects that drinking pattern can have on blood pres­
sure.290-292 The Intersalt study, for instance, found that a highly variable pattern of 
alcohol consumption predicted a high mean blood pressure among heavy drinkers, 
regardless of the amount of alcohol consumed the day before measurement.131 Fur­
thermore, it is thought that platelet aggregation may be increased among heavy 
drinkers during periods of withdrawal.293
Does the evidence about the benefits of regular light to moderate drinking suggest that 
non-drinkers should be advised to begin drinking? In the absence of clinical trial evidence, 
it would be difficult to recommend drinking alcohol as a preventive measure, particularly 
given the myriad of other health and social problems associated with alcohol, the risks 
associated with heavy drinking and the observation that many non-drinkers abstain for a 
particular reason (e.g. religion, previous health conditions, family history of alcoholism). 
However, without encouraging alcohol use, it seems reasonable to state that moderate 
alcohol intake can form part of a healthy lifestyle.
2.5 T he novel risk factors
As the mechanisms behind atherosclerosis and CHD have become better understood, a 
variety of new hypotheses have been generated that implicate the potential importance of a 
number of novel risk factors for CHD. Interest in these factors has been driven by the widely 
held belief that the established risk factors described so far are only partially responsible 
for determining CHD risk.30-40 In this section, a broad review of these new areas of 
research is provided; the background for each research hypothesis is briefly described and 
the evidence supporting the hypothesis reviewed.
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2.5 .1  H o m o cy ste in e
Homocysteine is a sulphur-containing amino acid present in all cells which, in the nor­
mal course of events, is broken down into other non-damaging amino acids by three B 
vitamins: folate, B-6 and B-12. Plasma homocysteine levels reflect both environmental 
and genetic factors,294’295 and are inversely related to the dietary intake of folate and, 
to a lesser extent, vitamin B-12.294 Individuals with the rare autosomal recessive con­
dition homocystinuria have extremely high blood levels of homocysteine (>100 //mol/1), 
and a high incidence of vascular disease (approximately half of homozygotes are affected 
by the age of 30).296 Studies of such individuals who died have prompted the hypothesis 
that even moderately elevated blood concentrations of homocysteine may be relevant to 
cardiovascular disease.297
Observational and trial evidence
The first studies to address this hypothesis were case-control studies of patients with CHD. 
These studies did report higher blood homocysteine levels in cases than in age matched 
controls who were free of disease, though the studies were small.298’299 Since these early 
reports however, the amount of evidence from prospective studies has increased substan­
tially. In 2002, a meta-analysis of 30 observational studies involving over 5,000 CHD 
events found that a 25% lower homocysteine level was associated with an 11% lower CHD 
risk (95% confidence interval 4 to 17%), and tha t this reduction was independent of other 
established coronary risk factors.300 Results from genetic studies published the same year 
supported these findings, strengthening the view that the relationship is causal.301 This is 
particularly relevant as homocysteine levels can easily be reduced by taking folic acid and 
other B-vitamins. A meta-analysis of 12 randomised trials of homocysteine reduction 
found that dietary supplementation with folic acid reduced blood homocysteine by ap­
proximately one quarter (independently of dose), and tha t further supplementation with 
vitamin B-12 produced an additional 7% reduction.302 In the United States, folic acid has 
been added to flour since 1997, resulting in a significant reduction in average serum homo­
cysteine.303 In the late 1990’s, several large-scale randomised trials in people with prior 
CHD, prior stroke or renal disease were initiated to test the hypothesis that homocysteine- 
lowering with folic acid could reduce the risk of recurrent cardiovascular disease.304 Two 
of these studies were ended prematurely; the Second Cambridge Heart Antioxidant Study
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(CHAOS-2) of 1,882 people with prior CHD was terminated early because of a perceived 
lack of power to address the hypothesis (although it was reported that lowering homo­
cysteine by 13% had no significant effect on any vascular outcome),305 while the Vitamin 
Intervention for Stroke Prevention (VISP) study of 3,600 people with prior stroke was 
terminated when the interim analyses showed little possibility of demonstrating any effect 
of treatment on vascular events.306 The remaining trials should be completed from mid 
2005 onwards.
M echanisms
The mechanism through which homocysteine can increase the risk of CHD is thought to be 
due to the damage it can cause to the endothelium and its tendency to promote the buildup 
of LDL cholesterol, leading to blockage of the arteries. Genetic factors also modulate total 
plasma homocysteine levels, in particular the thermolabile variant of methylenetetrahydro- 
folate reductase (MTHFR),307 the presence of which may be a risk factor in folate-depleted 
individuals (see section 2.5.7).308 However, until the largest homocysteine lowering trials 
are reported, it is uncertain whether supplementation of foods with folic acid should be 
recommended for CHD prevention, though careful attention to conventional risk factors 
in individuals with a raised plasma total homocysteine is warranted regardless.
2 .5 .2  A n tiox id an ts
When LDL crosses the endothelial membrane to enter the artery wall, it becomes subject to 
a number of modifications, including an oxidation process which results in the production 
of free radicals. Free radicals are atoms or molecules with an odd number of electrons 
(making them unstable, short lived and highly reactive). As they combine with other 
molecules with unpaired electrons, new free radicals are produced, leading to a chain 
reaction that can damage important cellular components, including the cell membrane. 
The body’s natural response to this damage can lead to the creation of macrophages 
that take up the LDL before being converted to foam cells (see section 2.5.3 for further 
details). Indeed, oxidised LDL is thought to play a key role in the inflammatory processes 
that underpin the development of atherosclerosis. For these reasons, there has been much 
interest in the potential role tha t antioxidants (the body’s natural defence against free 
radicals) may have in CHD prevention.309
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Evidence from observational studies and clinical trials
Many epidemiological studies have shown tha t individuals whose diets are rich in the prin­
cipal antioxidants (vitamin C, vitamin E and /3-carotene) experience lower risks of car­
diovascular disease.310-318 A systematic review of all such studies published up to March 
2001 (20 studies) estimated that a high intake of /3-carotene or ascorbic acid (compared 
with a low intake) reduced the risk of CVD by approximately 11%, while a high intake 
of o-Tocopherol reduced this risk by 26%.319 Furthermore, a recent pooled meta-analysis 
of ten American and European prospective studies found that after adjustment for de­
mographic factors, body mass index and lifestyle factors, a 10 gram/day increase in total 
dietary fibre was associated with a 14% reduction in all coronary events and a 27% re­
duction in coronary death.320 However, these findings from epidemiological studies have 
generally not been supported by evidence from randomised controlled trials in either in­
dividuals with,321-325 or individuals without326-331 previous evidence of CVD. For studies 
published before March 2001, there were no significant differences in the risks of cardio­
vascular disease between individuals randomised to receive /3-carotene, a-Tocopherol or 
ascorbic acid relative to individuals randomised to placebo.319 In 2002, the very large 
MRC-BHF Heart Protection Study confirmed these findings, by reporting no effect of 
vitamin supplementation on the 5-year risk of vascular (or cancer) mortality (despite the 
vitamin supplements leading to substantial increases in blood vitamin levels).322 In 2003, 
a summary of all cohort and trial evidence on vitamin supplementation and cardiovascular 
disease (reported to the US Preventive Service Task Force) stated that:
“Despite promising evidence from cohort studies, randomised controlled trials 
have failed to demonstrate a consistent or significant effect of any single vita­
min or combination of vitamins on incidence of or death from cardiovascular 
disease. ”332
The discrepancy between the observational studies and the randomised controlled trials 
may be due to residual confounding in the observational studies, i.e. unknown or un­
measured factors which influence CHD risk but are also related to the level of fruit and 
vegetable intake in individuals, though another explanation is that the beneficial effects 
of antioxidants need to accrue over a period of many years.333
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2 .5 .3  In flam m ation  and In fection
The inflammatory response by the body to injuries to the endothelium has long been 
suggested as an important factor in the process of atherogenesis.334 There are many ways in 
which the endothelium can become damaged. However, whatever the cause of endothelial 
injury, atherosclerosis appears to be a characteristic response of particular arteries.
Inflammation, infection and atherosclerosis: pathological evidence
When LDL cholesterol particles become trapped in an artery they become subject to a va­
riety of modifications (of which oxidation is the most well known; see section 2.5.2). These 
modified LDL particles are proinflammatory, attracting monocytes into the subendothelial 
space and promoting the differentiation of monocytes into macrophages (large white cells 
that protect against infections and toxins). This is a key step in the inflammatory process 
because macrophages take up LDL through scavenger receptors, accumulate the lipid, and 
are converted to the foam cells that form the basis of atherosclerosis. Though cholesterol 
is the inflammatory agent most regularly present in the walls of the arteries, other causes 
of endothelial dysfunction have been proposed. In particular, it has been suggested that 
certain infections may aggravate the inflammatory processes already present in the arterial 
walls (though perhaps without initiating the processes themselves). Chlamydia pneumo­
niae and helicobacter pylori have been identified as the likeliest infectious microorganisms 
that may contribute to the development of atherosclerosis and CHD. However, though 
there is no direct evidence to suggest that these can cause the lesions of atherosclerosis,335 
this possibility has become an area of widespread interest.
Epidemiological and trial evidence
Chlamydia pneumoniae infection was first proposed as an avoidable cause of coronary 
heart disease in a small retrospective study in 1988.336 Subsequent studies suggested a 
twofold or larger odds ratio for coronary heart disease in people with markers of chronic 
C pneumoniae infection, though these studies tended to be small, retrospective, subject 
to confounding and liable to biases.337-339 In comparison, in 2000 a meta-analysis of 14 
prospective studies consisting of over 3,000 cases found that after adjustment for smoking 
and social class, only a  small and insignificant association between C pneumoniae infection 
and CHD risk remained.340 In addition, the contribution of helicobacter pylori to CHD
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risk has been shown in prospective studies to be only weak and possibly due to social 
confounding.341’342 C-reactive protein however, a marker of the inflammatory response to 
tissue damage, has consistently been shown to be prospectively related to CHD risk,343-345 
independently of traditional risk factors. In a meta-analysis of 7 long-term prospective 
studies of CHD published before 1998, a difference in C reactive protein of 1.4 mg/L (from
1.0 mg/L to 2.4 mg/L) corresponded to a 70% increase in the risk of CHD.343 Addition­
ally, in 2003, an 8-year follow-up of 14,000 initially healthy women found that differences 
in CHD risk by CRP level were similar in magnitude to those based on having at least 
3 components of the metabolic syndrome and, furthermore, that CRP added prognostic 
information on subsequent CHD risk at all levels of severity of the metabolic syndrome.344 
These findings may have overestimated the true importance of C-reactive protein however 
because of the preferential publication of positive results in earlier studies. In a recent 
updated meta-analysis of 22 prospective studies, those in the top tertile of the C-reactive 
protein distribution had a 58% higher risk of CHD than those in the lowest tertile, which 
was reduced to 49% when only the four largest studies (4107 cases) were used.346 How­
ever, randomised controlled trials have failed to demonstrate any effectiveness of antibiotic 
treatment on coronary risk. In the Weekly Intervention With Zithromax for Atheroscle­
rosis and Related Disorders (WIZARD) study of 7,747 adults with a history of CHD and 
exposure to C pneumoniae, a  3-month course of azithromycin had no effect on recurrent 
CHD over the following 14 months.347 Similarly, recent results from two large trials: the 
Azithromycin and Coronary Events Study (ACES) and the Pravastatin or Atorvastatin 
Evaluation and Infection Therapy trial (PROVE-IT), presented in August 2004 at the 
European Society of Cardiology annual conference in Munich, showed no beneficial effects 
on CHD risk following treatment with antibiotics among patients with prior cardiovascu­
lar disease.348’349 Taken in conjunction with the results from the WIZARD study, these 
findings indicate that antibiotics should not be taken to prevent coronary heart disease.
2 .5 .4  T h rom b otic  and fib rino lytic  factors
Following a plaque rupture, platelets bind to the site of the wound (and to each other) 
to form a blood clot (thrombosis), reducing the supply of blood and oxygen to the heart 
and causing damage or death (infarction) of the affected tissues. Most major heart at­
tacks and deaths from coronary heart disease are caused in this way. The process through
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which blood clots are naturally broken down in the body is known as fibrinolysis, the 
effectiveness of which depends both of the level of platelet activity and the body’s own 
level of fibrinolytic activity. Epidemiological studies have shown that platelet aggrega­
tion is positively associated with CHD risk.350;351 Furthermore, several fibrinolytic factors 
(factors involved in the process of fibrinolysis) have been proposed as being potentially 
relevant to CHD risk. High levels of fibrinogen and factor VII, two of the most important 
proteins used in the clotting process, have been shown to be associated with an increased 
risk of CHD.343’352-355 In addition, high levels of D-dimer (a protein that is released into 
the blood stream during the process of fibrinolysis) have also been found to be associ­
ated increased CHD risk. D-dimer circulates for several days in the blood stream after a 
thrombotic event, and can therefore provide a valuable marker of the presence of unwanted 
thrombotic events, and potentially, therefore, of future coronary events. A review of six 
studies of the prospective relationship between D-dimer and CHD risk estimated that 
for individuals in the top third of the D-dimer distribution relative to individuals in the 
bottom third, the relative risk of CHD was 1.7 (95% Cl 1.3 to 2.2).356 Tissue plasminogen 
activator (t-Pa), the substance that activates the enzyme plasmin which actually dissolves 
the blood clot, may also be a potentially relevant risk factor,357 as might von Willebrand 
factor, a substance released from endothelial cells which is involved in platelet adhesion 
of the damaged vessel wall and also in platelet aggregation.358
Randomised controlled trials have demonstrated that by inhibiting the body’s ability 
to form a blood clot, CHD risk may be substantially reduced. In 2002, the Antithrombotic 
Trialists Collaboration of 287 studies involving over 135,000 patients in comparisons of an­
tiplatelet therapy versus control reported that antiplatelet drugs (such as aspirin) reduce 
the risk of CHD by around one quarter and the risk of non fatal myocardial infarction 
by about one third.359 Randomised controlled trials have also demonstrated the benefits 
of fibrinolytic therapy (“clot busting drugs”) in patients with suspected acute myocar­
dial infarction.360 In individuals without clicical evidence of CHD however, randomised 
controlled trials have yet to establish whether targeting fibrinolytic factors could have an 
influence on preventing the occurrence of CHD. The role of fibrinolytic factors in terms of 
CHD prevention is therefore currently unclear.
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2.5 .5  P sych o so c ia l factors and  stress
Psychosocial factors include both environmental stressors and individual personality pat­
terns or psychological reactions to stress. Typical environmental stressors are both stres­
sors during everyday life and stressful work environments, the latter usually being char­
acterised by both high demand and time pressure, and low control or decision making 
powers. This pattern is typically found in low status jobs, and is thought to account for 
some of the socio-economic gradient in CHD (see section 2.8.1 for description of social 
inequalities in CHD). The Whitehall II study361 was one of the first studies to explore 
these issues after it was discovered that the large differences in CHD risk between men 
in the highest employment grade (administrators) and men in the lowest (messengers) 
observed in the Whitehall I study could only partially be explained by the established 
coronary risk factors.362 The Whitehall II study thus set out to assess the possible role 
that “job related factors” including social isolation and support, coping styles, hostility 
and stress may have in the causation of coronary heart disease. Results have indicated that 
differences in psychosocial work environment363 and in particular job control364 may be 
independent risk factors for CHD, and that much of the observed differences in CHD risk 
between individuals a t different grades of employment may be explained by these factors 
(though it is unclear to what extent these findings may simply be due to the strong cor­
relation between job control and employment grade). Overworking,365 depression,366’367 
social support368 and hostility369’370 have also been linked with increased risks of CHD, 
though mechanisms and preventive strategies remain unclear.
Possible mechanisms
One way in which psychosocial factors may influence CHD risk is through the neuroen­
docrine system; both work stress371’372 and social isolation373 have been shown to be 
associated with increased fibrinogen levels. In addition, depression374 and anger375 may 
be associated with low heart rate variability or sustained elevated heart rate. Can the po­
tential effects of psychosocial factors be reversed? At the individual level, counselling and 
stress techniques have had some effect in reducing CHD risk,376 however these findings 
have not been entirely consistent. It is therefore currently unclear as to what role these 
factors may have in terms of CHD prevention.
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2 .5 .6  F etal orig ins (th e  Barker h yp oth esis) and “early  life” factors
The fetal origins or “Barker” hypothesis is perhaps the most controversial hypothesis re­
lating to coronary heart disease. It states that adaptations made by the fetus in response 
to undernutrition lead to long-term changes in the metabolism and organ structure which 
predispose the individual to atherosclerosis and cardiovascular disease in later life.377-379 
The hypothesis was developed from observations made in studies of British men born 
in Sheffield during 1907-25380 and Hertfordshire during 1911-30,381 both of which found 
that birth weight was inversely associated with the risk of death from coronary heart 
disease. Further large studies in other populations, including Sweden382 and the United 
States,383 confirmed that these inverse associations were apparent in women as well as 
men. If the Barker hypothesis is true, then it is possible that the mechanism through 
which fetal growth influences subsequent CHD risk is through its effects on the estab­
lished coronary risk factors in adulthood; slow fetal growth has been found to be asso­
ciated with increased blood pressure,132-135 increased serum total cholesterol,135’384-386 
impaired glucose tolerance and type II diabetes,387 and impaired fibrinolytic activity388 
during adulthood. However, a recent systematic review has suggested that the association 
between birth weight and adult blood pressure reflects nothing more than a tendency to 
emphasise results that show the largest effects (which tend to be the smaller studies), and 
that really there is little or no effect of birth weight on adult blood pressure.136 Similarly, 
a systematic review of the relationship between birth weight and blood cholesterol levels 
revealed only a very weak relationship.389 In any case, since it is not yet clear which, if 
any, nutritional factors may play a role in determining CHD risk during adulthood, it is 
likely to be some time before specific advice given to women during pregnancy can be 
improved. In addition to the possible role that fetal factors may play in the causation of 
CHD in adulthood, numerous studies,169’362’377’390-394 though not all,395 have displayed 
an inverse relation between adult height and CHD mortality. This is consistent with the 
hypothesis that adverse environmental factors in early life have a direct effect on the risk 
of coronary heart disease.377’378
2 .5 .7  G en etic  factors
In 1994, a study of over 21,000 Swedish twins born between 1886 and 1925 reported 
that after adjustment for other risk factors, individuals whose twin had died from CHD
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before the age of 55 had substantially greater risks of dying from CHD themselves than 
individuals whose twin had not died of CHD before the age of 55, and that these risks 
were greater for monozygotic (identical) twins than for dizygotic twins.396 The authors 
concluded that at younger ages in particular, genetic factors influenced the risk of death 
from coronary heart disease in both men and women. In recent years, the potential for 
genetic research to make an important contribution to the understanding of the causes of 
coronary heart disease has been greatly increased by the completion of the human genome 
project,397’398 as well as by the development of new technologies for genomic analysis. 
Genetic factors are thought by some to form a substantial component of an individual’s 
risk of developing CHD.112 However the observation that individuals who migrate from 
one country to another tend to acquire the disease risks of their chosen country rather 
than retaining the risks of their country of origin,399 suggests that (at the population 
level) environmental factors play a more important role.
So do genes really m atter and, if not, how can genetic research further our understand­
ing of CHD? Genetic research has certainly played an important role in therapeutic drug 
development (e.g. the identification of HMG-CoA reductase as the enzyme which regulates 
cholesterol production in the liver), and it has a large potential for helping to understand 
and predict variations in responses to drug treatments (e.g. the variable responses differ­
ent individuals have to blood pressure lowering drugs). Furthermore, genetic research has 
already identified several important genetic mutations that lead to increased CHD risk. 
Probably the most established of these is familial hypercholesterolaemia, which is caused 
by codominant mutations in the LDL receptor gene, and which affects approximately 1 
in 500 individuals in Western societies. Individuals with familial hypercholesterolaemia 
present with cholesterol concentrations approximately twice the average for their age and 
sex and, as such, can be easy to identify. However, there are other genetic variations af­
fecting blood cholesterol concentrations that are, as yet, harder to identify. These include 
variations in the apolipoprotein B gene and the apolipoprotein E gene. In addition to 
their effects on serum cholesterol, it is also thought that genetic variations may also be 
important in determining the levels and effects of other established risk factors for CHD, 
including blood pressure, diabetes and even cigarette smoking.400-402
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M endelian Random isation
Genetic association studies are currently undergoing a renaissance under the banner of 
“Mendelian randomisation”, a term that refers to the suggestion that population-based 
studies of genotype-disease associations share with randomised controlled trials the ad­
vantage that confounding may be excluded as an explanation for any relations.403 This is 
because at the time of gamete formation, the assortment of alleles is, by Mendel’s second 
law, theoretically random. Therefore, the allocation of alleles should be independent of 
any environmental factors (both known and unknown) as well as any other variants at 
unlinked genetic loci, and hence any observed differences in disease risk should not be due 
to confounding (effectively these are naturally occurring randomised controlled trials). In 
addition, for genes known to modulate the effects of environmental exposure, genetic vari­
ants with known functional effects (e.g. the effect of codominant mutations in the LDL 
receptor gene on total cholesterol level) may also be considered as markers of altered en­
vironmental exposure, and hence (through the same Mendelian randomisation argument) 
may be used to assess an environmental risk factor’s causal importance. This concept has 
been applied to several of the novel risk factors, notably homocysteine where a partic­
ular mutation in the MTHFR gene (that increases homocysteine level by approximately 
20%) is known to exist.307 In an analysis of 72 studies in which the prevalence of this 
mutation in the MTHFR gene was determined, individuals homozygous for the mutant 
allele (TT) had a 2.7 /zmol/1 higher serum homocysteine and a 21% higher risk of CHD 
than individuals homozygous for the wide type allele (CC), with no differences in any of 
the established coronary risk factors observed between TT and CC individuals.301 Equiv­
alent evidence for the causal involvement of fibrinogen and C-reactive protein appears 
less strong however.404 Though the development of Mendelian randomisation provides an 
exciting promise for observational studies of gene-disease associations, several cautionary 
notes should be made. In particular, the size of the study is crucially important, as are 
the assumptions that the function of the gene is known and that alleles at nearby loci 
will not be preferentially associated with the alleles of interest. Furthermore, it should be 
noted that important gene-environment interactions may still exist even if gene-disease 
relationships appear not to .405
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2.6 C ontribution  o f different factors to  C H D  risk
Of the CHD risk factors described in sections 2.4 and 2.5, high blood cholesterol, high 
blood pressure and cigarette smoking have historically been regarded as the most impor­
tant in public health terms because of the large causal relative risks associated with them, 
and because of their widespread prevalence in Western populations (cholesterol levels, in 
particular, are universally high throughout most Western populations). Given current 
trends in sedentary behaviour and obesity, it is likely that in the future, physical inactiv­
ity, obesity and diabetes will also become increasingly important causes of CHD at the 
population level. However, for many years it has been claimed that these established coro­
nary risk factors, and in particular the three strongest causally related factors (high serum 
total cholesterol, high blood pressure and cigarette smoking), account for, at most, around 
half of all CHD cases.30-40 To state that only half of CHD cases can be attributed to the 
established coronary risk factors has important implications. First, it suggests that the 
scope for prevention of CHD by reducing exposure to these factors is somewhat limited, 
reducing CHD at the population level by 50% at most, and second, it suggests that other 
widespread risk factors, including those as yet unknown, may be of critical importance.
While the origin of the “50% claim” goes back to at least 1975,30 it doesn’t seem to 
have been based on any empirical data.42 Subsequent inappropriate analysis and/or inter­
pretation of published reports, including the assessment of the impact of very high-risk 
groups on CHD (rather than the impact of above optimal risk factor levels on CHD)31;35;40 
and the inappropriate citation of studies that examine the extent that established risk fac­
tors explain psychosocial or socioeconomic gradients in CHD33 (quite a different issue), 
has helped to perpetuate the myth. Furthermore, there is the potential for studies that 
seek to explain changing CHD death rates, and in particular the proportion explained by 
changing risk factors, to be misinterpreted, and reported as “evidence supporting the 50% 
claim”. Increasingly however, various authors have provided evidence suggesting that the 
50% figure may be an underestimate, and that the true contribution of the established 
risk factors to the population attributable risk of CHD is higher.41-47 A summary of this 
evidence is now provided.
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2 .6 .1  A  re -a ssessm e n t o f th e  “50% cla im ”
In 1993, an analysis of the relationship between major risk factors and long term mortality 
from CHD in several large American cohorts, including the Multiple Risk Factor Inter­
vention Trial (MRFIT) and the Chicago Heart Association (CHA) Detection Project in 
Industry study, found that compared with observed levels of serum and dietary cholesterol, 
blood pressure and cigarette smoking, the long-term CHD risks of those with “favourable” 
levels of these factors were between 60 and 89% lower, and that these individuals lived 
for up to nine years longer on average.41 A secondary report from the same investigators 
presented six years later found that among 270,000 initially disease free men aged 40-57 
years in MRFIT, the 16-year CHD death rate observed in non-smoking individuals with 
a serum total cholesterol < 5.17 mmol/L and a blood pressure no higher than 120/80 was 
78% lower than in the rest of the sample.44 In CHA, the 22-year CHD death rate in nearly
14,000 middle-aged men and women who were initially free from CHD was 77% lower (in 
men), and 79% lower (in women), for “low-risk” individuals compared with all remaining 
individuals.44 These risk differences were even larger for men and women who were aged 
<40 years at time of recruitment. Similar sized differences between “low” and “high risk” 
individuals have also been found in other studies including the National Co-operative 
Pooling Project (where CHD risk was estimated to be 70% lower for men in the lowest 
quintile of risk, compared with all other men),406 the Nurses Health Study (where risk 
was 82% lower in women who were “low-risk” according to a score derived from smoking, 
physical activity, obesity and diet),45 and the Framingham study.407 In the United King­
dom, the Whitehall I study of over 17,000 middle-aged British civil servants found that if 
the average CHD mortality rate in the whole population could have been reduced to that 
experienced by individuals who had never smoked cigarettes and who were in the lowest 
quintiles of blood cholesterol and blood pressure levels, then about two-thirds of the CHD 
deaths would have been avoided.42 Most recently, two studies estimating the prevalence of 
established risk factors in a large number of individuals with coronary heart disease found 
that between 80 and 90% of such individuals were exposed to at least one of the main risk 
factors (high blood cholesterol, high blood pressure, smoking or diabetes),46’47 in stark 
contrast to the “only 50% claim” . All of these studies provide evidence against the “50% 
claim”. However, none of these studies were able to take into account “within-person” 
variation in coronary risk factors, the effects of which are now described.
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The use of baseline measures in analyses o f incident disease
Analyses of incident disease in epidemiological studies typically use “baseline” assessments 
of individuals as estimates of the individual’s “exposure” to that particular risk factor, 
in order to separate “cause” from “effect” . However, baseline measurements often do not 
reflect an individual’s true usual level over time (because of measurement errors, short 
term “random” fluctuations from the individual’s average level and longer term system­
atic changes). Though these effects are random, meaning that the baseline measurement 
is just as likely to over- as under-estimate the subject’s true level, the differences between 
individuals estimated from a baseline sample (the between person variation) tend to exag­
gerate the true differences that really exist between those patients over a period of time. In 
other words, the differences in the level of the risk exposure between the study participants 
are not as large as one would estimate from the baseline sample alone. In consequence, for 
single continuous risk factors that display linear “dose-response” relationships with dis­
ease risk (as total cholesterol and blood pressure do for CHD), the estimated association 
derived from baseline measures underestimates the true association,15-18 a phenomenon 
that has become known as “regression dilution bias” 17;19;2° (see section 3.5.2 for further 
details). These effects are important when assessing the true combined importance of 
the established coronary risk factors, and while the studies previously described provide 
evidence against the “only 50% claim”, none of them were able to take this source of bias 
into account.
2.7 S trateg ies for C H D  P revention
When considering the prevention of coronary heart disease, it is usual to draw the dis­
tinction between primary and secondary prevention.48 Primary prevention refers to the 
prevention of CHD amongst individuals without CHD. Secondary prevention on the other 
hand refers to the prevention of new CHD events in individuals who already have clinically 
manifest CHD (e.g. angina or non-fatal myocardial infarction). In secondary prevention, 
it is generally recognised that all individuals should be offered advice to modify their 
lifestyle or given drugs to reduce their CHD risk. In the United Kingdom, for instance, 
the current National Service Framework (NSF) for coronary heart disease recommends 
that all individuals with established CHD should receive statin treatment providing that
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their total cholesterol is greater than 5.0 mmol/L or their LDL cholesterol is greater than
3.0 mmol/L408 (though it is argued by many that statins should be given to these indi­
viduals irrespective of their cholesterol concentrations).71’73 In primary prevention, where 
the absolute risk of CHD is lower, there are two accepted approaches to  prevention: the 
“high-risk” and “population” approach, as illustrated in figure 2.5. High-risk approaches 
to prevention aim to identify and treat those individuals thought to be at greatest risk of 
developing disease. The key processes governing the potential effectiveness of the high-risk 
approach are: (1) the ability to identify those at greatest risk of CHD; (2) the choice of 
the “threshold” level of predicted risk deemed sufficient to warrant treatment; and (3) the 
effectiveness of the risk reducing measures available. In contrast, the population approach 
to prevention seeks to bring about a downwards shift in the population distributions of 
the most important risk factors (see figure 2.5). Each of these approaches to prevention 
is now considered in more detail.
2.7 .1  H ig h -r isk  approaches to  prevention  
Identifying the high-risk group
Originally, high-risk approaches to the primary prevention of coronary heart disease have 
been based on the identification and treatment of individuals with elevated levels of sin­
gle risk factors, for example elevated levels of total cholesterol or blood pressure. More 
recently however, high-risk approaches to prevention have been based on the estimated 
overall risk of CHD, taking into account several risk factors simultaneously. The con­
cept of being able to develop a tool for predicting the absolute CHD risk in any specific 
individual was one of the primary objectives of the Framingham Heart Study, with the 
first “risk equations” from this cohort being published in 1976.409 These equations were 
superseded in 1991 in order to take into account more data on individuals over 60 years 
old (including data from the Framingham Offspring Study) as well as to include new risk 
factors such as HDL cholesterol.410 Six new equations were derived for predicting the risk 
of: (1) myocardial infarction; (2) coronary death; (3) any CHD event (including silent 
myocardial infarction and coronary insufficiency); (4) stroke; (5) cardiovascular death; 
and (6) any cardiovascular event. While several other risk scoring methods have been pro­
posed,411-413 it is the equations from Framingham that are the most widely used. In the 
United Kingdom, for instance, current guidelines on the primary prevention of CHD are
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based on the Framingham equation relating to “any CHD event” . The National Service 
Framework for coronary heart disease (published in 2000) states that individuals without 
symptoms of CHD, but with a (Framingham) predicted risk of at least 30% of developing 
it within 10 years, should be identified and considered for treatment with statins.408 Simi­
larly, other European, American and Canadian guidelines have based their risk prediction 
methods on equations derived from the Framingham study.4;414_416 Recently however, new 
European guidelines417 have recommended risk prediction based on the newly published 
SCORE equations,418 which are derived from many different European studies and which 
take into account the differing background risks of different European populations. The 
decision to replace the use of the Framingham equations with a set of new ones may have 
been partially motivated by the growing evidence that the Framingham equations tended 
to overestimate absolute coronary risk in European populations.419-424
Potential effectiveness
Assuming that individuals can be suitably “ranked” in order of CHD risk, the effective­
ness of the high-risk approach to prevention depends on the threshold at which treatment 
is provided and the risk reducing capabilities of the interventions available. As already 
stated, the NSF for CHD in the United Kingdom recommends a ten-year CHD risk thresh­
old of 30% or more for treatment intervention. In the British Regional Heart Study, this 
criterion identifies (at baseline) only approximately 6% of the healthy men as being “high- 
risk” , thereby limiting the potential for this approach to substantially influence population 
levels of CHD. European guidelines have generally set lower thresholds. Prior to the recent 
recommendations of the Third European Joint Task Force Report on Coronary Preven­
tion, European guidelines recommended treatment based on a Framingham ten-year CHD 
event risk of 20% or more.4 Regardless of the threshold level chosen however, the potential 
for reducing the CHD risks of those at greatest risk has been greatly increased in recent 
years by the availability of several safe, effective and apparently independent treatments.51 
It has been suggested that by combining several drugs (such as statins, aspirin and one or 
more blood pressure lowering drugs), the risk of CHD in individuals could be reduced by 
at least 70%,51 and possibly by even more.425
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2 .7 .2  P o p u la tion  approaches to  preven tion
The high-risk approach to CHD prevention is a natural approach for medical practitioners 
who are concerned with the occurrence of disease in individuals, providing them with a 
quantitative tool that enables them to “rank” individuals in order of priority so that re­
sources can be allocated appropriately. However, the occurrence of coronary heart disease 
is not confined only to those at greatest risk. Indeed, the majority of CHD cases occur 
amongst individuals whose absolute excess risk is small,49 and whose risk exposure levels 
are “normal” or “usual” for their own population, meaning that they are near to the av­
erage level in that population. However, when compared with a different population their 
exposure may be considered anything but normal.
A striking example of this is provided by the population levels of serum total choles­
terol levels in Finland and Japan (as measured in the Seven Countries study),29 where 
the distributions barely overlapped (mean levels were approximately 6.8 and 4.4 mmol/1 
respectively). These kinds of “between-population” differences have led some to advo­
cate that (primary) prevention policies should be “population” rather than “individual” 
based.48 Population approaches to prevention aim to cause a downwards “shift” in the dis­
tribution of causally-related risk factors throughout the entire population (see Figure 2.5), 
rather than targeting specific individuals. For CHD, this would logically involve reduc­
ing the population average levels of blood cholesterol and blood pressure, and reducing 
cigarette smoking rates. However, though the absolute benefits experienced by the popu­
lation following such reductions may be great, the marginal benefits experienced by each 
of its individuals due to “population shifts” would be relatively small (except for cigarette 
smokers who give up). Individuals may not be prepared to alter their lifestyle so that the 
population as a whole can enjoy lower rates of CHD.
Population approaches are therefore often implemented through government interven­
tions such as increased taxes on cigarettes and tighter regulation of the salt and fat content 
in processed foods. These types of approaches to causing changes in the distribution of 
a risk factor within a population are feasible; numerous studies have demonstrated that 
community levels of serum total cholesterol and blood pressure can be reduced (in some 
cases substantially) through changes in diet.104;426_43° In North Karelia, Finland, choles­
terol levels have been reduced by 18% in both men and women and blood pressure by 
8% in men and 13% in women since the introduction of community based cardiovascular
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disease prevention project in 1972.426 Similarly, in a study of adults living on the island 
of Mauritius, mean total cholesterol fell from 5.5 mmol/1 to 4.7 mmol/1 over 5 years fol­
lowing the implementation of a population-wide intervention programme aimed at the 
promotion of a healthy lifestyle,427 though the fall in cholesterol was probably attribut­
able to a change in the island’s supply of cooking oil from palm to soy bean oil rather than 
any behavioural effect of health promotion.431 Meta-analysis of metabolic ward studies in 
Western countries has indicated that a reduction in total cholesterol of this size could be 
achieved in the United Kingdom if 60% of saturated fats could be replaced by other fats 
and 60% of dietary cholesterol could be avoided.104 Similarly, analysis of clinical trials of 
salt reduction indicate that simple dietary changes (reducing salt intake by approximately 
50 mmol (3 grams) per day) could easily reduce systolic blood pressure in the population 
by 5 mmHg, while reduction also in the amount of salt added to processed foods would 
lower population blood pressure by twice as much.127 These estimates are consistent with 
observed reductions in population blood pressure in a community trial of salt reduction 
in Portugal.430 Current public health recommendations in the UK432 and US433 are to 
reduce salt intake from 9 to 12 grams a day to 6 grams or less, however it has been sug­
gested that, given the consistency in the dose-response relationship observed between salt 
intake and blood pressure, the long-term target for population salt intake should be no 
more than 3 grams a day.434 This may best be achieved through governmental regulation 
of the salt content in processed foods, a policy that has been shown to be a particularly 
cost-effective method of preventing cardiovascular disease.435 Furthermore, such changes 
to processed foods are unlikely to be resisted, as there is evidence that small and repeated 
decreases in salt intake are not discernible on the grounds of taste.436
The key feature of the population approach to prevention is that it seeks to remove 
or reduce the underlying causes that make the disease common in the population. The 
approach therefore has a large potential for the population as a whole. However, in order 
to estimate the effect that population approaches to CHD prevention may have in the 
long-term, an accurate assessment of the true relationships between risk factors and CHD 
risk is required.
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2.8 Social and geographic inequalities in C H D
Inequalities in the incidence of coronary heart disease in the United Kingdom have been 
observed for many years. In this section, social and geographic inequalities in CHD risk 
are described, with particular emphasis on why they occur, how large they are, and how 
they have influenced prevention strategies in the United Kingdom.
2.8.1 S ocioecon om ic inequalties  
W hat is socioeconom ic status?
In order to be able to interpret the meaning of social inequalities in CHD, one needs to 
first define what is meant by “socioeconomic position” or “socioeconomic status” (SES). 
The term “socioeconomic status” usually comprises of a variety of measures including 
level of education, income, occupation and living conditions. However, precisely what is 
meant by socioeconomic status has long been debated in the history of sociological theory, 
with approaches generally reflecting the orientation of either Weber437 or Marx.438 The 
Weberian approach of sociology sees social stratification as being organised around the 
three independent entities of economic interest, status and power. Under such an approach, 
subjective measures of status as well as more objective measures such as income and 
education will form the basis for a summary socioeconomic measure. Indeed many studies 
have emphasised the role of status (as recorded by job occupation) thereby preserving this 
historical basis. In comparison, the Marxist approach views socioeconomic status as the 
opposing interests of those who differ with respect to ownership of the means of production. 
To (over) simplify, individuals who differ in their roles in the production process are thought 
to be locked in conflict with each other. Though a large number of indices are available that 
combine these different aspects of SES,439’440 these summary measures can often result in 
difficulties over and above those of their individual components. Indeed, several reviews 
of SES and health have recommended that summary measures of socioeconomic status 
should not be used.439-441 Rather, epidemiological studies generally use single measures 
of SES as simple and convenient markers of the underlying socioeconomic factors. In this 
thesis, occupational social class (determined in the UK by the Registrar General’s six- 
category classification)442 is used as a simple measure of an individual’s position within 
the “socioeconomic spectrum” .
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R easons for social differences in CH D
Social inequalities in the incidence of coronary heart disease and stroke, with higher rates 
amongst lower SES groups, are well documented.34:362:443-445 However, in the United 
Kingdom, though absolute CHD rates have fallen during the last 20 years,446,447 the fall 
has been concentrated among higher social class groups so that the relative differences 
between those at the top and those at the bottom of the social scale have widened.54 This 
observation has led to considerable emphasis being placed in recent public health policies 
on reducing social class inequalities in CHD.54,-55
But why do these inequalities occur? Many studies have estimated the extent to which 
social inequalities in the development of atherosclerosis and CHD may be attributed to 
differences in the established risk factors, most of which have found this to provide only 
a partial explanation.362;448-451 Of the individual risk factors, cigarette smoking has often 
been found to provide the greatest explanation for social class inequalities in CHD, because 
it is both strongly correlated with social class (negatively) and because it is an important 
determinant of CHD risk.153;450;451 However, the failure of the established risk factors to 
entirely explain social class inequalities in CHD has prompted several authors to claim that 
other risk factors must be of critical importance in the causation of CHD.443 The Whitehall 
II study was designed with this question in mind, and in particular to explore the potential 
for psychosocial factors to act as mediators in the social class-CHD relationship361 (see 
section 2.5.5 for discussion of psychosocial factors and CHD risk). A further explanation 
for social inequalities in cardiovascular disease in adulthood may lie in the role of childhood 
socioeconomic circumstances. Numerous studies,169:362:377:390-394 though not all,395 have 
found an inverse relationship between adult height and cardiovascular mortality. This is 
consistent with the hypothesis that adverse environmental factors in early life may have 
a direct effect on the risk of cardiovascular disease in adulthood,377,-378:452-454 (though, as 
demonstrated by two reports from the same study reaching opposite conclusions,4555456 
this evidence is not entirely consistent).
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2 .8 .2  G eographic inequalities  
Differences betw een countries
Large international differences in the occurrence of CHD and stroke have been observed for 
many years. The Seven Countries study was one of the first studies to explore the reasons 
for these differences, with results indicating that many of the differences in CHD rates were 
likely to be due to differences in national diet, in particular the percentage of total energy 
intake derived from saturated fat. However, despite these findings, large international 
differences in the risk of CHD are still evident today. Recent data from the World Health 
Organization, for instance, revealed that the age standardised mortality rate of CHD and 
CVD in the Russian Federation was six times that in France.457 The same data showed 
how eastern European countries such as the Ukraine, the Russian Federation, Hungary, 
and the Czech Republic currently have among the highest CVD rates in the World and 
that, in contrast to most economically stable European countries, the rates of CHD in 
eastern European countries are increasing so that the differences between these countries 
and other European countries are likely to increase. Many of the differences in CHD 
and stroke rates between different European countries can be explained by differences in 
the classical risk factors,8 though it has been hypothesised that the French, who have 
very low CHD rates, may experience additional benefits due to a high consumption of 
wine.458 1 In comparison with European and American populations, CHD rates in Japan 
have traditionally been very low, probably due to low levels of serum total cholesterol 
resulting from a national diet low in saturated fat and cholesterol. Japan differs from 
most western countries in that stroke rates are higher than CHD mortality rates.460 This 
is thought to be due to a combination of low total cholesterol with high population levels 
of blood pressure and high cigarette smoking rates, the two main risk factors for stroke.
Differences within countries
In addition to differences in CHD between countries, many countries experience substantial 
risk differentials (albeit smaller ones) within their own population. In the United Kingdom
‘The low CHD rates in Prance are despite high smoking rates and a high population average blood 
cholesterol (the “French Paradox”). While this may partially be explained by a high consumption of wine, 
it may also reflect poor death certification in France or possibly the observation that cholesterol levels have 
only been high for a relatively short period of time (the “time-lag” effect).459 However since trial evidence 
strongly suggests that CHD risk is responsive to changes in blood cholesterol over a relatively short period 
of time, the latter explanation is becoming less and less likely.
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for instance, it is well established that the risk of CHD is higher in the North of England 
and Scotland than in the South of England461 (as illustrated in Figure 2.6). Similarly, 
the risk of CHD is higher in Southern and Eastern states of America than Northern and 
Western ones,462 higher in urban India compared with rural India,463 higher in northern 
China (Beijing) compared with southern China (Shanghai and Guangzhou),464 and higher 
in rural Australia compared with urban Australia.465 Various studies have demonstrated 
that geographic differences in CHD within a country are substantially, though not entirely, 
explained by geographic differences in the established risk factors.461’466-468
2.9 C onclusions
Observational and experimental studies have emphatically demonstrated the crucial role 
that blood lipids, blood pressure and cigarette smoking have in determining CHD risk, 
both in explaining the fundamental reasons for between population differences in CHD 
as well as predicting the risk of CHD within a population. Other risk factors for CHD 
including physical activity, obesity and diabetes have also been shown to greatly influence 
CHD risk in individuals, and though the consistency of findings regarding the protective 
effects of alcohol consumption strongly indicate a causal effect, the protective mechanisms 
are not yet entirely understood. There is a widespread belief however, that these risk 
factors only partially explain CHD risk. As a result, a vast number of new hypotheses 
have been suggested as playing important roles in CHD risk, though the evidence in 
favour of these hypotheses is variable. Despite some research indicating that the role 
of the established risk factors may have been underplayed, the effects of using baseline 
assessments of individuals in analyses (which leads to biased estimates of risk associations), 
has not been adequately addressed with regard to assessing their combined “importance” . 
Furthermore, strategies to prevent the occurrence of CHD in the population have not been 
formally compared in terms of assessing the impact that these sources of bias may have 
on the estimated effectiveness, or in taking account of advances in preventive therapies for 
CHD. Additionally, though inequalities in the incidence of CHD are recognised, several 
issues regarding their causes and their “real” importance remain unanswered. Important 
themes therefore need to be re-addressed: (1) what impact does within-person variation 
in the major risk factors have on their estimated relationships with CHD risk?; (2) what
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impact does this have on the estimated combined contribution of the major risk factors to 
population levels of disease, and what implications does this have for CHD prevention?; 
and (3) do these influences affect the estimated size of social class inequalities in CHD or 
the extent to which they may be attributed to differences in the established risk factors?
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Table 2.1: Primary findings of the six “statin” trials
Trial Study population Treatment Primary endpoint Risk
reduction
4S
(1994)
4444 men and women aged 
35-70 with history of CHD 
and TC 5.5-8.0 mmol/L
Simvastatin Total mortality 30% 
(15%,42%)
WOSCOPS
(1995)
6569 men aged 45-64 with 
no previous MI, 
average TC 7.0 mmol/L
Pravastatin CHD event inc­
luding silent MI
31% 
(17%,43%)
CARE
(1996)
4159 men and women aged 
21-75 with recent MI,
TC <  6.2 mmol/L
Pravastatin CHD event 24% 
(9%,36%)
LIPID
(1998)
9014 men and women aged 
31-75 with recent MI or 
unstable angina,
TC 4.0-7.0 mmol/L
Pravastatin CHD death 22% 
(13%,31%)
AFC APS/Tex 
CAPS (1998)
6605 men and women aged 
45-73 with no clinical 
CVD, average TC 5.7 mmol/L
Lovastatin CHD event or 
unstable angina
37% 
(15%,48%)
HPS
(2002)
20536 men and women aged 
40-80 with diagnosed CHD, 
other arterial disease, or 
diabetes, TC > 3 . 5  mmol/L
Simvastatin Total mortality 13% 
(6%,19%)
MI =  myocardial infarction, TC =  total cholesterol, CHD event =  Coronary death or non fatal 
MI, RR =  relative risk, Cl =  confidence interval, 4S =  Scandinavian Simvastatin Survival Study, 
WOSCOPS =  West of Scotland Coronary Prevention Study, CARE =  Cholesterol and Recurrent 
Events Trial, LIPID =  Long term Intervention with Pravastatin in Ischaemic Disease study, AF- 
CAPS/TexCAPS =  Air Force/Texas Coronary Atherosclerosis Prevention Study, HPS =  Heart 
Protection Study
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Figure 2.1: Incidence of ischaemic heart disease, age adjusted with 95% confidence inter­
vals, according to fifths of distribution of serum cholesterol concentration in the Multiple 
Risk Factor Intervention Trial. Figure amended and reproduced with permission from the 
BMJ Publishing Group (BMJ 2002 324: pp 1570 -  1576).
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Figure 2.2: Relationship between the CHD event rates in the five statin trials published 
before 1999 and the LDL cholesterol levels achieved in those studies (4S =  Scandinavian 
Simvastatin Survival Study; AFCAPS =  Air Force/Texas Coronary Atherosclerosis Pre­
vention Study; CARE — Cholesterol and Recurrent Events trial; LIPID =  Long-term 
Intervention with Pravastatin in Ischaemic Disease study; WOSCOPS =  West of Scotland 
Coronary Prevention Study). Figure reproduced from Ballantyne. Am J  Cardiol 1998, 
82: pp 3Q-12Q
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Figure 2.3: Ischaemic heart disease (IHD) mortality rate in each decade of age versus 
usual blood pressure at the start of that decade. Reprinted with permission from Elsevier 
( The Lancet 2002, 360: pp 1903-1913).
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Figure 2.4: Relation between odds ratio for cardiovascular mortality, and corresponding 
differences in systolic blood pressure observed in 27 randomised controlled trials of blood 
pressure lowering drugs. Reprinted with permission from Elsevier (The Lancet 1997, 358: 
pp 1305-1315).
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Figure 2.5: The high-risk approach (left) and the population approach (right) to the 
primary prevention of coronary heart disease
Risk level Risk level
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Figure 2.6: Age standardised CHD death rates per 100,000 population by local authority 
for men under 65, 1998/2000, United Kingdom. Figure reprinted from the 2003 edition of 
the British Heart Foundation Coronary Heart Disease Statistics database
Age-standardised 
death rates per 
100,000 by quintile
□  20.6 - 41.1 
3 412 - 50.7 
IH 50.8 - 57.7 
H  57.8 - 68.9 
B f l  69.0 - 136.7
Chapter 3
Statistical M ethods
3.1 Sum m ary
Numerous classical and regression based techniques are available with which the impor­
tance of a risk factor for CHD may be quantified. These methods are commonly employed 
to estimate the relative risk of CHD for one level of a risk factor relative to another. How­
ever, the relative risk of CHD (or other similar statistics such as the odds ratio or hazard 
ratio) does not allow the assessment of how removal of a high-risk exposure throughout 
a population would affect population levels of disease (for example, how removal of cigar 
rette smoking would affect CHD). Under such circumstances, the population attributable 
risk fraction (PARF) may be of more relevance, as it takes into account the proportion 
of the population “exposed” to the high-risk factor as well as the relative risk of disease. 
For continuous risk factors that are linearly related to disease risk however, the use of a 
“threshold” level to define “high-risk” is arbitrary, and so it may be necessary to consider 
the PARF as a function that varies with the threshold used to define the high-risk group. 
Regardless, these measures of “aetiological force” depend on accurate assessments of av­
erage exposure levels in individuals. However, within-person variation in coronary risk 
factors can lead to underestimation (or in some cases overestimation) of the assessments 
of risk associations, when these estimates are derived from single “baseline” measurements 
of study participants. Methods to estimate and correct for this bias are available however 
provided that repeated measurements of study participants are available.
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3.2 Introduction
In this chapter, the principles that underlie the key statistical analyses presented in this 
thesis are described. In particular, the effects of within-person variation in coronary 
risk factors on estimated associations with CHD risk are reviewed for both continuous 
risk factors (where the effects are usually referred to as “regression dilution bias”) and 
categorical factors (where the term “misclassification bias” is often used to describe the 
effects). In sections 3.3 and 3.4 of this chapter, the relative risk and population attributable 
risk fraction are defined and the range of different regression methods used throughout 
this thesis are described. In sections 3.5 and 3.6, the effects of within-person variation in 
continuous and categorical risk factors are described and methods to estimate and adjust 
for these effects reviewed. In section 3.7, these effects are discussed in the more general 
context of estimating risk-relationships after taking into account several coronary risk 
factors subject to within-person variation. Specific methods relevant to the analyses in 
this thesis are described separately in each of the results chapters 5 to 9.
3.3 M easures o f  association
3.3 .1  T h e rela tive  risk, th e  od d s ratio  and th e  hazard ratio
The most common measure of “aetiological force” used in epidemiology is the relative risk 
(RR), defined as the risk (or probability) of disease in one group of individuals divided by 
the risk of disease in another. The relative risk provides a simple means of summarising 
the relative differences in risk between two groups of individuals and, for this reason, is 
regularly used to quantify the “importance” of the characteristic (or group of character­
istics) that distinguish the first group from the second. However, in statistical analyses, 
it is more usual to consider the odds of disease in a particular group. This is defined as 
the number of diseased individuals in a group divided by the number of disease-free indi­
viduals in that group (rather than the total number as is used for the relative risk). The 
odds ratio (OR) is then defined as the odds of disease in one group divided by the odds of 
disease in another and is preferred in statistical analyses to the relative risk because it ex­
hibits certain “desirable” properties (specifically the sampling distribution of its (natural) 
logarithm is normally distributed) that allow it to be “modelled” in (logistic) regression 
analyses. However, it is noted that when the disease is rare, the odds ratio and the rela­
CHAPTER 3. STATISTICAL METHODS 90
tive risk do give similar estimates and it is perhaps for this reason that the two are often 
used interchangeably (usually the odds ratio is mistakenly referred to as the relative risk). 
The relative risk and odds ratio are not the only measures of relative differences between 
groups however. In time-to-event or survival analyses (see section 3.4.2), it is more usual 
to refer to a hazard ratio (HR), defined as the ratio of the “instantaneous hazard” in two 
groups. This measure takes into account the fact that disease events (failures) may occur 
at any point in time over a  particular follow-up period, and that information regarding 
the “importance” of a particular risk exposure are gained, not only from whether these 
events occur or not, but also from when the events occur.
3.3 .2  T h e p op u la tion  a ttr ib u tab le  risk fraction
For risk factors that are causally related to disease risk, the relative risk, odds ratio and 
hazard ratio all provide appropriate measures of its relative importance. However, they 
do not take into account the number of individuals in the population exposed to the risk 
factor of interest. Therefore, a high relative risk may not be indicative of a serious public 
health problem if the prevalence of the risk factor in the population is small, or if the 
disease is rare. In contrast, a causal factor with low relative risk may be important if a 
high proportion of the population is exposed to the factor and the disease is common. 
In this context, the population attributable risk fraction is a more useful measure of the 
public health importance of the risk factor since it takes into account both the proportion 
of the population exposed to the factor and the relative risk associated with the factor.
Levin’s population attributable risk
The population attributable risk fraction (PARF) is the proportion of all disease events 
in the population that could be eliminated if the high risk factor was not present. It can 
be calculated from the prevalence of the risk factor in the population (7r) and the relative 
risk of the exposed to the unexposed (RR) through Levin’s equation469
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If the risk factor is rare, so that 7r is close to zero, the PARF will be small even if the 
relative risk associated with the risk factor is large. This indicates that removal of the 
factor from the population would have only a small effect on population disease rates. 
When the prevalence of the risk factor is high however, the PARF will approach the value 
of the “relative risk reduction” (1 — 1 /RR),  experienced by individuals without the risk 
factor compared with individuals with the factor.
Levin’s measure of the population attributable risk fraction compares a low risk group 
with a single high risk group. Suppose however that the marginal contribution of several 
distinct high risk groups to the combined PARF was required. For instance, a high risk 
group containing all individuals with either ‘high’ total cholesterol or ‘high’ blood pressure 
could separated into three subgroups: those with high cholesterol only; those with high 
blood pressure only and those with both high cholesterol and high blood pressure. Through 
a simple extension to Levin’s equation, the separate contributions of these three high risk 
groups to the overall combined PARF of high blood cholesterol and high blood pressure 
can be calculated. Supposing that there are N  possible high-risk groups, the marginal 
PARF for the j th  high risk group is calculated by
7Tj(RRj 1)
PARF; =  . J-.N — -  (3-2)
where RRj  is the relative risk for the j t h  high-risk group compared with the reference 
(low-risk) group and 7Xj is the proportion of the population falling into the j th  high- 
risk group. The combined PARF is then simply calculated as the sum of the marginal 
contributions:
Zk=iMRRk-i)
i  +  £ E W « f l k - i )
PARF =  , (3-3)
3 .3 .3  T h e lo w -r isk  group and “P A R F  cu rves”
When estimating a population attributable risk fraction associated with one or more risk 
exposures, the choice of the low-risk (or reference) group is particularly important as it 
affects both of the measures used in its calculation: (1) the prevalence of the high-risk
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factor(s); and (2 ) the relative risk of disease between the high risk group and the low 
risk group. For categorical risk factors, the choice of the low risk group may be clear 
(e.g non-cigarette smokers as the low-risk group for smoking exposure), and under such 
circumstances, the PARF may be easily calculated (either through classical methods or 
through fitting a binary term in a generalised linear model), and easily interpreted (it is 
the reduction in disease that would be expected if nobody smoked cigarettes). However, 
for continuous risk exposures, in the absence of a “threshold” level above which risk is 
known to be uniformly elevated and below which risk is known to be constant, it becomes 
necessary to separate the low and high-risk groups based on an arbitrary cut-off level. In 
fact, when no “threshold” exposure level is present (for example when there is a log-linear 
relationship between the risk exposure and the odds of disease), it is more appropriate to 
consider the PARF as a smooth function of the cutoff used to calculate it (hereon referred 
to as a “PARF-curve”), rather than as a single true value.
3.4 R egression m ethods
Regression is used in epidemiological studies for two reasons: (1) to estimate the relation­
ship between one or more predictor variables and the risk of disease; and (2 ) to predict 
the probability of disease given the values of certain predictor variables. A regression 
model extends the boundaries achievable from univariate analyses by allowing multiple 
risk factors to be simultaneously related to the risk of disease, thus enabling the “indepen­
dent” contribution of separate risk factors to be assessed. Furthermore, regression models 
can easily identify whether certain risk factors are more or less important depending on 
the level of other factors (tests for interaction) and can be used to determine the “best” 
model given a wide range of potential factors. In this section, a brief review of regres­
sion models including generalised linear models (of which linear regression is the simplest) 
and “survival” regression models is presented. A complete discussion of regression based 
techniques may be found elsewhere. 470-473
3.4.1 G eneralised  linear m od els
Generalised linear models (GLMs) provide a method of simultaneously relating one or 
more predictor variables (which can be continuous and/or categorical) to a single outcome
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variable. In the case of linear least squares regression (the simplest GLM), variables are 
related to a continuous normally distributed outcome (such as blood pressure) through 
the equation:
Y  ~  X/3 (3.4)
where Y  is a vector of observed outcomes, X  is a “design matrix” of observed predictor 
variables and (3 is the vector of regression coefficients that show the strength of relation­
ship between the predictor variables and the outcome. When the outcome variable cannot 
be modelled as a linear function of the explanatory variables however (for example when 
the response data are not continuous), the generalised linear model assumes that some 
function of Y , rather than Y  itself, is linearly related to X/3. This function is known as 
the “link function” and provides a method of relating predictor variables to many different 
types of outcome data (not just normally distributed outcomes). For logistic regression, 
which allows predictor variables to be related to a single binary outcome, the usual (though 
not only) link function is the “logit” link defined as l(p) =  log(p/(l — p)), where p is the 
expected probability of the outcome. Logistic regression is commonly used in epidemi­
ological studies where the outcome of interest is the occurrence of a particular disease. 
However, a further class of regression methods (survival regression methods) extends this 
approach by considering the time until an event occurs as well as the occurrence of the 
event itself. These “time-to-event” or “survival” analyses are now described.
3.4 .2  Survival an alyses
Survival analyses differ from conventional regression methods in that both the occurrence 
(or not) of an event and the time until that event are taken into account, and it is for 
this reason that they have become the preferred method of analysis in many prospective 
epidemiological studies. Individuals who do not experience an event after a certain period 
of follow-up has elapsed or individuals who have otherwise been lost to follow-up during 
the follow-up period are said to be “censored” at the time they were last observed to be 
free from disease. Denoting the time until the first event by T, the time until censoring 
by U, and the occurrence of an event by an indicator variable S, the “survival function”,
CHAPTER 3. STATISTICAL METHODS 94
S(t), and the hazard function, h(t), are defined as follows:
S(t) = Pr ( T > t ) (3.5)
(3.6)
Parametric and N on—parametric estim ates o f the survival function
Survival analysis regression methods tend to be either parametric or non-parametric in 
nature. Parametric methods impose distributional assumptions on the form of the survival 
function and the hazard function. One such assumption which is widely used in parametric 
survival regression methods is the proportional hazards assumption. This assumes that 
the survival function and hazard function can be represented in the form
assumption is that relative differences in risk (hazard) between individuals remain constant 
over the period of follow-up. In contrast, non-parametric methods make no assumptions 
about the family of distributions that S(t) and h(t) can belong to.
Kaplan—Meier survival curves and the log—rank test
s ( t )  = s 0( t y
h(t) =  nfh0{t)
(3.7)
(3.8)
where 7  is a function of the predictor variables X/?, and So(t) and ho(t) are the baseline 
(average) survival and hazard functions respectively. The key to the proportional hazards
The most common non-parametric estimate of the survival function is the Kaplan-Meier 
(or product-limit) estimate , 474 defined as the product of survival probabilities
Sk m {£) = (3.9)
where U is the failure (event) time of the zth individual, r(ti) is the number of individuals 
“at risk” at U (after the failure of the ith  individual), and d(U) is the number of failures
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(events) observed up to and including U. The Kaplan-Meier estimate is usually shown 
graphically as a step function with a drop occurring at each event, though often, it is 
one minus the Kaplan-Meier estimate that is displayed in order to show the cumulative 
events rather than the survival probabilities. Differences in survival function between 
two or more Kaplan-Meier curves are usually assessed through the log-rank test. This 
non-parametric test tests the null hypothesis that the groups have the same survival 
distribution by analyzing and comparing the number of observed and expected events for 
each group each time an event occurs. Details on how the log-rank test is performed can 
be found elsewhere. 472
Semi—parametric Cox proportional hazards regression
Cox proportional hazards regression is probably the most widely used form of survival 
regression. The method is called “semi-parametric” because, while it makes the propor­
tional hazards assumption (see equations 3.7 and 3.8), with
7  =  exp(X/3) (3.10)
the baseline survival and hazard functions are computed directly from the data. Further­
more, the survival curves depend only on the ranks of the survival times not the times 
themselves (though the method remains sensitive to skewed covariates). The estimated 
regression coefficients from a Cox model are the logarithms of the hazard ratios associated 
with those variables, so by taking the exponential of the regression coefficients, estimates 
of the hazard ratios are obtained. Cox proportional hazards regression is often preferred 
to fully parametric methods of survival analysis (such as exponential or Weibull models) 
as it gives very efficient (hazard ratio) estimates compared with parametric proportional 
hazards models. The key assumption of the Cox model, namely the proportional hazards 
assumption, may be assessed through examination of a smoothed plot of the Schoenfeld 
residuals against time . 475
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Time dependent covariates
In certain circumstances, it may become necessary to fit “time-dependent covariates” :
(1 ) when the covariates themselves change over time (e.g. an individual may receive a 
coronary angioplasty during the period of follow-up which would greatly influence their 
subsequent risk of CHD); and (2) when the regression coefficients vary over time (for 
instance the influence of a risk factor may become more or less important as one gets 
older). When either, or both, of these are true, the proportional hazards assumption 
of the semi-parametric Cox model is violated and account needs to be taken of this 
“non-proportionality” in analyses. One way of doing this is to adopt the Cox regression 
approach using discrete time intervals for each individual. This approach is referred to 
as the Anderson-Gill approach476 (which views the “time to first event” as a Poisson 
process with a low rate). Each row corresponds to a different follow-up interval, with 
independence between rows for the same individual being guaranteed through the “lack 
at memory” property of the Poisson process.
3.4 .3  F loatin g  ab so lu te  risks
Risk estimates from epidemiological studies are usually presented in terms of relative risk 
with respect to a reference exposure level. However, when the categorical risk factor has 
more than two levels, the confidence intervals for the non-reference categories contain a 
common component of variance due to random variation in the reference category. This 
can make it difficult to interpret whether or not there are any real differences in relative 
risk between any two “non-reference” levels. One solution to this problem is to present the 
relative risks as “floating absolute risks” . 477 This does not alter their values but ascribes an 
appropriate variance to each group (rather than having variances for each group relative 
to one group that is arbitrarily chosen to have a relative risk of 1 and no associated 
error). This technique is particularly useful for graphical presentations, because it allows 
confidence intervals for the relative risk to be presented for all levels of the risk exposure, 
not just the non-reference levels. However, the use of floating absolute risks has proved 
controversial because of problems of interpretation . 478-482  In this thesis, floating absolute 
risks are therefore calculated for the purpose of displaying relative risks estimates in figures 
only, with tables displaying the “normal” confidence intervals for each level relative to the 
single reference category. The method used to calculate the floating absolute risks can be
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found in Easton and Peto . 477
3 .4 .4  R e -sa m p lin g  techn iques  
The jack-knife technique
When both estimation of risk associations and prediction of absolute risk are required from 
a single sample of data, it is usual to partition the data into two groups: a “training” group 
that is used to estimate regression parameters (to build the model); and a “prediction” 
group that is used to predict risks. The reason for this is that if the same sample were 
used in both steps (i.e. if the linear predictor were applied to the same sample from which 
it was derived) then it is well known that the predicted risks would be biased, leading to 
over-estimation of true risk differentials in the population . 483’484 However, partitioning 
the sample into a training group and a prediction group can lead to a loss of information 
both in the estimation of the regression coefficients and prediction of event risks, and may 
even lead to other sources of bias being introduced. An alternative method of estimation 
and prediction that uses all the data is provided by the “jack-knife” technique. 485 This 
method predicts the risk of failure for the ith  individual from regression coefficients &\-i] 
derived from the regression model that includes all subjects except the ith. Though this 
method of prediction is computationally intensive (N  different regression procedures, each 
of which are based on N  — 1 individuals, need to be fitted), the “jack-knife” predicted 
risks {p[i], • • •, P[n\} are both unbiased and efficient, and provide a valuable method of both 
estimating associations and predicting disease risks from a single sample.
Bootstrap resampling and bias-corrected percentiles
Bootstrap resampling is a method for statistical inference often used to estimate standard 
errors and confidence intervals for statistics when the sampling distribution of that star 
tistic is not known. For instance, suppose that independent and identically distributed 
observations X{, i = 1, . . .  ,n  are observed, and that one wishes to estimate a parameter 
that can be defined as some function 0 = T{x) of the values in the population, which is 
estimated from the data by the statistic 0 = T (X ) .  Providing that the observed data are 
representative of the underlying data, bootstrap resampling may be used to empirically 
approximate the unknown cumulative distribution function of 0. This is done by repeat­
edly sampling (with replacement) from the data to obtain a large number (m) of bootstrap
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replicate data sets (at least 1 0 0 0  replications is usually recommended), and then evaluat­
ing the function for each replicate to give a set of bootstrap values {Of}, i = 1 , . . .  ,ra. 
The empirical distribution of these bootstrap values Fb(X) approximates the theoretical 
sampling distribution Fq(x ). Therefore, approximate 100(1 — a)% confidence intervals for 
6 may be obtained by taking the a /2  and 1 — a /2  quantiles of Ff,(X) as the lower and 
upper limits. 473 When the sample size is not very large however, the empirical percentiles 
of Fb(X) may not be very accurate. One method of adjusting for this is to calculate bias 
corrected percentiles, which take into account any differences between the estimate of the 
statistic from the original data (0) and the median of the estimated values from the boot­
strap sample {0 f} -473 This provides an improved estimate of the percentiles over the raw 
(observed) bootstrap percentiles.
3.5 W ith in -p erson  variability in continuous risk factors
3.5.1 In trodu ction
In order to describe the effects of within-person variation in continuous coronary risk fac­
tors on estimated disease relationships, the differences between an individual’s “baseline” 
risk factor level and an individual’s “true” or “usual” level over a period of time need to 
be defined. The “baseline” risk factor level is simply the level that is measured at a single 
point in time (usually at the start of a prospective study). In contrast, the true or usual 
measurement level is the “long-term” or average risk exposure level for that individual 
over a certain period of time. For each person in a prospective study, this period will 
be defined as the interval over which the individual is “at risk” of CHD. In prospective 
studies of cardiovascular disease, it is the relationship between these usual or long-term 
risk factor levels and disease risk that is truly of interest. In practice, the accepted method 
of estimating these relationships is to use baseline levels as estimates of usual levels, and 
to perform analyses that examine the relationships between these levels and the risk of 
disease over the following period. However, baseline measurements of risk factors may 
differ from usual levels for a number of reasons:
1. Random measurement error, due to one or more of laboratory error, observer error 
or subject-recall error.
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2. Short-term but true deviations from an individual’s usual level. For example, an 
individual’s usual heart rate in any one day would be unlikely to be estimated ap­
propriately if measured immediately after vigorous exercise, as the rate would be 
temporarily high.
3. Long-term changes in an individual’s risk factor level.
These collective influences are hereon referred to as sources of “within-person” variation. 
In order to describe the effects that within-person variation can have on the assessment 
of true relationships between risk factors and disease risk, it is helpful to introduce the 
following simple notation for the case of a single continuous risk factor subject to within- 
person variation. Consider a prospective study consisting of N  individuals, whose observed 
baseline risk factor levels are denoted by {rri,. . .  ,xjv}- For each individual, the observed 
baseline level X{ may be assumed to be related to an unobserved usual value Zi through 
the equation
Xi = Zi+£i (3.11)
where £* is random within-person variation having mean zero. Furthermore, let the mean 
exposure level in the population be fi = E\zi\, the true between-person variance be a 2 — 
Var(zi) and the within-person variance be r 2 =  Var(ej), and assume that within-subject 
variation is independent of the true measurement level so that the variance of the observed 
measurement level is Var(xj) =  cr2-f r 2. Finally, denote the intraclass correlation coefficient 
(the ratio of the true between-person variance to the observed variance) by:
A =  - £ - 2  (3.12)
< J Z  - f
3.5 .2  R egression  d ilu tion  bias
In order to assess the influence of Zi on another normally distributed variable yi, the usual 
approach would be to perform a least squares linear regression analysis with Z{ as the 
predictor variable as follows:
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yi =  (** +  where Si ~  N(0,<p2) (3.13)
However, as Zi is not actually observed, it is usually replace by its “baseline” estimate X{. 
Providing that z*, £{ and Si are independently distributed it is known that the regression 
of yi on Xi is linear as follows:
yi =  a  +  pXi 4- 7i, where 7 * ~  N(0, ip2) (3.14)
where
(3 =  /TA (3.15)
Therefore, by regressing yi on the baseline levels Xi rather than the true average levels 
zi, the estimated “baseline” regression coefficient (3 underestimates the true regression 
coefficient (3* by a factor equal to 1/A. This bias has long been recognised in linear 
regression, 486-488  and has also been shown to occur with logistic regression16’489 and also 
Cox proportional hazards regression. 490’491 In the case of a single continuous risk factor, 
provided that the random within-person variation £* is unbiased and independent of the 
underlying usual value and of the response variable, the regression coefficient is always 
underestimated. This phenomenon is therefore often referred to as “regression dilution 
bias” , while the correction factor A is known as the “regression dilution ratio” , 17 a term 
used throughout this thesis.
Regression dilution bias and the null hypothesis
Within-person variation results in underestimation of a  risk factor’s association with dis­
ease risk. However it is important to note that, under the assumptions stated in sec­
tion 3.5.1, correction for within-person variation should not affect the statistical sig­
nificance of a risk factor’s association. The reason for this is that the null hypotheses 
Hq : (3* =  0  and Hq : (3 = 0  are equivalent and so they should have the same rejection
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regions. Confidence intervals for adjusted regression coefficients should therefore preserve 
the significance (or lack of significance) of the observed baseline association.
3 .5 .3  E stim a tin g  th e  regression  d ilu tion  ratio
In order to adjust for the effects of regression dilution bias, information regarding the 
regression dilution ratio A is required. This can most easily be estimated from repeated 
measurements of risk factors, and a variety of methods are available for its estimation . 20 
A brief review of some of the main methods is now provided. For each of these methods it 
is assumed that X{j represents the jth. repeat measurement for the ith  individual. Further­
more, it is assumed that individuals with repeated measurements are either separate from 
the main study used to estimate /?, or else form a small subset of the main study (so that 
the estimates of (3 and A are essentially independent). If the data are from an independent 
source then it is important that they are also representative of the population under study. 
The descriptions that follow are based on the situation where two observed measurements 
are available for each individual (the “baseline” and “follow-up” measurements), which 
are denoted by {rrn, . . . ,  arjvi} and {x\2 , • • •, £N2 } respectively. A complete review of the 
various methods available to estimate A, as well as a discussion of their relative efficiency, 
is provided elsewhere. 20
M acM ahon’s non—parametric m ethod
This method was developed by MacMahon et al.17 to correct for the effects of within- 
person variation in a baseline blood pressure measurement when estimating the subsequent 
relationship with the risk of stroke and coronary heart disease. The method divides the 
baseline sample into equal groups (usually fifths) and uses the fact that for each group the 
mean follow-up measurement x k2 (k = 1, . . . ,  5) is an unbiased estimate of the true mean 
follow up level z k. The correction factor A can therefore be estimated by comparing the 
range in means at follow-up with the range at baseline as follows:
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The method is appealing because it shows how the regression dilution bias may be thought
treme values are, on average, more extreme than their true underlying values. However, 
MacMahon’s method has several flaws. First, the choice of five groups is arbitrary: re­
peating the analysis with divisions based on quartiles or deciles would be equally valid
top and bottom categories only, the information provided by the middle three categories 
is lost. Though this could be overcome by using regression to estimate the slope of the 
relationship between the baseline group means and the follow-up group means, the logical 
extension of this (whereby individual data is used, rather than group means) forms the 
basis for the following method.
Rosner’s regression m ethod
MacMahon’s method uses the fact that, conditional on xn , Xi2  is an unbiased estimate of 
Zi, and so the relationship between Xi2  and xn  can be used to estimate A. This principle 
also underlies the regression method proposed by Rosner et al. 16 Consider the special case 
of equation 3.13 where yi =  2^2 - It follows that ft* = 1 because the observed follow-up 
measurements 2^2 deviate from the true levels Z{ only by random within-person variation. 
Therefore the regression relationship between 2^2 and xn  is:
and hence an unbiased estimate of A can be obtained from the usual least squares regression 
slope
of as a result of “regression to the mean”, the phenomenon that reflects the fact that ex-
but would lead to different estimates in practice. Second, by using the mean levels in the
x i2 =  a  +  \ x i i + ' y i , where 7 * rsj N(0,ip2)
(3.17)
Confidence intervals for A r e g  can be calculated using the usual formulae for least squares 
regression.
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C orrela tion  coefficient m ethods
The “regression-based” methods considered so far depend only on the ordering of the base­
line and follow-up measurements (and for Rosner’s method also that the usual assumptions 
of linear regression are satisfied). However, if the baseline and follow-up samples have the 
same distributional assumptions then the decision to regress the second measurement on 
the first is arbitrary and an equally valid correction factor would be obtained by regressing 
the first on the second. Since the correlation coefficient is the geometric mean of these 
two coefficients, the correction factor could also be estimated as:
This is because the (product moment) correlation coefficient above has very similar prop­
erties to the intraclass correlation coefficient (in fact, it is the same when each pair of 
observations axe counted twice, the second time in reverse) . 492
3 .5 .4  C orrection  for regression  d ilu tion  bias
Equation 3.15 illustrates that in order to correct for regression dilution bias in a single 
continuous risk exposure, one simply needs to divide the observed association (3 by the 
estimate of the regression dilution ratio. An equivalent method of estimating the true 
coefficient (3* is obtained by “shrinking the data towards the mean” by calculating the 
conditional expectation of Zi given which, under the assumptions of section 3.5.1 is 
equal, to
(3* may then be estimated as the coefficient obtained through the regression of yi on Wi 
as follows:
E O ^l ~ Xj\)(Xi2  -  x i2) (3.18)
Wi  - E[zi I Xi ]  — ft +  A ( X i  -  ft) (3.19)
Vi — ot A (3* Wi -t- 6i, where 6i ~  N (0, rj2) (3.20)
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It can easily be shown that this “regression calibrated” coefficient /?' is exactly the same 
as P* obtained through equation 3.15. One advantage of using this approach in practice 
is that there is no restriction on the form that the relationship between the observed 
baseline level Xi and the expected true usual level Wi may take. In particular, the func­
tional relationship described in section 3.5.1 may be extended to allow for “higher-order 
relationships” (e.g a quadratic relationship) between the baseline level and the expected 
usual level. This technique was utilized in the analyses of the influence of blood pressure 
on vascular disease risk performed by the Prospective Studies Collaboration in 2002, 113 
where the authors estimated that the relationship between baseline blood pressure x  and 
the usual blood pressure 3.4 years later F  was quadratic,
F  = 145.9 +  0.669(a: -  150) -  0.0017(x -  150)2
3.6 W ith in -p erson  variability in categorical risk factors
3.6.1 In trodu ction
Categorical risk factors (such as cigarette smoking) are equally susceptible to the effects 
of within-person variation as continuous risk factors. In the past, many researchers have 
addressed the effects of within-person variation for categorical risk factors in terms of 
estimating the extent and effects of “misclassification” of exposure. 22_24;493 However, the 
term “misclassification” is generally used to describe only the “random error” component 
of within-person variation, and not the other components described in section 3.5.1. In 
this thesis, the definition of misclassification is extended to include changes in risk factor 
level as well as random error in risk factor assessment. A review of the established methods 
for correcting for within-person variation (“misclassification”) in categorical risk factors 
is now provided.
3.6 .2  “M isclassifica tion ” o f  a  s in g le  d ich o tom ou s risk factor
In the simplest case of a dichotomous (binary) risk factor, the likelihood of an individual 
being “misclassified” based on a baseline screening is usually defined in terms of “sensi­
tivity” and “specificity” :
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Sensitivity =  Pr(Subject observed to have the risk factor when they truly do) 
Specificity =  Pr(Subject not observed to have the risk factor when they truly don’t)
If the risk factor is recorded without error then both the sensitivity and the specificity 
are equal to 1. However when one or more of the sensitivity and specificity are less 
than one, observed associations between the risk factor and disease risk underestimate the 
true associations (as for single continuous risk factors). In the special case whereby the 
probability of a false positive (1  - specificity) is equal to the probability of a false negative 
(1  - sensitivity), it can be shown that the overall probability of being classified correctly, 
denoted by a , may be estimated from repeated data through the equation
1 1 /JV — 2 n \ 1 /2
2 2V N J  (3-21)
where N  individuals are measured twice and there are n  disagreements between the first 
and second measurements. 23 This estimate of the likelihood that the information provided 
by a baseline assessment of a binary risk factor is “correct” allows associations between 
the risk factor and the occurrence of disease to be adjusted. Denoting the log odds of 
disease (equivalently the log hazard) obtained from the use of baseline data in analyses by 
P, the true log odds ratio /3* may be estimated by
r  = x b i <3-22>
3 .6 .3  C ategorica l factors w ith  m ore th a n  tw o  levels
The method of correcting an association for misclassification of a binary risk factor is not 
easily generalisable to the case of categorical factors that have more than two exposure 
levels. In this section, two methods of talcing into account within-person variation in 
categorical factors that have more than two levels are described (note that these methods 
are also equally appropriate for continuous factors). These approaches differ from the
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methods so fax described for dealing with within-person variation in a single continuous 
risk factor in that the effect of the adjustment on the estimated disease relationship can­
not necessarily be predicted. The goal of these methods is to use information obtained 
from repeated risk factor measurements to derive exposure levels that are in some way 
“superior” at predicting disease risk than baseline exposures alone. For each of the meth­
ods described, it is assumed that repeated follow-up measurements of the risk factor are 
available at various points over the study period.
Fitting tim e updated effects
As described in section 3.4.2, repeated measurements of an individual’s risk factors during 
a study may be taken into account in a survival analysis by fitting “time-updated covari- 
ates” . An example of where it may be of particular interest to fit such effects would be in 
an assessment of the effects of cigarette smoking on long-term disease risk. A prospective 
study may compare the incident disease rates between those who were active smokers at 
baseline with those who who non- or ex-smokers at baseline, however these risk differences 
may not truly quantify the risks from continual smoking if a substantial number of active 
smokers quit during the study (as these individuals may have been more likely to develop 
the disease if they continued). However, if it were known at what point the individuals 
gave up smoking, then providing that this was before they developed disease (i.e. while they 
were still “at risk”), a time updated effect could be included which would automatically 
“switch” individuals from “current smokers” to “ex-smokers” at the appropriate time. In 
this way, the effects of continual smoking on disease risk throughout the study could truly 
be evaluated. This approach would not estimate the effect on disease risk of giving up 
smoking, but it would take into account the fact that this occurs when making estimates 
of the effects of continual current smoking. The method is generalisable to known changes 
in any risk factor (not just categorical factors), but does require knowledge of how much 
and, more importantly, when these changes occur.
Cumulative “average” exposures
If frequent repeated measurements of risk factors are available during the study period 
then, rather than using the baseline risk level in analyses, one could use the cumulative 
average exposure to that factor over the study period. For instance, if blood pressure
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were recorded every week throughout a prospective study then, for each individual, the 
average blood pressure per week “at risk” could be evaluated and related to disease risk in 
preference to the baseline measure. This is likely to provide a blood pressure assessment 
that is substantially nearer the true long-term average blood pressure for that individual 
than their baseline level. This method of using “cumulative” exposures may be generalised 
to categorical exposures, particularly ordinal categorical variables. In chapter 5 of this 
thesis, this “averaging approach” to risk factor assessment is applied to physical activity 
level and alcohol intake (which are defined an ordinal variables: none, occasional, light, 
etc.) and is also applied to the assessment of the average number of cigarettes smoked 
“per day at risk of CHD” for individuals defined as current smokers at baseline.
3.7 M ultivariate correction for w ith in -p erson  variation
3.7.1 In trodu ction
The methods described in sections 3.5 and 3.6 use information from repeated measure­
ments of risk factors to help better determine relationships between “usual” risk factor 
levels during the study and disease risk over the same period. In the case of a single 
continuous risk factor linearly associated with disease risk, it was shown how the risk of 
disease is underestimated when single baseline measures are used in analyses. However, 
when one or more covariates are subject to within-person variation, it does not necessar­
ily follow that multivariate relationships are underestimated to the same degree as would 
be estimated when considering them in isolation. Indeed, it has been shown that under 
such circumstances observed regression coefficients may either under or overestimate true 
regression coefficients, 26:27 particularly if the variables are highly correlated . 27 Further­
more, risk relationships for other factors, even those with no within-person variation may 
be inaccurately assessed. In this section, a review of the methods for correcting for within- 
person variation in multiple covariates is provided. A more detailed description of these 
methods may be found in Rosner et al. 26
3.7 .2  R o sn er’s m u ltivaria te  correction  m eth o d
Rosner’s multivariate correction method generalises the method described in section 3.5.2 
where the effects of within-person variation in a single continuous risk factor were con­
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sidered. Comparable notation to that used in section 3.5.2 is used now to describe the 
multivariate method.
Let X  be a k\ x 1 vector of observed normally distributed exposure variables subject 
to within-person variation and Z  be the associated k\ x 1 vector of true observations. 
Furthermore, define U to be a fc2 x 1 vector of exposure variables (continuous or categorical) 
that are not subject to within-person variation, and P  to be probability of a particular 
dichotomous disease outcome D. We suppose that the probability of disease is related to 
the true risk exposure variables Z  and U through the vectors of true regression coefficients 
P*^ and P*2^  in the following (logistic) regression model:
l n ( Tf Z j  =  c f  + p f a z  + Fm u
and that the probability of disease is related to the observed risk exposure variables X  
and U through the vectors of observed regression coefficients P ^  and P^) yia
I n ( j ^ p )  = a + PmX + f a U
Now define the vector of true regression coefficients by B* =  (P(iyP(2)) (where P*^ is the 
vector corresponding to the true log odds ratios of D on Z  (after controlling for U) and 
P*2j is the vector corresponding to the true log odds ratios of D on U (after controlling for 
Z)), and suppose that in addition to having information on the observed exposure levels 
X  and U, an external sample of repeated measurements of Z  (denoted by X \  and X<i for 
the first and second measurements), as well as a corresponding sample of U , are available. 
Defining A(^ and A(2) to be the k\ x k\ and k\ x fc2 matrices of regression coefficients 
obtained through the multivariate linear regression of X 2 on X \  and U obtained from the 
model
X 2 — ot 4- A(i)A!d +  \ 2 )U +  e (3.23)
where a' is a vector of intercept terms and e is an error vector vector which follows a
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multivariate normal distribution, the true regression coefficients B* may be estimated 
from the observed regression coefficients B =  (/3(i),/5(2)) through the equation
B* =  B A 1 (3.24)
where
A(i) A(2)
0&2 x k i  ^ k 2  x k 2
This method leads to approximately unbiased estimate of B providing that the conditional 
distribution of the true exposure Z  on the observed exposures (X  and U) is the same for 
the main and external study data and also that the distribution of the observed exposure 
X  given the true exposure Z  is the same for both diseased and non-diseased subjects.
3.8 Overview
This chapter provides an overview of the statistics commonly used to quantify a risk fac­
tor’s importance, reviews some of the main regression methods employed in analyses of 
prospective studies, and provides an overview of the effects that within-person variation 
in risk factors can have on estimated disease relationships (both in a univariate and a mul­
tivariate setting) as well as the methods with which one may take account of these effects. 
In particular, it is noted that within-person variation in continuous risk factors tends to 
lead to underestimation of a risk factor’s importance (regression dilution bias) when these 
estimates are derived from baseline risk factor levels. Similarly, for binary risk factors, 
misclassification of exposure can lead to underestimation of the true risks associated with 
the factor. Established methods to correct for these effects are available provided that 
repeated risk factor measurements are available. Methods to take into account within- 
person variation in categorical exposures with more than two levels are also available. 
When multiple risk factors subject to within-person variation are related simultaneously 
to disease risk however, estimated baseline associations may under or overestimate true 
disease relationships. Under such circumstances, extra care should be taken to explore the
(3.25)
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nature and effect of the correlation structure between the variables.
Chapter 4
The British Regional Heart Study
4.1 Sum m ary
The British Regional Heart Study (BRHS) is a prospective study of cardiovascular disease 
in one General Practice in each of 24 British towns. Between 1978 and 1980, 7,735 men 
aged 40-59 years were recruited into the study (78% response). These men were represen­
tative of all middle-aged British men in terms of social class and were representative of all 
major regions at that time. Since the baseline assessment, surviving men have attended 
for follow-up examinations after approximately 16 years (in two towns only) and after 2 0  
years (in all towns). Postal follow-up questionnaires, sent to study participants in 1983- 
85, 1992, 1996 and 1998-2000, and completed by a high percentage of participants, have 
provided information on lifestyle risk factor changes and medication use over the entire 
follow-up period. Major coronary heart disease events including non-fatal myocardial 
infarction and deaths from coronary heart disease have been ascertained from a combina­
tion of National Health Service central registers and two yearly reviews of General Practice 
records. The British Regional Heart Study has obtained high participant response rates 
throughout its history and losses to follow-up have been minimal. In this chapter, a broad 
overview of the design and methods of the BRHS is provided; more specific details perti­
nent to the work in this thesis are described in the relevant results chapters. In addition, 
descriptive statistics for the number and causes of death observed after twenty years of 
follow-up are provided.
Ill
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4.2 Background
4.2 .1  A im s
The British Regional Heart Study61 was established in 1978 to determine: (i) the oc­
currence, natural history and management of cardiovascular disease in British men; (ii) 
the individual determinants of cardiovascular disease; and (iii) the factors responsible for 
the considerable geographic variations in cardiovascular mortality in Great Britain. The 
first phase of the BRHS was an ecological study which examined cardiovascular and other 
mortality over a five year period around the 1971 census from 253 towns in England, Scot­
land and Wales. 494 The original study hypothesis was that factors operating at a town 
level such as water hardness, climate and air pollution may have been responsible for the 
variations in disease observed between different towns across Great Britain. Twenty four 
of these towns subsequently formed the basis of the prospective phase of the BRHS, the 
selection process for which is described below.
4 .2 .2  S election  o f  stu d y  tow ns
Study towns were selected according to the following general principles: (i) they repre­
sented all standard regions in Great Britain; (ii) each town had a population at the 1971 
census between 50,000 and 100,000 and was separate from major conurbations; (iii) geo­
graphic variations in cardiovascular mortality and water hardness were represented; (iv) 
the towns were representative of the region in terms of socio-economic factors; (v) towns 
with recent large housing developments, noticeable population movement (migration) or 
unusual population structures were excluded; and (vi) the towns should include some 
of the towns that were ‘outliers’ when mortality from cardiovascular disease was plotted 
against water hardness (e.g. Hartlepool, Exeter and Harrogate). Towns that met these 
general criteria were randomly selected for inclusion into the prospective phase of the 
BRHS. In order to provide strong geographic representation, the size criteria was relaxed 
in specific cases -  those of Ipswich, whose population was 122,700 at the 1971 census, 
and the Scottish towns of Dunfermline, Ayr and Falkirk, whose populations were below 
50,000. The 24 towns selected for participation in the main study are shown in figure 4.1 
and table 4.1.
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4 .2 .3  S election  o f general practices
In order to increase the likelihood of a good initial response and good follow-up rates, as 
well as to facilitate the organisation and administration of the field work, it was decided 
that study participants would be recruited from one group practice in each town. The 
criteria for choosing the practice included its size (over 7,500 patients and two or more 
general practitioners) and its representativeness of the socio-economic profile of the town 
population. Potential practices were then sent information about the study and asked 
about their interest and willingness to participate. After visiting each practice, one group 
practice from each town was invited to participate in the study. If no age and sex register 
existed for the practice, one was prepared by the study team. This was required for 19 of 
the 24 practices.
4 .2 .4  S election  o f  stu d y  participants
Prom the age and sex register of each practice, 450 men aged 40-59 stratified by 5-year 
age groups were selected at random. Individuals for whom it was felt (by the general 
practitioner) that they would be unable to participate due to severe mental or physical 
disability were excluded. It was emphasised that men with cardiovascular disease should 
not be excluded unless there was another reason to do so. Exclusions accounted for some 
6  to 10 men per practice. The remaining subjects were invited to participate in the study 
in a letter signed by the practice doctors. Response rates were high, ranging from 70% to 
85% between the different towns (see Table 4.1).
4.3 B aseline exam ination
The baseline assessment of study participants took place between January 1978 and June 
1980. A team of three nurses visited each town in turn. The assessment consisted of: (i) an 
administered questionnaire; (ii) physical measurements; (iii) a resting electrocardiogram 
(ECG); and (iv) a blood sample. The nurses were trained in order to standardize proce­
dures, including administering the questionnaire, before the study and at regular intervals 
throughout the period of baseline data collection. A summary of the main methods used 
at the baseline examination is shown in Table 4.2, a detailed description of which now 
follows.
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4.3 .1  Q uestionnaire
The baseline questionnaire (shown in Appendix B) was administered at the screening site 
by one of the nurses. The questionnaire covered demographic details, family history, socio­
economic details, cardiovascular and respiratory symptoms, medical history and lifestyle 
risk factors. The areas of the questionnaire particularly relevant to the work in this thesis 
are summarised below:
1. C hest pain: The World Health Organisation (WHO) Rose chest pain questionnaire 
was used with some modifications to assess presence and intensity of current angina 
symptoms. The modifications included a reordering of the questions:
(a) use of the present tense rather than the past tense (i.e. “Have you ever had 
any pain...” , was replaced with, “Do you ever have any pain...” ),
(b) inclusion of two additional questions eliciting frequency of occurrence of chest 
pain, and
(c) rephrasing of the two exertion questions (subjects were asked whether walking 
or hurrying ‘produced’ the chest pain rather than simply whether they got chest 
pain when walking or hurrying).
Current chest pain was categorised as: (i) no chest pain; (ii) non-exertional chest 
pain, defined as chest pain not brought on by walking or hurrying; and (iii) angina, 
defined as chest pain brought on either by walking uphill or hurrying, or by walking 
at an ordinary pace on the level. The latter group was subdefined as definite angina 
if the pain caused the subject to stop or slow down in response to the pain, if the 
pain was relieved on stopping, if relief occurred within 1 0  minutes and if the site of 
the pain included the sternum or left anterior chest (sites 4, 5 or 8  in Figure 4.2), and 
as possible angina if a t least one of these criteria was satisfied. In addition, definite 
and possible angina were classified as grade I  if the chest pain was brought on only 
by walking uphill or hurrying, and as grade II  if it was brought on by walking at an 
ordinary pace on the level.
2 . Severe chest pain: Analysis of a separate question together with a ‘site of pain’ 
diagram allowed further assessment of possible myocardial infarctions. This was 
defined as severe chest pain lasting half an hour or more, situated in the sternum
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or left anterior chest (sites 4, 5 or 8  in Figure 4.2), that caused the participant to 
consult a doctor.
3. Recall o f d o c to r diagnoses: Participants were asked about whether they had ever 
been told by a doctor that they had had (among other things): angina, a heart attack 
(with alternatives of ‘myocardial infarction’ and ‘coronary thrombosis’), a stroke or 
diabetes. Recall of a diagnosis of either angina or a heart attack was subsequently 
defined as recall of doctor diagnosed CHD.
4. C u rren t tre a tm e n t: The men were asked which treatments they were currently 
taking that were prescribed by a doctor. These included specific questions on the 
use of blood pressure lowering and lipid lowering drugs.
5. Social class and  geographic region: Men were asked about their longest held 
occupation in terms of type, designation and status. On the basis of this, social class 
was determined using the Registrar General’s classification (I, II, IIINM, HIM, IV, V 
or Armed Forces; see Table 4.3) . 495 Men not in the armed forces were subsequently 
classified as non-manual (I, II and IIINM) or manual (IIIM, IV and V). Geographic 
region was also defined according to study town, and grouped as: (i) Scotland; (ii) 
northern England; (iii) Midlands and Wales; and (iv) southern England . 496 These 
regions are shown in Figure 4.1.
6 . Lifestyle risk  factors: Cigarette sm oking s ta tus , defined as current smokers, 
ex-smokers or non smokers, was ascertained from an adapted form of a smoking 
questionnaire developed in 1970 by the Medical Research Council Social Medicine 
Unit, London School of Hygiene and Tropical Medicine. Those who smoked less 
than 1 cigarette per day were classified as non-smokers (or ex-smokers if they had 
previously regularly smoked more than 1 cigarette per day). Alcohol intake  was 
ascertained from questions inquiring about frequency, quantity and type of alcoholic 
beverage consumed, and was categorised into eight groups: (1 ) lifetime tee-totallers;
(2) one to two times a month or on special occasions; (3) weekend drinkers (one to 
two drinks per day); (4) weekend drinkers (three to six drinks per day); (5) weekend 
drinkers (more than six drinks per day); (6 ) daily drinkers (one to two drinks per 
day); (7) daily drinkers (three to six drinks per day); and (8 ) daily drinkers (more 
than six drinks per day). These categories were then re-classified into the following
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five groups: (i) lifetime tee-totallers (1  above); (ii) occasional drinkers ( 2  above); 
(iii) light drinkers (3, 4 or 6  above); (iv) moderate drinkers (5 and 7 above); and
(v) heavy drinkers ( 8  above). Physical activ ity  during work and leisure time was 
assessed by a number of questions regarding regular walking or cycling, recreational 
activity and sporting activity. Based on the frequency and type of activity, a physical 
activity score was derived for each man , 193 from which a six-level index was created: 
(i) inactive; (ii) occasional (regular walking or recreational activity); (iii) light (more 
frequent recreational activities or vigorous less than once a week); (iv) moderate 
(cycling, very frequent recreational activities or sporting activity once a week); (v) 
moderately vigorous (sporting activity at least once a week or frequent cycling, plus 
frequent recreational activities or walking, or frequent sporting activity only); and
(vi) vigorous (very frequent sporting exercise or frequent sporting exercise plus other 
recreational activities). Baseline lifestyle characteristics by study town are shown in 
Table 4.4.
4.3 .2  P h ysica l exam in ation
Height was measured without shoes using a Harpenden Stadiometer with digital meter 
which recorded to the nearest millimetre. Weight in trousers and socks was measured 
to the nearest 0.1 kg using an MPS110 filed survey scale (beam balance). Body mass 
index (BMI) was subsequently calculated as weight in kilograms divided by height in 
metres squared (kg/m2). Blood pressure was measured twice in succession in the right 
arm, with the subject seated and the arm supported, using the London School of Hy­
giene and Tropical Medicine sphygmomanometer. Diastolic blood pressure was recorded 
at the disappearance of Korotkoff sounds (phase V). Blood pressure readings were sub­
sequently adjusted for observer variation within each town497 and the mean of the two 
blood pressure measurements on each individual was used in analyses. Lung function was 
measured using a Vitalograph spirometer; forced expiratory volume in one second (FEV1) 
was subsequently standardised for height. Baseline physical measurements by study town 
are shown in Table 4.4.
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4.3 .3  E lectrocard iogram  (E C G )
A resting electrocardiogram was recorded on computer tape using the three-lead orthogo­
nal system498 and viewed on an oscilloscope for any major abnormalities. The completed 
tapes for each town were analysed by computer in the Department of Medical Cardiology 
in Glasgow. On the occasions where technical problems occurred, 12-lead electrocardio­
grams were recorded on a Hewlett-Packard (1515-B) machine and sent for analysis. The 
validity of using the three-lead system and the interpretation of results have been pre­
viously reported . 499’500 Ischaemic abnormalities were classified into one of four groups. 
Definite MI  was defined as a broad Q wave in any lead, together with a Q -R amplitude 
ratio greater than 1:3 if the Q wave was in the anterolateral (X) or inferior (Y) leads. This 
equates closely to Minnesota codes 1-1 and 1-2-1 to 1-2-6.499 Possible MI  was defined as 
above but was dependent on the width of the Q wave and the magnitude of the Q-R ampli­
tude ratio. This equates with Minnesota codes 1-2-7, 1-2-8 and 1-3. Definite myocardial 
ischaemia and possible myocardial ischaemia required a combination of ST segment de­
pression and T wave changes (negativity or low positivity). The degree of ST depression 
required for abnormality is less than that required by the Minnesota code, although flat or 
downward sloping ST segment is additionally required in the three-lead system. Definite 
ischaemia equates with Minnesota code 4-1 or 5-1, and possible ischaemia with 4-1, 4-2, 
5-2, 5-3.
4.3 .4  B lo o d  m easu rem en ts
Blood samples were taken in the non-fasting state between 0800 and 1830 hours, separated 
and transferred overnight to central laboratories. Estimation of serum total cholesterol 
and HDL cholesterol was carried out at the Wolfson Research Laboratories, Birmingham. 
Serum total cholesterol was measured by a modified Liebermann-Burchard method on a 
Technicon SMA 12/60 analyser and HDL cholesterol by the Liebermann-Burchard or en­
zymic procedures after precipitation with magnesium phosphotungstate . 501 For 18 towns 
only (excluding Harrogate, Shrewsbury, Lowestoft, Mansfield, Southport and Merthyr 
Tydfil), triglycerides were measured using an enzymic method at the Department of Chem­
ical Pathology, Royal Free Hospital, London. For men in these towns, LDL-cholesterol 
was subsequently calculated using the Friedrickson-Friedwald equation: LDL cholesterol 
=  Total cholesterol - HDL cholesterol - (0.45 x Triglycerides). Measurements of base­
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line lipids were subsequently adjusted for the effects of time of day. 502 Serum insulin 
was measured at the Department of Diabetes and Metabolism, University of Newcastle, 
using an enzyme-linked immunosorbent assay (ELISA) which does not cross-react with 
proinsulin. 503 Glucose was estimated by a Technicon SMA 12/60 analyser at the Wolf- 
son Research Laboratories, Birmingham. For men in 18 towns, baseline levels of cotinine 
were analysed in 2 0 0 1  using a gas-liquid chromatography method (detection limit 0 .1  
ng/ml) . 504 Baseline biochemical measurements by study town are shown in Table 4.4.
N ested case—control studies o f new risk factors
Between 1998 and 2000 several nested case-control studies were carried out on the BRHS 
data in order to examine the potential influence on CHD risk of a range of new risk factors 
including homocysteine, C-reactive protein and various haemostatic factors including von 
Willebrand factor, fibrin D-dimer and t-P a  antigen . 356’358’505’506 Cases were selected from 
those men that had had a major CHD event before 1996, and were frequency matched 
with controls based on age and town. For analysis of C-reactive protein, von Willebrand 
factor, fibrin D-dimer and t-P a  antigen, approximately 600 cases and 1,200 controls were 
selected, 356’358’505 for homocysteine 386 cases and 454 controls were selected. 506 Baseline 
blood samples were then thawed and reanalysed for these new risk factors. Details of the 
methods and laboratories used to estimate these factors are given in section 4.4.4.
4.3 .5  E v id en ce o f  p r e -e x is tin g  C H D
Several criteria were used to assess whether study participants had experienced any coro­
nary heart disease prior to entry into the study. These included:
1 . recall of doctor diagnosis of angina or myocardial infarction based on the question­
naire.
2. World Health Organization (Rose) chest pain questionnaire evidence of definite or
possible angina (grade I or grade II). 1
'This relaxed criteria has a high sensitivity for identifying men with angina (when compared with 
the “gold standard” of expert clinical opinion) while maintaining a reasonable degree of specificity.507-509 
Though some men will inevitably be identified as “false positives”, since the purpose of this assessment 
is to identify all those men with any evidence of CHD (with a view to excluding them from analyses) an 
inevitable trade-off in terms of specificity was deemed acceptable.
CHAPTER 4. THE BRITISH REGIONAL HEART STUDY 119
3 . a history of severe chest pain lasting half an hour or more that caused them to 
consult with a doctor (possible myocardial infarction).
4. ECG evidence of definite or possible myocardial infarction or ischaemia.
Table 4.5 shows the responses of the study participants to each of these assessments 
and how these answers varied by geographic region. 15% of all study participants had 
symptoms of or recalled a diagnosis of myocardial infarction or angina (using criteria 1 -  
3), and a further 10% had ECG evidence of definite or possible myocardial infarction or 
ischaemia, so that one quarter of all men had some evidence of coronary heart disease. 
This figure was lower in the South of England than elsewhere. Few individuals (< 1%) 
recalled a doctor diagnosis of stroke.
4.4 Follow -up  procedures
Since the baseline assessment of study participants, all men have been systematically fol­
lowed for fatal and non-fatal cardiovascular events for over twenty years. Information 
on mortality has been ascertained from National Service registers in Southport (England 
and Wales) and Edinburgh (Scotland) and information on cardiovascular morbidity has 
been ascertained from a notification system supplemented by two-yearly reviews of general 
practice records. At regular periods since the baseline examination in 1978-80, surviv­
ing men have also been asked to complete questionnaires enquiring about their health 
and lifestyle characteristics. These questionnaires were completed by study participants 
after an average of 5, 13, 17 and 20 years of follow-up for each individual, as shown in 
Figure 4.3. In 1996, a study investigating the interrelationships between cardiovascular 
risk factors, clinical disease, intima media thickness and carotid plaque was carried out 
in Dewsbury and Maidstone (two towns with widely differing CHD rates), during which 
physical measurements and blood samples were remeasured. 510 After 20 years of follow-up 
for all individuals (between 1998 and 2000), all surviving men were invited to attend for 
rescreening, at which physical and biochemical measurements were measured. In order to 
estimate short-term within-subject variability in both established and novel risk factors, 
physical and biochemical measurements were repeated one week apart on an age-matched 
sample from a local general practice in Islington, North London. The measurements taken 
for this study were exactly the same as for the 20-year rescreening of the BRHS partici­
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pants. A detailed review of the follow-up procedures, questionnaires and examinations is 
now provided.
4.4 .1  M orta lity  fo llow -u p
Information on death was collected through the established “tagging” procedures provided 
by the National Health Service Central Registers (NHSCR) in Southport (England and 
Wales) and Edinburgh (Scotland). Copies of death certificates were sent to the study cen­
tre at three-monthly intervals, and included identification details, place, date and cause of 
death, the name of the certifier, and whether a post mortem examination was performed. 
A fatal CHD event was defined as a death with ischaemic heart disease (International 
Classification of Diseases (ICD) 9th revision codes 410-414) as the underlying cause in­
cluding sudden death of presumed cardiac origin. In cases of contradictory or inconsistent 
causes of death, clarification was sought with the general practitioner, hospital consultant, 
or pathologist.
Of the 7,735 men enrolled into the study, 2,077 (26.9%) died of all causes within the 
first 20 years. Table 4.6 shows a breakdown of these deaths. Ischaemic heart disease 
was the single most common cause of death over 20 years, accounting for 36% of all 
deaths occurring, marginally higher than all cancer related deaths combined (35%). Stroke 
contributed a further 6 % of observed deaths, and other circulatory disease a 7%, so that 
approximately half of all deaths were due to diseases of the circulatory system. For only 
13 deaths was the cause unknown, accounting for 0.6% of all deaths.
4.4 .2  C ardiovascular m orb id ity  fo llow -u p  
Record review process
On entry to the study, the medical record of each man was stamped and a blue card inserted 
which could be completed by the general practitioner and returned to the study centre in 
the event of a new diagnosis of one of: (i) myocardial infarction; (ii) stroke; (iii) angina; 
or (iv) transient ischaemic attack. Additionally, each practice co-ordinator carried out 
two yearly reviews of study participants’ medical records, using a listing supplied by the 
study centre. The practice co-ordinator updated the list with new deaths, emigrations 
and removals, and reviewed each subject’s medical records in order to identify all new 
cardiovascular events and diagnoses occurring in the preceding two years. In the event of
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an uncertain diagnosis, copies of medical records and/or hospital letters were forwarded to 
the study centre for interpretation. After the first eight years of follow-up (between 1986 
and 1988) a complete retrospective review of study participants’ notes over the preceding 
eight years was carried out in order to check diagnoses to that date. The blue card system 
was subsequently withdrawn but the two yearly record review has continued ever since. 
Men who registered with a new general practitioner in Britain subsequent to the baseline 
examination were tracked through the registration procedures at the Family Health Service 
Authorities and, where necessary, through the NHSCR. After twenty years of follow-up, 
fewer than 1 % of study participants had been lost to follow-up. 511
Assessm ent of cardiovascular morbidity events
Evidence regarding non-fatal heart attacks were obtained from the two yearly reviews of 
the patients’ notes, including hospital and clinic correspondence, as described above. A 
non-fatal heart attack was diagnosed according to established World Health Organization 
criteria, which included any report of myocardial infarction accompanied by at least two of 
the following: a history of severe chest pain, electrocardiographic evidence of myocardial 
infarction, and cardiac enzyme changes associated with myocardial infarction. Throughout 
this thesis “major” coronary heart disease events are defined as non-fatal myocardial 
infarction or death from coronary heart disease.
4 .4 .3  F o llow -u p  questionnaires
Figure 4.3 shows the dates that study participants completed the various health and 
lifestyle questionnaires. Following the initial baseline questionnaire, three additional ques­
tionnaires were sent to all surviving men who were still resident in Britain. The first 
was sent at the fifth anniversary of each man’s baseline assessment (Q5), the second in 
November 1992 (Q92) and the third in November 1996 (Q96). A fourth questionnaire was 
completed by all surviving men who attended for re-examination after 2 0  years of follow- 
up (Q20). Men in Dewsbury and Maidstone who took part in the carotid-plaque substudy 
in 1996 completed their Q96 questionnaire in February and March of that year rather than 
in November. W ith the exception of Q20, all follow-up questionnaires were self admin­
istered. A maximum of two reminders (with additional questionnaires and reply-paid 
envelope) were sent to non-responders. Response rates for the follow-up postal question­
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naires were 98% for Q5, 90% for Q92 and 8 8 % for Q96. Of men who survived 20 years, 
77% attended for examination and completed the Q20 questionnaire. Similar questions 
as were asked in the baseline questionnaire (including questions on lifestyle characteris­
tics such as cigarette smoking and alcohol consumption) were also asked in each of the 
follow-up questionnaires. Level of physical activity was asked in all questionnaires except 
Q5, though additional questions about housing tenure and car ownership (which were not 
asked in the baseline questionnaire) were included in the Q5 questionnaire. In the twenty 
year follow-up questionnaire (Q20), participants were asked to record their current or 
most recent occupation (rather than their longest held occupation) and the duration of 
that employment. From this information occupational social class after 20 years was again 
derived using the Registrar General’s classification. 442
4 .4 .4  F o llo w -u p  screen ings
Follow-up examination of study participants took place after approximately 16 years (for 
men in Dewsbury and Maidstone) and after 20 years (in all towns), as shown in Fig­
ure 4.3. The short-term variability study among men in Islington took place in 2000. 
Three observers made all measurements at the 20-year screening; one observer made all 
measurements at 16-year screening and the short-term variability study. At all screen­
ings, men were asked to attend for examination between 0800 and 1800; for the short-term 
variability study this was at the same time on both occasions. Men were not asked to fast 
at the 16-year screening; at the 2 0 -year screening and the short-term  variability study, 
all men not taking insulin or oral hypoglycaemic treatment for diabetes were asked to fast 
for a minimum of six horns, during which they were instructed to drink only water. At 
all examinations, physical measurements including height, weight and blood pressure were 
recorded, and blood samples (taken using the Sarstedt Monovette system) were collected 
for measurement of a range of established and novel coronary risk factors. These samples 
were separated and frozen at -20° C on the day of collection and transferred in batches to 
central laboratories. A review of the methods used to ascertain these measures at each 
screening is now provided.
• Physical m easu rem en ts: Height and weight were recorded to the nearest millime­
tre and 0.1 kg respectively. Blood pressure was measured twice in succession in the 
right arm, with the subject seated and the arm supported, using a Dinamap 1846
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oscillometric blood pressure recorder; over-reading of systolic pressure by the instru­
ment512 was corrected in analysis. At the 20-year screening, blood pressure readings 
were adjusted for observer variation within each town . 497 The mean of the two blood 
pressure measurements on each individual was used in analyses throughout.
• B lood lipids, insu lin  an d  glucose: Blood lipids and glucose were analysed at 
the Department of Chemical Pathology, Royal Free Hospital, London (Prof. A 
Winder, Dr M Thomas); insulin was measured at the Department of Diabetes and 
Metabolism, University of Newcastle (Prof. KGMM Alberti, Ms P Shearing). Serum 
total cholesterol was measured using the method of Siedel513 and HDL cholesterol 
using the method of Sugiuchi, 514 both on a Hitachi 747 automated analyser which 
also analysed triglyceride concentrations. LDL-cholesterol values were again calcu­
lated using the Friedrickson-Friedwald equation. Serum insulin was measured using 
the same method used at baseline; plasma glucose was measured using the method 
of Trinder515 using a Falcor 600 automated analyser. At the 20-year screening, LDL 
cholesterol, triglycerides, insulin and glucose levels were adjusted for the effects of 
time of day and time since last meal. 516
• H aem osta tic  an d  in flam m ato ry  variab les an d  hom ocysteine: Haemostatic 
and inflammatory variables were measured in citrated blood plasma at the Depart­
ment of Medicine, University of Glasgow (Prof. GDO Lowe, Dr A Rumley). Fib­
rinogen was measured using the Clauss method. Plasma levels of t-PA  antigen 
and D-dimer were measured with enzyme linked immunosorbent assays as was von 
Willebrand factor (vWF) antigen. C-reactive protein was assayed by ultra sensitive 
nephelometry. Serum total homocysteine was determined using a modified auto­
mated assay, based on pre-column derivatisation with monobromobimane, followed 
by reverse phase high performance liquid chromatography with fluorescence detec­
tion, and was measured at the Department of Pharmacology, University of Bergen 
(Prof. H Refsum, Prof. P Ueland).
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Table 4.1: Towns included in the British Regional Heart Study
Town SMR for CVD in 
men aged 35-64
Population 
size (1971)
Number of 
men examined
Response 
rate (%)
Ayr 140 47,890 301 70
Bedford 80 72,880 298 73
Burnley 114 76,130 287 80
Carlisle 1 2 1 71,820 389 85
Darlington 109 85,900 382 82
Dewsbury 142 51,130 325 79
Dunfermline 118 48,890 352 80
Exeter 90 93,800 332 84
Falkirk 98 37,600 309 75
Gloucester 84 89,980 311 73
Grimsby 96 95,610 318 71
Guildford 78 58,090 335 82
Harrogate 82 63,470 280 77
Hartlepool 1 0 1 97,110 313 77
Ipswich 92 122,700 362 85
Lowestoft 85 52,120 324 83
Maidstone 99 71,250 318 72
Mansfield 95 57,820 321 80
Merthyr Tydfil 135 55,100 283 76
Newc-Under-Lyme 115 77,320 293 77
Scunthorpe 109 70,900 332 76
Shrewsbury 95 56,630 311 83
Southport 114 84,870 322 80
Wigan 134 81,140 337 77
SMR =  standardised mortality ratio.
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Table 4.2: Summary of key measurements taken at the baseline examination
Measurement Method
Current chest pain
Severe chest pain
Recall of diagnosis 
Electrocardiogram
Blood presssure
Serum total choles­
terol
HDL cholesterol
Triglycerides 
LDL cholesterol
Serum insulin 
Glucose
Cigarette smoking
Physical activity
Alcohol intake
WHO (Rose) chest pain questionnaire. Categorised as: (i) no chest 
pain; (ii) non-exertional chest pain; and (iii) angina. Angina subde­
fined as definite or possible depending on severity of symtoms, and 
as grade I or grade II depending on the conditions under which the 
symptoms occur.
Rose angina questionnaire together with ‘site of pain’ diagram (Fig­
ure 4.2). Defined as symptoms lasting half an hour or more requiring 
consultation with a doctor.
Ever told by a doctor that they had had (among other things): 
angina, a myocardial infarction, a stroke or diabetes 
Three lead system. Ischaemic abnormalities classified according to 
Minnesota criteria into four groups, definite and possible MI, and 
definite and possible myocardial ischaemia.
Average of two seated measurements using London School of Hygiene 
and Tropical Medicine sphygmomanometer. Diastolic blood pressure 
recorded at the disappearance of Korotkoff sounds (phase V). 
Modified Liebermann-Burchard method on a Technicon SMA 12/60 
analyser. 501
Liebermann-Burchard or enzymic procedures after precipitation with 
magnesium phosphotungstate . 501 
Enzymic method (18 towns only) . 501
Estimated from total, HDL and triglycerides through the Friedrickson 
Friedwald equation (18 towns only).
ELISA assay that does not react with proinsulin . 503 
Measured using a Technicon SMA 12/60 analyser.
Several questions used to ascertain cigarette smoking exposure, in­
cluding type and amount of tobacco smoked, and the number of years 
since started (or quit) smoking.
Several questions used to gauge type of activity and frequency. Cat­
egorised as: (i) inactive; (ii) occasional; (iii) light; (iv) moderate; (v) 
moderately vigorous; and (vi) vigorous. 193
Several questions used to gauge frequency, quantity and type of al­
coholic beverage. Categorised as: (i) lifetime tee-totallers; (ii) occa­
sional drinkers; (iii) light drinkers; (iv) moderate drinkers; and (v) 
heavy drinkers. 265
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Table 4.3: Registrar General’s six category classification of social class
Class Description Examples
I Professional Doctors, lawyers, scientists
II Managerial and technical occupations Managers, teachers, white-collar workers
IIINM Skilled occupations (non-manual) Nurses, shop assistants
IIIM Skilled occupations (manual) Electricians, plumbers
IV Partly skilled occupations Bus drivers
V Unskilled General labourers, cleaners
Armed forces Army, Navy, Air Force
Table 4.4: Selected mean baseline characteristics by study town of the 7,735 men in the British Regional Heart Study
Town
Mean
TC
Mean
HDL
Mean
SBP
Mean
DBP
Mean
BMI
Mean
Height
Current 
smokers (%)
Physically 
active (%)
Heavy 
drinker (%)
Manual (%)
Ayr 6.27 1 .2 2 143.4 81.2 25.1 171 50.8 35.1 11.3 64.5
Bedford 6.08 1 .1 1 148.0 85.0 25.4 174 27.9 37.9 5.0 47.9
Burnley 6.40 1.14 146.0 84.5 25.1 172 45.8 22.3 14.0 69.9
Carlisle 6.58 1.19 149.9 8 8 .2 25.3 173 40.6 31.7 1 1 .1 59.5
Darlington 6.45 1.14 146.6 84.0 25.3 174 33.8 42.0 1 1 .0 43.0
Dewsbury 6.44 1 .2 0 150.8 82.7 25.5 173 50.5 28.9 13.8 65.2
Dunfermline 6.30 1.09 152.4 88.5 25.4 173 45.9 42.8 7.1 63.7
Exeter 6.51 1.13 138.9 78.5 25.8 174 37.9 40.4 4.8 47.5
Falkirk 6 .2 1 1.13 147.9 85.5 26.1 172 49.2 37.1 11.3 74.8
Gloucester 6.05 1.15 144.8 81.2 25.9 172 44.8 38.6 9.0 72.6
Grimsby 6.24 1.15 148.4 85.9 25.6 172 60.4 27.8 19.2 84.0
Guildford 6.27 1.17 135.9 77.6 24.8 176 24.2 45.5 3.6 23.8
Harrogate 6.41 1 .2 2 138.6 82.6 25.8 175 31.8 44.2 1 0 .0 35.7
Hartlepool 6 .1 1 1.14 147.7 85.8 25.6 173 42.5 29.9 26.8 74.6
Ipswich 6.28 1.15 142.6 79.3 25.5 174 32.0 46.7 5.0 42.8
Lowestoft 6.50 1 .1 2 142.2 76.0 25.2 174 37.2 43.3 3.1 64.7
Maidstone 6.26 1 .1 2 146.3 83.4 25.5 174 43.1 33.8 8 .8 56.5
Mansfield 6.43 1.15 143.7 79.0 25.7 174 40.6 37.0 8.4 60.1
Merthyr Tydfil 6.19 1.18 148.8 82.1 25.6 171 47.7 27.2 15.9 72.5
N-U-L 6.27 1 .1 2 149.0 82.1 25.7 173 48.1 34.4 14.0 68.4
Scunthorpe 5.99 1.07 140.4 78.2 25.8 173 48.8 41.8 10.5 78.9
Shrewsbury 6.45 1.19 135.8 77.4 25.3 174 33.9 45.1 8 .0 41.7
Southport 6 .2 2 1 .1 2 147.2 82.0 25.3 174 36.4 44.5 7.5 44.3
Wigan 6.15 1.17 147.9 82.4 25.4 173 39.9 30.4 2 1 .1 65.5
All towns 6.30 1.15 145.2 82.2 25.5 173 41.3 37.2 10.8 59.1
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Table 4.5: Percentage of men with baseline evidence of cardiovascular disease by study 
area
Criterion South 
n = 2280
Midi/Wales 
n  =  1208
North 
n = 3285
Scotland 
n — 962
Total 
n =  7735
Recall of doctor diagnosis 
of myocardial infarction 
or angina
3.5 7.1 5.8 7.0 5.5
Rose angina questionnaire 
evidence of definite or 
possible angina
5.4 9.1 8.5 9.9 7.9
History of severe chest 
pain
7.9 1 0 .2 9.4 9.6 9.1
Any o f above 11.9 16.6 15.9 17.4 15.0
ECG evidence of definite 
or possible myocardial 
infarction or ischaemia
13.6 16.1 14.7 14.6 14.6
Any of above 22.2 26.9 26.2 26.3 25.1
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Table 4.6: Causes of death over 20 years of follow-up in the BRHS
Cause of death n (%)
1 . Ischaemic heart disease 751 36.2%
2 . Malignant neoplasms 729 35.1%
3. Diseases of the respiratory system 151 7.3%
4. Other diseases of the circulatory system 142 6 .8 %
5. Stroke 129 6 .2 %
6 . Diseases of the digestive system 46 2 .2 %
7. Disease of the nervous system and sense organs 2 2 1 .1 %
8 . Endocrine, nutritional and metabolic diseases 15 0.7%
9. Diseases of the genitourinary system 14 0.7%
1 0 . Diseases of blood and blood-forming organs 9 0.4%
1 1 . Mental disorders 6 0.3%
1 2 . Diseases of the musculoskeletal system and connective tissue 4 0 .2 %
13. Other causes 46 2 .2 %
14. Unknown cause 13 0 .6 %
Total number of deaths 2,077 100%
CHAPTER 4. THE BRITISH REGIONAL H EART STUD Y 130
Figure 4.1: Twenty-four towns of the BRHS split into four areas
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Figure 4.2: Chest pain chart shown to study participants at baseline
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Figure 4.3: Follow-up in the British Regional Heart Study
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Chapter 5
E xtent o f w ithin—person variation  
in CHD risk factors
5.1 Sum m ary
In this chapter the repeated measurements available in the British Regional Heart Study 
are used to examine the extent of within-person variation for established and novel CHD 
risk factors. For the physical and biochemical factors, this is examined by estimating 
regression dilution ratios over periods of one week, four years, sixteen years and twenty 
years. The influences of age, disease severity, treatment and social class on the regression 
dilution ratios are examined, and the effect that regression dilution in one factor may 
have on risk associations for other risk markers, including both precisely and imprecisely 
measured markers, is assessed. For the categorical risk factors, including cigarette smoking 
and physical activity, the extent of within-person variation is estimated using information 
provided by the follow-up questionnaires. The results show substantial levels of within- 
person variation in both continuous and categorical risk factors over the study period. For 
continuous risk factors, the use of baseline measures of both established and novel risk 
factors in analyses results in marked underestimation of their associations with disease 
risk, the extent of which increases with duration of follow-up. For example, the use of 
baseline measurements to estimate associations with CHD risk 20 years later results in 
underestimation by an estimated 47% (95% confidence interval (Cl) 44% to 50%) for 
serum total cholesterol, 51% (95% Cl 48% to 55%) for systolic blood pressure, and 76% 
(95% Cl 73% to 78%) for diastolic blood pressure. In a multivariate setting where the
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independent relations of a blood lipid and a blood pressure measure (and other factors) are 
to be assessed, the use of total cholesterol and systolic pressure was found to result in the 
least residual bias in estimation of other risk associations. For the categorical risk factors, 
a substantial amount of within-person variation was observed over the study period. In 
particular, there was a tendency for baseline levels to overestimate the proportion of the 
population at either end of the risk exposure distribution, particularly the proportion of 
the population who are truly heavy smokers or heavy drinkers.
5.2 Introduction
5.2 .1  B ackground
In chapter 3 it was described how within-person variation in coronary risk factors (random 
error, short term biological variability and long term variability) can lead to inaccurate as­
sessments of risk relationships. For single continuous risk factors, it was shown that these 
relationships are underestimated when derived from observed baseline measurements (a 
phenomenon referred to as regression dilution bias). This bias exists because the differ­
ences between subjects estimated from a single baseline measurement exaggerate the true 
differences that exist between those subjects over a period of time. Therefore any varia­
tions in risk that are attributed to the risk exposure at baseline should really be attributed 
to a narrower range of values. The effects of regression dilution bias are particularly rele­
vant to coronary heart disease, as several of the key established and novel risk factors are 
subject to within-person variation over time. Previous reports have tended to examine 
these effects as they apply to measures of blood cholesterol and blood pressure, two of 
the key determinants of CHD risk. 17;19;517~522 Lcmg-term follow-up of individuals in the 
Whitehall and Framingham studies, for instance, has led to the conclusion that true asso­
ciations between total cholesterol and blood pressure with CHD risk are underestimated 
by around one third during the first decade of follow-up, one half during the second and 
by as much as two thirds during the third decade of follow up . 19
However, with the exception of these studies, there is relatively little published in­
formation on the extent of regression dilution bias at different follow-up intervals for 
established, and particularly for novel, coronary risk factors. Furthermore, the extent of 
within-person variation in categorical risk factors has been little studied and the validity
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of performing univariate correction methods in a multiple covariate setting is uncertain.
5 .2 .2  O b jectives
The aim of this chapter is to assess the extent of within-person variation in both estab­
lished and novel CHD risk factors in middle-aged British men followed for 20 years, and 
the likely effect that this would have on estimated disease relationships in both a univari­
ate and a multivariate setting. For the continuous coronary risk factors, the regression 
dilution ratio over a variety of follow-up periods (one week, and four, sixteen and twenty 
years) is estimated for the established risk factors (blood lipids and blood pressure), a 
range of novel potential risk factors (including glucose, insulin, fibrinogen, fibrin D-dimer, 
homocysteine, C-reactive protein and Von Willebrand factor, all of which have been as­
sociated with coronary heart disease risk), 30°;343;356;358;505;523 as well as other potentially 
relevant haemostatic measurements (factor VII and tissue plasminogen activator (t-PA)). 
A secondary objective is to assess whether the effects of regression dilution bias depend on 
other factors (including age, town, presence of disease and social class), in order to assess 
the potential generalisability of these effects to other populations. For the categorical risk 
factors, the extent of within-person variation is estimated using information from the four 
follow-up questionnaires (Q5, Q92, Q96 and Q20) to derive “average” exposure levels to 
the factors, in order to allow comparisons with the baseline classifications.
5.3 M ethods
5.3 .1  D a ta  sources
The extent of within-person variation in physical and biochemical risk factors was assessed 
by estimating regression dilution ratios over various interval periods using the following 
data:
1. Baseline data (1978-80); all physical measurements, blood lipids, insulin and glucose.
2. Sixteen-year Dewsbury Maidstone screening (1996); all physical and biochemical 
measurements.
3. Twenty-year screening (1998-2000); all physical and biochemical measurements.
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4. Nested case-control studies of new risk factors (1998-2000); subset of stored baseline 
samples from 18 towns were thawed and reanalysed for assessment of all new risk 
factors (except fibrinogen and factor VII).
5. One week repeatability study (Islington; 2000); all physical and biochemical mea­
surements.
These data allow estimation of the regression dilution ratio for all physical and biochemical 
risk factors over periods of one week (Islington study), four years (Dewsbury/Maidstone 
1996-2000), sixteen years (Dewsbury/Maidstone 1980-1996 plus nested case-control sub­
group), and twenty years (all towns 1978/80 to 1998/00 plus nested case-control sub­
group). For the categorical risk factors, information on each individual was taken from 
the baseline questionnaire together with (potentially) each of the four follow-up question­
naires (Q5, Q92, Q96 and Q20), in order to assess the extent of within-person variation 
in cigarette smoking, physical activity and alcohol intake over the study period.
5 .3 .2  W ith in -p e r so n  variation  in con tin u ou s risk factors
Estim ating and interpreting the regression dilution ratio (R D R )
In the case of a single continuous risk factor subject to within-person variation, the RDR 
was estimated using Rosner’s regression method described in section 3.5.3. This method 
estimates the RDR by the regression coefficient obtained from regressing the follow-up 
measurement on the baseline measurement, with 95% confidence intervals being calculated 
in the usual way for a regression coefficient. For variables that are normally distributed, 
the amount by which the “baseline association” underestimates the true association may 
be obtained by subtracting the RDR from 1, and multiplying by 100% (for instance, if the 
RDR calculated over a 5-year period was 0.8, then the association (say, the log odds ratio) 
between baseline levels and disease risk would underestimate the association between 5- 
year levels and disease risk by 20%). For variables where the underlying distribution is 
positively skewed, such as triglycerides, analyses were performed on the log scale. The 
interpretation of the RDR for these variables is the same, though applied to a variable on 
the log scale (it is the amount through which the association between the logarithm of the 
usual exposure and disease risk is underestimated because of the use of the logarithm of 
baseline levels in analyses).
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D ependence o f the R D R  on the interval period
For each risk factor (except fibrinogen and factor VII where repeated data is only available 
over two periods), the relationship between the RDR and the interval over which it was 
calculated was approximated by fitting an inverse variance weighted negative exponential 
curve through the plot of the RDR against the interval period (see Figures 5.2 to 5.5). This 
was done by first regressing the logarithm of the RDR on the interval period (weighted by 
the inverse variances of the individual estimates) so that the “best” straight line relation­
ship through the plot of log RDR against the interval could be obtained, and second, by 
transforming this straight line relationship back to the exponential scale (therefore, if the 
relationship between log(RDR) and the interval in years was expressed as, y = a — bx, the 
relationship between the RDR and the interval would be y =  exp (a — bx)).
Tests for heterogeneity
In order to test whether the regression dilution ratio corresponding to a particular risk 
factor over a certain interval period differed significantly between two or more groups of 
individuals (e.g. whether it differed by age group), the inverse variance weighted average 
of the separate estimates was first calculated,
, = S(V«?)
where Si is the estimated standard error of the ith  estimate A*, 
squared (weighted) deviations from this statistic was calculated
* 2 =  -  L)/s' f  <5-2)
This statistic was then compared with a chi square distribution with k — 1 degrees of 
freedom in order to assess significance, where k is the number of subgroups being compared.
(5.1)
and then the sum of the 
as shown below,
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5.3 .3  W ith in -p e r so n  variation  in ca tegor ica l risk factors
Using the baseline data together with data from (potentially) each of the four follow-up 
questionnaires, “average” exposures to cigarette smoking, alcohol, and physical activity 
over the study period (or until the time to first CHD event if observed) were calculated for 
each individual. For cigarette smoking, men were defined as being either never smokers or 
ex-smokers throughout the study if they were defined as such at every questionnaire they 
responded to. For men who were current smokers a t baseline, the number of cigarettes they 
reported to smoke at each questionnaire (zero if they had given up) was used to calculate 
the average number of cigarettes they smoked per day on the study. It was assumed 
that any changes in the number of cigarettes smoked between consecutive questionnaires 
occurred linearly over the intervening period (unless a CHD event occurred during that 
period in which case it was assumed that the individual continued to smoke at the same 
rate as reported at the last questionnaire prior to the date of that event). Men who were 
non-smokers at baseline (never or ex-smokers) but subsequently reported that they were 
current smokers were classified as “new/recurrent” smokers. For alcohol intake, a five- 
point scale was used to denote the intake level at the baseline assessment and each of the 
follow-up assessments (from 0 (none) to 4 (heavy); a six-point scale was used for physical 
activity). Using these data, average alcohol intake during the study (and average physical 
activity level) was calculated as indicated in Figure 5.1 (changes between questionnaires 
were again assumed to occur linearly unless the individual had a CHD event during that 
time). For instance, in the third scenario shown in Figure 5.1 where the subject has a non- 
fatai MI after 18 years of follow-up and has their risk exposure coded as ‘4’ at baseline, ‘3’ 
at Q92, ‘3’ at Q96 and ‘2’ at Q20 (and no response to Q5), the average exposure over the 
18 years they were ‘at risk of CHD’ would be calculated as (42 (area of A) +  12 (area of B) 
-f 6  (area of C))/18 =  3.3 (note that the information from Q20 is ignored because a CHD 
event was obserevd between Q96 and Q20 which may have subsequently caused in change 
in lifestyle). From these average exposure levels calculated for all 7,735 men, each subject 
was reclassified on the original categorical scale according to the nearest whole number (for 
example for alcohol intake, an average exposure of <0.5 was defined as “never drinker” ,
0.5 -  1.5 was defined as “light drinking” etc.).
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5 .3 .4  E ffects o f  w ith in -p erso n  variation  in m ore th an  on e risk factor
In order to estimate the effect that within-person variation in more than one risk fac­
tor could have on estimated disease relationships in a multivariate setting, the inter­
relationships between different blood lipid and blood pressure indices, and their rela­
tionships with other important coronary risk factors (age and cigarette smoking) were 
examined using the 20-year repeated data. In particular, in section 5.4.6 of this chapter, 
estimates of A (a matrix of regression coefficients obtained by regressing follow-up levels 
on baseline levels; see Chapter 3, section 3.7) are calculated to display the relationships 
between a blood lipid measure (total or HDL cholesterol), a blood pressure measurement 
(systolic or diastolic), age and cigarette smoking status (defined as never, ex- or current). 
However, because it is the inverse of A (and not A itself) that determines the extent 
to which baseline associations are modified (through the equation (3* — /3A_1; see sec­
tion 3.7), it is the inverse of A that is presented (this is referred to as the “modifying 
matrix”). The extent to which the off-diagonal components of A - 1  deviate from zero 
indicate the extent to which univariate correction methods will be misleading. For con­
sistency with later chapters, this particular analysis is restricted to men with no baseline 
evidence of CHD (symptoms, recall or doctor diagnosis of CHD).
5.4 R esu lts
5.4 .1  C haracteristics o f  rep ea ted  d ata
Of the 7,735 men examined at baseline in 1978-80, 5,658 survived the following 20 years 
and 4,252 of these attended the 20-year re-screening. In Dewsbury and Maidstone, of 
643 men examined at baseline, 532 survived to 1996 and 425 of these (80%) participated 
in the 16-year re-screening. Of the men who attended the Dewsbury-Maidstone 16-year 
screening in 1996, 400 survived to 2000 and 297 of these (74%) participated in the 20- 
year re-screening. The short-term variability study included 112 men who completed all 
measurements at two screenings taken a week apart. Data on regression dilution ratios for 
the established physical and biochemical risk factors after one week and four, sixteen and 
twenty years of follow-up (as well as estimates for the new risk factors over one week and 
four years) are therefore based on 112 men, 297 men, 425 men and 4,252 men respectively. 
In addition, the case-control studies performed between 1998 and 2000 that reanalysed
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stored baseline samples provided further information on new risk factors over a 16-year 
period for 65 men (Dewsbury/Maidstone case-control participants that survived and were 
re-examined in 1996), and over a 20-year period for between 700 and 850 men (all case- 
control participants that survived and were re-examined in 1998-2000); though fewer (330 
repeat samples) were available for homocysteine.
Table 5.1 shows the mean values of selected characteristics of the men who attended 
each of the screening examinations. For blood pressure, it is noticeable that for the 
short-term variability study the mean blood pressure (both systolic and diastolic) was 
lower at the second measurement than the first. Over 20 years, mean blood pressure 
increased by approximately 6  mmHg (systolic) and 4 mmHg (diastolic). Blood lipids 
were reasonably constant over short periods, but generally fell over 2 0  years (mean total 
cholesterol decreased from 6.3 mmol/L in 1980 to 6.0 mmol/L in 2000). Men who died 
before the 2 0 -year examination or survived but failed to attend the 2 0 -year examination 
had higher baseline systolic and diastolic blood pressure than surviving men that attended 
the 20-year examination (both p < 0.0001). However, baseline levels of triglyceride, total 
cholesterol, LDL cholesterol and HDL cholesterol did not differ significantly between these 
groups. For men in Dewsbury and Maidstone, there were no differences in baseline blood 
lipids (triglycerides and total, LDL and HDL cholesterol) or blood pressure levels between 
those men that attended both the 16 and 2 0 -year screenings and those who did not.
5.4 .2  E stim a tes  o f  th e  regression  d ilu tion  ratio  for con tin u ou s factors
Tables 5.2 and 5.3 show estimates of the regression dilution ratio with 95% confidence 
limits for each of the measurements after 1 week and 4, 16 and 20 years of follow-up; these 
estimates are also displayed graphically in figures 5.2 to 5.5 where weighted regression has 
been used to identify the ‘best’ exponential fit to the estimates (for the new risk factors 
where only two estimates are available, the curve has been extrapolated to 2 0  years for 
illustrative purposes).
R D R  estim ates for blood lipids
For blood lipids, the effects of measurement error and short-term biological variation are 
apparent even over a one-week period; use of baseline measures as estimates of usual levels 
would result in short-term  associations being underestimated by approximately 10-15%
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for total cholesterol, LDL cholesterol and triglycerides. Associations with HDL cholesterol 
and the ratio of total to HDL cholesterol are subject to the least within-person variability, 
being hardly affected over this period. After four or more years, associations with usual 
levels would be underestimated by less than 15% for HDL cholesterol, by between 25-35% 
for total cholesterol, triglyceride and total:HDL cholesterol, and by around 40% for LDL 
cholesterol. For long-term associations, say those occurring 20 or more years after baseline, 
the effects of regression dilution bias when quantifying blood lipid associations axe marked 
-  use of baseline measures would result in true associations being underestimated by 
approximately one half for total cholesterol, LDL cholesterol and triglyceride. Associations 
with HDL cholesterol and the ratio of total to HDL cholesterol would be more accurately 
assessed, but would still be underestimated by, respectively, one quarter and one third.
R D R  estim ates for blood pressure
For blood pressure, the effects of regression dilution bias are large because of the greater 
degree of within-person variability associated with this measure. Even over a one week 
period, true associations would be underestimated by approximately 30% if single mea­
surements were used in analyses. The magnitude of this underestimation increases sharply 
(particularly for diastolic pressure) as the interval period increases so that after four or 
more years, associations with usual blood pressure levels at that time would be underesti­
mated by around 40% for systolic pressure and 50% for diastolic pressure. For mid blood 
pressure (the average of systolic and diastolic pressure) and mean arterial pressure (two 
thirds diastolic pressure plus one third systolic), the effects are between those for systolic 
and diastolic pressure. For long-term associations the effects of regression dilution for 
blood pressure are large; associations with systolic pressure would be underestimated by 
approximately one half (similar to that for total cholesterol), but for diastolic pressure, 
baseline associations would underestimate true associations by around three quarters.
R D R  estim ates for body mass index, insulin and glucose
Of all the risk factors presented, body mass index displayed by far the least within- 
person variation over the study period. Correspondingly, even over a 20-year interval, the 
effect of using baseline measures of body mass index as estimates of usual levels around 
that time would be virtually nil, possibly resulting in underestimation by around 7%.
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For insulin and glucose, the effects of regression dilution bias were fairly modest over a 
one week period, but became considerably more marked from four years onwards. After 
four years, associations with usual insulin and glucose levels around that time would be 
underestimated by 50% or more. Over a 20-year interval period, these estimates increased 
to 73% for insulin and 67% for glucose.
R D R  estim ates for novel coronary risk factors
For the range of novel risk factors measured in the BRHS, including homocysteine, C- 
reactive protein and the haemostatic factors, repeat measurements were available over 
periods of one week, and four, sixteen and twenty years using a combination of data from 
the main study cohort as well as from the nested case-control studies performed between 
1998 and 2000. For fibrinogen and factor VII only one week and four year data are 
available. Table 5.3 and Figures 5.4 and 5.5 show estimates of the regression dilution ratio 
for these factors over the various follow-up periods. Similar effects of regression dilution 
bias were observed as for the established risk factors; the regression dilution ratios for the 
novel risk factors are similar in magnitude to those of established risk factors, generally 
lying between those of total cholesterol and diastolic pressure. Over an interval period of at 
least four years, the use of baseline measures to estimate associations with usual exposure 
levels would result in underestimation by between 40-50% for fibrinogen and C-reactive 
protein, approximately 30% for Von Willebrand factor and t-PA, and approximately 25% 
for factor VII, D-dimer and homocysteine.
5.4 .3  Factors in fluencing  th e  regression  d ilu tion  ratio
In order to assess the extent that estimates of the regression dilution ratio may be gener- 
alisable to other study populations, the 2 0 -year estimates for the blood lipid and blood 
pressure indices were calculated separately according to age, baseline evidence of CHD (re­
call of doctor diagnosis of MI or angina, Rose questionnaire evidence of angina, or history 
of severe chest pain), social class (manual versus non-manual) and geographic location 
(the South, Midlands and Wales, the North, Scotland). These estimates together with x 2 
tests for difference are shown in Figures 5.6 to 5.11.
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Age
In order to investigate whether the size of the regression dilution ratio varies with age 
we divided the study participants into four age groups at baseline: 40-44 years, 45-49 
years, 50-54 years and 55-59 years. Separate RDR estimates for the primary blood lipid 
measurements (total, HDL, and LDL cholesterol, and the ratio of total to HDL) and 
blood pressure measurements (systolic and diastolic pressure) were then calculated for 
each of these groups over the following 20 years. For HDL and LDL cholesterol, as well 
as the ratio of total to HDL cholesterol and both blood pressure indices, no evidence of 
heterogeneity between the different estimates by age group was observed (all p > 0.05). 
For total cholesterol however, some evidence of heterogeneity was observed; the RDR for 
total cholesterol among men originally aged 55 to 59 years was slightly higher than that 
observed amongst other men, indicating that this group experienced slightly lower levels 
of within-person variation over the 2 0 -year follow-up period.
Evidence of CHD and treatm ent
Of the 4,252 men for whom 20-year interval data were available, 452 (10.6%) had evidence 
of CHD at the baseline examination. The RDR estimates for the blood lipid and blood 
pressure measurements obtained from these men were generally slightly lower than the 
RDR estimates obtained from all remaining men (indicating potentially greater degrees of 
long-term within-person variation in these measurements experienced by individuals al­
ready with CHD), though these differences did not reach statistical significance. However, 
when individuals who developed CHD over the interval period were also included in the 
‘diseased’ group, much larger differences in the RDR estimates were observed which did 
reach statistical significance. As would be expected, the 20-year RDR estimates for blood 
pressure differed markedly between the 1,139 men who had (at some time) received blood 
pressure lowering drugs and the 3,113 men who had not (0.37 versus 0.60 for systolic, 0.18 
versus 0.30 for diastolic; both p < 0.0001). Furthermore, the 20-year RDR estimate for 
total cholesterol differed markedly between the 324 men receiving lipid lowering drugs at 
follow-up (predominantly statins) compared with all other men (0.35 compared with 0.64; 
p <  0  .001). However, these differential effects did not explain the differences in the RDR 
estimates for blood pressure and blood cholesterol observed between those who did and 
those who did not develop CHD (interaction terms between the development of CHD and
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the RDR remained highly significant p < 0.002 even after adjustment for drug use). 
Social class an d  geographic location
Finally, estimates of regression dilution ratios over 20 years were compared by social 
class (manual versus non-manual) and geographic location (South England, Midlands 
and Wales, North England, and Scotland). Relatively little difference in the size of the 
regression dilution ratio by social class was observed, though some heterogeneity was 
observed for diastolic blood pressure, where the level of within-person variation over 2 0 -  
years was marginally greater for manual men (possibly due to inter-relationships between 
social class and the development of CHD and subsequent treatment). For systolic and 
diastolic pressure, no geographic differences in the regression dilution ratio were observed. 
For total and LDL cholesterol, significant heterogeneity was observed between the different 
geographic regions; within-person variation tended to be greater in the North of England 
than the South, again possibly reflecting the higher incidence of CHD (and effects thereof) 
experienced in the North of England, though these differences could also simply reflect 
the role of chance.
5 .4 .4  L ifesty le  risk factors and w ith in -p erso n  variation
Table 5.4 shows the responses for cigarette smoking status (never, ex, current (1-20 a 
day), current (21-39 a day) or current (>40 a day)), physical activity (none, occasional, 
light, moderate, moderately vigorous or vigorous), and alcohol intake (none, occasional, 
light, moderate or heavy) at the baseline questionnaire (Q0) and each of the follow-up 
questionnaires (Q5, Q92, Q96 and Q20). It can be seen that cigarette smoking patterns 
recorded at each questionnaire changed considerably over the study period, due in part 
to real changes in smoking habits in the men and in part to the increased ‘selectiveness’ 
of the group as follow-up increases (due to the excess number of deaths amongst active 
smokers). These selection effects are reflected in the gradual increases that are observed 
in the proportion of men who are defined as ‘never smokers’ at each of the questionnaires, 
which increases from 24% at baseline to 29% at Q20. Of men who survived 20 years, 
only approximately 1 in 200 reported to be actively smoking at least 40 cigarettes a day, 
compared with 1 in 25 at the baseline examination. For physical activity, the modal 
exposure category at each of the follow-up questionnaires was ‘occasional’, comprising
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nearly one third of the group at baseline, and approximately one quarter of the surviving 
cohort members at Q92, Q96 and Q20. The proportion of men reported to be ‘inactive’ 
at each questionnaire was fairly stable at around 1 0 %; though a slightly higher proportion 
(15%) was reported at Q96, this could be artificially high because of the role of chance, 
rather than reflecting a true increase in physical inactivity in 1996 compared with other 
years. The proportion of men exercising ‘vigorously’ increased from 7% at baseline to 15% 
at Q20. For alcohol consumption, approximately one third of the men were categorised as 
‘light’ drinkers at baseline, with a further one quarter of men categorised as ‘occasional’ 
drinkers and one quarter categorised as ‘moderate’ drinkers. During the follow-up period, 
there was a steady downwards trend in the amount of alcohol consumption reported by 
surviving study participants (due to a combination of the cohort becoming older and 
drinking less, secular changes in alcohol consumption with time, and possible survival 
‘selection’ effects). After 20 years of follow-up, only 3% of the surviving men were classified 
as heavy drinkers (compared with nearly 1 1 % at baseline), while 1 0 % were classified as 
non-drinkers (compared with 6 % at baseline).
5 .4 .5  M isclassification  o f  “average” lifesty le  risk ex p o su res
For each individual, ‘average’ cigarette smoking group, physical activity level and alcohol 
intake during the individual’s personal exposure period (either 2 0  years or the time of 
censoring/first CHD event, whichever is lower) was calculated as described in section 5.3.3, 
and compared with the baseline exposure. These comparisons axe shown in Tables 5.5 to 
5.7.
M isclassification o f cigarette smoking
At baseline, 1,819 men were defined as never smokers (see Table 5.5). Of these, men 1,802 
(99%) were confirmed as being never smokers when follow-up questionnaires were taken 
into account. The 17 men who were, at some later point, recorded as being current smokers 
were probably either due to random measurement error (by the study investigators) or 
subject recall error (misreporting by subject at baseline), though they may also reflect 
men who truly first began regular smoking during middle-age. Of the 2,715 men who 
were classified as ex-smokers at baseline, only a small proportion (7%) were subsequently 
categorised as active smokers. For the men who were active smokers at baseline, the
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degree of ‘misclassification’ when compared with average smoking levels during the study 
varied considerably by the amount of tobacco reportedly smoked each day. Of those who 
initially reported smoking 1-20 cigarettes a day, the vast majority (96%) were classified as 
such when follow-up questionnaires were taken into account and classifications were based 
on average smoking exposure. For heavy smokers however, the baseline assessment alone 
tended to greatly overestimate the proportion of men that consistently smoked heavily 
during the study. Of men who (at baseline) reported smoking 21-39 cigarettes a day, less 
than half were classified as such after follow-up questionnaires were taken into account 
(the vast majority of the rest were classified as smoking 1-20 a day), while for the 316 men 
who initially reported to smoke at least 40 cigarettes a day, only 83 (26%) truly smoked 
to that degree throughout the study. Overall, the degree of misclassification in cigarette 
smoking status was modest: 6,739 men (87%) were classified the same based on baseline 
and average exposure levels.
M isclassification o f physical activity
Reported physical activity levels at baseline and average levels throughout the study are 
shown in Table 5.6. At any given level of physical activity reported at baseline, only 
approximately 50-60% of the group were defined in the same category when follow-up 
questionnaires were taken into account. Most individuals (around 90%) were either defined 
the same based on average levels or else were within one category of their baseline exposure 
group. Overall, 4,531 men (57%) were categorised in the same group, but there was a 
tendency for baseline levels to overestimate both the proportion of the population that 
were inactive as well as the proportion that were highly active.
M isclassification o f alcohol intake
Alcohol intake at baseline and average alcohol intake dining the study are shown in Ta­
ble 5.7. Within-person variation can be seen to increase with increasing alcohol intake, 
as reflected by the observation that 80% of those originally defined as non-drinkers were 
defined the same when based on average levels, compared with 65% of those originally 
defined as light drinkers and only 28% of those originally defined as heavy drinkers. Base­
line assessment of alcohol exposure resulted in substantial overestimation of the number 
of men who were truly heavy drinkers during the follow-up period and underestimation
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of the number of men who, on average, could be classified as non-drinkers.
5 .4 .6  In ter -re la tio n sh ip s  b etw een  risk m easu rem en ts
To examine the effects that within-person variation in blood lipid and blood pressure 
measurements have on their estimated associations, as well as their effects on associations 
for age and cigarette smoking status (two factors that, for this analysis, are assumed to be 
measured precisely), the “modifying matrix” of regression coefficients A - 1  over a 20-year 
period was calculated for the following four hypothetical scenarios:
1 . an analysis that adjusts for total cholesterol, systolic blood pressure, age and ciga­
rette smoking status.
2 . an analysis that adjusts for total cholesterol, diastolic blood pressure, age and ciga­
rette smoking status.
3. an analysis that adjusts for (log) HDL cholesterol, systolic blood pressure, age and 
cigarette smoking status.
4. an analysis that adjusts for (log) HDL cholesterol, diastolic blood pressure, age and 
cigarette smoking status.
In each scenario, estimates were restricted to men with no baseline evidence of CHD, and 
for each estimate of A -1 , the rows/columns correspond to the variables presented in the 
following order: (1 ) blood lipid measurement; (2 ) blood pressure measurement (per 2 0  
mmHg systolic or 10 mmHg diastolic); (3) age (years); (4) ex-smoker (l=yes, 0=no); and 
(5) current smoker (l=yes, 0=no). These four matrices are shown below (recall that the 
vector of true regression coefficients /3* is obtained from the vector of baseline associations 
(3 through the equation /3* =  /3A-1):
Estim ates of A - 1
1.84 0.30 0 . 0 2 0 . 0 2 0.08
0.04 2.13 -0.05 0.06 0.07
0 0 1 0 0
0 0 0 1 0
0 0 0 0 1
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A3 1
/ 1 .8 8 0.64 0.04 0.08 0.18 \
0.46 4.19 0.06 0.37 0.51
1 _
0 0 1 0 0
0 0 0 1 0
V 0 0 0 0 1 /
( 1.32 0.04 0 .0 0 0 . 0 0 -0 .0 1 \
-1.63 2 .1 0 -0.05 0.06 0.08
0 0 1 0 0
0 0 0 1 0
\ 0 0 0 0 1
1.31 0.05 0 .0 0 0 . 0 0 0 . 0 0 \
-1.56 3.99 0.05 0.38 0.47
0 0 1 0 0
0 0 0 1 0
\ 0 0 0 0 1 /
The matrices above show the extent by which the vector of “baseline” associations should 
be modified in order to obtain the vector of true associations between risk and risk factors 
20-years after baseline. The diagonal components describe the extent to which each risk 
association is underestimated, because of the use of its baseline level in analyses, while 
the off-diagonal terms show the degree that these new associations are altered because 
of their relations with the blood lipid and blood pressure measure. For age and cigarette 
smoking (variables 3, 4 and 5 in the model), exposures are assumed to be known precisely 
and hence the diagonal components for these variables are equal to 1 (so that the baseline 
association is the true association). However, because of their relations with the blood 
lipid and blood pressure indices, their true regression coefficients are also modified by the 
estimated associations for these factors (by the amount shown in the top two rows of each 
matrix, in the last three columns). The off-diagonal terms determine the bias that would 
be introduced if univariate correction methods (i.e. just using the diagonal terms to adjust 
the associations) were employed in these multivariate settings.
As an example, the first matrix (which illustrates these effects for total cholesterol and
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systolic blood pressure) indicates that in order to calculate the true association between 
total cholesterol 2 0  years after baseline and disease risk around that time, one should 
multiply the baseline association by 1.84 (equivalently, divide by 0.54) and add 0.04 times 
the baseline association for systolic blood pressure (recall that this association corresponds 
to a 20 mmHg change in SBP). Similarly, the true association for systolic pressure is 
obtained from the baseline association by multiplying it by 2.13 and adding 0.3 times the 
baseline association for total cholesterol. In this example, the true associations for age and 
cigarette smoking are virtually the same as the baseline associations, as they are modified 
very little through their relationships with total cholesterol and systolic pressure (since 
the modifying factors are all relatively small (between -0.05 and 0.08)).
Overall, it can be seen that the associations for age and cigarette smoking are modi­
fied quite substantially by their relations with diastolic pressure (second row of A2 1 and 
A J1), much less so by their relations with systolic pressure (second row of AJ"1 and A3 x), 
virtually not at all by their relations with HDL cholesterol (first row of A 3 1 and A J1), 
and only marginally by their relations with total cholesterol (first row of A^f1 and A ^ 1).
5.5 D iscussion
5.5 .1  In terp reta tion  o f  findings
These results suggest that for continuous risk factors, the use of baseline levels of phys­
ical, biochemical and haemostatic measurements in univariate analyses leads to marked 
underestimation of their associations with disease risk, and that the extent of this under­
estimation increases with duration of follow-up. Long-term associations with CHD (say 
those occurring 15-25 years after baseline) would be underestimated by about one half 
for systolic blood pressure and blood lipids (total cholesterol, LDL cholesterol and triglyc­
eride) and three quarters for diastolic blood pressure, while associations between glucose 
tolerance or insulin resistance and CHD would be underestimated by two thirds or more 
if based on single baseline measures of insulin and glucose. In contrast, regression dilution 
effects for HDL cholesterol and the ratio of total to HDL cholesterol were less marked, 
so that the use of a baseline HDL measurement to estimate associations with disease risk 
20 years later would only result in underestimation by about one quarter. Even in the 
short-term however, say over a period of a few weeks or months, associations with usual
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risk exposure levels would still be underestimated by between 1 0  and 2 0 %, and for blood 
pressure, this figure is likely to be nearer 30%.
For the categorical ‘lifestyle’ risk factors, substantial within-person variation was also 
evident. Nearly one half of all men had their physical activity level or alcohol intake 
group defined differently at baseline from that defined according to usual reported levels 
(taking into account follow-up questionnaires). This reflects the general decline in physical 
activity and alcohol intake observed with increasing age, but also reflects the tendency for 
individuals to have, upon re-measurement, exposure levels that are ‘less extreme’ than 
observed at baseline (as happens for continuous variables). While a greater degree of 
agreement was observed for cigarette smoking, a combination of secular trends in smoking 
habits and true measurement errors in the ascertainment of smoking exposure together 
led to a substantial overestimation of the proportion of men estimated to be regular heavy 
smokers. This could have implications for the estimation of relationships between disease 
risk and true levels of cigarette smoking.
In analyses relating blood lipids, blood pressure, age and cigarette smoking simultane­
ously to disease risk, it would seem that the use of total cholesterol together with systolic 
blood pressure would result in the least residual bias from using univariate correction 
methods to adjust for within-person variation in a multivariate setting.
5 .5 .2  V alid ity  o f  analyses: e stim a tin g  th e  R D R
The ‘regression based’ methods used in the analyses presented in this chapter to estimate 
the regression dilution ratio can be used to calculate a valid correction factor when the 
distributions of the baseline and follow-up measurements are different (as may be expected 
in an ageing cohort), and it is for this reason that they have been preferred to the other 
approaches, particularly the correlation approaches, described in chapter 3 . 20 One poten­
tial problem in the estimates of regression dilution presented in this chapter however, is 
that they are based on different follow-up periods on different individuals at somewhat 
different ages. However, given that the estimates of the RDR were fairly similar between 
individuals of different ages (see Figures 5.6 to 5.11), it is likely that this potential source 
of bias is not of paramount importance. The estimates were also generally found to be in­
dependent of geographical area or social class, and may therefore be generalisable to other 
populations. However, one factor tha t may affect estimates of regression dilution bias, and
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hence the extent that it may be appropriate to use the estimates in other settings, is the 
proportion of the population with evidence of CHD at baseline. Men who developed CHD 
during the study were certainly observed to experience a greater degree of within-person 
variation in their risk factors than men who remained disease free, though it is hypothe­
sised that much of this variation would occur after the CHD event had occurred. It may 
therefore be prudent to  ensure that the relevance of the RDR estimate to  the population 
for which it is to be applied, is considered before correction for regression dilution bias is 
performed. In general however, our estimates of the regression dilution ratio are similar to 
those from many other prospective studies of cardiovascular disease, the findings of which 
axe now described.
5.5 .3  C om parison  w ith  o th er  stu d ies  
Blood pressure and tota l cholesterol
Many previous cardiovascular studies have explored the effects of regression dilution bias 
for total cholesterol and blood pressure, two of the strongest CHD risk factors. A sum­
mary of the estimates from some of these studies is shown in Figure 5.12.17;19;5i7-522 Qne 
of the first studies to assess these effects was an analysis of nine prospective studies, which 
aimed to estimate the associations between usual levels of diastolic blood pressure and the 
risks of CHD and stroke. 17 The authors used repeated DBP measurements from several 
studies including the Framingham study to estimate the effects of regression dilution bias 
in DBP over a four year period and, from these data, estimated that the true associa­
tions would be about 60% greater than that estimated from baseline measurements of 
DBP (corresponding to  a regression dilution ratio for diastolic pressure of 0.62). Since 
this analysis, numerous subsequent studies have published estimates of regression dilution 
ratios for blood pressure and total cholesterol. In ten cohorts of Japanese and Chinese 
individuals, repeat measurements of diastolic blood pressure and total blood cholesterol 
were taken over an average five year interval. 517 Over this period, regression dilution ra­
tio estimates of 0.48 for diastolic pressure and 0.52 for total cholesterol were observed -  
the figure for total cholesterol being somewhat lower than our estimate taken over a four 
year period. In the Israel Ischaemic Heart Disease Project, regression dilution ratios for 
systolic and diastolic pressure over a two year period were 0.65 and 0.54 respectively, 518 
while in the Finrisk Haemostasis study, estimates of 0.70 and 0.61 for these measures were
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obtained over a three year interval. 519 Among men in the Renfrew/Paisley study, RDR 
estimates of 0.56 were observed for both systolic and diastolic blood pressure over a four 
year interval; for men in the Collaborative study, these estimates were approximately 0.63 
over five years. 520
Though numerous studies have provided estimates of the regression dilution ratio over 
short periods of follow up, fewer studies have been able to provide long-term estimates 
(>10 years). One which has is the Framingham study, where after 16 and 26 years of 
follow-up RDR estimates of 0.52 and 0.34 were observed for systolic pressure, 0.38 and 0.26 
for diastolic pressure, and 0.52 and 0.43 for total cholesterol. 19 Similarly, in the Whitehall 
I study, RDR estimates of 0.32, 0.29 and 0.28 were calculated for SBP, DBP and total 
cholesterol over a 26 year interval. 19 In a study of 6,137 middle-aged men of Japanese 
descent in the Honolulu Heart Program, repeated total cholesterol measurements were 
available over a 16 year interval. 521 The authors found tha t the crude baseline association 
between serum total cholesterol and CHD death underestimated the true association by 
40% (RDR=0.6). Correspondingly, their corrected association was 67% greater (since 
1/0.6 =  1.67) than their uncorrected association (though in their paper they quoted 
a 2 2 % increase, this is misleading as it should have been calculated on the log scale). 
Resurveys of study participants after 30 years of follow-up for men and women in the 
Glostrup ‘1914-cohort’ and the Framingham study estimated regression dilution ratios as 
low as 0.27 for systolic pressure and 0.14 for diastolic pressure. 522 It can be seen from 
Figure 5.12 that our own long-term estimates taken over 20 years are fairly consistent 
with these other studies.
Our observation that the effects of regression dilution were more marked amongst in­
dividuals developing CHD over the interval period (Figures 5.6 to 5.11) is also consistent 
with data from three large studies of patients with cardiovascular disease: the UK-TIA 
trial, 524 the Dutch TIA tria l525 and the European Carotid Surgery Trial. 526 These stud­
ies included regular repeated blood pressure measurements over intervals of between 5 
months and 3 years, and found that even after only 4-5 months, use of baseline measures 
in analyses would result in usual associations with disease risk over that period being 
underestimated by 50% or more. 527
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N ovel risk factors
Since the mechanisms behind regression dilution bias applies to any setting in which the 
primary interest is to estimate the prospective relationship between usual risk exposure 
levels and the risk of a particular disease occurring, interest has naturally shifted in recent 
times to the effects of regression dilution bias for new risk factors for CHD. For instance, 
a recent study of repeated homocysteine measurements measured in the Rotterdam Scan 
study, the Hordalan study, the Framingham study and the United Kingdom Prospective 
Diabetes Study revealed regression dilution ratio estimates for homocysteine of 0.83 at 
2 years, 0.71 at 6  years and 0.53 at 12 years. 528 In their analyses, the authors used 
the quintile method to estimate the RDR (see section 3.5.3); when the 4-year repeated 
data were re-analysed using this method, an RDR estimate for homocysteine of 0.76 
was obtained -  highly consistent with the results from these four other studies. In the 
Cholesterol and Recurrent Events (CARE) trial of the effects of pravastatin in patients 
with a recent myocardial infarction , 79 C-reactive protein was measured at baseline and 
after five years of follow-up in a random sample of 472 participants who remained free 
of recurrent coronary events during follow-up. The correlation between the baseline and 
follow-up measurements (which may also be used as an estimate of the regression dilution 
ratio) for these individuals was 0.60, almost exactly the same as our estimate taken over a 
similar period . 529 Recent results from the Reykjavik prospective study provide an estimate 
for C-reactive protein of 0.59 over a  1 2 -year period . 346 Despite the apparent inconsistency, 
reference to Figure 5.4 reveals that this estimate is also in general agreement with the 
estimates in this chapter. For haemostatic factors, fibrin D-dimer and von Willebrand 
factor were measured in 1,009 subjects over a 5-year period in the Edinburgh Artery 
Study. The correlation between fibrin D-dimer levels measured at baseline and after 
5 years was 0.51,356 somewhat lower than our estimate. However, for von Willebrand 
factor, the correlation was 0.63,358 which although lower is not inconsistent with our 4- 
year estimate of 0.71. Fibrinogen was measured over a 3-year period in a sample of 473 
men and women in the Finrisk Haemostasis study -  a correlation of 0.72 was observed 
between these measurements . 519
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5 .5 .4  Is correction  alw ays appropriate?
Correction for regression dilution bias is a useful tool for estimating associations between 
usual or average exposure levels and a  particular outcome of interest and, as we have 
demonstrated, failure to take these effects into account can lead to true associations being 
greatly underestimated. However, it should be stressed that in situations where the aeti- 
ological relationship is not with the underlying usual value of the predictor, adjustment 
for regression dilution bias may not be appropriate . 530 For instance, suppose that recent 
levels of an exposure, or perhaps peaks in an exposure, were more important predictors 
of a particular outcome than the usual level. Attempting to estimate the association 
with the ‘usual” level in these situations would not necessarily be appropriate. In the 
Intersalt study, for example, the association between sodium excretion and blood pressure 
was corrected for regression dilution bias . 531 The validity of performing such a correc­
tion was subsequently strongly debated, both because of the relevance of recent (and not 
usual) levels in determining this relationship and also because of the problems caused 
by the potential correlation between the errors in measurement of the predictor and the 
outcome. 530’532 In the context of quantifying the long-term observational relationships 
between coronary risk factors and coronary heart disease risk however (where the disease 
outcome is measured with precision), it would seem perfectly reasonable to assume that 
risk is determined by average risk exposures during adulthood (or at least average risk 
exposure levels over, say, the previous decade), and hence it would be appropriate to use 
the estimates of regression dilution bias presented in this chapter to correct estimated 
exposure-disease relationships. Where it may not necessarily be appropriate to correct 
for regression dilution bias however, is in the use of risk prediction equations (e.g. the 
Framingham equations) , 50 ’410 because these equations are commonly derived from the 
same information that will be available to the clinician attempting to use them (i.e. risk 
factor levels measured at a single point in time).
5.5 .5  C onclusions: e x te n t  o f  w ith in -p e r so n  variation
In this chapter the extent of within-person variation in both continuous and categorical 
risk factors for CHD has been estimated for men in the British Regional Heart Study. 
For continuous risk factors, this variation has been quantified in terms of the extent that 
univariate relationships with disease risk over particular periods of follow-up would be
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underestimated due to the use of baseline measures in analyses (the extent of ‘regression 
dilution bias’). These effects have been shown to be substantial. For categorical ‘lifestyle’ 
risk factors, estimated average exposures to these factors over the ‘risk period’ have been 
calculated through a combination of the baseline and follow-up questionnaires. For these 
factors, the extent of within-person variation (in terms of the degree of misclassification) 
was also found to be considerable, particularly amongst certain high-risk exposure groups 
(e.g. heavy smokers, heavy drinkers). In a multivariate analysis setting, correlations 
between different risk factors can lead to under or overestimation of risk associations, 
even for risk factors measured precisely. Under such circumstances, the appropriateness of 
performing univariate correction methods may be evaluated by calculating a “modifying 
matrix” A-1 .
Table 5.1: Selected characteristics over periods of 1 week, 4, 16 and 20 years. For each measure, men that attended only the first screening 
in the pair are presented alongside those that attended both screenings. Data indicate mean (SD) unless otherwise indicated.
1 week period 4 year period 16 year period 20 year period
Initial FU Initial FU Initial FU Initial FU
Year of screening 2000 2000 1996 2000 1980 1996 1980 2000
Number of men 112 112 297 297 425 425 4252 4252
Age (years) 70.0 (5.2) 70.0 (5.2) 65.0 (5.5) 69.0 (5.5) 49.6 (5.7) 65.6 (5.7) 48.9 (5.5) 68.9 (5.5)
Total cholesterol (mmol/L) 5.7 (1.1) 5.5 (1.0) 5.9 (1.1) 5.9 (1.1) 6.4 (1.0) 5.9 (1.0) 6.3 (1.0) 6.0 (1.1)
LDL cholesterol (mmol/L) 3.8 (1.0) 3.7 (0.9) 3.6 (1.0) 3.8 (1.0) 4.3 (0.9) 3.7 (0.9) 4.2 (1.0) 3.9 (1.0)
HDL cholesterol (mmol/L) f 1.12
(0.90-1.30)
1.07
(0.90-1.20)
1.24
(1.00-1.40)
1.27
(1.10-1.50)
1.14
(0.99-1.30)
1.23
(1.00-1.40)
1.12
(0.97-1.29)
1.28
(1.10-1.50)
Triglyceride (mmol/L) f 1.4 
(1.1-1.8)
1.4 
(1.0—1.8)
2.0 
(1.4-2.7)
1.6 
(1.1-2.2)
1.8 
(1.2-2.7)
2.0 
(1.4-2.9)
1.7 
(1.2-2.5)
1.6 
(1.2-2.2)
SBP (mm Hg) 149 (24) 140 (21) 149 (25) 151 (25) 148 (19) 149 (25) 143 (20) 149 (24)
DBP (mm Hg) 85.8 (11.7) 83.0 (10.4) 85.0 (11.2) 86.4 (10.8) 83.5 (13.1) 84.3 (11.0) 81.4 (12.8) 85.1 (11.2)
Glucose (mmol/L) f 6.1 
(5.5-6.3)
6.0
(5.5-6.4)
5.7 
(5.1-5.9)
6.4
(5.6-6.4)
5.4 
(5.0-5.9)
5.8 
(5.1-6.2)
5.5 
(4.9-5.9)
5.9 
(5.3-6.1)
Insulin (mU/L) f 8.6
(6.1-11.7)
8.5
(5.9-12.0)
10.7
(5.6-19.1)
8.4
(5.4-11.8)
12.7
(7.4-21.2)
10.9
(5.6-20.6)
12.5
(7.3-20.5)
8.7
(5.7-12.4)
fGeometric mean (interquartile range)
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Table 5.2: Estimates of the regression dilution ratio (RDR) by duration of follow-up for 
the blood lipids, blood pressure, body mass index, insulin and glucose.
Risk exposure
One week
RDR (95% Cl)
4 years 16 years 2 0  years
Total cholesterol 0.87 (0.80,0.94) 0.70 (0.61,0.80 0.59 (0.50,0.67) 0.53 (0.50,0.56)
HDL cholesterol § 1.00 (0.93,1.06) 0.87 (0.79,0.95 0.68 (0.60,0.76) 0.74 (0.71,0.77)
LDL cholesterol 0.86 (0.79,0.94) 0.61 (0.51,0.71 0.49 (0.40,0.59) 0.48 (0.45,0.51)
Triglyceride § 0.86 (0.73,0.98) 0.66 (0.58,0.75 0.47 (0.39,0.56) 0.43 (0.41,0.46)
TotakHDL § 0.95 (0.89,1.00) 0.77 (0.69,0.86 0.65 (0.57,0.74) 0.64 (0.61,0.67)
Body mass index 1.02 (1.00,1.03) 0.91 (0.84,0.97 0.94 (0.86,1.02) 0.93 (0.91,0.96)
SBP 0.69 (0.58,0.80) 0.61 (0.52,0.70 0.66 (0.55,0.77) 0.49 (0.45,0.52)
DBP 0.72 (0.62,0.83) 0.51 (0.41,0.60 0.27 (0.19,0.35) 0.24 (0.22,0.27)
Mid blood pressure 0.70 (0.60,0.80) 0.59 (0.50,0.68 0.48 (0.38,0.57) 0.40 (0.37,0.43)
Mean arterial pressure 0.71 (0.60,0.81) 0.57 (0.48,0.67 0.40 (0.31,0.49) 0.35 (0.32,0.38)
Glucose § 0.83 (0.71,0.96) 0.52 (0.40,0.63 0.29 (0.19,0.39) 0.33 (0.30,0.37)
Insulin § 0.87 (0.72,1.02) 0.34 (0.26,0.42 0.30 (0.20,0.41) 0.27 (0.24,0.30)
§Analysed on the log scale; Cl =  confidence interval; SBP =  systolic blood pressure; DBP 
=  diastolic blood pressure; Mid blood pressure =  (SBP +  DBP)/2; Mean arterial pressure 
-  (1/3) SBP +  (2/3) DBP.
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Table 5.3: Estimates of the regression dilution ratio (RDR) for the novel coronary risk 
factors by duration of follow-up
Risk exposure RDR (95% Cl)
One week 4 years 16 years 2 0  years
Homocysteine § 0.87 (0.81,0.93) 0.81 (0.73,0.90) 0.49 (0.32,0.67) 0.41 (0.31,0.50)
C-reactive protein § 0.74 (0.61,0.87) 0.61 (0.51,0.72) 0.50 (0.27,0.72) 0.42 (0.35,0.49)
Fibrinogen 0.84 (0.75,0.93) 0.52 (0.41,0.64) - -
Factor VII 0.88 (0.80,0.96) 0.75 (0.65,0.85) - -
vWF § 0.83 (0.73,0.92) 0.71 (0.64,0.78) 0.67 (0.49,0.85) 0.51 (0.46,0.56)
t-P a  § 0.71 (0.58,0.83) 0.68 (0.58,0.79) 0.33 (0.12,0.53) 0.34 (0.28,0.39)
D-dimer § 0.85 (0.78,0.93) 0.76 (0.67,0.86) 0.20 (-0.04,0.43) 0.17 (0.11,0.24)
§Analysed on the log scale; Cl =  confidence interval; SBP =  systolic blood pressure; DBP 
=  diastolic blood pressure; vWF =  Von Willebrand Factor
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Table 5.4: Responses to each of the study questionnaires regarding cigarette smoking, 
physical activity and alcohol intake. Figures indicate column percentages.
Study Questionnaire
Baseline
(n=7735)
Q5
(n=7275)
Q92
(n=5925)
Q96
(n=5263)
Q20 
(n—4252)
Cigarette smoking
Never smoked 23.6 24.1 26.1 27.2 29.0
Ex-smoker 35.2 43.6 54.5 57.5 58.3
Current (1-20 a day) 26.2 23.7 16.0 12.9 1 1 .0
Current (21-39 a day) 1 1 .0 6.4 2 . 6 2 .1 1.3
Current (>40 a day) 4.1 2.3 0.9 0.4 0.5
Physical activity
None 9.0 - 7.7 15.1 11.5
Occasional 30.7 - 26.7 26.6 23.4
Light 23.1 - 22.9 19.6 18.7
Moderate 15.8 - 15.9 13.0 14.4
Moderately vigorous 14.7 - 15.5 14.7 16.8
Vigorous 6.7 - 11.3 1 1 .1 15.2
Alcohol intake
None 6 . 0 9.8 17.4 16.5 10.4
Occasional 23.9 29.7 23.8 2 1 .8 27.0
Light 32.9 37.1 41.0 44.1 43.9
Moderate 26.4 19.3 14.3 14.3 15.7
Heavy 1 0 .8 4.1 3.5 3.3 3.0
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Table 5.5: Comparison of cigarette smoking status measured at baseline with “average” 
cigarette smoking status over the follow-up period -  no. (row %)
“Average” exposure to cigarette smoking during the study
Baseline smoking 
status
Never Ex New* Current
(1-20)
Current
(21-39)
Current
(>40)
Total
Never 1802 (99) - 17 (1) - - - 1819 (100)
Ex-smoker - 2525 (93) 190 (7) - - - 2715 (100)
Current (1-20) - - - 1936 (96) 81 (4) 6 ( 0 ) 2023 (100)
Current (21-39) - - - 447 (53) 393 (46) 6 ( 1 ) 846 (100)
Current (>40) - - - 106 (34) 127 (40) 83 (26) 316 (100)
Total 1802 (23) 2525 (33) 207 (3) 2489 (32) 601 (8) 95 (1) 7719 (100)
* New or recurrent cigarette smoker
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Table 5.6: Comparison of physical activity level measured at baseline with “average” 
physical activity level over the follow-up period -  no. (row %)
“Average” physical activity level during the study
Baseline physical 
activity level
None Occasional Light Moderate Moderately
vigorous
Vigorous Total
None 389 (57) 227 (33) 52 (8) 18 (3) - - 686 (100)
Occasional 128 (5) 1470 (63) 504 (21) 216 (9) 27 (1) - 2345 (100)
Light - 378 (21) 1062 (60) 252 (14) 69 (4) - 1761 (100)
Moderate - 55 (5) 366 (30) 576 (48) 208 (17) - 1205 (100)
Mod. vigorous - 8 ( 1 ) 145 (13) 282 (25) 586 (52) 99 (9) 1120 (100)
Vigorous - - 23 (4) 82 (16) 140 (27) 268 (52) 513 (100)
Total 517 (9) 2138 (31) 2152 (23) 1426 (16) 1030 (15) 367 (7) 7630 (100)
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Table 5.7: Comparison of alcohol intake measured at baseline with “average” alcohol 
intake over the follow-up period -  no. (row %)
“Average” alcohol intake during the study
Baseline alcohol 
intake
None Occasional Light Moderate Heavy Total
None 371 (80) 80 (17) 12 (3) 3(1) - 466 (100)
Occasional 327 (18) 1147 (62) 357 (19) 14 (1) - 1845 (100)
Light 46(2) 655 (26) 1654 (65) 188 (7) 1 (0 ) 2544 (100)
Moderate 1 0  (0 ) 195 (10) 975 (48) 806 (39) 56 (3) 2042 (100)
Heavy 1 (0 ) 24(3) 143 (17) 430 (52) 234 (28) 832 (100)
Total 755 (10) 2101 (27) 3141 (41) 1441 (19) 291 (4) 7729 (100)
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Figure 5.1: Four hypothetical examples illustrating the method used to calculate average 
exposures over the follow-up period from the study questionnaires (QO, Q5, Q92, Q96 and 
Q20). In each case assume the man was enrolled into the study in November 1980 so that 
the intervals between successive questionnaires are 5 years, 7 years, 4 years and 4 years 
respectively.
(i) subject dies of CHD after 13 years 
(average exposure = (10 + 17.5 + 3)/1 3) = 2.3 Fatal Ml
4
3
2
1
0
1980(00) 1985 (Q5) 1992 (Q92) 1996 (Q96) 2000(020)
(ii) subject has a non-fatal Ml after 8 years but survives 20 years 
(average exposure = (5 + 3) / 8) = 1.0
4
Non-fatal Ml
3
2
1
0
1980(00) 1985 (Q5) 1992(092) 1996 (096) 2000 (020 )
(iii) no response to Q5, subject has a non-fatal Ml after 18 years 
(average exposure = (42 + 12 + 6) /18) = 3.3
§
Non-fatal Ml
1980(00) 1985(05) 1992(092) 1996 (096) 2000 (Q20)
(iv) no response to 092 or Q20, subject remains events free for 20 years 
(average exposure = (0 + 11 + 8) / 20) = 0.95 
41
S ......................
0 — ..- ................. .................
....... (B) (C)
1980 (QO) 1985 (Q5) 1992 (Q92) 1996(096) 2000(020)
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Figure 5.2: Regression dilution ratio estimates (with 95% CIs) for blood lipid measure­
ments and body mass index by length of interval period.
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Figure 5.3: Regression dilution ratio estimates (with 95% CIs) for blood pressure, insulin 
and glucose by length of interval period.
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Figure 5.4: Regression dilution ratio estimates (with 95% CIs) for homocysteine and C- 
reactive protein by length of interval period.
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Figure 5.5: Regression dilution ratio estimates (with 95% CIs) for the haemostatic factors 
by length of interval period.
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Figure 5.6: Estimates of the RDR for total cholesterol over 20 years by age, history of 
CHD, social class and geographical location.
Age
40-44 years 
45-49 years 
50-54 years 
55-59 years
Baseline evidence of CHD 
Yes 
No
CHD by end of 20-year interval 
Yes 
No
Social class
Manual
Non-manual
Geographic location
South
Midlands/Wales
North
Scotland
p-value
(difference)
0.02
0.17
< 0.001
0.61
0.03
r~
0.0
— r ~
0.2
I
0.4
I
0.80.6
RDR (95% Cl)
i
1.0
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Figure 5.7: Estimates of the RDR for HDL cholesterol over 20 years by age, history of 
CHD, social class and geographical location.
Age
40-44 years 
45-49 years 
50-54 years 
55-59 years
Baseline evidence of CHD 
Yes 
No
CHD by end of 20-year interval 
Yes 
No
Social class
Manual
Non-manual
p-value
(difference)
e iiiii
*
0.41
0.2
0.04
0.72
Geographic location
South
Midlands/Wales
North
Scotland
0 . 2 2
I
0.2
I
0.40.0
I
0.6
— r ~
0.8
I
1.0
RDR (95% Cl)
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Figure 5.8: Estimates of the RDR for LDL cholesterol over 20 years by age, history of 
CHD, social class and geographical location.
Age
40-44 years 
45-49 years 
50-54 years 
55-59 years
Baseline evidence of CHD 
Yes 
No
CHD by end of 20-year interval 
Yes 
No
Social class
Manual
Non-manual
Geographic location
South
Midlands/Wales
North
Scotland
p-value
(difference)
0.29
0.21
< 0.001
0.75
0 .0 1
r~
o.o
— r ~
0.2
—T~-
0.4
i
0.6
—r~
0.8
I
1.0
RDR (95% Cl)
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Figure 5.9: Estimates of the RDR for the ratio of total to HDL cholesterol over 20 years 
by age, history of CHD, social class and geographical location.
Age
40-44 years 
45-49 years 
50-54 years 
55-59 years
Baseline evidence of CHD 
Yes 
No
CHD by end of 20-year interval 
Yes 
No
Social class
Manual
Non-manual
Geographic location
South
Midlands/Wales
North
Scotland
p-value
(difference)
0.13
0.29
< 0.001
0.55
0.64
I----------1----------1----------[~
0.0 0.2 0.4 0.6 0.8 1.0
RDR (95% Cl)
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Figure 5.10: Estimates of the RDR for systolic blood pressure over 20 years by age, history 
of CHD, social class and geographical location.
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55-59 years
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(difference)
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0.25
0 . 1 2
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0.6
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0.0 0.4
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i
0.8
“ I
1.0
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Figure 5.11: Estimates of the RDR for diastolic blood pressure over 20 years by age, 
history of CHD, social class and geographical location.
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Figure 5.12: Estimates of the RDR for blood pressure, total cholesterol and HDL choles­
terol from previous studies. The blue circles correspond to the 4-, 16- and 2 0 -year BRHS 
estimates presented in this chapter.
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Im pact o f w ithin—person variation  
on CHD risk associations
6.1 Sum m ary
In this chapter, the age-adjusted relations between the established coronary risk factors 
(blood lipids, blood pressure, body mass index, and lifestyle characteristics including ciga­
rette smoking and physical activity) and major CHD risk (coronary death or non-fatal 
myocardial infarction) over the first twenty years of the BRHS are estimated. Estimates of 
the relative hazard for these factors are presented before and after correction for within- 
person variation, and are presented separately by each decade of follow-up. The combined 
effects of regression dilution bias in more than one risk factor on estimated multivariate 
relationships are also assessed. The results indicate strong positive (negative for HDL) 
linear associations between different blood lipid and blood pressure indices and major 
CHD risk, and a weaker positive relationship for body mass index. After correction for re­
gression dilution bias, major CHD risk increased by 63% for each mmol/1 increase in total 
cholesterol, and increased by 48% for every 20 mmHg increase in systolic blood pressure. 
Before correction for regression dilution bias these estimates were 39% and 25% respec­
tively. Taking within-person variation in categorical risk factors into account improved 
the predictiveness of these exposures. On average, cigarette smokers had approximately 
a twofold risk of major CHD over never smokers; this risk increased with amount of ciga­
rettes smoked each day. Men who were moderately active had nearly a 70% lower risk 
of CHD than inactive men; those who were “light” drinkers had a 22% lower risk than
175
CHAPTER 6. W ITHIN-PERSON VARIATION AND CHD RISK RELATIONS  176
non-drinkers. The estimated effects of these risk factors appeared to vary over the period 
of follow-up, though for the continuous risk factors, this dependency was largely abol­
ished by performing “time-dependent” correction for regression dilution bias. Estimated 
regression coefficients in a multivariate analysis varied little depending on whether “multi­
variate” or “univariate” correction methods were employed, though some small differences 
were observed.
6.2 Introduction  and ob jectives
In chapter 5, the extent of within-person variation in continuous and categorical risk fac­
tors over a twenty year period was assessed. For the established continuous risk factors, 
this was described in terms of estimating the regression dilution ratio (RDR) over a va­
riety of follow-up periods and then approximating the nature of the relationship through 
these estimates by fitting a negative exponential curve (see Figures 5.2 and 5.3). For the 
categorical risk factors, the follow-up questionnaires (Q5, Q92, Q96 and Q20) were used 
to derive “average” exposures to these factors over the period of risk. For these factors, it 
was shown that baseline risk factor levels tended to be more extreme than the true under­
lying exposures to these factors. In this chapter, the effects of this variation on estimated 
relationships between established CHD risk factors and major CHD risk (coronary death 
or non-fatal myocardial infarction) over 2 0  years are examined.
For the continuous risk factors (in particular the blood lipid and blood pressure indices 
and body mass index), the estimated relationships between the RDR and the interval 
period over which it is estimated are used to relate 20-year major CHD risk with levels 
of these factors at the midpoint of this interval (i.e. after 10 years) . 19 Relations between 
categorical risk factors and 20-year major CHD risk are estimated, both before and after 
adjustment for within-person variation. The relative ability of different blood lipid and 
blood pressure measures to  predict CHD risk, as well as the relative “superiority” of using 
average lifestyle risk factors in analyses rather than baseline levels is also assessed. Due 
to the long period of follow-up of study participants, the degree to which risk factor 
associations are constant over time (the proportional hazards assumption) is also assessed 
by comparing risk associations during the first and second decades of follow-up. Finally, 
the impact of within-person variability in two risk factors on the adjusted CHD relations
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of several factors (including factors measured precisely) are assessed. This is done by 
estimating the associations between total cholesterol and systolic blood pressure with 
CHD risk after adjustment for each other, age and cigarette smoking (current, ex, never) 
for men with no baseline diagnosis of CHD.
6.3 M ethods
This chapter examines the relations between the established coronary risk factors and ma­
jor CHD risk, defined as coronary death or non-fatal myocardial infarction, over 20 years 
of follow-up. Four different blood lipid indices (total, LDL, HDL, and the ratio of total 
to HDL) and four blood pressure indices (systolic, diastolic, mean arterial pressure, and 
mid blood pressure) are selected and compared in terms of strength of association and 
predictive ability. Pulse pressure (the difference between systolic and diastolic pressure) 
was not considered as evidence from other studies suggests that this measure is a rela­
tively poor predictor of CHD risk (compared with the other blood pressure indices) . 113 
Lifestyle characteristics before and after adjustment for within-person variation (baseline 
measurements vs measurements that take into account follow-up questionnaires) are also 
compared in terms of strength of association and predictive ability. Each of these risk 
factors is considered first in isolation (adjusted only for age). In section 6.4.8, the effect 
of within-person variation in several risk factors on estimated multivariate associations is 
considered. In this analysis, only men with no baseline evidence of CHD are included.
6.3 .1  K aplan—M eier  cu rves and  re la tive  “in form ativen ess”
Kaplan-Meier curves stratified by baseline fifth of blood lipids (total, LDL, HDL and to- 
tal:HDL), blood pressure (systolic, diastolic, mean arterial and mid blood pressure), and 
body mass index were used to display differences in the cumulative incidence of major 
CHD events over 20 years by levels of these variables; tests for difference were based on 
the log-rank test. Kaplan-Meier curves were also used to display differences in the cumu­
lative incidence of CHD by cigarette smoking exposure, physical activity level and alcohol 
intake, both before and after taking within-person variation (follow-up questionnaires) 
into account. The “relative informativeness” of different blood lipid and blood pressure 
indices (divided into fifths) was assessed by comparing their respective log-rank statistics.
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Similarly, the relative informativeness of baseline versus “average” exposures to cigarette 
smoking, physical activity and alcohol intake was ascertained by comparing the magni­
tude of the log-rank statistics before and after adjustment for within-person variation 
(i.e. comparing the log-rank statistic calculated using baseline exposures to that obtained 
when using the “average” exposures).
6 .3 .2  R ela tion sh ip  b etw een  baseline leve ls  and  2 0 -y ea r  m ajor C H D  risk
Cox proportional hazards regression was used to estimate the age adjusted relative hazard 
of major CHD over 20 years for each fifth of the baseline distributions of blood lipids, blood 
pressure and body mass index, and for baseline categories of cigarette smoking, physical 
activity and alcohol intake level. Relative hazards corresponding to unit increases in BMI, 
blood lipid and blood pressure levels were estimated by fitting these terms as continuous 
variables in an age-adjusted model. These are presented per 1 mmol/1 increase in total 
and LDL cholesterol, per 20 mmHg increase in systolic blood pressure, per 10 mmHg 
increase in diastolic, mean arterial and mid blood pressure, and per 1 kg/m 2 increase 
in BMI. For HDL cholesterol and the ratio of total to HDL cholesterol, analyses were 
performed on the log scale and hazard ratios are presented per 2 0 % increase in these 
factors (calculated by 1.2^, where (3 is the estimated log hazard ratio). For presentation 
purposes, the proportional hazards regression coefficients relating log relative hazard to 
each these risk factors (by fifth of the blood lipid, blood pressure and BMI distributions and 
for each category of cigarette smoking, physical activity and alcohol intake) are presented 
as “floating absolute risks” 477 (see Figures 6 .1  to 6.9).
6 .3 .3  R ela tion sh ip  b e tw een  “u sual” levels and  2 0 -y ea r  m ajor C H D  risk
For the continuous measurements, 20-year major CHD risks were related to estimated 
levels at the midpoint of this interval (i.e. after ten years) by estimating the 1 0 -year re­
gression dilution ratios for these variables (see Table 6.1), calculating the expected 10-year 
level conditional on the baseline level for each individual (see equation 3.19), and recalcu­
lating the hazard ratios and floating absolute risks from these data. For the categorical 
risk factors, hazard ratios and floating absolute risks were calculated for the estimated 
“average” exposure categories rather than the baseline categories.
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6 .3 .4  P ro p o rtio n a l hazards assu m p tion
For each of the CHD risk factors, separate estimates of the hazard ratio were calculated 
over the first and second ten years of follow-up, in order to assess the magnitude of 
possible deviations from the proportional hazards assumption by decade of follow-up. For 
the continuous risk factors (blood lipids, blood pressure and body mass index), this was 
examined:
1. By relating CHD risk in both decades to usual risk factor levels at the midpoint of 
the twenty year interval (1988/90);
2. By relating CHD risk in each decade separately to usual risk factor levels during that 
decade (time-dependent correction for regression dilution bias),533 i.e. risk in the 
first decade was related to usual risk factor levels approximately 5 years after baseline 
and risk in the second decade was related to usual risk factor levels approximately 
15 years after baseline.
Formal tests of non-proportionality were performed through assessment of the Schoenfeld 
residuals (as described in section 3.4.2). For cigarette smoking, physical activity and 
alcohol intake, it would have been problematic to estimate decade-specific risk associations 
in the same manner as for the continuous risk factors, not least because no information 
was available at ten years of follow-up. Rather, the bulk of the information about these 
risk exposures was collected after the first decade of follow-up had already elapsed.
6 .3 .5  M u ltivaria te  a sso c ia tio n s
In multivariate analyses where two or more variables are subject to within-person vari­
ation, estimated regression coefficients may under or overestimate true regression coeffi­
cients depending on the degree of correlation between the variables.26’27 Rosner’s multi­
variate correction method (described in chapter 3), estimates the vector of true regression 
coefficients (3*, from the vector of observed regression coefficients /3, using the equation 
(3* = /3A_1, where A is a m atrix of regression coefficients relating follow-up levels of all 
measurements (including those measured precisely) to observed baseline levels. In chap­
ter 5, estimates of A -1 were presented to describe the relations between a blood lipid 
measurement (total or HDL cholesterol), a blood pressure measurement (systolic or dias­
tolic pressure), and two variables that can be thought of as precisely measured (age and
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cigarette smoking status, classified as never, ex, or current), for men with no baseline 
evidence of CHD followed over 20 years. These estimates showed that the combination 
of using total cholesterol and systolic blood pressure yielded the least bias in estimation 
of other associations. In this chapter, this estimate of A -1 is used to estimate the true 
relative hazard of major CHD 15-25 years after baseline, for age, total cholesterol, systolic 
blood pressure, and cigarette smoking status, after multivariate correction for regression 
dilution bias in total cholesterol and systolic blood pressure. The results from four models 
are presented:
1. an analysis that ignores the effects of regression dilution bias entirely;
2. an analysis that corrects for regression dilution bias in total cholesterol only;
3. an analysis that corrects for regression dilution bias in systolic blood pressure only; 
and
4. an analysis that corrects for regression dilution bias in both total cholesterol and 
systolic blood pressure.
95% confidence intervals for the regression-dilution-corrected hazard ratios were obtained 
by using bootstrap resampling (with 1000 replicates) to estimate the 2.5 and 97.5 bias- 
corrected percentiles of the distribution of the corrected coefficients (see section 3.4.4).
6.4  R esu lts
6.4 .1  P o p u la tio n  ch a racter istics
Table 6.2 shows the baseline characteristics of the 7,735 men in the British Regional Heart 
Study together with the estimated usual risk factor levels over the 20-year study period. 
Mean total cholesterol was 6.3 mmol/1, mean LDL cholesterol 4.2 mmol/1, mean HDL 
cholesterol 1.12 mmol/1 and the mean ratio of total to HDL cholesterol was 5.6. Mean 
blood pressure was 145/82 mmHg and mean BMI was 25.5 kg/m2. After taking within- 
person variation in lifestyle risk factors into account (as described in chapter 5), 1,802 men 
(23.4%) were categorised as “never smokers” throughout the study, 2,525 men (32.8%) 
as “ex-smokers since 1978/80” , and 207 men (2.7%) as “new” or “recurrent” cigarette 
smokers. Of the remaining men, the vast majority smoked an average of between 1 and 20
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cigarettes a day (2,489 men), with 601 men (7.8%) smoking 21-39 cigarettes a day and just 
95 men (1.2%) truly smoking at least 40 cigarettes a day. For physical activity, after taking 
within-person variation into account, the modal exposure categories were “occasional” and 
“light” , with approximately 28% of men falling into each category. Relatively few men 
were either inactive throughout the study (6.8%) or vigorously active throughout the study 
(4.8%). For alcohol intake, nearly 70% of all men were either occasional or light drinkers 
throughout the study, with a further 19% of men classified as “moderate drinkers” . Few 
men (3.8%) were truly heavy drinkers based on average alcohol intake during the study. 
Over the first twenty years of follow-up, 1,299 men (16.8%) experienced a major CHD 
event. The age-adjusted relations between the established coronary risk factors and major 
CHD risk are now described.
6 .4 .2  B lo o d  lip ids and  m ajor C H D
The age-adjusted relationships between blood lipids and 20-year CHD risk (both before 
and after correction for regression dilution bias) are shown in Figures 6.1 and 6.2. For 
serum total cholesterol and LDL cholesterol, the Kaplan-Meier CHD event curves and 
floating absolute risks (by fifth of the baseline distribution) display a clear positive con­
tinuous relationship with major CHD risk over 20 years. Before correction for regression 
dilution bias, the estimated relative hazard corresponding to a 1 mmol/1 increase in total 
cholesterol was 1.39 (95% confidence interval 1.32 to 1.46). After correction for regres­
sion dilution bias, this hazard ratio increased to 1.63 (95% Cl 1.52 to 1.76). For LDL 
cholesterol, the relative hazard of major CHD per 1 mmol/1 increase was 1.41 (95% Cl 
1.32 to 1.50) before, and 1.74 (95% Cl 1.57 to 1.93) after correction for regression dilution 
bias. HDL cholesterol displayed a continuous negative relationship with major CHD risk 
(Figure 6.2). For each 20% increase in HDL cholesterol, major CHD risk was estimated 
to decrease by 18% (95% Cl 14% to 21%) before correction and by 21% (95% Cl 16% to 
25%) after correction for regression dilution bias. The ratio of total to HDL cholesterol 
displayed a similarly strong positive relationship with major CHD risk as was observed 
for total cholesterol. For each 20% increase in the ratio of total to HDL cholesterol, major 
CHD risk was estimated to increase by 29% (95% Cl 25% to 34%) before correction and 
by 40% (95% Cl 34% to  47%) after correction for regression dilution bias. For each of the 
blood lipid indices, there was no evidence of any “threshold” level below which a lower
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level did not confer a lower (respectively higher for HDL) risk of major CHD, though it 
is acknowledged that these analyses would have had only limited power to detect such 
a threshold, if one did exist. The log-rank statistics by fifth of the distributions of the 
different blood lipid indices were highest for total cholesterol and the ratio of total to HDL 
cholesterol (x2 =  161 and 174 respectively), and lowest for HDL cholesterol (x2 =  68).
6 .4 .3  B lo o d  p ressure and m ajor C H D
The age-adjusted relationships between blood pressure and 20-year CHD risk (before and 
after correction for regression dilution bias) are shown in Figures 6.3 and 6.4. Continuous 
graded positive relationships are seen for all blood pressure indices, with no evidence of 
any threshold levels below which a lower exposure does not confer a lower CHD risk. 
Before correction for regression dilution bias, the risk of major CHD was estimated to 
increase by 25% for each 20 mmHg increase in systolic pressure, by 19% for each 10 
mmHg increase in diastolic pressure and mean arterial pressure, and by 17% for each 10 
mmHg increase in mid blood pressure. After correction for regression dilution bias, a 20 
mmHg increase in systolic pressure was estimated to increase CHD risk by 48% (95% Cl 
36% to 61%), while a 10 mmHg increase in diastolic pressure and mean arterial pressure 
was estimated to increase CHD risk by 56% (95% Cl 42% to 72%) and 42% (95% Cl 33% 
to 53%) respectively. A 10 mmHg increase in mid blood pressure was associated with a 
36% (95% 28% to 44%) increase in major CHD risk after correction for regression dilution 
bias. The relative informativeness of the different blood pressure indices was highest for 
systolic pressure (log-rank x 2 =  149) and lowest for diastolic pressure (log-rank x 2 =  83).
6 .4 .4  B o d y  m ass in d e x  an d  m ajor C H D
The relationship between body mass index and major CHD risk is shown in Figure 6.5. 
The risk of major CHD decreased steadily with decreasing BMI, at least down to a level 
of 21 kg/m2. However, the strength of relationship was weaker than that observed for the 
blood lipid or blood pressure indices, with less than a twofold difference in risk between 
those in the top and bottom  fifths of the distribution. The effects of regression dilution 
bias for body mass index were minimal, due to the stability of this measure over time. 
For a 1 kg/m 2 increase in BMI, the risk of major CHD was estimated to increase by 6% 
(96% Cl 4% to 8%).
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6 .4 .5  C om parison  o f  aetio log ica l force b etw een  different risk factors
Figure 6.6 shows age-adjusted estimates of the hazard ratio for major CHD for each of the 
blood lipid and physical measures (blood pressure and body mass index), by comparing 
the risks of those in the top fifth of the distribution with the risks of those in the bottom 
fifth (vice versa for HDL cholesterol). The difference in major CHD risk across the risk 
factor distribution is greatest for the blood lipid indices (particularly total cholesterol 
and the ratio of total to HDL cholesterol) where approximately a threefold difference in 
risk is observed, and is lowest for body mass index (less than a twofold difference). The 
different blood pressure indices displayed almost identical gradients in major CHD risk 
across their distributions (approximately a  twofold difference in major CHD). For the 
blood lipid indices, the gradient in major CHD risk was notably lower for HDL cholesterol 
than for the other blood lipid measures.
6 .4 .6  L ifesty le  ch a racter istics  and m ajor C H D
The age-adjusted relationships between cigarette smoking, physical activity and alcohol 
intake and major CHD risk over 20 years are shown in Figures 6.7 to 6.9, both before and 
after correction for within-person variation (changes in lifestyle recorded on the follow-up 
questionnaires).
C igarette sm oking
Figure 6.7 shows the relationship between cigarette smoking and major CHD risk. Relative 
to individuals who had never smoked cigarettes, ex-smokers had a 42% higher risk of 
CHD according to baseline data. After taking within-person variation into account, this 
decreased to a 37% excess risk, due to the prior inappropriate inclusion of a number of 
“new/recurrent” smokers amongst the “ex-smokers” (a group that had a 75% excess risk 
of CHD over never smokers). When baseline data were used to define smoking exposure, 
CHD risk varied little by amount smoked -  the relative hazard of CHD compared with 
never smokers was 1.90 (95% Cl 1.60 to 2.25) for those who smoked 1-20 cigarettes a day, 
2.34 (95% Cl 1.92 to 2.86) for those who smoked 21-39 cigarettes a day, and 1.79 (95% 
Cl 1.32 to 2.42) for those who smoked 40 or more a day. However, when reported changes 
in cigarette smoking habits over time were taken into account, a clear dose response 
relationship between CHD risk and amount smoked was observed. Compared with never
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smokers, the true relative hazard of CHD was 1.71 (95% Cl 1.45 to 2.02) for those who 
smoked 1-20 cigarettes a day, 3.05 (95% Cl 2.48 to 3.76) for those who smoked 21-39 
cigarettes a day, and 4.17 (95% Cl 2.81 to 6.20) for those who smoked 40 or more a day. 
The informativeness of baseline cigarette smoking exposure was substantially lower than 
the informativeness of a smoking exposure category that took follow-up questionnaires into 
account (log-rank statistic equalled 105 before and 149 after correction for within-person 
variation).
Physical activity
Figure 6.8 shows the relationship between physical activity and major CHD risk. Risk 
was highest amongst inactive men, and decreased progressively with increasing levels of 
physical activity up to moderate levels, after which a small increase in risk was observed. 
Relative to inactive men, the age-adjusted relative hazard of major CHD for moderately 
active men was 0.47 (95% Cl 0.42 to 0.65) before correction and 0.32 (95% Cl 0.25 to 0.39) 
after correction for within-person variation. The relative risk reduction corresponding to 
vigorous levels of physical activity was similar before and after correction for within-person 
variation, the vigorously active had approximately half the risk of major CHD of the 
inactive. The informativeness of the six-level physical activity scale was vastly improved 
by taking within-person variation into account (the log-rank test statistic increased from 
82 to 194).
Alcohol intake
The relationship between alcohol intake (defined as none, occasional, light, moderate or 
heavy) and major CHD risk is displayed in Figure 6.9. A U-shaped relationship was 
observed by baseline levels of alcohol intake, with men who were non-drinkers at base­
line having the highest subsequent rates of major CHD. “Light” drinkers had the lowest 
observed risks of major CHD, 34% (95% Cl 18% to 47%) lower than than those of non­
drinkers. However, after taking account of within-person variation in alcohol intake, the 
risks of non-drinkers were not significantly different from those of either occasional or 
moderate drinkers, and the estimated benefits from “light” levels of drinking were re­
duced from 34% to 22% (95% Cl 6% to 36%). Furthermore, men who were truly heavy 
drinkers throughout the study had a 75% higher risk of CHD (95% Cl 31% to 133%)
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over non-drinkers (compared with an estimated 16% lower risk from baseline data). As 
was observed for cigarette smoking and physical activity, the relative informativeness of 
the five-level alcohol intake scale was increased after taking within-person variation into 
account (the log-rank test statistic increased from 22 to 56).
6 .4 .7  N o n -p ro p o r tio n a lity  and tim e—d ep en d en t correction  for regres­
sion  d ilu tion  b ias
Table 6.3 shows the relationships between usual risk factor levels over the twenty-year 
period and the risk of major CHD in each decade of follow-up (1978/80 -  1988/90 and 
1988/90 to 1998/00). It can be seen that for the blood lipid and blood pressure indices, the 
strength of relationship between levels ten years after baseline (1988/90) and major CHD 
risk is stronger for the first ten years than the second. The apparent “non-proportionality” 
of these indices is confirmed by a formal test of the Schoenfeld residuals (see last column 
of Table 6.3). Similarly, for cigarette smoking and alcohol exposure, some degree of non­
proportionality is observed, though relative hazard estimates corresponding to physical 
activity were fairly stable over the follow-up period. However, by relating CHD risk in 
each decade to usual exposure levels after ten years of follow-up, no account is taken of 
the fact that the interval between the baseline measurement and the date of first major 
CHD event is substantially shorter for individuals who have their event in the first decade 
than for individuals who have their event in the second. The average “time to event” for 
the 652 men who experienced a first major CHD event between 1978/80 and 1988/90 was 
5.3 years. In comparison, for the 647 men who experienced their first major CHD event 
between 1988/90 and 1998/00, it was 14.9 years. Therefore, in order to properly assess 
whether blood lipid and blood pressure effects are constant over the period of follow-up, 
one should relate CHD risk in the first decade to usual risk factor levels approximately 5 
years after baseline, and relate CHD risk in the second decade to usual risk factor levels 
approximately 15 years after baseline. The effect of performing such “time-dependent” 
correction for regression dilution bias is shown in Table 6.4, where it can be seen that the 
hazard ratio estimates are now fairly similar between the two decades, indicating that the 
effects of usual blood lipids, blood pressure and BMI on CHD risk are actually reasonably 
constant throughout the study.
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6 .4 .8  M u ltiv a r ia te  ad ju stm en t
The effects of adjustment for regression dilution in two major imprecisely measured CHD 
risk factors, systolic blood pressure and serum total cholesterol, their relations with CHD 
outcome -  and with the influence of other factors generally regarded as precisely measured 
-  age, and smoking status, were examined in 6,576 men initially free from CHD. Relative 
hazards for major coronary heart disease risk in the long term (15-25 years after baseline) 
adjusted for age, systolic blood pressure, total cholesterol and smoking status are shown 
in Table 6.5 both before and after correcting for the effects of regression dilution at 20 
years. Four models are presented, all of which assume that age and smoking status are 
known precisely. The first model corresponds to an analysis using baseline measures 
alone, and ignores the effects of regression dilution for both total cholesterol and systolic 
blood pressure. This analysis provides the ‘naive’ hazard ratio estimates corresponding 
to a 20 mmHg increase in SBP and a 1 mmol/L increase in cholesterol of 1.31 and 1.35 
respectively. The second model corrects for the effects of regression dilution for SBP only. 
This results in an increase of the adjusted hazard ratio for SBP to 1.76, with little change 
to the other hazard ratios. Similarly, the third model corrects solely for regression dilution 
of total cholesterol, increasing its hazard ratio to 1.75. Again, relatively little change in 
the hazard ratios for the other factors is observed. Correction for regression dilution 
of both total cholesterol and systolic blood pressure is shown in the final model, where 
hazard ratio estimates for SBP and total cholesterol increase to 1.94 and 1.77 respectively. 
For systolic pressure, this hazard ratio is greater than tha t obtained after correction for 
regression dilution in SBP alone. In model 4, where multiple correction for regression 
dilution in both SBP and total cholesterol is performed, the hazard ratios for age and 
cigarette smoking status change very little.
6.5 D iscussion
6.5 .1  In terp reta tion  o f  findings
Over twenty years of follow-up, strong continuous relations were observed between blood 
lipid and blood pressure indices and major CHD risk; the magnitudes of these associations 
were increased after correction for regression dilution bias. Major CHD risk increased by 
63% for each mmol/1 increase in usual total cholesterol and by 48% for every 20 mmHg
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increase in usual systolic blood pressure (respectively 56% per 10 mmHg increase in usual 
diastolic pressure). Body mass index also displayed a consistent, albeit weaker, positive 
relationship with CHD risk, with risk increasing by 6% for every kg/m2 increase in BMI. 
The ability to separate high and low-risk individuals based on levels of cigarette smoking, 
physical activity and alcohol intake was greatly improved when information from follow- 
up questionnaires was taken into account. In particular, the large excess risks of heavy 
smoking and the full benefits of moderate physical activity only became truly apparent 
after within-person variation in these factors was adjusted for. The use of average levels of 
alcohol exposure in analyses (rather than baseline levels) reduced the size of the apparent 
benefits on CHD risk from light levels of drinking, and identified the potential risks from 
regular heavy drinking which were not previously observed. The associations between 
average risk exposure levels and major CHD risk appeared to vary over the period of 
follow-up, though for the continuous risk factors, this variation was largely abolished 
after time-dependent correction for regression dilution bias was performed.
When examining the multivariate effects of age, total cholesterol, systolic blood pres­
sure and cigarette smoking on CHD risk in men with no prior evidence of CHD, correction 
for regression dilution bias in both systolic blood pressure and total cholesterol had little 
effect on the hazard ratio estimates for age or cigarette smoking. However, correction for 
regression dilution in both factors led to a slightly higher hazard ratio for systolic pressure 
than was observed after correction for regression dilution bias in systolic pressure alone.
6 .5 .2  V alid ity  o f  m eth o d s
For the continuous risk factors, correction for regression dilution bias was performed by 
estimating the regression dilution ratio for each factor over a ten-year interval, so that 
CHD risk over the period 1978/80 to 1998/00 could be related to risk factor levels at 
the midpoint of this interval (ten years after baseline). This approach to correction for 
regression dilution bias has previously been employed in several studies of cardiovascular 
disease.17’19’113’533-535 One aspect in which the analyses presented in this chapter differ 
from these previous studies however, is that the 10-year regression dilution ratios used 
were not estimated from real data over a 10 year period. Rather, they were predicted 
from the estimated functional relationship between the RDR (estimated over periods of 
one week, and 4-, 16- and 20 years) and the interval period (see Table 6.1). While it would
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have been preferable to base these adjustments on estimates of the RDR taken from real 
data over a ten year period, the consistency of the relationships between the RDR and the 
interval (see Chapter 5; Figures 5.2 and 5.3), as well as the agreement between the 10- 
year estimates derived from this prediction approach and the ten-year estimates obtained 
from real data in other studies (see Chapter 5; Figure 5.12), suggest that the estimates 
used in this chapter are likely to be valid. In order to examine the influence of these risk 
factors by decade of follow-up, this correction approach was subsequently extended to 
allow for “time-dependent” correction for regression dilution bias. This was performed 
by estimating the 5- and 15-year RDR estimates so that risk in the first decade could 
be related to five-year risk factor levels and risk in the second decade could be related 
to 15-year risk factor levels, an approach that has previously been used in other large 
prospective studies.113’533
For the categorical risk factors, an “averaging approach” (described in section 5.3.3 
and illustrated in Figure 5.1) was used to define exposure categories that take into account 
information supplied by the follow-up questionnaires. The key feature of this approach 
that greatly affects its validity in this setting is that only information on risk factor changes 
that was obtained while the individuals were still at risk of a first major CHD event were 
used to derive the summary average exposures. This is important in order to eliminate the 
potential for reverse causality bias, i.e. the onset of disease causing a change in subsequent 
risk exposures. Though men with pre-existing CHD were also included in the analyses 
(a group likely to have already had their risk exposures modified because of CHD), the 
relationships between their risk exposures and their risk of further major CHD remain 
relevant to the assessment of CHD risk factor associations in the population of all middle- 
aged British men, and hence they were kept in the analyses. In any case, the impact of 
keeping these men in analyses was small; very similar results were obtained when they 
were excluded from analyses. Similar approaches of taking into account within-person 
variation in lifestyle coronary risk factors (particularly physical activity) have been used 
elsewhere.1905536
6 .5 .3  C om parison  w ith  o th er  s tu d ies
The associations between the established CHD risk factors and the occurrence of major 
CHD presented in this chapter are generally consistent with those of previous studies,
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though many of these axe based on fatal CHD rather than all major CHD, and most 
(though not all) have not corrected for within-person variation (regression dilution bias). 
A brief comparison between the findings in this chapter and those of other large studies 
(and meta-analyses of studies) is now provided. A detailed description of the epidemio­
logical evidence regarding each risk factor is given in chapter 2.
Blood lipids, blood pressure and body mass index
In the Prospective Studies Collaboration, blood pressure was related to the occurrence 
of fatal CHD in nearly one million adults from 61 separate cohort studies (including the 
BRHS), and time-dependent correction for regression dilution bias was performed.113 In 
men aged 60-69, a 20 mmHg increase in systolic blood pressure was found to be associated 
with an 82% increase in the risk of CHD death. This estimate is somewhat higher that 
the estimate obtained in this chapter (48%), which may, a t least partially, be due to the 
different endpoint used in the PSC analysis. For total cholesterol, a study published in 
1994 consisting of ten prospective studies, three international studies, and 28 randomised 
controlled trials estimated that at age 60 (the average age of the men in the BRHS after 10 
years of follow-up), a reduction in total cholesterol of 1 mmol/1 was associated with a 41% 
reduction in the risk of fatal CHD.70 This estimate (which was corrected for regression 
dilution bias in total cholesterol) is almost exactly the same as the estimate presented in 
this chapter (where a 1 mmol/1 decrease in total cholesterol was associated with a 39% 
reduction in major CHD risk; since 1/1.63 =  0.61). Our estimates of the relationship 
between body mass index and CHD risk are also in general agreement with previous 
publications. For instance, in Finnish men aged 30-59 years, a unit increase in BMI 
was associated with a 4% increase in the risk of CHD226 (compared with a 6% increase 
presented in this chapter). A recent meta-analysis of the effects of body mass index on 
CHD risk in Chinese adults also estimated a 7% increase in risk per 1 mg/m2 increase in 
BMI.229
C igarette sm oking, physical activity and alcohol
In a case-control study of 14,000 survivors of myocardial infarction (and 32,000 controls), 
cigarette smokers had about five times the risk of myocardial infarction than non-smokers 
at age 40-49, three times the risk at age 50-59 and two and a half times the risk at age
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60-69.151 In the BRHS, when all cigarette smokers were considered together, a twofold 
difference in risk of major CHD was observed between current smokers and never-smokers. 
In the 40-year report from the British Doctors Study,145 the rate of fatal CHD was 56% 
higher in cigarette smokers than non-smokers (892 vs 572 deaths per 100,000 men per 
year). For physical activity, a meta-analysis of the effects of physical activity on CHD risk 
published in 1990 found that those in “active” occupations had approximately half the risk 
of CHD of those in sedentary occupations.173 These data have recently been supported by 
a review of the benefits of physical activity on the risk of CHD, which concluded that being 
physically active was associated with about a 40 to 50% reduction in the risk of CHD.196 
However, most of these previous studies used baseline measures in analyses. The conclusion 
that risk can be halved through moderate levels of physical activity is consistent with the 
estimate in this chapter obtained from baseline measurements (see Figure 6.8). However, 
after taking within-person variation in physical activity into account, moderately active 
men were observed to have approximately a 70% lower risk of CHD than inactive men. 
These estimates of the potential true benefits of physical activity are difficult to assess 
in the context of other studies however, due to the few studies that have attempted to 
control for within-person variation. However, one study that used repeated measurements 
of physical activity exposure to quantify “physical activity group” found that women who 
(on average) walked for a t least two hours a  week had a 67% lower risk of CHD than women 
who did not walk regularly.182 Men whose usual physical activity level was “moderately 
vigorous” or “vigorous” appeared to have a greater risk of major CHD than men who 
exercised moderately (see Figure 6.8), a phenomena that has also been observed in the 
Harvard College Alumni Study172 and the Multiple Risk Factor Intervention Trial.194 The 
mechanism behind this increased risk remains unclear, though (in the BRHS at least) it 
does not appear to be mediated through an increased risk of sudden cardiac death.196
As observed for physical activity, the age-adjusted relationship between baseline al­
cohol intake and CHD risk was consistent with previous studies that have used baseline 
measures in analyses.255’256 Baseline alcohol intake displayed a U-shaped relationship 
with CHD risk, with men who drank light to moderate amounts of alcohol experiencing 
around 25-30% lower CHD risks than men who did not drink. However, after correc­
tion for within-person variation, a smaller protective effect of moderate levels of alcohol 
was observed and a  previously unobserved excess risk associated with heavy drinking was
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identified. These findings are difficult to assess in the context of other studies however, as 
few authors have commented on the likely effects that within-person variation in alcohol 
consumption could have on estimated alcohol-CHD relationships. 1
6 .5 .4  C onclusions: 20—year assoc ia tion s w ith  m ajor C H D
In the British Regional Heart Study, continuous linear relationships were observed be­
tween blood lipid and blood pressure indices and major CHD risk over 20 years. After 
correction for regression dilution bias, a 1 mmol/1 increase in serum total cholesterol was 
associated with 63% increase in CHD risk and a 20 mmHg increase in systolic pressure 
was associated with a 48% increase in CHD risk. Lifestyle risk factors, including cigarette 
smoking, physical activity and alcohol intake, were improved as explanatory factors when 
information from follow-up questionnaires was taken into account. After correction for 
within-person variation, clear dose-response relationships were observed between amount 
of tobacco smoked and CHD risk, and the estimated benefits of regular physical activity 
during middle-age increased. For alcohol intake however, the apparent benefits from light 
to moderate levels of drinking were attenuated when within-person variation was taken 
into account, and the group of regular heavy drinkers were shown to have a substantially 
higher CHD rate than the non-drinkers. In a  multivariate setting, within-person variation 
in more than one factor had some residual effects on the estimated importance of other 
factors, including those measured precisely, though these effects were relatively small.
'While the potential impact of within-person variation on alcohol-CHD relationships was discussed 
in a report from the British Doctors’ Study,260 the authors were unable to directly assess these effects, 
though a reasonable degree of consistency between alcohol intake at the beginning and end of the study 
(for surviving men) suggested that their results may have been fairly robust to these effects.
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Table 6.1: Predicted regression dilution ratios for blood lipids, blood pressure and body 
mass index over a ten year interval
Risk factor Relationship between RDR 
and interval period (years)
RDR(10)
Blood lipids
Serum total cholesterol RDR(*) =  exp(—0.175 -  0.023*) 0.67
LDL cholesterol RDR(*) =  exp(—0.228 -  0.026*) 0.61
HDL cholesterol* RDR(*) =  exp(—0.036 — 0.014*) 0.84
Ratio (total to HDL cholesterol)* RDR(*) =  exp(—0.090 -  0.018*) 0.76
Blood pressure
Systolic blood pressure RDR(£) =  exp(—0.383 -  0.016£) 0.58
Diastolic blood pressure RDR(£) =  exp(—0.411 -  0.051*) 0.40
Mean arterial pressure! RDR(*) =  exp(—0.384 -  0.033*) 0.49
Mid blood pressure! RDR(*) =  exp(—0.380 -  0.027*) 0.52
Body mcbss index RDR(£) =  exp(0.014 — 0.004*) 0.97
* Analysed on the log scale 
f(2/3)DBP +  (1/3)SBP 
t(SBP +  DBP)/2
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Table 6.2: Risk factor levels recorded for all men at baseline and estimated true risk factor 
levels over the period of follow-up. Data indicate mean (SD) or n (%) unless otherwise 
stated
Risk exposure Baseline level True level \
Blood lipids
Total cholesterol (mmol/L) 6.3 (1.0) 6.3 (0.9)
LDL cholesterol (mmol/L) 4.2 (1.0) 4.2 (0.8)
HDL cholesterol (mmol/L) f 1.12 (0.96 - 1.29) 1.12 (0.98 - 1.26)
Total to HDL ratiof 5.6 (4.6 - 6.7) 5.6 (4.8 - 6.4)
Blood pressure
Systolic pressure (mmHg) 145 (21) 145 (16)
Diastolic pressure (mmHg) 82 (13) 82 (8)
Mean arterial pressure (mmHg) 103 (15) 103 (10)
Mid blood pressure (mmHg) 114 (16) 114 (11)
Body mass index (kg/m2) 25.5 (3.2) 25.5 (3.2)
Cigarette smoking
Never smoked cigarettes 1819 (23.6%) 1802 (23.4%)
Ex-cigarette smoker 2715 (35.2%) 2525 (32.8%)
New cigarette smokers NA 207 (2.7%)
Current smoker (1-20 a day) 2023 (26.2%) 2489 (32.3%)
Current smoker (21-39 a day) 846 (11.0%) 601 (7.8%)
Current smoker (40 or more a day) 316 (4.1%) 95 (1.2%)
Physical activity
None 686 (9.0%) 517 (6.8%)
Occasional 2345 (30.7%) 2138 (28.0%)
Light 1761 (23.1%) 2152 (28.2%)
Moderate 1205 (15.8%) 1426 (18.7%)
Moderately vigorous 1120 (14.7%) 1030 (13.5%)
Vigorous 513 (6.7%) 367 (4.8%)
Alcohol
None 466 (6.0%) 755 (9.8%)
Occasional 1845 (23.9%) 2101 (27.2%)
Light 2544 (32.9%) 3141 (40.6%)
Moderate 2042 (26.4%) 1441 (18.6%)
Heavy 832 (10.8%) 291 (3.8%)
fGeometric mean (interquartile range);
fEstimated level after taking within-person variation into account;
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Table 6.3: Estimated age adjusted relative hazard of major CHD over the first and second 
ten years of follow-up after adjustment for within-person variation.*
Risk factor First ten years Second ten years pf
(652 events) (647 events)
HR 95% Cl HR 95% Cl
Blood lipids
Total cholesterol (1 mmol/L) 1.70 (1.53,1.88) 1.57 (1.42,1.74) 0.02
LDL cholesterol (1 mmol/L) 1.85 (1.60,2.13) 1.64 (1.41,1.90) 0.02
HDL cholesterol (20% increase) 0.76 (0.71,0.82) 0.84 (0.77,0.91) 0.01
Total to HDL ratio (20% increase) 1.46 (1.37,1.55) 1.33 (1.24,1.43) <0.01
Blood pressure
Systolic pressure (20 mmHg) 1.56 (1.39,1.75) 1.39 (1.23,1.57) 0.08
Diastolic pressure (10 mmHg) 1.70 (1.49,1.95) 1.42 (1.24,1.64) 0.04
Mean arterial pressure (10 mmHg) 1.51 (1.37,1.67) 1.33 (1.20,1.48) 0.04
Mid blood pressure (10 mmHg) 1.43 (1.31,1.55) 1.29 (1.18,1.41) 0.05
Body mass index (kg/m 2) 1.07 (1.04,1.09) 1.06 (1.03,1.09) 0.22
Cigarette smoking
Never smoked cigarettes 1.00 1.00
0.05
Ex-cigarette smoker 1.48 (1.15,1.90) 1.28 (1.01,1.61)
New cigarette smokers 2.03 (1.25,3.30) 1.53 (0.93,2.52)
Current smoker (1-20 a day) 1.74 (1.35,2.22) 1.70 (1.35,2.13)
Current smoker (21-39 a day) 3.39 (2.53,4.54) 2.71 (2.00,3.67)
Current smoker (40 or more a day) 3.78 (2.15,6.64) 4.70 (2.70,8.21)
Physical activity 
None 1.00 1.00
0.85
Occasional 0.58 (0.45,0.73) 0.64 (0.49,0.85)
Light 0.41 (0.32,0.53) 0.41 (0.31,0.55)
Moderate 0.29 (0.21,0.39) 0.35 (0.26,0.49)
Moderately vigorous 0.35 (0.26,0.49) 0.42 (0.30,0.58)
Vigorous 0.47 (0.31,0.71) 0.54 (0.35,0.82)
Alcohol
None 1.00 1.00
<0.01
Occasional 1.26 (0.94,1.69) 0.93 (0.72,1.19)
Light 0.99 (0.74,1.32) 0.64 (0.49,0.82)
Moderate 1.51 (1.11,2.04) 0.79 (0.60,1.05)
Heavy 2.49 (1.68,3.68) 1.22 (0.79,1.87)
* for continuous risk factors, major CHD related to levels after 10 years of follow-up. 
ftest of the Schoenfeld residuals for non-proportionality.
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Table 6.4: Estimated age adjusted relative hazards of major CHD over the first and second 
ten years of follow-up after time-dependent correction for regression dilution bias f
Risk factor First ten years Second ten years
(652 events) (647 events)
HR 95% Cl HR 95% Cl
Blood lipids
Total cholesterol (1 mmol/L) 1.60 (1.46,1.75) 1.66 (1.48,1.87)
LDL cholesterol (1 mmol/L) 1.71 (1.51,1.94) 1.75 (1.48,2.08)
HDL cholesterol (20% increase) 0.77 (0.72,0.83) 0.83 (0.76,0.90)
Total to HDL ratio (20% increase) 1.41 (1.33,1.50) 1.37 (1.27,1.48)
Blood pressure
Systolic pressure (20 mmHg) 1.51 (1.36,1.68) 1.42 (1.25,1.63)
Diastolic pressure (10 mmHg) 1.51 (1.36,1.68) 1.58 (1.32,1.90)
Mean arterial pressure (10 mmHg) 1.42 (1.31,1.54) 1.40 (1.24,1.59)
Mid blood pressure (10 mmHg) 1.37 (1.27,1.47) 1.33 (1.20,1.48)
Body mass index (kg/m2) 1.07 (1.04,1.09) 1.06 (1.03,1.09)
fMajor CHD risk related to usual risk factor levels 5 years after baseline for the first 
decade and 15 years after baseline for the second decade.
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Table 6.5: Estimated relative hazard of major CHD after 15-25 years of follow-up before 
and after correcting for the effects of regression dilution in serum total cholesterol and 
systolic blood pressure
(a)
HR 95% Cl
(b)
HR 95% Cl
(c)
HR 95% Cl
(d)
HR 95% Cl
Age (years) 1.07 (1.05,1.08) 1.05 (1.04,1.06) 1.07 (1.06,1.09) 1.06 (1.04,1.07)
Smoking status 
Non-smoker 
Ex-smoker 
Current smoker
1.00
1.16
1.97
(0.96,1.42)
(1.64,2.36)
1.00
1.18
2.01
(0.95,1.45)
(1.68,2.46)
1.00
1.17
2.02
(0.95,1.42)
(1.69,2.50)
1.00
1.19
2.06
(0.94,1.48) 
(1.71,2.57)
Usual SBP 
(20 mmHg)
1.31 (1.23,1.38) 1.76 (1.55,2.01) 1.36 (1.28,1.45) 1.94 (1.67,2.24)
Usual TC 
(1 mmol/L)
1.35 (1.28,1.43) 1.36 (1.28,1.45) 1.75 (1.57,1.96) 1.77 (1.59,2.01)
SBP =  systolic blood pressure;
TC =  serum total cholesterol;
HR =  hazard ratio;
Cl =  confidence interval;
(a) Uncorrected for regression dilution;
(b) Corrected for regression dilution in SBP only;
(c) Corrected for regression dilution in TC only;
(d) Corrected for regression dilution in SBP and TC;
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Figure 6.1: Age-adjusted associations between total and LDL cholesterol and 20-year 
major CHD risk before (black circles) and after (white circles) correction for regression 
dilution bias. Hazard ratio estimates correspond to unit (1 mmol/1) increases in cholesterol 
level.
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Figure 6.2: Age-adjusted associations between HDL and the ratio of total to HDL choles­
terol and 20-year major CHD risk before (black circles) and after (white circles) correction 
for regression dilution bias. Hazard ratio estimates correspond to 20% increases in choles­
terol level.
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Figure 6.3: Age-adjusted associations between systolic and diastolic blood pressure and 
20-year major CHD risk before (black circles) and after (white circles) correction for 
regression dilution bias. Hazard ratio estimates correspond to increases of 20 mmHg for 
systolic, and 10 mmHg for diastolic pressure.
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Figure 6.4: Age-adjusted associations between mean arterial and mid blood pressure 
and 20-year major CHD risk before (black circles) and after (white circles) correction 
for regression dilution bias. Hazard ratio estimates correspond to 10 mmHg increases in 
pressure.
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Figure 6.5: Body mass index and 20-year major CHD risk before (black circles) and after 
(white circles) correction for regression dilution bias.
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Figure 6.6: Age adjusted relative hazard of major CHD within 20 years. Comparisons 
shown are between the top and bottom fifths of the distributions of each factor (for HDL 
cholesterol this is the bottom fifth relative to the top fifth).
Risk factor
Total: HDL cholesterol 
Total cholesterol 
LDL cholesterol 
Mid blood pressure 
Mean arterial pressure 
Diastolic blood pressure 
Systolic blood pressure 
HDL cholesterol 
Body mass index
HR (95% Cl)
3.14(2.57 -  3.83) 
2.81 (2.34 -  3.38) 
2.52(2.04 -  3.12) 
2.14 (1.78 -- 2.58) 
2.12 (1.76 -  2.55) 
2.07 (1.73 -  2.46) 
1.97 (1 .64- 2.35) 
1.94(1.59 -  2.33) 
1.71 (1.44-2.04)
Relative hazard of major CHD
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Figure 6.7: Cigarette smoking and 20-year major CHD risk before (top) and after (bottom) 
taking into account information from follow-up questionnaires.
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Figure 6.8: Physical activity and 20-year major CHD risk before (top) and after (bottom) 
taking into account information from follow-up questionnaires.
0 .35- None
Occasional
Light
Moderate
Moderate/Vigorous
Vigorous
0 .3 -
0 .25-
C h ^  = 82 
p < 0.001
0 .2 -
0.15- 0.5-
0.05-
0.3-
Occasional Moderate Vigorous100 5 15 20
None Light Moderately
Years of follow up vigorous
0 .35- None
Occasional
Light
Moderate
Moderate/Vigorous
Vigorous
_  0.9-
¥  0 .8 -•e
O® 0.7- 
X  3
O g  0.6-
0 .25-
0 .2 -
0.5-
0 . 1 -
0.4-
0 .05-
Occasional Moderate Vigorous0 5 10 15 20
None Light Moderately
Years of follow up vigorous
Physical activity group HR1 (95% Cl) HR2 (95% Cl)
None 1.00 1.00
Occasional 0.71 (0.60,0.85) 0.60 (0.50,0.72)
Light 0.64 (0.53,0.77) 0.41 (0.34,0.49)
Moderate 0.47 (0.37,0.58) 0.32 (0.25,0.39)
Moderately vigorous 0.52 (0.42,0.65) 0.38 (0.30,0.48)
Vigorous 0.52 (0.40,0.69) 0.50 (0.37,0.67)
1. HR estimates from baseline data
2. HR estimates taking into account within-person variation
CHAPTER 6. W ITHIN-PERSON VARIATION AND CHD RISK RELATIONS  205
Figure 6.9: Alcohol and 20-year major CHD risk before (top) and after (bottom) taking 
into account information from follow-up questionnaires.
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Chapter 7
R e—assessing the “only 50%” claim
7.1 Sum m ary
The aim of this chapter is to assess the validity of the claim that only half of all CHD 
cases may be “attributed” to its three strongest causal risk factors: blood cholesterol, blood 
pressure and cigarette smoking. The relationships between these factors and major CHD 
events are examined over a ten-year period for the 6,576 men with no baseline evidence of 
CHD. Analysis is carried out before and after multivariate correction for regression dilu­
tion bias in blood cholesterol and blood pressure, and the estimated risk associations are 
used to assess the potential combined contribution of these factors to population attribut­
able CHD risk. In men with no pre-existing evidence of CHD, clear positive relationships 
between usual blood cholesterol and blood pressure levels and major CHD risk were ob­
served, with no evidence of any threshold below which a lower level did not confer a lower 
risk. When the CHD risk of non-smoking individuals with “low” cholesterol and “low” 
blood pressure was compared with those of all remaining “high-risk” individuals, large 
differences were observed. In direct contrast to the “only 50% claim” , the combined popu­
lation attributable risk fraction for “high” cholesterol, “high” blood pressure and cigarette 
smoking ranged from around 70% to over 90% (depending on how the low-risk (reference) 
group was defined) after correction for regression dilution bias. Narrowing the low-risk 
group to exclude ex-smokers and passive smokers increased relative risk and population 
attributable risk estimates still further. Adjustment for other independent coronary risk 
factors, including body mass index, physical activity and social class had little effect on 
the results.
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7.2 In troduction
7.2 .1  B ackground
The claim that the three strongest risk factors for coronary heart disease (blood choles­
terol, blood pressure and cigarette smoking) account for only approximately half of CHD 
risk (the “only 50% claim”), has become widely accepted as fact,30-40 though it is often 
stated with no supporting data,30;32;34;38 or asserted with inappropriate citations.31’33’35 
Furthermore, despite evidence from large prospective studies suggesting that this figure 
may be an underestimate,41’43-47 the claim is still being made,35-39 and is even repeated in 
reviews presented as “state of the art” .38 The belief that half of CHD risk is explained by 
the established risk factors is crucially important. Not only does it suggest that the scope 
for prevention of CHD by altering exposure to these established risk factors is limited 
(reducing it by half, at most), but also that there must be an unexplained 50% of CHD 
risk, thus implying the existence of important undiscovered risk factors.42
7.2 .2  O b jectives
The objective in this chapter is to assess the validity of the “only 50% claim” for men in 
the British Regional Heart Study, before and after correction for within-person variation 
in CHD risk factors. In particular, the combined population attributable risk fraction 
(PARF) for “high” blood cholesterol, “high” blood pressure and current cigarette smoking 
is estimated, taking account of regression dilution bias in both blood pressure and blood 
cholesterol. Since the relations between blood cholesterol and blood pressure and CHD 
risk are continuous and “threshold free” , separation of individuals into “high” and “low” 
risk groups based on these risk factors is arbitrary. Therefore, estimates of the PARF 
are presented as curves (or functions) of the cut-off criteria used to define the high- 
risk group. In a subsidiary analysis the effects of using different thresholds for cigarette 
smoking exposure taking account of previous active smoking and passive smoking, and the 
effects of adjustment for other CHD risk factors are examined.
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7.3 Sub jects and m ethods
The analyses in this chapter are restricted to the 6,576 men with no baseline evidence 
or symptoms of CHD (defined as recall of a doctor diagnosis of myocardial infarction or 
angina, Rose chest pain questionnaire evidence of definite or possible angina, or a history of 
severe chest pain; see Chapter 4, Table 4.5). This is to reduce the likelihood of associations 
being influenced by reverse causality (i.e. pre-existing disease causing a change in the risk 
factor). In addition, in contrast to the previous chapters, only major CHD events over the 
first ten years of follow-up (rather than for 20 years) are included. This is for a number 
of reasons:
1. By using ten years rather than twenty years of follow-up, the four-year repeated 
measurements in Dewsbury and Maidstone (between 1996 and 2000) can be used to 
perform multivariate correction for regression dilution bias in both the blood lipid 
and the blood pressure measurement, thus allowing 10-year risk to be related to risk 
exposure levels at (approximately) the midpoint of the interval. Note that while the 
individual regression dilution ratios could also have been predicted over a ten-year 
interval (as was done in Chapter 6 when univariate adjustments were performed), this 
would not allow assessment of the potential effects following multivariate correction 
for regression dilution bias.
2. When examining associations over 20 years (in Chapter 6), some “non-proportionality” 
was observed for each of the risk factors considered in this chapter. Though this was 
overcome (for the continuous risk factors) by performing “time-dependent” correc­
tion for regression dilution bias, such an approach could not easily be adopted in the 
current multivariate setting without additional repeated risk factor measurements.
3. For consistency with the following chapter (that examines different approaches to 
the primary prevention of CHD) it is advantageous in this chapter to:
(a) reduce the effect that preventive drugs would have on observed CHD rates 
by concentrating on events between 1978/80 and 1988/90 (these drugs would 
predominantly (exclusively for statins) have been taken during the 1990s, i.e. 
the second decade of follow-up),
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(b) concentrate exclusively on CHD events occuring during middle-age (as these 
events may be considered as preventable rather than (possibly) inevitable), and
(c) use a risk exposure-period over which current primary prevention policies rec­
ommend evaluating absolute CHD risk (i.e. ten years).
7.3 .1  A sso c ia tio n  b etw een  usual risk factor levels and m ajor C H D  risk
The associations between baseline risk factors and ten-year major CHD risk were esti­
mated through Cox proportional hazards regression; analyses were adjusted for age, blood 
cholesterol, blood pressure and cigarette smoking status (current vs ex/never). It was as­
sumed throughout that blood cholesterol and blood pressure were measured with error and 
subject to variation over time, but that cigarette smoking was known precisely (though 
some within-person variation in cigarette smoking exposure was identified in chapter 5, 
this was predominantly observed between different levels of current smoking, rather than 
between the current vs ever/never exposure groups considered in this chapter). The effects 
of within-person variation in blood lipids and blood pressure on 10-year disease relation­
ships were assessed using the four-year repeated data (from Dewsbury and Maidstone in 
1996 and 2000). As described in chapter 5 (and illustrated in chapter 6), regression coef­
ficients may underestimate or overestimate true regression coefficients when two or more 
variables are measured with error.521 The multivariate techniques developed by Rosner et 
al.26 (described in section 3.7) were therefore used to correct the 10-year baseline associa­
tions for (multivariate) regression dilution bias. This method estimates the true regression 
coefficients (3* from the baseline coefficients /3 through the equation (3* = /3A-1 , where 
A -1 is the “modifying matrix” described in chapter 5. 95% confidence intervals for (3* 
were calculated using bias-corrected bootstrap re-sampling of size 1000.
7.3 .2  C h oosin g  th e  “b e s t” b lo o d  ch o lestero l and  b lood  pressure indices
Some indices of blood cholesterol and blood pressure may be better or worse at predicting 
major CHD events than others. In the age-adjusted analyses presented in Chapter 6, 
for instance, the Kaplan-Meier log-rank statistics (by fifth of the baseline distributions) 
provided one means of assessing the “informativeness” of a risk factor. In this chapter, the 
relative abilities of different blood cholesterol and blood pressure indices to predict CHD 
risk is assessed through examination of the overall contribution that different baseline
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measurements make to the x 2 likelihood ratio statistic in the Cox proportional hazards 
regression model.113 Three blood lipid indices (total cholesterol, HDL cholesterol and the 
ratio of total to HDL) and three blood pressure indices (systolic, diastolic and mean arterial 
pressure) were selected and compared in this way. LDL cholesterol was not considered 
in this analysis because it was only measured in 18 of the 24 towns studied. The results 
for mid blood pressure were virtually identical to those of mean arterial pressure, and are 
therefore not presented separately in this chapter.
7 .3 .3  S eparation  o f in d iv idu als in to  risk groups
To determine population attributable risk fractions it is necessary to distinguish a “low 
risk” group (assumed to be free of the relevant risk exposures) from one or more “high 
risk” groups in which the exposures are present. However, the relationships between 
blood cholesterol, blood pressure and CHD are continuous and threshold free,73’113 and so 
division of these factors into risk categories is arbitrary. In the primary analysis, a range 
of potential “cutoff” values have therefore been used, including the usual 10th and 20th 
centiles of the risk exposure distribution in the population, and the target levels currently 
recommended in the United Kingdom for preventive treatment with lipid lowering and 
blood pressure lowering drugs (total cholesterol 5 mmol/L and blood pressure 140/85).408 
Relative risk and PARF-curves are subsequently presented to describe the nature of the 
relationship between these statistics and the cut-off levels used to define the high-risk 
group. For cigarette smoking, “current smokers” have been used as the high-risk group in 
the main analysis; the effects of extending this group to include “ex-smokers” and subjects 
exposed to passive smoking are considered in subsidiary analyses.
7 .3 .4  P re d ic tin g  th e  re la tiv e  risk  (R R ) and th e  P A R F
Cox proportional hazards regression coefficients (before and after multivariate correction 
for regression dilution bias) were used to predict the 10-year risk of major CHD for any 
given level of total cholesterol, blood pressure and smoking status. For a particular cut-off 
criterion, the expected 10-year risk of major CHD for “high-risk” men was then calculated 
by taking the average over all possible high-risk men (obtained by numerically integrating 
the predicted risk distribution over the theoretical range of values defining the high-risk 
group). The expected 10-year risk of major CHD for “low-risk” men was calculated
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similarly, allowing calculation of the expected relative risk of major CHD for high-risk 
men relative to low-risk men. This was done both before and after taking regression 
dilution bias into account. The population attributable risk fraction corresponding to 
the high-risk factors was then calculated by estimating, before and after correction for 
regression dilution bias, the proportion of the population at high risk, and using Levin’s 
equation (chapter 3, equation 3.1) to calculate the PARF. Approximate 95% prediction 
intervals were calculated by calculating a large (B  = 1000) bootstrap sample {/3f} of (3 
and { A f} of A, repeating the above procedure for each sample, and taking the 2.5 and 
97.5 bias-corrected percentiles as estimates of the lower and upper limits (see chapter 3, 
section 3.4.3).
Iden tify ing  th e  co n trib u tio n  of sep a ra te  h ig h -risk  g roups
The method used to calculate the population attributable risk fraction for a single high risk 
group above can easily be used to calculate the marginal PARFs for each of the different 
possible high-risk groups (see Chapter 3, equations 3.2 and 3.3). In the analyses presented 
in this chapter where an individual can be defined to be “high-risk” based on any one of 
three conditions being satisfied (high cholesterol, high blood pressure or cigarette smoker), 
there are seven possible high risk groups that could be considered separately (e.g. high 
cholesterol only, high blood pressure only, high blood pressure and smoker, etc.). These 
are listed in Table 7.5. Labeling these groups with the indices 1 to 7, the marginal PARF 
of the j th  high risk group is estimated by
PARF, =  -----------------------  (7.!)
1 + ELiPfctR-Kfc-i)
The sum of the seven marginal PARFs equals the overall PARF previously estimated.
7.4 R esu lts
7.4 .1  U su a l risk  factor leve ls  during th e  first te n  years
Of the 7,735 men examined a t the baseline screening, 6,576 (85.0%) had no evidence of 
CHD at baseline (doctor diagnosis or symptoms of angina or myocardial infarction). Of 
the 361 men with no previous history of CHD who attended the 16-year screening in
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Dewsbury and Maidstone (80% response), 259 (76% of survivors) also attended the 20- 
year r-screening. Estimates of the regression dilution ratio over this period (shown in 
Table 7.1) were calculated for each of the blood lipid and blood pressure indices. Using 
these values, the estimated usual risk factor levels in the population during the first decade 
of follow-up were then calculated from the observed baseline levels; these are shown in 
Table 7.2. Mean blood cholesterol and blood pressure levels were similar in smokers and 
non-smokers, and virtually no correlation between total cholesterol and blood pressure 
was observed (p =  0.08 for systolic, p — 0.11 for diastolic). Both serum total cholesterol 
and blood pressure (systolic, diastolic and mean arterial) were approximately normally 
distributed (see Figure 7.1); HDL cholesterol and the ratio of total to HDL cholesterol 
were normally distributed when plotted on the log scale.
7 .4 .2  R ela tiv e  in form ativen ess
The relative informativeness of the different blood cholesterol and blood pressure indices 
at predicting 10-year CHD risk was assessed in the subgroup of men with complete data 
on total and HDL cholesterol, blood pressure and a self reported cigarette smoking status 
(n =6,299, 96% of disease free population). This is shown in Table 7.3 where “informar 
tiveness” is expressed as a reduction in deviance from the model that adjusts only for age 
and smoking status and is presented as a percentage relative to the model that includes 
total cholesterol and systolic blood pressure. Relative to this reference model, most of the 
alternative models were inferior in terms of predictive ability. Mean arterial pressure was 
equal in terms of predictive ability to systolic pressure, and the logarithm of the ratio of 
total to HDL cholesterol was, if anything, slightly more predictive than total cholesterol 
alone. However, in the interests of having to take just one measure of each index (and, for 
the logarithm of total:HDL cholesterol, in the interest of a simple interpretation of the risk 
association), systolic pressure and total cholesterol were selected for use in the analyses 
that follow.
7.4 .3  R e la tio n sh ip s  w ith  10—year m ajor C H D
Of the 6,576 men with no baseline symptoms or diagnosis of CHD, 6,515 (99.1%) had 
complete baseline data on total cholesterol, systolic blood pressure and cigarette smoking 
status. Of these men, 426 (6.5%) had a definite major CHD event within the following 10
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years. The relations between usual levels of serum total cholesterol and systolic blood pres­
sure and CHD (adjusted for age, cigarette smoking, and each other) were approximately 
linear (Figure 7.2), and were unaffected by adjustment for body mass index, usual phys­
ical activity level, usual alcohol intake and history of diabetes. No significant non-linear 
or interaction effects between the variables were observed. After multivariate correction 
for regression dilution bias in total cholesterol and systolic pressure, major CHD risk was 
estimated to increase by 60% for a 1 mmol/1 increase in total cholesterol and by 79% for a 
20 mmHg increase in systolic pressure. Multivariate correction for regression dilution bias 
in both total cholesterol and systolic pressure caused a small reduction in the estimated 
hazard ratios for current cigarette smoking and age.
7 .4 .4  R ela tiv e  and  a ttr ib u ta b le  risks -  in d iv id u a l risk factors
Table 7.4 shows predictions of the relative risk and population attributable risk fraction 
associated with high serum total cholesterol and high systolic blood pressure (before and 
after correction for regression dilution bias) for the cases where the low risk group is 
defined by the 20th or 10th centiles of the usual risk factor distributions as well as when 
these are defined by thresholds currently used for clinical interventions. The estimates of 
the RR and the PARF as a function of the threshold criteria used to define the low-risk 
group is shown in Figure 7.3; each “RR-curve” and “PARF-curve” is adjusted for age and 
cigarette smoking and mutually adjusted for total cholesterol and systolic blood pressure. 
It can be seen that for threshold criteria set below the mean level in the population, the 
relative risk and PARF increase as the threshold criteria used to define the low-risk group 
decreases. The relative risks associated with high serum total cholesterol at the 20th and 
10th centiles are 1.85 and 1.97 respectively, increasing to 2.10 and 2.31 after correction for 
regression dilution bias. At these levels, the PARFs for “high” serum total cholesterol are 
39% and 45% before correction, and 47% and 54% after correction for regression dilution 
bias. If all men had experienced the risks of men with a total cholesterol of less than 4.5 
mmol/L, then up to two-thirds of the major CHD events may have been avoided, however 
this should be stated cautiously given the very small proportion of men falling into the 
low-risk group at this level (approximately 3%). For systolic blood pressure, the relative 
risks of major CHD at the 20th and 10th centiles are 1.70 and 1.78, increasing to 2.30 and 
2.58 after correction for regression dilution bias. This leads to PARF estimates of 35%
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and 40% before, and 51% and 59% after correction. At the level above which intervention 
is recommended to reduce CHD risk, the PARF for high serum total cholesterol alone (>5 
mmol/L) is 48% (relative risk 2.02), increasing to 57% (relative risk 2.42) after correction 
for regression dilution, while for high systolic blood pressure (>140 mmHg), the PARF 
(respectively RR) is 28% (1.64) before correction, and 41% (2.10) after. For current 
cigarette smoking, the PARF is 23% before correction for regression dilution bias. After 
correction for regression dilution bias in cholesterol and blood pressure, this figure was 
reduced to 21%.
7.4 .5  R e la tiv e  and a ttr ib u ta b le  risk — com b in ed  risk factors
Figure 7.4 displays the RR and the PARF for high serum total cholesterol, high systolic 
blood pressure and current cigarette smoking considered simultaneously, both before and 
after correcting for the effects of regression dilution bias in total cholesterol and systolic 
pressure; estimates corresponding to specific criteria are shown in Table 7.4. Using the 
20th centiles of the usual risk factor levels to define the low-risk group, and after correction 
for regression dilution bias, high risk individuals had an estimated risk of major CHD 5.24 
times that of low-risk individuals and the PARF was 80%. Using the 10th centiles of usual 
risk factor levels to define the low risk group, the relative risk was 7.06 after correction for 
regression dilution and the PARF was 86%. For the intervention thresholds, the relative 
risk was 5.33 and the PARF 81% after correction for regression dilution bias.
Separating the high risk groups
Table 7.5 shows estimates of the marginal relative risks and PARFs for each of the seven 
separate high risk groups for two scenarios: (1) high-risk individuals are defined by the 
lowest tenths of the population distributions; and (2) high-risk individuals are defined by 
the lowest fifths. It can be seen that at these “cutoff” values, the majority of the population 
fall into the “high” total cholesterol and “high” blood pressure categories (with or without 
cigarette smoking), which leads to large marginal PARF estimates for these groups. In 
contrast, for high-risk groups that capture only a small proportion of the population (e.g. 
cigarette smoking and high blood pressure only), their contribution to overall population 
attributable risk is small despite large relative risks. For instance, after correction for 
regression dilution bias, a cigarette smoker with an SBP of at least 131 mmHg has, on
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average, four times the risk of major CHD of a non-smoker whose SBP is 131 mmHg or 
lower, but the contribution of this group to all major CHD is small (around 3%), because 
only around 6% of the population fall into this group.
7 .4 .6  S ubsid iary  an a lyses
Varying the definition o f cigarette smoking exposure
In the subset of 5,885 subjects who had either ever regularly smoked cigarettes or (if they 
had never been a smoker) had had their cotinine level recorded, the effect of using different 
low-risk thresholds for cigarette smoking on PARF estimates was examined (Figure 7.5). 
Restricting the low-risk group to subjects who had never smoked (i.e. adding ex-smokers 
to the high-risk group) had little effect on the relative risk or PARF estimates. How­
ever, restricting the low-risk group further to subjects who had never smoked and were 
not heavily exposed to environmental tobacco smoke (cotinine levels <1.5 ng/ml, exclud­
ing subjects exposed to a partner smoking 20 cigarettes or more per day)537 increased 
estimates of the relative risk substantially (approximately a ten-fold difference in risk be­
tween the high and low-risk groups was predicted) and consequently the PARF estimates 
increased to approximately 90%. Use of the “usual” cigarette smoking exposure category 
(described in chapter 5) rather than the “baseline” exposure did not affect the results 
because all current cigarette smokers were considered as a  single high-risk group in these 
analyses.
Effects o f other CHD factors
Further analyses adjusting for other coronary risk factors (body mass index, usual physical 
activity level, usual alcohol intake, and history of diabetes), markers of deprivation in early 
and adult life (height and social class) and town of residence had very little effect on the 
relative risk and PARF estimates obtained, reducing them by approximately 3% (see 
Table 7.6). In addition, further exclusion of individuals with baseline ECG evidence of 
myocardial ischaemia or infarction (definite or possible) had no effect on the estimated 
combined population attributable risk fractions.
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7.5 D iscussion
7.5 .1  In terp reta tio n  o f  findings
Using the 4-year repeated risk factor data, it has been possible to estimate the associations 
between usual risk factor levels over the first decade and major CHD risk over this period, 
after multivariate correction for regression dilution bias in both cholesterol and blood pres­
sure. From this information, the relative risks and population attributable risk fractions 
associated with “high” total cholesterol, “high” blood pressure and cigarette smoking, both 
individually and simultaneously, have been estimated. These analyses allow estimation of 
the true contribution of blood cholesterol, blood pressure and cigarette smoking to CHD 
risk, providing a means of assessing the validity of the “only 50%” claim in the BRHS. 
Defining low-risk individuals as being in the lowest quintile (fifth) of usual levels of serum 
total cholesterol and systolic blood pressure and current non-smokers, the PARF was 70% 
before and 80% after correction for regression dilution bias. Therefore, had all individuals 
experienced the average risk of those in the low-risk group, four fifths of major CHD 
events within the following 10 years would have been avoided. Had everyone experienced 
the average risk levels of those in the bottom tenths of these distributions, 86% would 
have been avoided. Changing the definition of non-smokers to exclude ex-smokers and 
those exposed to heavy passive smoking increased these estimates still further to around 
90%.
7 .5 .2  V alid ity  o f  an a lyses
The validity of the analyses presented in this chapter depends on the appropriateness of 
the estimates of regression dilution used and the levels used to define individuals as “low 
risk” . The estimates of regression dilution bias were based on repeat blood pressure and 
cholesterol measurements taken four years apart, and were restricted to individuals with 
no previous history of CHD. Though the subjects were older at the time of the repeat 
measurements than at baseline, estimates of regression dilution do not appear to vary 
markedly with age (as demonstrated in Chapter 5; Figures 5.6 to 5.11). Moreover, the 
4-year regression dilution ratios of 0.72 and 0.62 for serum total cholesterol and systolic 
blood pressure respectively are consistent with those derived from other studies over similar 
periods (see Figure 5.12). By presenting relative risks and population attributable risk
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fractions as “curves” or functions of the criteria used to calculate them, their relationships 
with the definition of the low-risk group have been identified. The separation of low and 
high risk groups on the basis of blood cholesterol and blood pressure levels is somewhat 
arbitrary, as evidence from other study populations strongly suggest that the relations 
between these factors and CHD risk have no threshold and continue below the levels of the 
bottom tenths of our study population.71’73’113 Thus, even in the groups defined as “low- 
risk” in this chapter, the effects of cholesterol and blood pressure exposure on CHD risk 
are likely to be appreciable, compared for example with the Japanese cohorts of the Seven 
Countries Study, in whom both mean serum total cholesterol level and CHD mortality risk 
were markedly lower than was the case even in the lowest risk group considered here.29 
For example, an ecological study carried out in 1989 of diet, mortality and lifestyle in 69 
nationally representative counties in rural China observed that average total cholesterol 
was 3.8 mmol/1, substantially lower than the “usual” average of 5.4 mmol/1 estimated 
from men in the bottom fifth of the BRHS distribution, and that the death rate from CHD 
was only about one sixth of that in the UK. Reducing risk factors to levels below those 
experienced by the low-risk groups defined in this chapter (if possible) would therefore be 
likely to increase further the proportion of all CHD events prevented.
An alternative estim ation  approach
An alternative method of estimating the PARF corresponding to high levels of a continuous 
risk exposure would be to simply partition the data into two groups at the cut-off point 
and estimate the PARF directly from the data (either using classical methods or through 
fitting a binary term in a generalised linear model). However, in order to obtain the 
relationship between the PARF and the cut-off value used to define it (the “PARF- 
curve”), one would need to apply this technique at several cut-off levels and then fit 
a smooth function through the values. In addition, while methods exist for correcting 
binary risk factors for measurement imprecision,21’22’24’493’538 (see chapter 3; section 3.6.2) 
these are usually based on the assumption that misclassification is non-differential. For 
a continuous symmetrically distributed exposure which is categorised as either “high” or 
“low” based on a cut-off level, this assumption is only likely to be true when the cut-off 
level is set to be equal to the mean. For all other cut-off levels (for instance levels below 
the mean), this assumption would be invalidated.
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7 .5 .3  C om parison  w ith  o th er  stu d ies
The estimates of the PARF of 70-75% presented in this chapter (before correction for 
regression dilution bias) are consistent with estimates from earlier reports using the same 
risk factors. In the Multiple Risk Factor Intervention Trial (MRFIT), CHD death rates in 
over 270,000 men aged 40-57 years, who were initially free from disease, were compared 
between those at “low” risk (defined as serum total cholesterol < 5.17 mmol/L, blood 
pressure no higher than 120/80, and no cigarette smoking), and all remaining individuals. 
After 16 years of follow-up, the CHD death rate observed in the low-risk group was 78% 
lower than in the rest of the sample (PARF=77%).44 The authors also estimated these 
risk differences for 7,490 middle-aged men and 6,229 middle-aged women who were free 
from CHD at initial screening into the Chicago Heart Association Detection Project in 
Industry study. After 22 years, CHD death rates in the low-risk group were 77% lower 
in men (PARF=76%), and 79% lower in women (PARF=78%), than CHD death rates 
in the high-risk groups. Even larger relative risks reductions were observed for men and 
women who were aged <40 years at time of recruitment. In each of these studies, low 
risk individuals comprised only approximately 5 to 10 percent of the cohorts, leading to 
the virtual equivalence between the relative risk reductions and the corresponding PARF 
values. Similarly, in the National Co-operative Pooling Project, risk of a first major 
coronary event was estimated to be lower by 70% for middle-aged men in the lowest 
quintile of risk (implying a PARF of approximately 65%), compared with all other men, 
406 while recent results from the Framingham study estimate CHD risk to be considerably 
lower in low-risk men and women compared with all men and women.407 In the United 
Kingdom, the Whitehall I study of over 17,000 middle-aged British civil servants found 
that if the average CHD mortality rate in the whole population could have been reduced 
to that experienced by individuals who had never smoked cigarettes and who were in 
the lowest quintiles of blood cholesterol and blood pressure levels, then about two-thirds 
of the CHD deaths would have been avoided.42 None of these studies however, took into 
account the effects of regression dilution bias in blood cholesterol and blood pressure when 
making their estimates, though in some cases,42’44 these effects were discussed. Most 
recently, the validity of the “50% claim” has been revisited from a different viewpoint. 
Two cardiovascular studies estimated the prevalence of established risk factors in a large 
number of individuals with coronary heart disease. The results showed that between 80
CHAPTER  7. RE-ASSESSING THE “ONLY 50%” CLAIM 219
and 90% of such individuals were exposed to at least one of the main risk factors (high 
blood cholesterol, high blood pressure, smoking or diabetes).46’47 While these findings 
also suggest that the “50% claim” may be somewhat of an underestimate, they are not 
as rigorous as the previously described studies (or indeed the analyses of this chapter) 
because of the possible influence that reverse causality bias may have played.
7 .5 .4  W ith in -p e r so n  variation  in c ig a re tte  sm ok in g  exp osu re
Though the analyses in this chapter have corrected for the effects of within-person vari­
ation in total cholesterol and blood pressure, they have not accounted for the possibility 
that the third factor, cigarette smoking exposure, is also subject to these influences. In 
chapter 5, it was observed that baseline cigarette smoking exposure was fairly represen­
tative of true “average” exposure to cigarette smoking throughout the study (with the 
possible exception of amount of cigarettes truly smoked). Therefore, it seems reasonable 
to assume that the categorisation of smoking exposure used in the analyses in this chapter 
(where all smokers are considered together) is appropriate. However, these analyses do 
not allow for the fact that by quitting smoking during the first ten years, some smokers 
may have influenced their CHD risk over that period (though it is more likely to take 
a few years for these benefits to be realised). In the BRHS, of the current smokers at 
baseline who survived event free for the following 5 years, 24% reported to have given up 
during that period. While this would not lead to misclassification of smoking status if 
current or ex-smoker were used as the defining high-risk group, if only current smoking 
were used (as in the primary analysis of this chapter), there is a potential for underes­
timation of the importance of current smoking.78’168 This is because the risks of these 
individuals after quitting are lower than they would have been had they continued to 
smoke, and so by analysing them as if they remained smokers, true relative risks (and 
therefore population attributable risks) associated with current cigarette smoking may 
have been underestimated (though as already stated, this would depend on how quickly 
risk could be reversed). In order to take these effects into account in analyses, one could 
fit smoking status as a “tim e-updated covariate” in the Cox proportional hazards model. 
In the BRHS, this had the effect of increasing (marginally) the baseline hazard ratio for 
current cigarette smoking (from 1.78 to 1.92). Therefore, the estimates of the PARF for 
cigarette smoking presented in this chapter are likely to underestimate the true PARF,
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though probably not by very much.
7.5 .5  C onclusions: th e  va lid ity  o f  th e  “50% cla im ”
In stark contrast to the “only 50% claim” it is likely that at least 75-80% of first major 
CHD cases during middle-age may be attributed to the three strongest coronary risk fac­
tors: high serum total cholesterol, high blood pressure and cigarette smoking. However, 
this estimate will vary depending on how the low-risk group is identified (as the relation­
ships between CHD risk and cholesterol and blood pressure are continuous and “threshold- 
free”). If all men in the BRHS had experienced the levels of risk of non-smokers, and had 
had the same cholesterol and blood pressure levels as those in the bottom fifths of the dis­
tribution, then an estimated 80% of all first major CHD events during middle-age would 
have been prevented. If the risks associated with all smoking (including previous smoking 
and passive smoking) could be eliminated, then up to 90% of all CHD events would have 
been prevented.
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Table 7.1: Estimates of the regression dilution ratio (RDR) plus 95% confidence inter­
vals taken over a four-year period for 259 men with no evidence of CHD at the 16-year 
screening
Risk factor RDR 95% Cl
Blood lipids
Serum total cholesterol 0.72 (0.61,0.81)
(log) HDL cholesterol 0.86 (0.78,0.95)
(log) total:HDL cholesterol 0.76 (0.67,0.85)
Blood pressure
Systolic blood pressure 0.62 (0.52,0.71)
Diastolic blood pressure 0.51 (0.42,0.61)
Mean arterial pressure 0.57 (0.48,0.67)
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Table 7.2: Characteristics of 6,576 men with no baseline diagnosis or symptoms of CHD
Observed value Estimated usual value four 
years after baseline
Total cholesterol (mmol/L)
Mean (SD) 6.3 (1.0) 6.3 (0.9)
10th centile 5.0 5.2
20th centile 5.4 5.5
HDL cholesterol (mmol/L)
Median (IQR) 1.12 (0.97-1.29) 1.12 (0.98-1.29)
10th centile 0.85 0.86
20th centile 0.93 0.94
Ratio of total to HDL cholesterol
Median (IQR) 5.5 (4.6-6.7) 5.5 (4.7-6.5)
10th centile 3.9 4.0
20th centile 4.4 4.5
Systolic blood pressure (mmHg)
Mean (SD) 145 (21) 145 (16)
10th centile 121 124
20th centile 128 131
Diastolic blood pressure (mmHg)
Mean (SD) 82 (13) 82 (10)
10th centile 66 70
20th centile 71 74
Mean arterial pressure (mmHg)
Mean (SD) 103 (14) 103 (11)
10th centile 86 89
20th centile 91 94
Current cigarette smokers -  no. (%) 2660 (41) 2660 (41)
SD =  standard deviation; IQR =  interquartile range
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Table 7.3: The relative “informativeness” of models that adjust for different indices of 
blood cholesterol and blood pressure. Figures indicate reductions in deviance from the 
age-adjusted model and are expressed as percentages relative to the “informativeness” of 
the model that adjusts for total cholesterol and systolic blood pressure
Blood pressure measure 
Systolic Diastolic Mean arterial
Blood lipid measure
Total cholesterol 113.2 (100%) 99.2 (88%) 111.1 (98%)
(log) HDL cholesterol 73.8 (65%) 58.7 (52%) 71.7 (63%)
(log) total.HDL cholesterol 119.2 (105%) 103.0 (91%) 115.3 (102%)
Table 7.4: Predicted relative risk (RR) and population attributable risk fraction (PARF) for a range of threshold criteria before and after 
multivariate correction for regression dilution bias*
RR estimate
(95% prediction interval)
PARF estimate
(95% prediction interval)
Definition of “low-risk” group Threshold used Before correction After correction Before correction After correction
Usual serum total cholesterol
< 5.0 mmol/L
< 5.2 mmol/L
< 5.5 mmol/L
Intervention 
10th centile 
20th centile
2.02 (1.68,2.40) 
1.97 (1.66,2.32) 
1.85 (1.58,2.14)
2.42 (1.70,3.82) 
2.31 (1.65,3.56) 
2.10 (1.56,3.06)
48% (38%,56%) 
45% (36%,53%) 
39% (30%,46%)
57% (39%,73%) 
54% (37%,70%) 
47% (31%,62%)
Usual systolic blood pressure
< 124 mmHg
< 131 mmHg 
<1 4 0  mmHg
10th centile 
20th centile 
Intervention
1.78 (1.49,2.10) 
1.70 (1.45,1.98) 
1.64 (1.41,1.89)
2.58 (1.86,3.86) 
2.30 (1.72,3.26) 
2.10 (1.63,2.83)
40% (30%,48%) 
35% (26%,43%) 
28% (20%,35%)
59% (44%,72%) 
51% (37%,64%) 
41% (29%,53%)
Non-smoker 1.75 (1.47,2.15) 1.64 (1.36,2.03) 23% (16%,31%) 21% (14%,29%)
Serum total cholesterol <  5.5 mmol/L, 
systolic pressure <131 mmHg and 
non-smoker
20th centile 3.45 (2.81,4.23) 5.24 (3.55,8.49) 70% (64%,75%) 80% (72%,87%)
Serum total cholesterol <  5.2 mmol/L, 
systolic pressure <  124 mmHg and 
non-smoker
10th centile 4.12 (3.27,5.19) 7.06 (4.47,12.55) 75% (69%,80%) 86% (79%,92%)
Serum total cholesterol < 5 .0  mmol/L, 
systolic pressure < 140 mmHg and 
non-smoker
Intervention 3.60 (2.94,4.43) 5.33 (3.49,9.04) 72% (66%,77%) 81% (72%,88%)
* All RR and PARF estimates axe adjusted for age, serum total cholesterol, systolic blood pressure and cigarette smoking status. The 
right hand columns also correct for regression dilution bias in both total cholesterol and systolic blood pressure
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Table 7.5: Marginal relative risks and PARF estimates for each of the separate high-risk 
groups before and after correction for regression dilution bias
Risk groups defined b y  lowest usual decile
TC SBP Smoker 
>5.2 mmol/L >124 mmHg
Before correction After correction
Pj RRj PARFj Pj RRj PARFj
X X X 0.01 1.00 - 0.01 1.00 -
V X X 0.08 1.96 2% 0.04 2.25 1%
X y/ X 0.07 1.78 1% 0.05 2.51 1%
X X V 0.01 1.79 0% 0.01 1.67 0%
V V X 0.44 3.64 28% 0.49 6.36 37%
V X y/ 0.05 3.43 3% 0.03 3.74 1%
X V y/ 0.05 3.13 2% 0.03 4.12 1%
V V y/ 0.29 6.30 38% 0.33 10.24 43%
Risk groups defined b y  lowest usual quintile Before correction After correction
TC
>5.5 mmol/L
SBP
>131 mmHg
Smoker Pj RRj PARFj Pj RRj PARFj
X X X 0.04 1.00 - 0.03 1.00 -
V X X 0.11 1.86 3% 0.08 2.10 2%
X V X 0.10 1.71 2% 0.09 2.30 2%
X X V 0.03 1.77 1% 0.02 1.66 0%
V V X 0.35 3.26 23% 0.39 5.17 32%
•J X y/ 0.07 3.24 5% 0.06 3.49 3%
X V y/ 0.07 2.98 4% 0.06 3.78 3%
V V y/ 0.23 5.63 32% 0.26 8.32 38%
TC =  serum total cholesterol, SBP =  diastolic blood pressure.
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Table 7.6: Effect of adjustment for a range of other coronary risk factors on the relative 
risk and PARF (after correction for regression dilution bias) associated with low total 
cholesterol, low blood pressure and non-cigarette smoker
Low-risk group
Unadjusted* Adjusted f
RR PARF RR PARF
10th centiles 7.06 86% 5.94 83%
20th centiles 5.24 80% 4.51 77%
30th centiles 4.23 75% 3.71 72%
* as shown in Table 7.4.
■[adjusted for usual physical activity level, usual 
alcohol intake, body mass index, history of dia­
betes, height, social class and town of residence.
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Figure 7.1: Baseline distributions of total cholesterol, the logarithm of the ratio of total to 
HDL cholesterol, systolic blood pressure and diastolic blood pressure. Normal probability 
distributions have been superimposed.
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Figure 7.2: Floating absolute risks of major CHD within 10 years by usual serum total 
cholesterol (left) and usual systolic blood pressure (right). Estimates axe presented for each 
of five equal sized groups and are adjusted for age, smoking status and, respectively, for 
systolic blood pressure and serum total cholesterol. Hazard ratio (HR) estimates adjusted 
for age, total cholesterol, systolic blood pressure and cigarette smoking status are shown 
below before and after multivariate correction for regression dilution bias
1 ■
Risk factor HR1 (95% Cl) HR2 (95% Cl)
Age 1.07 (1.05,1.09) 1.05 (1.03,1.08)
Serum total cholesterol (1 mmol/1) 1.41 (1.30,1.53) 1.60 (1.35,1.96)
Systolic blood pressure (20 mmHg) 1.35 (1.24,1.47) 1.79 (1.47,2.18)
Cigarette smoking status 
Never/Ex 
Current smoker
1 .00-
1.78 (1.47,2.16)
1 .00-
1.67 (1.15,2.36)
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1. HR estimates from baseline data
2. HR estimates after multivariate correction for regression dilution 
bias in total cholesterol and systolic blood pressure.
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Figure 7.3: Predicted relative risk and PARF before (thin line) and after (thick line) 
correction for regression dilution bias. The figures on the left shows these estimates for 
serum total cholesterol considered in isolation (high versus low); the figure on the right is 
for systolic blood pressure. In both graphs the lines correspond to (A) 20th centiles, (B) 
10th centiles and (C) current clinical intervention thresholds
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Figure 7.4: Predicted relative risk and PARF for serum total cholesterol, systolic blood 
pressure and cigarette smoking considered simultaneously before (thin line) and after 
(thick line) correction for regression dilution bias. The figures correspond to threshold 
criteria for systolic blood pressure based on (A) 20th centiles, (B) 10th centiles and (C) 
current clinical intervention thresholds. The dotted line in each panel corresponds to these 
criteria for serum total cholesterol.
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Figure 7.5: Effect of different threshold criteria for cigarette smoking on estimates of 
the relative risk and the PARF for high serum total cholesterol, high blood pressure and 
cigarette exposure. Analyses are based on 5,885 men with data on passive smoking.*
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Chapter 8
Strategies for the primary  
prevention of CHD
8.1 Sum m ary
In this chapter, the long-term potential effectiveness of “population” approaches to the 
primary prevention of coronary heart disease, namely the population-wide reduction of 
important causal risk factors, are estimated before and after correction for regression di­
lution bias. These estimates are compared with the potential effectiveness of “high-risk” 
approaches to prevention, including the identification and treatment (with statins, aspirin, 
/3-blockers and ACE inhibitors) of those men thought to be at greatest risk of developing 
CHD. The results indicate that even small downwards shifts in the population distribu­
tions of total cholesterol and blood pressure could have had a marked effect on reducing 
population levels of CHD. In men previously free from CHD, one in four of the major 
CHD events that occurred over the following ten years could have been prevented had 
average total cholesterol and systolic blood pressure levels been just 0.3 mmol/l (respec­
tively 7 mmHg) lower (approximately 5% of the mean levels). Failure to take into account 
regression dilution bias would have led to this estimate being only one in five. In compar­
ison, high-risk approaches were also potentially effective, but would have needed to have 
been used widely in order to have had a large impact on major CHD. Even if men with 
a predicted ten-year coronary event risk of 30% or more been identified and treated with 
a combination of a statin, aspirin, a /3-blocker and an ACE inhibitor, only approximately 
one in nine of all major CHD events occurring within the following ten years would have
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been prevented. The effects of regression dilution bias on the estimated effectiveness of 
the high-risk approach was negligible.
8.2 In troduction
8.2 .1  B ackground
Two general strategies for the primary prevention of coronary heart disease axe widely 
recognized -  the “high-risk” approach, in which individuals at greatest risk of disease 
are identified and targeted for preventive treatment, and the “population” approach, in 
which population-wide changes in risk factors axe made (see Figure 8.1).48 The high-risk 
approach is the natural approach for medical practitioners who are concerned with the 
occurrence of disease in individuals. However, most CHD cases occur not amongst the 
small number of individuals at greatest risk, but amongst the much larger numbers of 
individuals at lower levels of absolute risk.52 This is illustrated in Figure 8.2, where it can 
be seen that, amongst BRHS participants, individuals in the top fifth of the predicted risk 
distribution accounted for less than half of of all major CHD events that occurred over the 
following ten-years. It is the observation that risk is widely distributed in the population, 
and that CHD does not only affect those at greatest risk, that provides the basis for the 
great strength of the population strategy. Since the early description of these approaches 
for CHD prevention,49’539 the potential impact of the strategies has changed. High risk 
approaches have been facilitated both by the availability of scoring systems to detect 
absolute CHD risk,410 (rather than the traditional use of single risk factors) and by the 
advent of several treatments which produce maxked and apparently independent reductions 
in CHD risk in high risk subjects.51 However, it is also now recognised that the effectiveness 
of the population strategy has been underestimated by the failure to take account of 
regression dilution bias, so that relatively small reductions in the most important CHD 
risk factors (e.g. blood cholesterol and blood pressure) throughout the whole population 
could lead to unexpectedly large reductions in CHD.49 Despite this, little attempt has 
so far been made to examine the potential impact of different high-risk strategies and 
population strategies, taking account of both advances in preventive treatments for CHD 
and the underestimation of population strategies introduced by regression dilution bias.
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8 .2 .2  T h e F ram ingham  eq u ation s and current preven tion  gu id elin es
The risk assessment methods most regularly used for identifying individuals at greatest 
risk of CHD are adapted from published equations derived from the Framingham Heart 
Study and the Framingham Offspring Study.50 These studies followed 5,573 men and 
women aged 30-74 (who were initially free from cardiovascular disease) for 12 years, and 
derived risk prediction equations (based on age, gender, systolic blood pressure, cigarette 
smoking, the ratiS of total to HDL cholesterol, diabetes and ECG evidence of left ven­
tricular hypertrophy) for six outcomes: (1) myocardial infarction; (2) death from CHD; 
(3) all fatal and non-fatal CHD events; (4) stroke; (5) death from CVD; and (6) all fatal 
and non-fatal CVD events. Of these, the most commonly used equation is the “all CHD 
events” equation.
Current guidelines for primary prevention
In many European countries, the emphasis of current policy for the primary prevention 
of CHD is placed firmly with high-risk strategies, with little or no emphasis being placed 
on population-wide reduction of blood cholesterol and blood pressure.4’408 In the United 
Kingdom, the National Service Framework (NSF) for Coronary Heart Disease408 (pub­
lished in March 2000) states that people without diagnosed CHD or other occlusive ar­
terial disease but with a CHD risk greater than 30% over ten years (assessed using the 
Framingham CHD event equation50) should be offered:
• advice about how to stop smoking including advice on the use of nicotine replacement 
therapy.
• information about other modifiable risk factors and personalized advice about how 
they can be reduced (including advice about physical activity, diet, alcohol consump­
tion, weight and diabetes).
• advice and treatment to maintain blood pressure below 140/85 mmHg.
• statins to lower serum cholesterol concentrations EITHER to less than 5 mmol/l 
(LDL-C to below 3 mmol/l) OR by 30% (whichever is greater).
• control of blood pressure and glucose in people who also have diabetes.
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Similar high-risk strategies have been employed in Europe. The Second European Joint 
Task Force report on Coronary Prevention4 published in 1998 stated that in primary pre­
vention for individuals whose absolute risk of CHD is >20% over the next ten years (or 
will exceed 20% if projected to the age of 60), intensive risk factor modification is recom­
mended including, where appropriate, a selective use of proven drug therapies (absolute 
risk was predicted using coronary risk charts based on the Framingham CHD equations). 
This report was revised in September 2003 by the Third European Joint Task Force Re­
port on Cardiovascular Disease Prevention417 which, for primary prevention, recommends 
targeting:
• individuals with multiple risk factors resulting in a ten-year risk of >5% now (or if 
extrapolated to age 60) for developing a fa ta l C V D  even t,
• individuals with markedly raised levels of single risk factors: total cholesterol >8 
mmol/l, LDL cholesterol >6 mmol/l, blood pressure >180/110 mmHg,
• individuals with type 2 diabetes or type 1 diabetes with microalbuminuria,
• close relatives of patients with early onset atherosclerotic cardiovascular disease,
• close relatives of asymptomatic individuals at particularly high risk, or
• other individuals encountered in routine clinical practice.
These latest recommendations differ from previous guidelines in two ways. First, they are 
based on CVD risk, not CHD risk as previous guidelines have tended to use, and second, 
unlike previous guidelines they are not based on equations obtained from the Framingham 
study. Rather, a system of equations derived from the SCORE (Systematic COronary Risk 
Evaluation) project (derived using data from a number of different prospective studies 
including the BRHS) have been used to predict fatal CVD risk.418 These equations have 
the advantage of being based on European populations with differing background risks of 
cardiovascular disease.
8 .2 .3  P re v en tiv e  tr e a tm e n ts  and  m u ltip le  risk factor reduction
The potential effectiveness of the high-risk approach to CHD prevention has been greatly 
influenced by the availability of several safe and effective risk reducing drugs, including
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aspirin, (3-blockers, diuretics, ACE inhibitors and statins, each of which has been shown 
to reduce CHD risk by 20% or more84’118’359’540 (see Methods). Furthermore, the effects 
of these drugs have been shown to be fairly independent of one another, so that by taking 
multiple drugs, large reductions in CHD risk may be achievable.51 Recently, several authors 
have commented on this possibility, and in particular the possibility of combining these 
separate components into a single pill.51’425 Indeed, it has been claimed that a combination 
pill consisting of aspirin, a statin, three blood pressure lowering drugs at half dose, and 
folic acid (the “polypill”) may be able to reduce CHD risk in individuals by as much as 
88%.425
8 .2 .4  O b jectives
In this chapter, the potential effectiveness of population strategies (directed at the control 
of blood pressure and blood cholesterol levels in the population), and the potential effec­
tiveness of different high-risk strategies to the primary prevention of CHD (including both 
policies directed to the measurement and control of individual risk factors, particularly 
cholesterol and blood pressure, and those based on the identification and management of 
high overall CHD risk) are examined. In particular, relationships between the established 
risk factors and major CHD risk in the first ten years of follow-up in the BRHS (before 
and after correction for regression dilution bias) are used to predict the proportion of all 
major CHD events that may have been prevented had various prevention policies been 
implemented.
8.3 M eth od s
Using a combination of data from the British Regional Heart Study and estimates of rel­
ative risk reductions from meta-analyses of randomised controlled trials (where possible), 
the likely influences of population and high-risk strategies on first occurrences of major 
CHD events in middle-aged British men are assessed. As in the previous chapter, analyses 
are restricted to individuals with no baseline diagnosis or symptoms of CHD and only first 
major CHD events over the first ten years of follow-up are used in analyses. In this chap­
ter, because of the specific interest in the potential role of preventive strategies, analyses 
are further restricted to men not receiving lipid lowering or blood pressure lowering drugs
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at baseline.
8.3 .1  P o p u la tio n  approaches to  p reven tion
Three specific population approaches to prevention were considered:
1. Population-wide reduction in mean cholesterol.
2. Population-wide reduction in mean blood pressure.
3. Population-wide reductions in both mean cholesterol and mean blood pressure.
The effectiveness of these approaches were estimated as the epidemiologically expected 
reductions in major CHD risk corresponding to having certain lifetime lower measurement 
levels. Thus, it was implicitly assumed that the observed statistical associations between 
these exposures and major CHD risk were of a causal nature, reflecting the true differences 
in risk caused by long term differences in blood cholesterol and blood pressure level. Care 
was therefore taken to adjust for any potential confounding risk factors; analyses were 
adjusted for a range of other major risk factors as well as socio-demographic factors 
(see statistical methods; § 8.3.3). For each of the population approaches considered, 
the estimated effectiveness relates to the effects of producing a “downwards shift” in 
the population distributions of cholesterol and blood pressure (see Figure 8.1), not a 
proportional reduction in each individual’s measurement level. However, for presentation 
purposes, these downwards shifts are expressed as percentages of the mean risk factor level 
observed in the population.
8 .3 .2  H ig h -r isk  ap p roach es to  preven tion
A variety of different high-risk prevention strategies were considered including treatment 
with single drugs and treatment with multiple combined drugs. These included:
1. Identification and management of individual risk factors:
(a) set treatm ent threshold level for blood cholesterol and treat with a statin;
(b) set treatm ent threshold level for blood pressure and treat with a /3-blocker or 
diuretic.
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2. Identify treatment threshold level of 10-year Framingham risk (as recommended in 
the UK at a > 30% level)408 and treat with:
(a) a statin;
(b) a /3-blocker or diuretic;
(c) a combination of aspirin, a /3-blocker or diuretic, an ACE inhibitor and a statin. 
E s tim a tio n  o f d ru g  effects
Estimates of relative risk reductions for each class of drug were taken from relevant ran­
domised controlled trials or (where possible) meta-analyses of such trials. It was as­
sumed that blood cholesterol reduction with statins reduced the risk of MI by 31%,84 and 
that blood pressure reduction with first line antihypertensive drugs (a diuretic or a /3- 
blocker) reduced MI risk by 18%.540 Among “high-risk” individuals, it was also assumed 
that aspirin reduced the risk of MI by 26%359 and ACE-inhibitors reduced MI risk by 
20%.118 Treatment effects were assumed to be multiplicative so that the combined rela­
tive risk reduction from taking aspirin, statins, ACE-inhibitors and /3-blockers/diuretics 
was 67% (100% x [1 - 0.74 (aspirin) x 0.69 (statins) x 0.80 (ACE inhibitors) x 0.82 
(/3-blockers/diuretics)]).541 In a subsidiary analysis, the potential effects of a prevention 
approach based on age and the use of a combination of treatments including aspirin, a 
/3-blocker or diuretic, an ACE inhibitor and a statin was examined. This analysis was 
performed in order to provide a means of discussing the recent paper from Wald and Law, 
which suggested that CHD could potentially be reduced by up to 88% by treating all 
individuals over the age of 55 with multiple drugs (the “polypill”).425 1
Iden tifica tion  o f  h ig h -r isk  ind iv iduals
The Framingham “CHD event” equation was used to estimate an individual’s overall 
absolute risk of CHD risk over the first ten years of follow-up from their baseline levels. 
This method was used in preference to other approaches because, at the time of writing, 
the Framingham equations provide the most common method of estimating CHD risk,
"NB/ The difference between the 67% relative risk reduction assumed in this chapter and the 88% 
reduction estimated by Wald and Law in their “polypill’ paper is due mainly to their assertion that statin 
therapy alone could reduce CHD risk by as much as 61% (their estimate was based on cohort studies rather 
than clinical trials; see section 8.5.3 for discussion), as well as the additional component of folic acid in the 
polypill (assumed to reduce risk by 16%) which does not feature in the combination treatment described 
in this chapter.
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particularly in the United Kingdom. Though there is growing evidence that Framingham 
equations tend to overestimate true risk in European populations419-422’424’542 (including 
evidence from the BRHS),423 the original equations are used throughout this chapter to 
reflect current guidelines. The implications of using a score that may well overestimate 
the true risk of CHD in British men are discussed in section 8.5.
8 .3 .3  S ta tis tica l m eth o d s
The regression m odel and the estim ates o f the R D R
The association between baseline risk exposures and ten-year major CHD risk was as­
sessed using Cox proportional hazards regression; analyses were adjusted for age, blood 
cholesterol, blood pressure, cigarette smoking status, body mass index, physical activity, 
alcohol intake, history of diabetes and area of residence (the South, Midlands & Wales, 
the North, Scotland). As in the previous chapter, the relative abilities of different in­
dices of blood cholesterol (total cholesterol, HDL cholesterol and the ratio of total to HDL 
cholesterol) and blood pressure (systolic, diastolic and mean arterial) to predict major 
CHD risk was assessed through examination of its y2 likelihood ratio statistic in the fully 
adjusted model. These analyses are repeated in this chapter because a wider range of risk 
exposures are considered in the model. Furthermore, the sample differs slightly from that 
used in chapter 6 as it excludes men taking drugs to lower cholesterol or blood pressure 
at baseline.
Estimates of the regression dilution ratio were taken over the four year interval between 
the 16- and 20-year screenings in Dewsbury and Maidstone. Analyses were restricted to 
men with no previous evidence of CHD (at the 16-year screening) and not taking lipid 
lowering or blood pressure lowering drugs at either the 16- or 20- year screenings. These 
estimates were used to examine true associations over the first ten years of follow-up from 
observed “baseline” associations (regression calibration (see equation 3.20) was used to 
estimate expected usual exposure levels and true regression coefficients).26
Predicting th e effectiveness o f the prevention strategies
Having determined the “most informative” blood cholesterol and blood pressure indices 
for CHD risk prediction purposes (and having corrected the regression coefficients for re­
gression dilution bias), the potential effectiveness of each of the “high-risk” prevention
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strategies was assessed using the regression results to predict absolute CHD risk corre­
sponding to a certain set of covariates (using the recalibrated blood pressure and blood 
cholesterol measurements). When predictions are made on the sample from which the 
prediction tool is derived, estimates of risk differences may be biased, often seriously.543 
Therefore, predicted risks were obtained using the “jack-knife” technique (described in 
section 3.4.4) which eliminates such bias from being introduced.485 The mean of these 
predicted risks provides an estimate of the expected ten-year absolute CHD risk in the 
population prior to implementation of the prevention strategy (which should be close to 
the observed CHD risk). Individuals whose observed risk exposure levels were sufficiently 
high to warrant preventive treatment (i.e. the high risk group) subsequently had their 
predicted risks recalculated to take into account the effects of treatment. The mean pre­
dicted risk after implementation of the strategy was then calculated, allowing calculation 
of the expected reduction in major CHD risk due to the high-risk strategy. For the “pop­
ulation strategies” , the expected reduction in major CHD over 10 years was estimated by 
comparing the predicted CHD risk in the observed sample with the predicted risks for 
the same sample following absolute reductions in each individual’s blood cholesterol and 
blood pressure level. For these approaches, the reductions in major CHD correspond to 
reductions that would be expected if the sample had had lifetime lower blood pressure 
and blood cholesterol levels.
8.4  R esu lts
Of the 6,576 men with no baseline evidence of CHD, 220 were receiving blood pressure or 
lipid-lowering lowering drugs and were excluded from these analyses. Of the remaining 
men, 6,011 (94.6%) had complete risk factor data. The baseline characteristics of these 
men are displayed in Table 8.1. Over the following ten years of follow-up, 371 men (6.2%) 
had a major CHD event. The “relative informativeness” of different blood cholesterol and 
blood pressure indices a t predicting CHD risk was assessed by examining the likelihood 
ratio x 2 statistics in the fully adjusted model. As was previously observed, systolic pressure 
was more informative than diastolic pressure and total cholesterol was more informative 
than HDL cholesterol. Mean arterial pressure and the ratio of total to HDL cholesterol 
were at least as predictive as systolic pressure and total cholesterol, but the latter indices
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were again preferred for simplicity.
Repeat blood pressure and blood cholesterol measurements over four years (between 
16 and 20 years) were available for 165 men with no previous evidence of CHD and not 
on treatment to lower blood pressure or blood cholesterol at either the 16- or 20-year 
examinations. Regression dilution ratio estimates of 0.79 (95% Cl 0.69 to 0.89) for total 
cholesterol and 0.75 for systolic blood pressure (95% Cl 0.63 to 0.88) were observed.
8.4 .1  E ffectiven ess o f  p op u la tion  s tra teg ies  for p reven tion
Using the estimated relative hazards for total cholesterol and systolic pressure (after ad­
justment for a range of other factors and for regression dilution bias) the predicted ef­
fectiveness of each of the “population” approaches to prevention was estimated. This is 
shown in Figure 8.4 and Table 8.2. If the total cholesterol levels of all men had been 0.3 
mmol/l lower and the systolic blood pressure levels been 7 mmHg lower (corresponding 
to reductions in average blood cholesterol and blood pressure of 5%), then it is estimated 
that there would have been 24% fewer first major CHD events during the first ten years. 
Had these reductions been twice as great (so that total cholesterol had been 0.6 mmol/l 
lower and systolic blood pressure been 14 mmHg lower in all men), then there would have 
been an expected 42% fewer major CHD events.
The effects of regression dilution bias on the estimated effectiveness of the population 
approach are shown in Table 8.3. It can be seen that for the population approaches 
considered, the true effect sizes are between 20 and 30 percent greater than the uncorrected 
estimates (depending on the size of the population shifts), so that if the “naive” estimate 
were a 40 percent reduction in CHD, the true estimate would be nearer 50 percent.
8 .4 .2  E ffectiven ess o f  h ig h -r isk  stra teg ies  for p reven tion
Table 8.2 shows the estimated effectiveness of each of the high-risk policies at specific 
“treatment thresholds” and Figure 8.3 the relations between the thresholds, effectiveness 
and the proportion of the population treated under the strategy. As the threshold for treat­
ment reduces (i.e. as the proportion of the population treated increases) the estimated 
reduction in major CHD events in the population increases. For a given intervention, the 
effectiveness of identification based on overall risk (through the calculation of a Fram­
ingham risk score) is generally greater than that based on identification of single risk
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factors, and becomes more so as thresholds fall. Multiple interventions have considerably 
greater benefits in terms of prevention than intervention based only on blood cholesterol 
or blood pressure. However, even with multiple drug treatment, the predicted reduction 
in first occurrences of major CHD following preventive treatment at a threshold based 
on a Framingham risk of >30% (as is currently recommended in the UK), was only 11%. 
This increased to 33% when the Framingham threshold was reduced to a 10-year risk of 
>20% (as recommended by the European Joint Task Force on Coronary Prevention), and 
48% when the threshold was reduced to >15%. At these lower thresholds, respectively 
one quarter and one half of the population without symptomatic CHD would be receiv­
ing multiple preventive treatment. Regression dilution bias had virtually no effect on the 
estimated effectiveness of the high-risk approach, as treatment effects were taken from 
randomised controlled trials.
Treatment based on age criterion alone
For the 371 men who experienced a first major CHD event over the ten-year follow- 
up period, 241 of them (65.0%), were aged 55 or over at the time of the event. If a 
prevention policy were introduced whereby men received the four-drug intervention when 
they reached the age of 55, then 161 of these first events (241 x 0.67) could potentially 
have been prevented. Therefore, approximately 43% of all first major CHD events over 
the following ten years (161/371) may have been prevented through implementation of 
this particular high-risk policy (assuming 100% prescription rates and adherence levels as 
high as those observed in the clinical trials). Reducing the age threshold to 50 would have 
increased this proportion to 59% ((325 x 0.67) /  371).
8.5 D iscussion
8.5 .1  In terp reta tio n  o f  find ings
Taking regression dilution bias of blood cholesterol and blood pressure into account, the 
potential effectiveness of a variety of high-risk and population strategies for the primary 
prevention of CHD was estimated. The results indicate that in order to have a substantial 
effect on CHD rates, high-risk multiple-intervention primary prevention policies would 
need to be used widely -  a t a level below the 3% predicted risk per annum recommended
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in the UK,408 and possibly even below the 2% predicted risk per annum recommended by 
the European Joint Task Force on Coronary Prevention.4 In comparison, relatively small 
absolute reductions in the population levels of two key risk factors (blood cholesterol and 
blood pressure) would potentially lead to large reductions in population levels of major 
CHD.
In these analyses, correction has been made for the effects of regression dilution bias 
(the underestimation of relationships between usual risk factor levels and disease risk 
caused by within-person variability). Though the high-risk approaches were robust to 
these effects (as treatment effects were taken from trials), the effects of regression dilution 
bias on the estimated effectiveness of the population approaches were marked (Table 8.3). 
This is because the true size of the shift in the exposure distribution relative to the 
exposure variance is greater than would be estimated if within-person variability were 
not taken into account. Put differently, a naive analysis of the effect on CHD of reducing 
cholesterol in the population by a certain level would produce an answer that, in reality, 
corresponds to a smaller change in population cholesterol levels. In such analyses, it is 
therefore crucially important to take regression dilution bias into account, as failure to do 
so would almost certainly lead to underestimation of the effectiveness of the strategy.
8.5 .2  E ffectiven ess an d  feasib ility  o f  th e  p op u la tion  approach
The effectiveness of the population approach to prevention depends critically on the size of 
population-wide changes tha t could realistically be achieved in practice. The population- 
wide reductions in total cholesterol and blood pressure assumed in this paper (Table 
8.2) are relatively modest and are consistent with reductions that may be achievable 
though changes in diet. 10 4 ; 1 27 ;4 2 6 -4 3 0 ;5 4 4  jn North Karelia, Finland, a community based 
cardiovascular disease prevention project (initiated in 1972 and followed up to 1997) has 
resulted in population cholesterol levels being reduced by 18% in both men and women and 
blood pressure being reduced by 8% in men and 13% in women.426 These changes in the 
population distributions of blood cholesterol and blood pressure were estimated to explain 
most of the 55% reduction in CHD mortality observed dining that period.544 Had mean 
cholesterol and blood pressure levels been 18% (respectively 8%) lower in the BRHS, 
it is predicted tha t major CHD would have been 51% lower. The consistency between 
this figure and the figure actually observed in Finland following these same changes in
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cholesterol and blood pressure is remarkable. Large population-wide changes in cholesterol 
have also been observed elsewhere. A study of the effects of a population-wide intervention 
programme in Mauritius found that between 1987 and 1992, average total cholesterol 
fell from 5.5 mmol/l to 4.7 mmol/l following a change in the island’s supply of cooking 
oil from palm to soy bean oil and the implementation of an intervention programme 
aimed at the promotion of a healthy lifestyle.427 In Western countries, meta-analysis of 
metabolic ward studies has indicated that, irrespective of age, sex or body weight, replacing 
saturated fats with complex carbohydrates for around 10% of dietary calories reduces 
serum total cholesterol by around 0.5 mmol/l (four-fifths of this reduction being in LDL 
cholesterol), and that further reductions are possible by replacing complex carbohydrates 
with polyunsaturated fats and avoiding dietary cholesterol intake.104 For typical British 
diets, the results indicate that if 60% of saturated fats could be replaced by other fats and 
60% of dietary cholesterol could be avoided, mean serum total cholesterol in the population 
would fall by approximately 0.8 mmol/l (that is, by 10-15%). Results from the Health 
Survey for England show that in middle-aged men and women, mean total cholesterol has 
fallen by between 0.4 and 0.6 mmol/l between 1994 and 1998,545 although this figure could 
be subject to bias because of a change in the laboratory methods used over this period.
Similarly, population-wide reduction in the amount of dietary salt could significantly 
reduce population blood pressure levels. For instance, in the Mauritius study mean systolic 
pressure fell by approximately 5 mmHg and mean diastolic pressure by approximately 2.5 
mmHg over the five year study period,427 while in a community study of salt restriction 
in Portugal, systolic and diastolic pressure both fell by an average of 5 mmHg within 
two years.430 A meta-analysis published in 1991 of 45 salt reduction trials estimated that 
reducing daily sodium intake by 50 mmol (about 3 grams of salt) would, after only a few 
weeks, reduce systolic blood pressure by an average of 5 mmHg and diastolic by around 
half as much.127 Interestingly, the authors estimated that reducing salt intake by this 
amount throughout the entire population would reduce the incidence of CHD by 16%, 
slightly more than our estimate (12% reduction in major CHD following a 7 mmHg (5%) 
reduction in SBP; see Table 8.2). The authors proceeded to claim that reduction also in 
the amount of salt added to  processed foods could lower population blood pressure by 
around twice as much (10 mmHg systolic and 5 mmHg diastolic). However, clinical advice 
to restrict salt intake is likely to be less effective, because of low levels of compliance
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as well as the fairly limited control an individual actually has on determining their salt 
intake. In a systematic review of trials examining the effects of advice to reduce salt intake 
carried out in 2002, only small reductions in blood pressure were observed.546 The authors 
suggested that intensive behavioural interventions were unsuited to population primary 
prevention programmes. Changes in population levels of blood pressure are achievable 
however; secular changes have been observed over relatively short periods of time. In a 
study of students entering Glasgow university between 1948 and 1968, mean systolic blood 
pressure for male students born after 1945 was 10 mmHg lower than for male students born 
before 1929; diastolic pressure was 5 mmHg lower on average.547 More recently, trends 
of a similar size, independent of antihypertensive treatment, have been reported in the 
Health Survey for England, where systolic blood pressure in men aged 55 to 74 has fallen 
by 2-3 mmHg over a four year period (1994 to 1998).545
Effects o f other risk factors
In this analysis, attention has been focussed on cholesterol, blood pressure and pharmaco­
logical interventions and no account has been taken of the important additional contribu­
tion made to CHD risk by cigarette smoking. Taking account of cigarette smoking would 
made a notable additional contribution to the effectiveness of both population and high- 
risk approaches (for instance, approximately one third of the falls in CHD mortality in 
Scotland over the last two decades has been estimated to be due to reductions in cigarette 
smoking).548 However, the balance of potential effectiveness of the two strategies is unlikely 
to be affected by taking cigarette smoking into account. The balance of effectiveness be­
tween the two strategies may be affected in other ways however. The high-risk approaches 
considered in this chapter were primarily focused on reducing CHD risk through reducing 
blood cholesterol and blood pressure (and, in the case of aspirin, clotting processes). For 
the purpose of comparison, population approaches were selected that aimed to cause a re­
duction in blood pressure and blood cholesterol at the population level. In reality however, 
it is likely that strategies directed towards lowering blood pressure and blood cholesterol 
in the population will have additional favourable benefits on other coronary risk factors, 
such as body mass index and, potentially, physical activity, the effects of which have not 
been taken into account in these analyses. In addition, population approaches are likely 
to offer benefits for secondary prevention, both by reducing the risk of subsequent CHD
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events in individuals already with clinically manifest CHD (which would be unaffected by 
high-risk primary prevention approaches) and by reducing the overall burden of CHD in 
the population (which in turn could enable secondary prevention strategies to be better 
focused).
8 .5 .3  E ffectiven ess o f  th e  h ig h -r isk  approach  
Assum ed treatm ent effects
The validity of the estimates for the high-risk approaches depends on the treatment ef­
fects assumed and the appropriateness of the strategies. The effects of statins, aspirin, 
and first line blood pressure lowering drugs were taken from meta-analyses of randomised 
controlled trials,84’359’540 while the effects of ACE inhibitors were estimated from a large 
randomised controlled trial of these agents118. These estimates were used in preference 
to estimates from cohort studies425 because while cohort studies allow estimation of the 
effects of differences in risk due to long-term differences in risk exposure levels, clinical 
trials show the extent to which these epidemiological associations are reversible through 
treatment. The clinical trial estimates also take non-adherence into account as they are 
obtained from “intention-to-treat” analyses, though they may still overestimate the true 
efficacy of the drugs in routine practice because: (1) trials often exclude those with poor 
adherence in “run-in” phases; (2) supervision is often more systematic than in usual care; 
and (3) adherence is likely to decrease over the longer term .549’550 In addition, since the 
treatment effects were generally obtained from studies of “high-risk” men (including men 
with previous CHD), by applying the results to men without previous CHD, the effective­
ness of the high-risk approach may have been overestimated. This may be particularly true 
for ACE inhibitors, for which evidence of effectiveness is substantially based on subjects 
with established CHD.118 For statins and aspirin, this assumption is more clearly valid, 
as relative risk reductions are reasonably stable across a wide range of risk groups.78’359 
Furthermore, by assuming that the treatment effects were multiplicative, the combined 
effects of taking all four drugs may have been overestimated (for example ACE inhibitors 
may be less effective when used in combination with aspirin).551 However, by combining 
different combinations of drugs (including multiple low dose drugs), greater reductions 
in CHD risk may be possible than assumed in this chapter,122 though even if this were 
the case, it is unlikely tha t the estimates would be greatly affected (if the true relative
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risk reduction of the combined pill was 85%, for instance, treatment of individuals with 
a > 30% Framingham risk would reduce major CHD by 14%, compared with 11% if the 
four drugs described in this chapter were used).
U se of the Framingham risk equations to  identify high-risk individuals
In order to reflect current practice in the United Kingdom, the analyses in this chapter 
have identified “high-risk” individuals based on the Framingham CHD event equation 
(published by Anderson and colleagues in 1991).50 This equation allows individuals to 
be ranked in order of risk so that a particular group (say those with a ten-year risk of 
>30%) may be identified and offered treatment. Recently however, many authors have 
found that the Framingham equations tend to overestimate absolute risk in European 
populations. 419~422;424;542 Indeed, recent evidence from the BRHS has shown that the 
Framingham equations overestimate true CHD risk in British men by around 50%.423 
W hat effect, therefore, would a recalibrated Framingham risk score have on the estimated 
effectiveness of the high-risk approach? If the predicted CHD risks from the Framingham 
equation were all divided by 1.5 (in order to take into account this overestimation) then 
the number of individuals meeting any specific “threshold” level for treatment (e.g. >30% 
or >20%) would be greatly reduced. Therefore the number of individuals treated would 
decrease and the estimated effectiveness of the high-risk approach would be reduced. In 
the British Regional Heart Study, of the 6,011 men used in the analyses presented in 
this chapter, 2830 (47%) had a predicted Framingham 10-year CHD event risk of 15% or 
more. However, if each of these scores were divided by 1.5 in an attempt to recalibrate the 
equation, then only 1143 men (19% of the whole population) would still have a predicted 
risk of >15% (i.e. men whose predicted risk was originally >22.5%). This would result 
in the effectiveness of the “high-risk approach” being substantially reduced (from a 48% 
reduction in major CHD to a 26% reduction). In practice however, it is likely that in 
Western societies (where most individuals are at least at moderate levels of risk) the 
thresholds used to define the high-risk group may be determined by the availability of 
resources, rather than by the level deemed worthy of intervention. If so, it is the ability 
of a risk equation to “rank” individuals in order of risk that is likely to be most relevant.
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8 .5 .4  C onclusions: approaches to  C H D  p reven tion
High-risk approaches to prevention are effective (reducing the risk of CHD in individuals 
by 70% or more for multiple combined drugs), but unless they are used widely, their impact 
on the level of first cases of CHD in the population is likely to be fairly small. However, 
small downwards shifts in the risk factor distributions of the key coronary risk factors 
(such as blood cholesterol and blood pressure) could have a large impact on population 
levels of disease in the long-term (perhaps even greater than estimated in this chapter), 
despite the small absolute risk reductions experienced by each individual. The estimated 
effectiveness of the population approach is particularly prone to underestimation due to 
regression dilution bias, and it is perhaps partially for this reason that its potential for 
reducing CHD has gone largely unrecognised. Population approaches targeted through 
changes in the national diet may be possible to implement with little noticeable effect 
to the individual and should eventually lead to a decreased pool of middle-aged people 
requiring drug treatment.
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Table 8.1: Baseline characteristics of 6,011 men with no baseline evidence of CHD and not 
receiving blood pressure lowering or lipid-lowering drugs at baseline. Data correspond to 
mean (SD) unless otherwise stated
Baseline risk factor Observed value
Age (years) 49.8 (5.8)
Serum total cholesterol (mmol/L) 6.3 (1.0)
TotakHDL cholesterol* 5.5 (4.6 - 6.7)
Systolic blood pressure (mmHg) 145 (20)
Diastolic blood pressure (mmHg) 82 (13)
Body mass index (kg/m2) 25.4 (3.2)
Current cigarette smokers -  no. (%) 2438 (41)
At least moderately active -  no. (%) 2384 (40)
Heavy drinkers -  no. (%) 630 (11)
History of diabetes -  no. (%) 68 (1)
* Geometric mean presented (interquartile range)
Table 8.2: A comparison of approaches to the primary prevention of CHD
Prevention approach RRR Predicted reduction in major CVD
“High-risk” approach Management
Top 10%
Group identified for treatment 
Top 20% Top 30%
Treat high total cholesterol Statin 31% 6% 10% 13%
Treat high blood pressure /5-blocker/diuretic 18% 4% 6% 8%
Treat high total cholesterol 1 
Treat high blood pressure > 
Treat high overall absolute risk J
Four drug combination 67%
( 14% 
< 16% 
{ 16%
22%
24%
27%
29%
30%
36%
>30%
Framingham 10-year CHD risk 
> 20% > 15%
Treat high overall absolute risk
( Statin 
< /5-blocker/diuretic 
{ Four drug combination
31%
18%
67%
5%
3%
11%
15%
9%
33%
22%
13%
48%
“Population” approach Shift the risk factor distribution by 
5% 10% 15%
Reduce mean total cholesterol in the population 13% 24% 34%
Reduce mean blood pressure in the population 12% 23% 33%
Reduce mean total cholesterol and blood pressure in the population 24% 42% 56%
RRR =  relative risk reduction (for the high-risk approach); four drug combination =  aspirin, statins, /5-blockers/ diuretcis and 
ACE inhibitors
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Table 8.3: Effect of regression dilution bias on the estimated effectiveness of the population 
approach. The figures shown are the amounts by which the uncorrected estimates of 
effectiveness should be multiplied by to obtain the true estimates.
Population reduction in systolic pressure 
0 mmHg 7 mmHg 15 mmHg 22 mmHg
Population reduction in total cholesterol
0 mmol/L NA 1.31 1.29 1.27
0.3 mmol/L 1.27 1.26 1.26 1.24
0.6 mmol/L 1.24 1.24 1.23 1.21
0.9 mmol/L 1.23 1.22 1.21 1.20
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Figure 8.1: The “population” approach to CHD prevention aims to cause downwards shifts 
in the most important causal risk factors throughout the whole population.
Risk exposure distribution
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Figure 8.2: Proportion of all m ajor CHD events occurring in the BRHS (within first 10 
years) by Framingham predicted CHD event risk.
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Figure 8.3: Predicted effectiveness of three different “high-risk” approaches to CHD pre­
vention as a function of the “threshold” used to define the high-risk group. In each case 
the bars above the axis indicate the proportion of the population treated  and the bars 
below the axis show the expected reductions in m ajor CHD as a  result of the policy
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Figure 8.4: Predicted effectiveness of three “population” approaches to CHD prevention. 
In each case the bars indicate the expected reduction in m ajor CHD following long-term 
reductions in: (a) blood cholesterol; (b) blood pressure; and (c) both blood cholesterol 
and blood pressure
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Chapter 9
Social inequalities in CH D
9.1 Sum m ary
In this chapter, the size of social inequalities in major CHD in middle-aged British men 
between 1980 and 2000 is estimated. Using social class (defined by job occupation) as 
a marker for a person’s socioeconomic position during adulthood, the relative differences 
in major CHD risk between manual and non-manual occupations are evaluated both 
before and after taking within-person variation in occupational social class into account. 
The relative abilities of the established coronary risk factors to explain these differences 
in CHD risk by social class are estimated and, through the calculation of population 
attributable risk fractions, the effect on population levels of CHD from eliminating social 
inequalities is calculated. Using data from 6,386 men with no evidence of CHD at baseline 
and not in the Armed Forces, the relative hazard of CHD over the following 20 years 
for manual men relative to non-manual men was 1.34. This figure increased to 1.41 
after correction for error in the ascertainment of occupational social class and changes in 
occupational social class during the exposure period. Cigarette smoking status during the 
study accounted for the greatest proportion of this difference, explaining 38% of the excess 
risks of manual men. When cigarette smoking, blood cholesterol, blood pressure, physical 
activity, body mass index, alcohol intake and lung function (height standardised) were 
considered together, 41% of the difference was explained. The population attributable 
risk fraction for manual social class was 19% after correction for within-person variation 
in social class, indicating that reducing the risks of all manual men to those of non-manual 
men would have prevented nearly one fifth of all first major CHD events observed from
256
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occurring. This figure was reduced to 11% after adjustment for the adult coronary risk 
factors, and 7% after further adjustment for height.
9.2 In troduction
9.2 .1  B ackground
Social inequalities in the incidence of CHD in the UK have been documented for many 
years.53’552 In the United Kingdom, these differences are most often calculated according 
to occupational measures of social class (e.g. the Registrar General’s six category classifi­
cation) .442 In recent years, though absolute decreases in CHD rates have been observed in 
categories, the rate of decline has been greater amongst the higher social classes (I, II and 
IIINM) than in the lower classes, and hence the relative difference between those at the top 
and those at the bottom of the social scale has increased.54 However, despite considerable 
emphasis being placed in recent public health policies on reducing social class inequalities 
in CHD,54’55 several important aspects of social class differences remain unresolved. First, 
in epidemiological studies that relate adult social conditions to subsequent disease risk, 
adult social class (as determined by job occupation) is often used as a convenient and 
available indicator of the underlying socioeconomic factors. However, even as an approxi­
mate index of socioeconomic status, adult social class is not always precisely categorised 
and may also change over time. Though these factors will lead to underestimation of the 
true extent of social class differences in CHD, the extent of such underestimation has not 
been fully resolved.553 In addition, the relative contribution of established risk factors to 
social inequalities in coronary heart disease remains uncertain. It is also possible that 
novel risk factors including early life influences may be important causes of socioeconomic 
differences in CHD.378 However the extent to which these factors may “explain” these 
risk inequalities, as well as the potential importance of identifying new factors influencing 
social inequalities, is unclear.
The choice of which measure of association to use when presenting evidence from 
observational studies can also greatly affect the interpretation and importance of the 
conclusions. For social inequalities in CHD, many previous studies have used the relative 
risk to display risk differences between social class groups, and have tended to overlook the 
more important epidemiological index of the population attributable risk fraction. The
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PARF is more relevant to the measurement of risk inequalities in public health situations 
as it indicates the total impact that control of the risk factor in the population could 
have on future disease rates. Although social class levels associated with high risks of 
disease cannot be “eliminated” in the same sense tha t other coronary risk factors could 
be (e.g. high blood cholesterol, high blood pressure, cigarette smoking), the assessment 
of a population attributable risk fraction for social class does allow the estimation of how 
much CHD could potentially be prevented if the social class divide could be narrowed or 
eliminated.
9 .2 .2  O b jectives
In the analyses presented in this chapter, the magnitude of social class differences (manual 
vs non-manual occupations) in the incidence of major CHD in men initially free from CHD 
are estimated, before and after correction for within-person variation in the assessment 
of occupational social class. The extent that any observed differences can be explained 
by the established coronary risk factors is calculated, and the population attributable 
risk fraction for social class (before and after adjustment for the established coronary risk 
factors) is presented. In a subsidiary analysis, the additional effects of reducing CHD risks 
to those of social class I are considered, and the effect that within-person variation in 
the established risk factors has on the estimated contribution of these factors to social 
differences in CHD are assessed.
9.3 M eth od s
Similarly to chapters 7 and 8, the analyses presented in this chapter are restricted to men 
with no baseline evidence of CHD. The primary analyses also exclude men in the Armed 
Forces. In contrast to chapters 7 and 8 however, major CHD events over the full 20-year 
period are used in the analyses in this chapter. This is because the repeated information 
on social class was recorded over a twenty-year interval.
9.3 .1  T im e  to  m ajor C H D  ev en ts  by  so c ia l c lass s ta tu s
Kaplan-Meier curves stratified by social class were used to display the differences in ma­
jor CHD by occupational social class over 20 years. 20-year CHD major event rates were
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calculated per 1,000 person years of exposure and directly standardised to the age dis­
tribution of the entire cohort. Relative hazards were estimated using Cox proportional 
hazards regression before and after adjustment for a range of coronary risk factors: blood 
pressure, blood cholesterol, body mass index, FEV1 and “usual” or “average” exposure to 
cigarette smoking, physical activity level and alcohol intake (see chapter 5 for definitions 
of these variables). Adult height was also included in analyses as a marker for adverse 
socioeconomic conditions during childhood. The proportion of the social class divide “ex­
plained by” each risk factor was estimated through the equation {(3q — where (3o
is the age adjusted (log) hazard ratio for manual social class, and (3\ the log hazard ratio 
after adjustment for the coronary risk factor.554 Approximate 95% confidence intervals for 
this statistic were calculated using bias-corrected bootstrap re-sampling of size 1000 to 
estimate the upper and lower limits.473
9 .3 .2  Error in  th e  ascerta in m en t o f  o ccu p a tio n a l socia l class
Two distinct sources of within-person variation in occupational social class have been 
considered: (1) misclassification of occupational social class at baseline; and (2) true 
changes in social class within the first 10 years of follow-up. Throughout this chapter, the 
combination of these influences is referred to as “social class imprecision” . The magnitude 
of social class imprecision was assessed by comparing the social class measurements taken 
at baseline with those recorded at the 20-year follow-up (survivors only); this analysis 
was restricted to subjects who reported at follow-up that they had been in the same 
occupation for at least 10 years, thus capturing the second component of imprecision 
mentioned above. 1 The proportion of individuals measured imprecisely (r) was then 
estimated through the equation
„ In  — 2nr  =  0 .5 -0 .5 y — ——  (9.1)
where N  individuals are measured twice and there are n  disagreements between the base­
line and follow-up measurements23. The adjusted log hazard ratio (3* was then obtained
‘NB/ While men who changed occupation during the second decade of follow-up were excluded when 
estimating the extent of within-person variation in occupational social class, they were not excluded from 
the analyses of social class risk-associations presented in this chapter.
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from the observed estimate (3 through the equation
r  = <9-2>
with approximate confidence intervals calculated from formulae that take into account the 
variability in both (3 and f . 24 The effect of within-person variation in other CHD risk 
factors (particularly total cholesterol and blood pressure) on the estimated relative hazard 
for social class was assessed using the methods of Rosner et al.26
9 .3 .3  T h e  p op u la tion  a ttr ib u ta b le  risk  fraction  for soc ia l class
The population attributable risk fraction for manual social class may be defined as the 
proportion of all disease events in the population that can be attributed to the excess risks 
experienced by manual men over those of non-manual men. This fraction is calculated 
through the equation p(R R  —1)/(1 + p (R R — 1)), where p is the proportion of manual men 
in the population and R R  is the relative risk of major CHD for manual men relative to 
non-manual men. For simplicity, the relative risk of major CHD for manual men relative 
to non-manual men was approximated by the relative hazard from the Cox proportional 
hazards model.555 These estimates were found to be very similar to those obtained when 
more complex prediction-based approaches (similar to those used in chapter 7) were used 
to estimate the true relative risk. Approximate 95% prediction intervals for the population 
attributable risk fraction (before and after correction for measurement imprecision in social 
class) were calculated using bias-corrected bootstrap re-sampling.
9.4 R esu lts
9.4 .1  R isk  factors b y  so c ia l c lass
Occupational social class at baseline was recorded for 6,563 out of the 6,576 men with no 
baseline evidence of CHD (99.8%). Of these men, 6,386 (97.3%) were not in the Armed 
Forces, 3,686 of whom (57.7%) were classed as “manual” and 2,700 (42.3%) as “non- 
manual” . The baseline characteristics of the men by occupational social class are shown 
in Table 9.1. Manual men were, on average, slightly older than non-manual men, had
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higher body mass index and blood pressure, were considerably more likely to be current 
cigarette smokers and heavy drinkers and less likely to be physically active. They were 
also shorter on average than non-manual men and had poorer lung function (FEV1, height 
standardised). Manual men did however have lower average total cholesterol levels than 
non-manual men (6.21 mmol/L vs 6.37 mmol/L; p<0.001).
9 .4 .2  Im p recision  in th e  assessm en t o f  o ccu p a tio n a l socia l class
Table 9.2 shows how social class recorded at baseline compares with social class ascertained 
at 20 years for men without CHD at baseline who, at the 20-year screening, claimed to have 
worked in the same job for 10 years or more (N  = 3,113). From these data, the probability 
that a single baseline assessment of occupational social class (categorised as manual/non­
manual) would be the same as the individual’s true occupational social class ten year later 
was estimated to be 0.92. The differences in reported occupational social class between 
the baseline and follow-up assessments are displayed fully in Figure 9.1. There was a 
tendency for individuals initially at the lower end of the social spectrum to be “upwardly 
mobile” (less than 40% of men initially classed as social group V were categorized into 
this group a t follow-up), though it can be seen that, overall, a similar number of men 
from each social class switched from manual to non-manual by the 20-year assessment, 
and vice versa. There were no significant differences in age, blood lipids, blood pressure, 
body mass index, cigarette smoking or physical activity between men whose “manual/non- 
manual” classification was the same at baseline and follow up (n =  2,668) and those men 
whose classification was different (n =  445), or between men who were ‘upwardly mobile’ 
(n =  569) compared with men who were “downwardly mobile” (n =  662). Men living 
outside the South of England at baseline were more likely to be “upwardly mobile” than 
men living in the South however (49% vs 41%; p  =  0.019).
9 .4 .3  S ocia l c la ss  varia tion  in  m ajor C H D
20—year m ajor C H D event rates by baseline social class
After 20 years of follow up, 580 men in manual occupations (15.7%) and 327 men in 
non-manual occupations (12.1%) had had a  major CHD event. Figure 9.2 displays 20- 
year major CHD event rates and Kaplan-Meier cumulative incidence curves by baseline 
occupational social class (in each of the six categories and combined manual vs non­
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manual). Major CHD event rates increased from 5.8 per 1,000 person years in social class 
I to 10.2 per 1,000 person years in social class V. For all manual social classes considered 
together, the age-standardised 20-year major CHD event rate was 9.4 per 1,000 person 
years; for all non-manual social classes the age-standardised 20-year major CHD event 
rate was 7.2 per 1,000 person years. These differences in the incidence of major CHD 
by baseline social class groups can clearly be seen in the corresponding Kaplan-Meier 
cumulative incidence curves.
R ela tive  h aza rd  of m a jo r C H D  by social class
The relative hazards of major CHD for men in manual occupations relative to men in non- 
manual occupations (before and after adjusting for the established coronary risk factors 
and before and after correcting for imprecision of social class) are shown in Table 9.3. The 
observed age adjusted hazard ratio for manual men relative to non-manual men before 
correction for social class imprecision was 1.34, which attenuated to 1.19 after adjustment 
for the adult coronary risk factors (blood cholesterol, blood pressure, body mass index, 
cigarette smoking, alcohol intake, physical activity and lung function). Correcting for 
imprecision of social class increased these estimates to 1.41 (95% Cl 1.20 to 1.66) and 1.23 
(95% Cl 1.03 to 1.46) respectively; indicating a 41% (95% Cl 18% to 79%) reduction in 
the magnitude of the social class differences. Once height was also taken into account, 
the observed differences between manual and non-manual social classes became non­
significant, and 61% (95% Cl 30% to 107%) of the original differences between social classes 
was accounted for. 11 Of the established adult coronary risk factors, cigarette smoking 
accounted for the greatest proportion of the CHD differences between social classes, 38% 
(95% Cl 23% to 78%). Physical activity explained 16%, systolic blood pressure 15%, 
and FEV1 (height standardised) explained 13%, while HDL cholesterol, diastolic blood 
pressure, body mass index and alcohol intake each explained less than 10% of the observed 
differences. Adjustment for total cholesterol increased the corrected hazard ratio for social 
class from 1.41 to 1.53. This was because total cholesterol levels were on average lower 
for the manual men (see Table 9.1). Thus the proportion of the differential CHD risks by
"NB/ The interpretation of the 107% upper confidence limit is that if these risk factors had been 
distributed equally across social classes, then true CHD risks in the population of manual social classes 
may have actually been lower than CHD risks in the population of non-manual social classes (as opposed 
to the same, i.e. 100% explained, or higher, i.e. <100% explained)
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social class explained by total cholesterol was -22% (indicating that the age adjusted log 
hazard ratio would have been 22% greater had total cholesterol levels been the same in the 
two groups). Height made a notable additional contribution to the social class gradient, 
explaining 26% of the difference. This increased the proportion explained by all factors 
combined from 41% to 61%.
9 .4 .4  P A R F  e stim a tes  for soc ia l class
Table 9.4 shows the population attributable risk fraction for social class (manual vs non- 
manual) before and after correction for imprecision in social class status and before and 
after adjustment for the adult coronary risk factors. For major CHD events, the age 
adjusted PARF for manual social class was 19% (95% Cl 11% to 28%) after correction 
for social class imprecision. If men from manual occupations had had the same average 
levels of blood cholesterol, blood pressure, body mass index, physical activity, FEV1, 
alcohol intake and smoking rates as men from non-manual occupations, the “imprecision 
adjusted” PARF would have been 12% (95% Cl 2% to 21%). Further adjustment for 
height reduced this estimate still further to 8% (95% Cl -2% to 18%).
9 .4 .5  S u b sid iary  a n a lyses
Effect o f redefining the “low—risk” group
When the “low-risk” group was re-defined to include only social class I (rather than all 
non-manual social classes), the hazard ratios for the high-risk group (social classes II -  
V) relative to the low-risk group (social class I) and the corresponding PARF estimates 
increased. The uncorrected age adjusted hazard ratio was 1.51 (95% Cl 1.14 to 2.00), 
which attenuated to 1.26 (95% Cl 0.94 to 1.70) after adjustment for the adult risk factors 
and 1.18 (0.88 to  1.59) after further adjustment for height. The proportion of the differ­
ence explained by all adult risk factors and height was almost identical to that observed 
when comparing manual men with all non-manual men. The uncorrected age adjusted 
population attributable risk fraction estimate based on this new classification was 32% 
(95% Cl 11% to 48%), which reduced to  19% (95% Cl -6% to 39%) after adjustment for 
the adult risk factors and 14% (95% Cl -12% to 35%) after further adjustment for height. 
No attem pt to correct these estimates for within-person variation in occupational social 
class was made as, in this case, it would not have been reasonable to assume that mis-
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classification was non-differential. To correct for within-person variation in this setting 
would have required repeated information on occupational social class during the study 
period (for instance, a t Q5, Q92 and Q96).
Effects o f w ith in -person  variation in th e established CHD risk factors
The results presented in Table 9.3 show the extent to which the established coronary risk 
factors “explain” differences in the incidence of major CHD by occupational social class. 
For cigarette smoking, physical activity and alcohol intake, these analyses were based on 
exposure measurements that accounted for within-person variation in these factors (i.e. 
the exposures derived in chapter 5 were used in analyses instead of the baseline exposures). 
Table 9.5 shows the proportion of social differences explained by these factors when base- 
fine levels were used in analyses. For cigarette smoking, failure to take within-person 
variation into account would have led to underestimation of the importance of cigarette 
smoking in explaining CHD differences (it would have been estimated that 33%, rather 
than 38%, of the social differences could be explained by differences in smoking). However, 
for physical activity and alcohol intake, the use of “average” exposures in analyses did not 
increase (or decrease) the estimated importance of these factors.
For the continuous risk factors (blood cholesterol, blood pressure, etc.), the possi­
ble effects that within-person variation (regression dilution bias) may have had on the 
estimated contribution of these factors to social differences in CHD is more difficult to 
quantify. Using the “expected conditional” values of these measures in analyses instead 
of the baseline levels (as in chapter 6) would have had no effect on the estimated pro­
portions explained, because though the relative hazards for these factors would increase, 
if the expected values were calculated across the whole population then the estimated 
differences in these levels between social classes would decrease, thus cancelling out any 
effect. However, if the estimated differences in the established risk factors between social 
classes (shown in Table 9.1) did represent true underlying usual differences, then the indi­
vidual contribution of the continuous risk factors to social differences in CHD risk would 
probably have been underestimated. However, when considered together, it is likely that 
because of the effects of regression dilution bias in blood pressure and total cholesterol 
would be acting in opposite directions (since men from manual occupations had higher 
blood pressure but lower to tal cholesterol), any effects would cancel each other out.
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Differential associations by age
In order to assess whether or not the associations between major CHD risk and social 
class differed according to age, analyses were performed separately for men aged under 
50 years at baseline, and men aged 50 years or over. Risk differences between manual 
and non-manual social classes appeared to be stronger in younger men; the (baseline) 
age-adjusted relative hazard of major CHD for manual versus non-manual men was 1.62 
(95% Cl 1.28 to 2.05) in men aged under 50 and 1.21 (95% Cl 1.02 to 1.43) in men aged 
50 or over. The corresponding PARF values (adjusted for age only) were 26% and 11% 
respectively. After adjustment for “usual” levels of the adult coronary risk factors these 
risk associations were reduced by 50% in men under 50 and by 32% in men aged 50 or 
over to, respectively, 1.27 (0.99 to 1.64) and 1.14 (0.95 to  1.36) -  the corresponding PARF 
values decreased to 17% and 5% respectively. Further adjustment for height reduced the 
relative hazards to 1.22 (0.94 to 1.58) and 1.05 (0.87 to 1.26) and the PARFs to 11% (in 
men aged under 50) and 3% (in men aged 50 or over).
9.5 D iscussion
9.5 .1  In terp reta tio n  o f  find ings
Among middle-aged British men with no previous evidence of CHD, the age-adjusted 
relative hazard of major CHD for men in manual occupations compared with men in non- 
manual occupations between 1978/80 and 1998/2000 was 1.41 (95% Cl 1.20 to 1.66) after 
correction for imprecision of social class measurement. This was reduced to 1.23 (95% Cl
1.03 to 1.46) once differences in the adult coronary risk factors were taken into account. 
This risk difference appeared to be greater in younger men than in older men. In the 
BRHS, if all manual men had experienced the same baseline levels of risk as non-manual 
men, then 19% of all first major CHD events would have been prevented. After taking 
account of adult coronary risk factors, the population attributable risk fraction for manual 
social class was 12% for major CHD cases, indicating that if social inequalities in adult 
coronary risk factors could be eliminated, the remaining risk differences between manual 
and non-manual men would account for approximately one in nine major CHD cases 
during middle age. This figure was reduced to 8% after further adjustment for height. 
The effects of “within-person variation” in the established coronary risk factors on the
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estimation of the proportion of social class differences explained by these factors was fairly 
small, though cigarette smoking did explain a greater proportion of the difference after 
within-person variation was taken into account (38% vs 33%).
9 .5 .2  V alid ity  o f  an a lyses
Using individuals who, at the 20-year screening, claimed to have been working in the same 
job for at least 10 years, it was possible to correct for both random misclassification of 
social class status at baseline and true changes in social class during the first ten years, 
thus enabling estimation of associations between “usual” social class held throughout the 
study period and disease risk over the study period. Although it is possible that the onset 
of coronary heart disease during the study may have led to a change in social class for 
some individuals, separate examination of social class changes in subjects developing CHD 
dining the follow-up period suggested that any such effect would be small. The primary 
analyses used occupational social class as the most convenient marker for socioeconomic 
conditions. In a subsidiary analysis, this measure was compared with two other measures 
(car ownership and housing tenure) both of which were available from the 5-year follow 
up questionnaire (Q5). Though owning a car and being an owner-occupier were related to 
lower subsequent CHD risk (between 5 and 20 years), neither was more strongly related 
than adult social class (over the same period). However, it is recognised that a combined 
baseline measure of the three socioeconomic factors might have been able to predict CHD 
outcome better than any single measure in isolation. Social class, though the most widely 
used, is only one potential measure of socioeconomic status and a combination of different 
socioeconomic measures may encapsulate different “social class dimensions” better than 
any single measure in isolation.556;557 In addition, area-based measures of social depriva­
tion may contribute additional socioeconomic information over and above that obtained 
from “individual-level” factors,558 though these types of analyses are beyond the scope of 
this thesis.
9 .5 .3  C om parison  w ith  o th er  stu d ies
The extent to which social class differences can be explained by established coronary risk 
factors has been assessed in a number of studies.362’448-451’559’560 In an earlier report from 
the British Regional Heart Study in 1987,448 the rate ratio of CHD mortality for all man­
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ual men relative to all non-manual men over 6 years of follow-up was estimated to be 
1.44. This was attenuated to 1.24 after adjustment for cigarette smoking, serum total 
cholesterol, blood pressure and physical activity (a 41% reduction on the log scale). In 
comparison, a recent 25-year follow-up of men in the Whitehall I study450 found that 
cigarette smoking, blood pressure, total cholesterol and glucose together accounted for 
56% of the CHD risk difference between low-risk men in the lowest and highest grades 
of employment. In the Chicago Heart Association Detection Project in Industry study, 
the relative odds of CHD death within five years for college graduates relative to those 
not graduating from high school decreased by 33% after adjustment for blood pressure, 
cholesterol, smoking, BMI and ECG abnormalities;559 a slightly higher estimate was ob­
tained for 20-year mortality rates of men in the Chicago Peoples Gas and Western Electric 
Studies.559 A wider range of risk factors including HDL cholesterol, triglyceride and fib­
rinogen was found to account for 39% of the CHD difference between social classes in 
the Scottish Heart Health Study (SHHS),451 the same estimate as was found in our cur­
rent analysis (Table 9.3). Further analysis of the SHHS however estimated that 14 risk 
factors (including the established factors as well as further risk factors including type A 
personality, fibrinogen and vitamin C consumption) together explained over 70% of the 
CHD risk differences observed between “renters” and “owner occupiers” .560 Consistent 
with the BRHS, average total cholesterol levels in the SHHS (as well as in Whitehall I) 
were greater in men from the higher social classes. Therefore, had total cholesterol levels 
been the same across the whole population, the CHD differences between social classes 
would have been greater than was observed (by approximately 22% in the BRHS). How­
ever, when assessing the overall combined contribution of the established coronary risk 
factors to the social class divide, this significant inverse relation with total cholesterol was 
excluded in the SHHS analyses, whereas in the analysis presented here, it was included. 
Though the estimated combined contribution of the remaining factors would have been 
somewhat larger than 41% had total cholesterol been excluded, since the hypothesis was 
defined a priori, it was felt tha t total cholesterol should remain. Finally, in an ecological 
study of risk factor prevalence and cause specific mortality in 403 local authority districts 
in England and Wales in 1992, cigarette smoking was estimated to account for as much 
as 85% of the observed difference in ischaemic heart disease mortality between the most 
and least deprived areas.561 However these findings should be compared with those of this
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chapter cautiously because of the ecological fallacy.562
When risk factors were considered individually, cigarette smoking was found to account 
for the largest proportion of observed difference in CHD by social class, explaining 38% 
of the CHD gradient (see Figure 9.3). Height explained 26% of the variation, and the 
remaining risk factors each explained 16% or less. The observation that height is the 
second most important determinant of the social class gradient in CHD suggests that 
early life factors may be important in the development of social differences in CHD -  
an observation consistent both with the inverse relationship between height and CHD in 
individuals169’362’377’390-394’563 and with recent evidence that childhood socio-economic 
environment may be directly related to the risk of CHD.452-454 The addition of height 
to the adult CHD risk factors resulted in 61% of the CHD difference being explained. 
Some of the remaining association may be explained by additional contributions made by 
homocysteine level,300’301’506 by job stress361 or by other unmeasured early life factors.378
9 .5 .4  E ffect o f  correction  for w ith in -p erso n  variation  in  m ajor risk fac­
tors
Estimating the long-term social inequalities remaining after adjustment for baseline risk 
factors depends on the assumption that the effects of within-person variation do not differ 
by social class. This is unlikely to be true for cigarette smoking because of differential 
rates of cigarette cessation.564 In the British Regional Heart Study, 33% of non-manual 
smokers had given up by five years compared with 24% of manual smokers. The effect 
of these (and subsequent) differential changes in smoking exposure on the extent that 
smoking “explains” social class differences in CHD was to increase the estimate from 33% 
to 38% (see Table 9.5). While taking account of within-person variation in physical 
activity and alcohol consumption had virtually no effect on the proportion explained by 
these factors (Table 9.5), it is likely tha t differential changes in mean total cholesterol 
by social class during the study may also have led to underestimation of the extent that 
social inequalities are truly explained by the established risk factors. This is because while 
mean total cholesterol was higher in non-manual social classes than manual social classes 
in 1978-80, little to no differences are observed in contemporary adults (Health Survey for 
England, 1998).565 Therefore, the average difference in total cholesterol between manual 
and non-manual men in the BRHS during the period 1978/80 to 1998/2000 is likely to
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have been lower than that estimated using baseline d a ta .111 Therefore, the (negative) effect 
of adjustment for total cholesterol in the analyses presented in Table 9.3 is likely to have 
had a greater effect than it would have had any differential changes in total cholesterol 
by social class been measured and taken into account, and hence the proportion of social 
class differences explained all major risk factors would have been greater. Similarly, other 
differential changes in risk factors by social class would most likely lead to underestimation 
of the extent that they “explain” social inequalities in CHD (because they are more likely 
to result in improvements in the risk profile of non-manual men relative to manual men).
9 .5 .5  C onclusions: so c ia l c lass in eq u alities
Social class inequalities in CHD risk are underestimated when based on measurements 
taken at a single point in time, irrespective of which marker of social class is used to repre­
sent the underlying socioeconomic factors. However, even taking account of measurement 
imprecision, the contribution of occupational social class to overall CHD risk is likely to be 
relatively modest. The analyses in this chapter suggest that approximately one-fifth of all 
major CHD events in the BRHS would have been prevented or postponed if the average 
risks of non-manual social classes had been experienced by the whole population. A re­
duction in CHD rates of this magnitude would be both important and desirable. However, 
compared with the reduction in CHD risk which could be achieved by population-wide 
changes in just two of the three most important causal factors for CHD (blood cholesterol 
and blood pressure; refer to chapter 8), this is a fairly limited reduction. Population-wide 
strategies to reduce major CHD risk factors across all social class groups are therefore 
likely to produce greater benefits for CHD prevention than strategies designed specifically 
to reduce social inequalities in CHD. However, to secure both effectiveness and equity 
in CHD prevention (and in the reduction of all-cause mortality), these population wide 
measures would logically include specific measures to encourage smoking cessation and 
physical activity among socially disadvantaged groups.
"'this is indirectly supported by the observation that at the 20-year rescreening of surviving BRHS 
participants, mean total cholesterol was 6.0 mmol/1 in both manual and non-manual men
Table 9.1: Mean baseline characteristics of the 6,563 men with no evidence of CHD at baseline, stratified by (baseline) social class group.
Risk factor Registrar General’s six category classification
Army
(n=177)
P-value*
N on-manual/Manual
I
(n=530)
II
(n=1532)
IIINM
(n=638)
HIM
(n=2763)
IV
(n=667)
V
(n=256)
I,II or 
IIINM
HIM, IV 
or V
Age (years) 49.0 49.7 50.1 50.1 50.2 49.8 49.7 <0.001 49.6 50.1
Total cholesterol (mmol/L) 6.34 6.38 6.36 6.22 6.19 6.16 6.46 <0.001 6.37 6.21
HDL cholesterol (mmol/L) f 1.15 1.13 1.11 1.12 1.13 1.14 1.09 0.12 1.13 1.12
BMI (kg/m2) 24.9 25.3 25.4 25.6 25.3 25.3 25.7 0.001 25.3 25.6
SBP (mm Hg) 141 143 146 147 146 148 140 <0.001 143.1 146.7
DBP (mm Hg) 80.7 81.1 83.1 82.8 83.0 82.7 80.3 <0.001 81.5 82.8
Height (cms) 176 175 174 172 171 171 174 <0.001 175 172
FEV1 (ml/sec) t 358 348 338 330 318 323 332 <0.001 347 327
Current smokers (%) 19.7 30.4 35.8 46.0 50.8 55.5 62.1 <0.001 29.6 47.5
Moderately active (%)§ 52.6 47.7 41.5 34.4 30.9 26.2 35.5 <0.001 47.2 33.2
Heavy drinkers (%)§ 1.5 3.2 2.8 4.2 4.5 3.9 5.1 <0.001 2.8 4.2
* P-value for test of trend across six categories (excluding Army); fGeometric mean; fheight standardised; § After taking within-person 
variation into account.
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Table 9.2: Repeat determination of social class status over a 20-year period for men 
without evidence of coronary heart disease at baseline who, at the 20-year screening, had 
worked in the same job for at least 10 years (N  — 3,113)
20-year follow-up
Baseline social class Manual Non-manual Total
Manual 1305 257 1562
Non-manual 188 1363 1551
Total 1493 1620 3113
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Table 9.3: Relative hazard of major CHD over 20 years (manual vs non-manual social 
class) before and after taking misclassification of social class into account. All models are 
adjusted for age
Variables 
adjusted for
Percentage 
explained *
Uncorrected 
HR (95% Cl)
Corrected 
HR (95% Cl)
None - 1.34 (1.17,1.54) 1.41 (1.20,1.66)
Total cholesterol -22% 1.43 (1.25,1.64) 1.53 (1.30,1.79)
HDL cholesterol 5% 1.32 (1.15,1.52) 1.39 (1.18,1.63)
Systolic blood pressure 15% 1.28 (1.12,1.47) 1.34 (1.14,1.58)
Diastolic blood pressure 9% 1.31 (1.14,1.50) 1.37 (1.17,1.61)
Cigarette smoking § 38% 1.20 (1.05,1.38) 1.24 (1.05,1.45)
Body mass index 7% 1.31 (1.15,1.51) 1.38 (1.18,1.62)
Physical activity § 16% 1.28 (1.11,1.47) 1.33 (1.13,1.57)
Alcohol § 6% 1.32 (1.15,1.51) 1.39 (1.18,1.63)
FEV1 13% 1.29 (1.12,1.48) 1.35 (1.15,1.59)
Height 26% 1.24 (1.08,1.43) 1.29 (1.10,1.52)
Smoking, blood pressure 
& blood cholesterol
34% 1.21 (1.05,1.40) 1.26 (1.06,1.48)
Adult coronary risk factors^ 41% 1.19 (1.03,1.38) 1.23 (1.03,1.46)
Adult coronary risk factors 
plus height
61% 1.12 (0.96,1.30) 1.14 (0.96,1.36)
* Percent reduction in the log hazard ratio relative to the model that adjusts only for age. 
Correction for imprecision in social class measurement has no effect no these estimates; 
§Usual exposure levels over the follow-up period; ^[Cigarette smoking, blood pressure, 
blood cholesterol, body mass index, physical activity, alcohol and height standardised 
FEV1; HR — hazard ratio; Cl =  confidence interval.
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Table 9.4: Population attributable risk fraction for manual social class for men with 
no baseline evidence of CHD. Estimates are presented before and after correction for 
measurement imprecision in social class status. All estimates axe adjusted for age.
Factor included Uncorrected Corrected
PARF 95% Cl PARF 95% Cl
None 16% (10%,24%) 19% (11%,28%)
Adult coronary risk factors* 10% (2%,18%) 12% (2%,21%)
Adult coronaxy risk factors plus height 6% (-2%,15%) 8% (-2%,18%)
* cigarette smoking, blood pressure, blood cholesterol, body mass index, physical 
activity, alcohol and height standardised FEV1.
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Table 9.5: Percentage of social class differences explained by the established coronary risk 
factors before and after correction for within-person variation in the established CHD 
factors.
Factor included Before correction After correction*
Cigarette smoking 33% 38%
Physical activity 15% 16%
Alcohol intake 6% 6%
All coronary risk factors § 39% 41%
* these figures are the same as those shown in Table 9.3; §cigarette smoking, blood pressure, 
blood cholesterol, body mass index, physical activity, alcohol and height standardised 
FEV1.
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Figure 9.1: M ovem ent in social class am ongst 3,113 men w ith  no baseline evidence of CHD  
who (at 20 years) claim ed to  have been working in the sam e job for at least 10 years
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Figure 9.2: Baseline social class differences in major CHD over 20 years among 6,386 men 
not in the Armed Forces and with no baseline evidence of CHD
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Figure 9.3: Percentage of the difference in CHD risk between manual and non-manual 
men that can be explained by the established CHD risk factors
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Chapter 10
Im plications o f the findings
10.1 Sum m ary
The findings of this thesis have implications for the design and analysis of epidemiological 
studies, and for the prevention of coronary heart disease. The thesis results demonstrate 
the extent of within-person variation in coronary risk factors typically observed over the 
duration of a  cardiovascular epidemiological study, and the effects that this variation can 
have on estimated relationships between risk factors and disease, both in a single and a 
multiple covariate setting. They also highlight the difficulties of assessing the effectiveness 
of CHD prevention policies, when estimates are based on single risk factor measurements 
taken at a baseline assessment, and the relative importance that should be attributed to 
reducing inequalities in CHD. The most important implications from this thesis are: (i) 
that epidemiological studies should recognise and, where appropriate, plan to correct for 
the effect tha t within-person variation has on estimated disease relationships; (ii) that the 
three strongest risk factors for CHD account for substantially more than half of CHD cases 
in British men; (iii) tha t currently recommended strategies for the primary prevention of 
CHD are likely to have a very limited effect on population levels of CHD unless used much 
more widely; (iv) tha t even small reductions in key causal risk factors throughout the 
population could have a large effect on reducing CHD; and (v) that social inequalities in 
CHD are larger than previously estimated, though reduction of social class inequalities is 
unlikely to provide a means through which CHD could be substantially reduced, even if 
they could be entirely eliminated.
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10.2 In troduction
This chapter considers the implications of the thesis results, first for epidemiological stud­
ies (section 10.3) and second for public health (section 10.4). The chapter builds on the 
results, discussion and conclusions of previous chapters, although in some sections addi­
tional relevant literature is introduced.
10.3 Im plications for ep idem iological stud ies
In this section, the implications of the results of this thesis for the design and analysis of 
future epidemiological studies are presented. Particular emphasis is paid to: (1) identifying 
relationships between long-term risk factors levels and disease risk for single continuous 
risk factors; (2) identifying relationships between average levels of categorical risk factors 
and disease risk; and (3) estimating the simultaneous contribution of several risk factors to 
disease risk while taking account of within-person variation in more than one risk factor.
10.3 .1  E stim a tin g  d isea se  rela tion sh ip s for con tin u ou s risk factors
The effect that within-person variation in a single risk factor has on its estimated re­
lationship with disease risk is most easily described for the continuous risk factor that 
displays a log-linear “dose-response” relationship with the risk of disease. These are risk 
factors for which a  unit increase in exposure to the factor leads to a constant proportional 
increase (or decrease) in risk, irrespective of the starting level. For coronary heart dis­
ease, two of the most im portant risk factors, blood cholesterol and blood pressure, display 
such relationships.70’113 CHD risk increases linearly with increasing blood pressure, serum 
total cholesterol, and the ratio of total to HDL cholesterol, and decreases linearly with 
HDL cholesterol (Chapter 6). Under these circumstances, the estimated relations between 
“baseline levels” of these risk factors and incident CHD underestimate the true strength 
of relation between average levels and disease risk, because of regression dilution bias 
(Chapter 3). The extent of this bias is determined by the degree that observed differences 
in baseline levels truly reflect long-term differences between individuals. Therefore, this 
bias may be corrected for if an estimate of the true “between-person” variation to the ap­
parent variation (the regression dilution ratio) can be obtained. Reassuringly, correction 
for regression dilution bias in a single continuous risk factor does not alter the statistical
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significance of its estimated relationship with disease risk. The reason for this is that, in 
its simplest form, the correction method simply multiplies the observed association by a 
correction factor. Therefore if the confidence interval for the observed association con­
tains zero (consistent with the null hypothesis) then so will the confidence interval for the 
corrected association.
E stim ates o f th e  regression dilution ratio (R D R )
Estimates of the extent of regression dilution bias are important if unbiased estimates of 
associations between usual risk factors and disease outcomes are to be obtained. Long­
term prospective studies therefore need to recognise these effects, and adjust for them 
using appropriate estimates of the regression dilution ratio. This can be done in a variety 
of ways (see chapter 3), but each requires the risk factor to be remeasured after a particular 
duration of follow-up. However, before correction for regression dilution bias is applied, 
several important issues need to be considered.
1. Over w hat follow -up interval should the R D R  correction factor be eval­
uated?
The decision on when to re-measure individuals depends on the length of follow-up 
over which risk-associations are to be calculated. The approach taken in this the­
sis has been to relate disease risk over a particular follow-up period to usual risk 
factor levels around the mid-point of that interval.19 Therefore, for the 20-year as­
sociations, major CHD risk was related to usual risk factor levels after 10 years of 
follow-up, while for the 10-year associations, risk was related to usual exposure levels 
after approximately 5 years of follow-up. Variations of this approach have been used 
elsewhere.113’533 In the Prospective Studies Collaboration, the risk of CHD death 
in each 10-year age group was related to the estimated usual blood pressure level 
at the start of tha t 10-year period,113 while in a recent analysis of the Whitehall 
I study, CHD mortality was related to usual blood pressure and blood cholesterol 
levels at about 5 years before death.533 By taking into account the observation that 
individuals who die from CHD later in life have, on average, been followed for longer 
periods of time, the authors of these reports were able to perform “time-dependent” 
correction for regression dilution bias, applying different correction factors for sub­
jects “at risk” during different decades of age. Similarly, by using separate correction
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factors for men a t risk of major CHD in the first and second decades of follow-up 
in the BRHS (see §6.4.7), time-dependent correction for regression dilution bias was 
performed in this thesis. Taking into account the longer follow-up periods for men 
at risk of a first major CHD event between 1988/90 and 1998/2000, the true rela­
tionship between usual blood lipid and blood pressure levels and major CHD risk, 
rather than diminishing over time as first it seemed, was shown to be fairly stable 
(see Table 6.4). The reason why it is important to  choose an appropriate period 
over which to correct for regression dilution bias, and the reason why its choice can 
greatly affect the results, is that for most risk exposures the regression dilution ratio 
tends to decrease (i.e. the regression dilution effect gets stronger) as the interval 
over which it is estimated increases (as can clearly be seen in Figures 5.2 to 5.5). If 
real data are not observed over this “ideal” period then it may still be possible to 
estimate the likely effects providing that sufficient repeated data over other intervals 
are available (for instance, the 10-year regression dilution ratio estimates used in 
chapter 6 were estimated, not from real data over a 10-year period, but from esti­
mates of the regression dilution ratio over periods of 1 week, 4 years, 16 years and 
20 years; see Table 6.1).
2. Should th e R D R  be estim ated from external data or from the sam e study?
In this thesis, estimates of the regression dilution ratio over 4, 16 and 20 years were 
taken from all BRHS men with repeated risk factor measurements available over 
those periods. The advantage of using these data to correct for regression dilution 
bias is tha t they should provide appropriate adjusted point estimates (because they 
are drawn from the population being studied). The disadvantage is that (unless they 
are excluded from other analyses) the observations are not independent of the stud­
ied population (because they form a subset of the main study). While this doesn’t 
affect the point estimates of the corrected disease-associations, it would mean that 
confidence intervals for these estimates would be too narrow if independence were 
to be assumed. This problem can be overcome by using bootstrap re-sampling 
to calculate the confidence intervals, as this method allows for any correlation be­
tween the uncorrected disease-association and the correction factor when calculating 
confidence intervals for the corrected disease-association. Alternatively, “external” 
data may be used to calculate correction factors. This may be data from the orig­
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inal study participants subsequently excluded from the estimation of uncorrected 
disease-associations, or else may be from an entirely separate study (e.g. the one- 
week repeated data in this thesis was taken from a study of men in Islington, North 
London, who were not BRHS participants). The advantage of using either of these 
two sources of external data to estimate correction factors is that the estimates 
would be independent of the uncorrected disease-outcome associations. However, 
one of two other problems may be introduced depending on which source of external 
data were used. If a subset of the main study were used, the subsequent exclusion 
of these participants from the estimation of disease-outcome associations could po­
tentially introduce certain selection biases, which could result in biased estimates. 
However, if data external to the main study were used, one would need to be sure 
that the estimated correction factors were truly generalisable to the population under 
study. In practice, the decision on which data to use to estimate correction factors 
(and, if from the main study, whether to subsequently exclude it when estimating 
disease-outcome associations) may depend on the statistical methods available to 
the researchers, as well as the relative weight that is given to avoiding selection bi­
ases on the one hand, and ensuring that the correction factor is appropriate on the 
other. The latter concern is now addessed in more detail.
3. Are R D R  estim ates similar betw een different populations?
Ideally, studies tha t wish to correct for regression dilution bias would probably wish 
to use repeated risk factors measurements from their own study participants, or at 
least a subset of the study participants, in order to ensure appropriate estimates of 
the regression dilution ratio. However, if repeated measurements of individuals are 
not available (or remeasurement of participants isn’t feasible), then estimates from 
other studies such as the BRHS may be helpful. The estimates of the RDR presented 
in this thesis were found to be fairly consistent with those from many other studies 
in many different populations (see Chapter 5; Figure 5.12). Therefore, it may be 
reasonable to assume tha t they can appropriately be used to correct for regression 
dilution bias in other study populations. Furthermore, the 20-year estimates of 
the regression dilution ratio for the blood lipid and blood pressure indices were 
found to be reasonably independent of age, social class and town of residence (see 
Chapter 5; Figures 5.6 to 5.11), providing further support for their likely validity
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in other settings. In addition, other studies have found that gender also seems to 
have little effect on the size of the regression dilution ratio ,19 indicating that the 
BRHS estimates shown in Chapter 5 may even be valid for producing corrected 
regression coefficients in studies of women. However, the level of pre-existing CHD 
in the population may affect the validity of performing such corrections. Consistent 
with previous studies,524-526 regression dilution effects were generally found to be 
greater (i.e. RDR estimates were lower) in men with evidence of CHD at baseline, so 
that applying correction factors derived from all BRHS men to populations initially 
without CHD may result in “over-correction” of regression coefficients, i.e. the 
corrected regression coefficients would be too large. It was for this reason that in 
chapters 7 and 8 of this thesis, four-year regression dilution ratio estimates were 
calculated only from men initially without CHD.
4. Can R D R  estim ates be applied to  the study o f other diseases?
The concept of regression dilution bias and the methods available to correct for it are 
quite general. Therefore, providing that interest lies in the relationship between usual 
risk factor levels over a period of time and disease risk, the regression dilution ratio 
estimates presented in this thesis do not need to be restricted to the original outcome 
of interest, in this case major CHD. They would be equally valid for assessing, say, 
long-term associations with the incidence of stroke, cancer or all-cause mortality, or 
indeed any outcome sharing at least one of the risk factors presented in this thesis.
10.3 .2  E stim a tin g  d isea se  re la tion sh ip s for ca tegor ica l risk factors
Continuous risk factors tha t display dose-response relationships with disease risk are eas­
ily adjusted for regression dilution bias, as their slopes are simply modified by a single 
correction factor (chapter 6). Similarly, categorical risk factors that can take one of two 
values can be corrected for misclassification bias through a simple adjustment (chapter 
9), provided that the misclassification is non-differential. However, for categorical risk 
factors tha t have more than two levels, including risk factors that are grouped into cat­
egories for analyses because they display non-linear relationships with disease risk (e.g. 
alcohol consumption and CHD), and risk factors whose underlying continuous scale is dif­
ficult to quantify (e.g. physical activity), the effects of within-person variation on their
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relationships with disease risk cannot necessarily be predicted. Therefore, the only way to 
establish the effect tha t within-person variation has on disease relationships is to obtain 
follow-up information on surviving individuals at regular periods throughout the study 
and to use the information by: (a) fitting changes in risk factors during the study as time- 
updated covariates; or (b) using the data to recalculate “average exposure” to the factor 
over a certain period of time. In this thesis, the second approach was used for cigarette 
smoking, physical activity and alcohol intake in order to derive average exposures to these 
factors over the 20-year study period (chapter 5). The first approach usually relies on 
precise information on when changes in risk factors occur and is often used for risk factor 
changes that are known without measurement error (for instance, the time to CHD death 
may be greatly influenced by a revascularisation procedure, which could then be fitted 
as a “known” time-updated covariate). Irrespective of how the follow-up data are used 
however, if the aim is to identify relationships between risk exposures and “first” inci­
dent disease events, then it is important tha t only follow-up information obtained while 
the subject remains “event free” should be used in analyses. For instance, a physically 
inactive man who experiences a non-fatal myocardial infarction after 1 year, and then 
subsequently becomes active and remains so for the next 19 years would, in the analyses 
presented in this thesis, be classed as “inactive” in the analysis of first major CHD events.
10 .3 .3  Id en tify in g  “d ose—resp o n se” rela tion sh ip s
A very important function of an epidemiological study is to try to identify causal risk 
factors for a particular condition. Though causality cannot be established from epidemio­
logical studies alone, this likelihood would be increased if a risk factor was shown to display 
a “dose-response” relationship with a disease, meaning that the risk of disease increased 
(or decreased) progressively with increasing exposure to the risk factor (one of the key 
criteria for causality proposed by Sir Austin Bradford-Hill).566 How does within-person 
variation therefore affect the ability to identify such relationships? For single continuous 
risk factors, any true dose-response relationships should still be identified when baseline 
measures are used in analyses (though their strength of relationship would of course be 
underestimated). However for categorical risk factors this is not necessarily true, and will 
depend on the nature of the within-person variation (“misclassification”). In the BRHS, 
the strong “dose-response” relationship between cigarette smoking and CHD was only
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observed across the entire spectrum of cigarette smoking exposure after adjustment for 
within-person variation was carried out (chapter 6). When baseline measures were used in 
analyses, the increasing CHD risks observed with increasing exposure to cigarette smok­
ing were weaker and were only observed up to a level of 21-39 cigarettes a day; men who 
smoked at least 40 cigarettes a day had similar observed CHD risks to men who smoked 
only 1-20 cigarettes a day. Furthermore, though the baseline association between alcohol 
and CHD indicated moderate benefits from light levels of drinking, and no excess risks 
from heavy drinking, the interpretation based on average alcohol drinking patterns was 
quite different, with large excess risks caused by heavy drinking being identified and only a 
small benefit from light drinking. In both these cases, many of the problems in ascertain­
ment of the true underlying risks from continued exposure to these factors were caused by 
a high degree of selective misclassification of certain levels of exposure, in particular the 
proportion of men truly exposed to heavy smoking and drinking. Of course, for cigarette 
smoking and CHD, the large differences in risk between the never-smokers and all current 
smokers provides the most compelling evidence for causality. However, not all epidemio­
logical studies examine relationships as strong as the cigarette smoking-CHD relationship, 
and the potential for even large studies to fail to identify a true “dose-response” relation­
ship, or even to incorrectly identify the nature of a true relationship (as appears to be 
the case for alcohol and CHD, in the BRHS at least), is concerning. Wherever possible, 
this potential error therefore needs to be taken into account by study investigators, by 
obtaining follow-up information on individuals and examining the potential effects that 
risk factor misclassification over time could have on estimated disease relationships.
10 .3 .4  E stim a tin g  “m u ltiv a r ia te” rela tion sh ip s
The simple methods of correcting for within-person variation in a single continuous risk 
factor do not necessarily translate to the case of simultaneous adjustment for several risk 
factors, when more than one of them is subject to within-person variation.25-27’521’567 In 
particular, observed baseline associations may under- or overestimate true risk-associations, 
even for risk factors not subject to within-person variation. The extent and direction of 
this bias depends on the correlation between the risk factors. In the analyses considered 
in this thesis, systolic blood pressure and total cholesterol were found to be fairly inde­
pendent of one another and, as a result, the simultaneous relations between these factors
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and CHD risk after multivariate correction for regression dilution bias were found to be 
similar to the associations after single adjustment methods were performed (though some 
small differences were observed, including a slightly reduced estimate of the relative haz­
ards for age and cigarette smoking; chapter 7). Studies tha t wish to employ univariate 
correction methods in multiple covariate analyses should therefore do so with caution. 
The only situation where it can reliably be assumed tha t this method leads to exactly the 
same estimates as if multivariate correction techniques were employed is where there is 
no correlation whatsoever between the explanatory variables (which, in practice, is rarely 
the case).
10.4 Im plications for public health
10.4.1 Im p lica tio n s  for th e  a e tio lo g y  o f  C H D
The findings from chapter 6 of this thesis show that for continuous risk factors that display 
“dose-response” relationships with CHD, failure to correct risk-associations for within- 
person variation can lead to marked underestimation of their importance. The findings are 
of particular importance for the aetiology of CHD, and particularly for those established 
risk factors known to be causally related to CHD, especially blood cholesterol and blood 
pressure. Before correction for regression dilution bias, the 20-year age adjusted relative 
hazard of major CHD per unit (1 mmol/1) increase in serum total cholesterol was 1.39 (95% 
Cl 1.32 to 1.46), and per 20 mmHg increase in systolic blood pressure the relative hazard 
was 1.25 (95% Cl 1.19 to 1.32). After correction for regression dilution bias, these estimates 
increased to 1.63 (95% Cl 1.52 to 1.76) and 1.48 (95% Cl 1.36 to 1.61) respectively. For 
systolic blood pressure, this risk difference increased further when restricted to men with 
no previous evidence of CHD (HR =  1.78; see Chapter 7, Figure 7.2). For the categorical 
“lifestyle” risk factors, where correction for within-person variation was performed by 
using information from follow-up questionnaires, the effects of within-person variation 
were less predictable. For cigarette smoking, approximately a twofold difference in CHD 
risk was observed between current smokers and never smokers. However, when baseline 
measures were used in analyses, the “dose response” relationship observed up to 21-39 
cigarettes a  day was not continued to levels of 40 or more cigarettes a day (see Chapter 6, 
Figure 6.7). After information from the follow-up questionnaires was taken into account
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however, and individuals were reclassified based on “average” exposure to tobacco during 
the study period, the risk gradient increased and a clear positive dose-response relationship 
was observed across all levels of cigarette smoking exposure (with men who, on average, 
truly smoked 40 or more cigarettes a day having over 4 times the risk of major CHD than 
never-smokers). The benefits of regular, moderate, levels of physical activity were also 
underestimated when baseline estimates were used in analyses. Compared with inactive 
men, major CHD risk in moderately active men was 53% lower before, and 68% lower after 
adjustment for within-person variation. Vigorously active men had half the risk of CHD 
than inactive men. For alcohol intake, there was a clear limitation of the use of baseline risk 
factors levels, namely the inability to detect true increased risks associated with continued 
heavy drinking. This was due to the observation that, of the men who were defined 
as heavy drinkers at baseline, only approximately one quarter of them were truly heavy 
drinkers throughout the study period. Comparing major CHD rates between these men 
and the men who were truly non-drinkers, a 75% excess risk was observed (95% Cl 31% to 
133%), compared with a 16% lower risk (95% Cl 35% lower to 8% higher) estimated from 
baseline data. The estimated benefits from light to moderate levels of drinking were also 
reduced when within-person variation was taken into account. These particular findings 
suggest that even more caution may be needed before any recommendation of alcohol 
consumption for health reasons is made.
Combined contribution o f th e  three major established risk factors
The overall combined contribution of blood cholesterol, blood pressure and cigarette smok­
ing to premature (before the age of 70) major CHD risk in apparently “healthy” men was 
examined in chapter 7. Serum total cholesterol and systolic blood pressure were selected 
as the most informative indices of blood cholesterol and blood pressure respectively, and 
the combined population attributable risk fraction corresponding to “high” cholesterol, 
“high” blood pressure and cigarette smoking was calculated for a range of cut-off criteria 
used to define the high-risk group. The results suggested that effective early primary 
prevention of CHD focussed towards the control of blood cholesterol, blood pressure and 
cigarette smoking a t the population level could virtually eliminate the disease. Claims 
that at least half of CHD risk cannot be explained by the established risk factors30-39 are 
completely untenable. Had all men had the blood cholesterol and blood pressure levels
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of those in the bottom fifth of the distributions, and been non-smokers, then four-fifths 
of early CHD would have been prevented. Even larger estimates were obtained when the 
risks associated with previous active smoking or heavy passive smoking were taken into 
account. Furthermore, these estimates do not take into account control of other closely- 
related risk factors for CHD, particularly obesity and physical inactivity, which would 
result in a further increases in the proportion of all CHD cases prevented.
How w idely do these findings apply?
Although the results in this thesis apply only directly to men in one reasonably wealthy 
country with a high prevalence of risk factors and CHD rates which were high by in­
ternational standards over the follow-up period studied,568 they are likely to be widely 
applicable. In particular, it is likely that they apply to women, in whom similar population 
risk factor distributions, relative risks and population attributable risk fractions apply for 
blood cholesterol and blood pressure.42’44 They are also likely to be of considerable rele­
vance to the epidemic of coronary heart disease now emerging in the less affluent countries 
of the world, in which rising levels of blood cholesterol and blood pressure, and marked 
increases in the prevalence of cigarette smoking and obesity are prominent.2 Controlling 
blood cholesterol, blood pressure and cigarette smoking throughout these populations is 
needed and should eventually lead to substantial decreases in CHD in the population.
10.4 .2  Im p lica tio n s  for n ovel C H D  risk factors
The widespread popularity of the “only 50% claim” has helped fuel the notion that other 
crucially important CHD risk factors remain undiscovered. By 1985, nearly 300 risk factors 
for coronary heart disease had been identified, and though it is unlikely that more than a 
small fraction of these actually increase the risk of the disease,569’570 the possibility that 
novel risk factors are im portant causal determinants of CHD risk has gained much support. 
In particular, there has been considerable interest in the role that nutritional factors (e.g. 
homocysteine, vitamin C, vitamin E) and chronic infections (e.g. Chlamydia pneumoniae, 
Helicobacter pylori or specific viral infections) may have, as well as the importance of 
inflammatory, genetic, social and haemostatic factors (see chapter 2).36;112;334;344;361;571 
There has also been considerable interest in the possibility that fetal nutrition influences 
CHD risk, possibly interacting with later obesity.572’573 Relationships between these fac­
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tors and CHD risk are also likely to be underestimated because of within-person variation 
(the extent of this underestimation for the novel risk factors measured in the BRHS is 
shown in Chapter 5; Figures 5.4 and 5.5), however this underestimation is only important 
when the association is confirmed to be causal. In addition, though any or all of these fac­
tors could be playing a role in the causation of CHD (the evidence for the involvement of 
homocysteine is particularly compelling),300’301 such factors would also need to be widely 
distributed and strongly related to CHD risk to make a substantial independent contri­
bution to the CHD epidemic. Even if this were not the case however, novel risk factors 
could still be important if they were found to have a direct effect on the major established 
factors, particularly blood lipids and blood pressure. Slow fetal growth, for instance, has 
been proposed to influence CHD risk, a t least partially, through possible adverse effects on 
adult blood pressure132-135 and blood cholesterol,135;384-386 though two recent systematic 
reviews have suggested tha t is not the case for either risk factor.136’389 Similarly, it is 
unlikely that blood cholesterol or blood pressure may mediate any relationships between 
chronic infections and CHD risk.340’574
10 .4 .3  Im p lica tio n s  for th e  prim ary p reven tion  o f  C H D  
H igh-risk strategies to  prevention
The findings from chapter 8 of this thesis indicate that high-risk strategies based on sin­
gle risk factor management (of blood cholesterol or blood pressure) would have only a 
marginal impact on the occurrence of CHD in the population, preventing at best one in 
ten CHD events from occurring (even if the top fifth of the distribution were all treated). 
This is consistent with a recent report from the BUPA cohort study, which found that 
persons in the top 20% of the distribution of systolic blood pressure experienced only 39% 
of the subsequent coronary deaths that occurred (of which perhaps one fifth may have 
been prevented or postponed through blood pressure lowering drugs).575 As was observed 
in a recent review of interventions to lower blood pressure and cholesterol and their ef­
fects on CVD risk,435 it was observed that by taking multiple risk factors into account, 
predicted Framingham risks generally provide a more effective measure on which to base 
treatment decisions than single measures of cholesterol or blood pressure. However, even if 
multiple risk reducing treatm ents (with aspirin, a statin, a ^-blocker/diuretic and an ACE 
inhibitor) were provided to individuals a t the threshold level currently recommended in
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the United Kingdom (10-yeax risk of a t least 30%),408 only approximately one in nine first 
major CHD events during middle-age would be prevented. In order to have a  large effect 
on population levels of CHD, multiple risk factor modification would need to be widely 
used (i.e. multiple combined drugs would need to be prescribed at lower treatment thresh­
olds). This is the same rationale as that underlying the “polypill” approach to prevention, 
where it has been suggested that everyone in the United Kingdom aged over 55 should 
be treated with multiple blood pressure lowering drugs, a statin, aspirin and folic acid.425 
In the analyses presented in this thesis, reducing the treatment threshold from 30% to a 
predicted ten-year CHD risk of at least 20% (as was, until recently, recommended in Eu­
ropean guidelines)4 increased the proportion of the BRHS men defined as “high-risk” to 
one quarter, and increased the proportion of all premature major CHD events potentially 
prevented to one third. Further reduction of this treatment threshold to a 15% ten-year 
risk may have prevented half of all events from occurring, at the expense of treating half 
the healthy population with multiple combined drugs. Such widespread use of drugs in 
the population should be advocated with caution however. Concerns regarding the use 
of drugs as a substitute for a healthy lifestyle, the speculative nature of the assumed ef­
fects the drugs would have in primary prevention, the failure to tackle other important 
risk factors including cigarette smoking, obesity, diabetes and physical inactivity, and the 
prohibitive costs of such a policy should not be forgotten.576
Population approaches to  prevention
In comparison to the fairly limited effectiveness of the high-risk approach, small population- 
wide reductions in total cholesterol and blood pressure would be likely to have a large 
long-term effect on population levels of CHD. Reducing everyone’s blood cholesterol by
0.3 mmol/1 and everyone’s systolic blood pressure by 7 mmHg (corresponding to a 5% re­
duction in population mean levels) would be expected to reduce major CHD events by 24%, 
though the true figure would most likely be greater than this due to additional favourable 
effects on other risk factors. Reducing both blood cholesterol and systolic pressure by 0.6 
mmol/1 and 15 mmHg respectively would have led to at least 42% fewer premature major 
CHD events. Importantly, these sized reductions in cholesterol and blood pressure are 
fairly small in comparison with the size of the international differences in cholesterol and 
blood pressure tha t exist,545 and should be achievable through concerted population-wide
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changes in diet, specifically reducing salt intake and the proportion of calories derived 
from saturated fa t.104;126;434 However, while many countries have indeed shown steady 
downwards trends in mean total cholesterol and systolic blood pressure levels over the 
last 20 years (as demonstrated by the WHO MONICA study of 38 different populations 
from 21 countries),577 cigarette smoking rates in women, as well as increasing mean body 
mass index (particularly in men) have also been observed. Such adverse population-wide 
changes in coronary risk factors are likely to have significant public health implications in 
the future.
10 .4 .4  C o n sisten cy  w ith  tren d s in  C H D
Since the late 1970’s, CHD mortality in the United Kingdom has declined sharply (by 
approximately 50%),3 while in other Western countries even larger reductions have been 
observed (see Chapter 1; Figure 1.2). Though these changes in CHD mortality are due 
in part to changes in survival following a CHD event (caused by the improvements in 
coronary care and secondary prevention observed dining the 1980’s and 1990’s),578 it is 
the changing coronary event rate (rather than the case fatality rate) that is likely to be the 
driving force behind these reductions in CHD mortality.6’579 To what degree, therefore, 
are changes in risk factors responsible for these reductions? Furthermore, if risk factor 
changes are responsible, which factors have had the greatest effect and is this consistent 
with the findings from this thesis? Numerous authors have attempted to estimate the 
extent that national reductions in CHD mortality rates can be attributed to population- 
wide changes in major risk factors, and the extent that they may be due to other factors 
operating at the population level including improvements in the prevention and treatment 
of CHD.544’548’578’580-588 In Scotland, for instance, risk factor changes between 1975 and 
1994 were estimated to explain approximately half of the decrease in CHD mortality 
observed over tha t period.548 This was predominantly caused by reductions in cigarette 
smoking between 1975 and 1994, with additional effects attributed to the relatively small 
secular reductions in cholesterol and blood pressure. Similarly, in New Zealand between 
1982 and 1994,580 in the Netherlands between 1978 and 1985,584 and in the United States 
between 1968 and 1976,585 and between 1980 and 1990,586 reductions in coronary risk 
factors were estimated to explain around one half of the reductions in CHD mortality 
observed in these countries during these periods. In Finland, most of the decline in CHD
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mortality observed between 1972 and 1992 could be explained by changes in three main 
coronary risk factors (serum total cholesterol, blood pressure and cigarette smoking),544 
while in the Seven Countries Study, CHD death rates during the latter part of the study 
were largely explained by changes in blood cholesterol levels during the early phases of the 
study.587 Most recently, an analysis of CHD mortality rates in England and Wales between 
1981 and 2000 estimated tha t 67% of the observed reduction in CHD mortality over that 
period could be explained by secular trends in cigarette smoking, blood cholesterol and 
blood pressure (though adverse trends in physical activity, obesity and diabetes resulted 
in the combined contribution of all risk factors being only 58%).588
In all these studies, the observation that blood lipids, blood pressure and cigarette 
smoking explain the vast majority of the combined effects attributable to changes in coro­
nary risk factors (including, in some cases,548’580 effects attributed to unknown factors) 
provides further supporting evidence regarding the combined importance of these factors. 
Furthermore, though the reduction in cigarette smoking rates observed in these studies was 
fairly large (30-40%), with the exception of the Finnish study,544 the observed trends in 
blood cholesterol and blood pressure in these studies were small (3-7% reduction in average 
total cholesterol and 2-9% reduction in average blood pressure).548’580’586’588 Therefore, 
had larger population-wide reductions in blood cholesterol and blood pressure occurred, 
substantially more CHD events would have been prevented. However, it is the ability of 
even small downwards trends in cholesterol and blood pressure to make notable contribu­
tions to reduced CHD mortality tha t confirms their importance, in addition to the more 
clearly demonstrated benefits from reducing cigarette smoking rates.
10.4 .5  Im p lica tio n s  for so c ia l in eq u a lities  in C H D
Motivated by the observation tha t despite decreases in CHD across all social class groups, 
relative differences between those at the top and those at the bottom of the spectrum 
are increasing, recent CHD prevention policies in the United Kingdom have placed an 
emphasis on reducing social inequalities in CHD.54’55 The findings from the BRHS (chapter 
9) are particularly relevant to the potential effects of these policies since the social class 
distribution of the men at study entry was close to that of all British men aged 35-64 at 
that tim e.589 Furthermore, the estimates of social class differences were very similar to 
those observed in national CHD mortality statistics over a similar period (1981-1992).590
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The key findings regarding social class and CHD from the work in this thesis are that:
1. Social class differences in CHD are marginally higher that would be estimated from 
baseline assessments of social class -  manual social classes have approximately 40% 
higher risks of major CHD than non-manual social classes.
2. Approximately two-fifths of this difference in risk can be explained by differences in 
the adult coronary risk factors, with a further one fifth explained by influences in 
early-life.
3. Approximately 19% of all major CHD can be attributed to the excess risks of manual 
social classes, so tha t if manual social classes had experienced the same risks as non- 
manual social classes, 19% of CHD events would have been prevented.
4. If manual and non-manual social classes had had the same levels of the established 
adult coronary risk factors, then only around 10% of all major CHD events could 
have been attributed to the (remaining) excess risks of manual social classes.
The implications of these findings are that even if the reasons for social inequalities in CHD 
were understood entirely (and the risks could subsequently be reversed), only one in five 
premature major CHD events would be prevented in the long-term. Though this effect on 
population levels of CHD is appreciable (it is twice as high as the potential effectiveness 
of the most aggressive “high-risk” approaches advocated in the UK), it is still fairly 
small in comparison with the estimated reductions in CHD following population-wide 
reductions in total cholesterol and blood pressure (where at least one in four events could 
be prevented if mean total cholesterol and blood pressure could be lowered by just 5%). 
The limited contribution of reducing social inequalities reflects the high CHD risk and the 
unfavourable coronary risk profile of non-manual men in this study. The findings further 
indicate that the potential impact of any unidentified factors predisposing manual workers 
to higher risks of CHD than non-manual workers is likely to be small compared with 
the impact of targeting known key risk factors across all social classes. Although these 
conclusions only apply directly to the period 1980-2000 on which the data are based, they 
are still likely to be relevant to coronary heart disease prevention in the early twenty- 
first century. Current patterns of blood cholesterol and blood pressure (as measured in 
the Health Survey for England) 565 show less evidence of a social class gradient than was
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observed in the British Regional Heart Study at baseline in 1978-1980, so that the case for 
population-wide prevention by reducing total cholesterol and blood pressure levels remains 
compelling. However, specific targeting of smoking cessation and physical activity among 
lower social class groups would clearly enhance the effectiveness of the population approach 
to prevention.
10 .4 .6  R eco m m en d a tio n s
The analyses presented in this thesis clearly show that the effectiveness of the “high-risk” 
approach to the primary prevention of CHD is likely to be extremely limited unless used 
very much more widely than is currently recommended (particularly as recommended in 
the UK). Over one third of the middle-aged male population without pre-existing CHD 
would need to  be treated with all four drugs to obtain benefits comparable with those 
following population-wide reductions in total cholesterol of 0.6 mmol/1 and population- 
wide reductions in systolic blood pressure of 15 mmHg. This scale of prescribing would 
be consistent with the recently published Third European Joint Task Force report on 
cardiovascular disease prevention,417 which recommends that priority should be given to 
individuals whose ten-year risk of fatal CVD (estimated from the SCORE project)418 is at 
least 5% -  under this criterion, 36% of the BRHS men would be defined as being at “high- 
risk” at baseline. However, treating such a large proportion of the “healthy” population 
would have considerable financial implications with pharmacological high-risk approaches 
becoming less cost effective as the absolute risk threshold is lowered. In comparison, pop­
ulation approaches have been shown to be highly cost effective,435 and, more importantly, 
focus on the determinants of risk factor distributions rather than simply the treatment of 
risk factors. Population approaches focused on blood lipids, blood pressure and cigarette 
smoking have been demonstrated to be feasible and effective; analysis of time-trend stud­
ies have demonstrated the im portant effects that even small population-wide changes in 
these factors can have. Population approaches may be more likely to reduce the devel­
opment of atherosclerosis, while a high-risk strategy implemented without priority given 
to population approaches would ensure a steady supply of middle-aged people requiring 
drug treatment.
The results emphasize the considerable potential benefits of population-wide strategies 
for CHD prevention. In the United Kingdom, mean total cholesterol and blood pressure
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levels remain high by international standards, and though the Health Survey for England 
does suggest that important reductions in mean cholesterol levels have been achieved in 
recent years,545 this is difficult to validate because of a change the laboratory methods 
used during this time. Current public health policy for CHD prevention in the United 
Kingdom gives little emphasis to the importance of reducing total cholesterol and blood 
pressure levels in the population, nor to the crucial role of Governmental action likely to 
be necessary to bring about such changes (for instance legislation to decrease salt and fat 
content in processed foods). Spending on such policies currently comprises only 1-2% of 
total spending on health in many Western countries including the United Kingdom.591;592 
It is likely tha t by giving greater priority to population-wide reductions in blood cholesterol 
and blood pressure, and continued emphasis to reducing cigarette smoking, the substantial 
gains in CHD prevention already achieved over the last two decades may be maintained, 
particularly in the face of adverse gradients in sedentary behaviour, obesity and diabetes.
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A p pendix  B
B aseline questionnaire
The baseline questionnaire completed by study participants is reproduced on the following 
pages. For information regarding the analysis and coding of this questionnaire refer to 
chapter 4, section 4.3.1.
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1
Serial Number 
Card Number 
Date of Screening
Time of Screening
GENERAL
\Miat is your date of birth? Day 
Month 
Year 19
\M iere w ere you bom ?
Town 
C ounty. 
Country
1.2 How many years have you lived within 10 miles of this town?
If you have moved to this area within the last five years, where did 
you m ove from? years
1,3 VUiat is your marital status?
Single 1 
Married 2 
Widowed 3  
Other 4
□
1.4 How many children do you have? M F
<5 yrs 
5-10 yrs. 
11-16 yrs. 
> 16 yrs.
2  YOUR FATHER
2.1 VJb ere wa s  your Father b om ?
Town ..
C ounty ...........................................
Country.........................................
2 .2  Is your father alive? (Y/N)
2 .3  How old' is he now? /  How old w as he when he died?
□
years
2 .4 If your father has died, what were you told w as the cau se  of his 
death?
Heart trouble 1
High blood pressure 2
Stroke 3
Respiratory d isease 4
Cancer of lung 5
Other cancer 6
Accident or injury 7
Other 8
Don’t know 9
3
3.1
3.2
3.3
3.4
YOUR MOTHER
\Miere w as your mother bom?
T ow n...............................................................
County............................................................
Country..........................................................
Is your mother alive? (YAnI)
Hew old is she now? / How old w as she when she died?
If your mother has died, what were you told w as the cause of her 
death?
Heart trouble 1
High blood pressure 2
Stroke 3
Respiratory d isease 4
Cancer of breast 5
Other cancer 6
Accident or injury 7
Other 8
Don’t know 9
4. OCCUPATION
4.1 Vtfiat is your present jo b ? ............................... ................
If employed g o to  question 4.4
4.2 If you are unemployed, for how long has this been?
<ftveeks
6wk.-5mo.
6mo. -1yr.
> 1 year
□
4 .3 Is this b e c a u s e  o f  ill health? (Y/N)
C I "
4 .4 W ia t kind o f  work have  you d on e  for the lon gest period of tim e?
4 .5 W ia t b u s in ess  or industry is  th is?
— I—
4 .6 How m any y ea rs  h ave  you d on e th is kind o f work? I I 1
years 48
4 .7 Are /  w ere y o u :
SELF-EM PLOYED with 25 or more em ployees 1
with less  than 25 employees 2
without employees 3 -----
MANAGER of 25 or more people 4 ___ 50
of less  than 25 people 5
FOREMAN ......................................... 6
ORDINARY EMPLOYEE ...................................................... 7
ARM ED SERVICES ...................................................... 8
5 SEV ERE  C H E ST PAIN
5.1 H ave vou ever  had a  sev e r e  pain in vour ch est lasting for half an
□
51
hour or m ore? (Y/N)
If N.P..qgJftjiK3i9n & -----
5 .2 W ie r e  did you ge t this sev e r e  pain?
(S h ow  chart.) -----
53
5 .3 Did you s e e  a  doctor b e c a u s e  o f this pain? (Y/N)
□
55
6 CHEST PAIN -----
6.1 Do you ever  h a v e  any pain or discom fort in your ch est?  (Y/N) ___ 56
If NO. a o  to  au estion  7.
6 .2 W ie n  last did you get th e pain?
Within 1 month 1
1-5  m on ths a g o 2 □ 57
6 -1 2  m onths ago 3
O ver 1 year a g o 4
O ccasionally 5
6.3 How often do you get it?
Daily 1
W eekly 2
Monthly 3
O nce only 4
O ccasionally 5
6.4  W ier e  do you get this pain or discomfort?
(Show  chart.)
6 .5  W ien  you walk at an ordinary p ace  on the level, d o e s  this produce 
the pain? (Y/N)
6.6 W ien  you walk uphill or hurry, d o e s  this produce the pain? (Y/N)
6.7  W ien  you get any pain or discomfort in your chest on walking, 
what do you do?
Stop 1
Slow  down 2
Continue at the sa m e p a ce  3
6.8  D oes the pain or discomfort in your chest go  away if you stand 
still? (Y/N)
6.9  How long d o es  it take to go 10 m inutes or le s s  1
away? more than 10 m inutes 2
7.0  PHLEGM, COUGH AND BREATHING
7.1 Do you usually bring up phlegm (spit) from your ch est first thing in 
the morning in th e winter? (Y/N)
If NO. go  to Question 7.4
7 .2  Do you bring up phlegm like this on m ost days for a s  much a s  3  
m onths in the winter each  year? (Y/N)
7.3  In the past 3  years have you ever had a  period of increased cough  
and phlegm lasting 3 w eek s or m ore?
Y es, on ce  1
Y es, tw ice or m ore 2
Never 3
7 .4  D oes your chest sound w h eezy  or whistling on m ost days (or 
nights)? (Y/N)
□  «
___59
n s!
03□
n *
□ 8s 
i i «
n e7 
□  -
i i » 
□  *
7.5 Does the weather affect your breathing?
And if so, at what season of the year is it most affected?
Net affected
Venter
Summer
Both
8 BREATHLESSNESS
8.1 Do you get short of breath walking with people your own age on 
level ground? (Y/N)
8.2 On walking up hills or stairs, do you get more breathless than 
people you on age? (Y/N)
8.3 Do you ever have to stop walking because of breathlessness?
(Y/N)
S.E.G. 
Social class 
Activity score
Serial Number
Card Number
9 LEG PAIN
9.1 Do you ever get pain in your calf muscles on walking at an 
ordinary pace, on the level? (Y/N)
9.2 Do you get pain in your calf muscles when you walk uphill or 
hurry? (Y/N)
10 MEDICAL HISTORY
10.1 Have you ever been told by a doctor that you have, or have had, 
any of the following?
Angina
Heart attack 
Coronary thrombosis 
Myocardial infarction 
C»ther heart trouble 
High blood pressure 
Stroke 
Diabetes 
Peptic ulcer 
Gout
Gall bladder disease  
Thyroid disease 
Arthritis 
Bronchitis 
Asthma
Other condition (s) 
including surgery........
(Y/N)
(Y/N)
(Y/N)
(Y/N)
(Y/N)
(Y/N)
(Y/N)
(Y/N)
(Y/N)
(Y/N)
(Y/N)
(Y/N)
(Y/N)
(Y/N)
(Y/N)
(Y/N)
10.2 Are you on any regular medical treatment from a doctor for
any condition? (Y/N)
If NO. oo to question 10.3
Do you know if the pills / medicines /injections are:-
Tranquillizers Y/N
Pain killers Y/N
Antihypertensive drugs Y/N
Anti coagulants Y/N
Lipid lowering drugs Y/N
□
□
Oral antidiabetics 
Injection of insulin 
Any others 
Don’t know
Y/N
Y/N
Y/N
Y/N
10.3 Have you taken any of these  in the last 48 hours?
Tranquillizers Y/N
Y/NPain killers 
Antihypertensive drugs Y/N
Anti coagulants Y/N
Lipid lowering drugs Y/N
Oral antidiabetics Y/N
Injection of insulin Y/N
Any others Y/N
Don’t know Y/N
11 DIET & AL£.Qil£L
11.1 How many times during an average week would you have the 
following foods?
M eat (including beef, lamb, pork, bacon in any form)
Chicken
Fish
Eggs - how many eggs do you eat in a  week
C heese -  how often do you eat cheese, including cheese 
dishes?
Breakfast cereals -  how often do you eat these  (porridge 
included)? S tate k in d ..................................................................
11.2 W ia t kinds of bread do you eat ?
White
Brown
Wholemeal
Other
Y/N
Y/N
Y/N
Y/N
m
11.3 Spreading fats: What kinds do you use  at hom e?
Butter Y/N
11.4 Do you take sugar?
M argarine.................................  Y/N
(State kind or brand name.)
In tea 
In coffee 
In other drinks
B
Y/N
Y/N
Y/N
11.5
11.6
Do you u se  milk?
On cereals  
In tea  
In coffee  
A s a  milk drink
Y/N
Y/N
Y/N
Y/N
(i) Would you describe your present alcohol intake as:
N one 1
On special occasions only 2
O nce or twice a month 3
W eekends 4
Daily / most days 5
If NONE, ao  to question 12
(ii) What type of drink do you usually take?
Beer 1
Spirits 2
Wine/sherry 3
Mixed beer & spirits 4
Mixed beer, spirits, wine 5
and sherry
(iii) Hew much do you usually take?
2 drinks a day or le s s  1
3-6 drinks a day 2
more than 6  drinks a day 3
(One drink is a single whisky, gin or brandy, a g lass of wine, sherry 
or port or half a pint of beer.)
□ *
□ *
□
Serial Nurrfcer
Card Number
12 SMOKING
12.1 (i) Do you sm oke at present?
Yes, regularly
No
Occasionally
If NO. go to question 12.6
(H) How old were you when you started?
(iii) Have you ever given up smoking? (Y/N)
(iv) If yes, what is the maximum time for which you have given 
up smoking?
12.2 (i) Do you smoke cigarettes now?
Yes regularly 1
No 2
Occasionally (<1 day) 3
If n q , or PCCAgiQNALlY m  t? ,12,2
(H) How many cigarettes do you usually smoke a day?
(iii) If hand rolled, how much tabacco do you use a week? (ozs.)
Now proceed to 12.4
12.3 (i) Were you previously a regular cigarette smoker? (Y/N)
(ii) If Yes, how many cigarettes did you usually smoke a day?
(iii) At what age did you change to a pipe and / or cigars?
12.4 (i) Do you smoke a pipe now?
Yes regularly
No
Occasionally
If NO or OCCASIONALLY go to question 12 
(H) If YES, how many ozs. a week do you smoke?
12.5 (i) Do you smoke a pipe now?
Yes regularly
No
Occasionally
(ii) If YES, how many cigars do you smoke a day?
Large
Small
□
y e a r s  12 
14
years 15 
□
OZS. 20
22
23
years "1 25 
□  „
m
OZS. 20 
□  »
If you smoke ANYTHING currently. 0 0  to question 13.
1 2 6  (i) Have you ever smoked for a more than 1 month ? (Y/N) 
How much did you usually s moke
Cigarettes (per day)
Pipe (ozs) (per week)
Cigars (per day) Large
Small
If NO. oo to question 13.
(ii) At what age did you start smoking?
(iii) At what age did you finally stop smoking?
(iv) Wiat was the maximum time between these two ages for 
which you gave up smoking?
□
m
years 44
m
y e a r s  46
m
years 40
13 EXERCISE
13.1 (i) Do you usually walk or cycle in the course of your journeys to
or from work each day?
No 1
Walk 2
Cycle 3
If YES, how many minutes do these journeys take?
(ii) Apart from your journeys to or from work, do you usually 
walk or cycle on weekdays?
No 1
Walk 2
Cycle 3
If YES, how many minutes do you walk/cycle each day?
(iii) Would you say that in your occupation you are physically:
Very active 1
Fairly active 2
Average 3
Fairly inactive 4
Very inactive 5
13.2 On average, a man of your age spends 4 hours on most weekends 
on some of the following activities: walking, gardening, household 
chores, DIY projects. Compared to such a man, how physically 
active do you consider yourself?
Very active 1
Fairly active 2
Average 3
Fairly inactive 4
Very inactive 5
n  » 
mumins 51
I I SO
mmins 51 
□  »
13.3 Apart from th ese  activities, do you take active physical exercise, 
e.g. running, digging, swimming, tennis, golf, sailing, etc.
No 1
Occassionally  
Frequently 
If NO or Occasionally -  stop here.
13.4 R e a se  state type of activity..........................................................
13.5 How many years have you been involved in this activity?
13.6 How many tim es a month (on average) do you undertake th ese  
activities?
Winter
Summer
□
m
years 59
Administrator
Coder
□
□
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